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ABSTRACT 
 
 
Outcomes after major surgery depend partly on patients’ physiological tolerance to 
iatrogenic trauma. Objectively measured fitness assessments (cardiopulmonary exercise 
testing; CPET) show a link between poor fitness and poor surgical outcome, especially in 
major colorectal surgery. However evidence on fitness of surgical patients undergoing 
neoadjuvant chemoradiotherapy (NACRT) and/or preoperative exercise training is lacking. 
This thesis focuses on the physiological effects of NACRT and a preoperative structured 
responsive exercise training programme (SRETP) on objectively measured physical fitness 
using cardiopulmonary exercise testing, and the related effects on mitochondrial function 
using 31-phosphorus magnetic resonance spectroscopy (
31
P MRS) in operable advanced 
rectal cancer patients.  
 
First, CPET variables (oxygen uptake ( V o2) at estimated lactate threshold ( ˆ L) and at peak 
exercise) were measured in advanced rectal cancer patients pre and post-NACRT and were 
followed up to 1 year postoperatively. A reduction in V o2 at ˆ L and V o2 at Peak exercise 
was observed (-1.5 and -1.4 ml.kg
-1
.min
-1
 respectively; p<0.0001), both significantly 
associated with in-hospital complications. This is the first direct evidence that the benefits of 
NACRT in tumour downsizing may be partly offset by increased perioperative risk due to a 
reduction in physical fitness. 
 
A SRETP was then constructed, and a feasibility and tolerability study carried out. The 
SRETP improved physical fitness within 6 weeks following NACRT ( V o2 at ˆ L +3.3 
ml.kg
-1
.min
-1 
and V o2 Peak by +5.8 ml.kg
-1
.min
-1
), enough to reverse the deleterious effects 
of NACRT. A 98% adherence proves the SRETP both feasible and tolerable, with no 
adverse events encountered.  
 
Next, locally advanced rectal cancer patients were recruited to an interventional pilot study 
scheduled to undergo standardised NACRT and a 6-week SRETP (exercise group n=22) or a 
control period (n=13). A significant benefit in V o2 at ˆ L of +2.12 ml.kg
-1
.min
-1
 (p<0.0001) 
in the exercise group was observed. This study reinforces the benefits of prehabilitation with 
exercise training to improve physical fitness after the deleterious effects of NACRT prior to 
the added insult of major surgery.  
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Lastly, patients were randomized to the SRETP or to negative control  after undergoing 
standardized NACRT, serial measures of whole body fitness and in vivo mitochondrial 
function by 
31
P MRS (measuring the rate constant of phosphocreatine recovery, kPCr). 
Significant reductions in V o2 at ˆ L (-2.36 ml.kg
-1
.min
-1
) were observed with NACRT, after 
which the SRETP improved fitness ( V o2 at ˆ L +3.85 ml.kg
-1
.min
-1
). A significant reduction 
in kPCr of -0.34 was found with NACRT, improved by +0.66 after SRETP.  
 
These novel, clinically relevant findings show a significant decline in fitness with NACRT 
in an advanced rectal cancer cohort, reversible by a tailored exercise intervention post-
NACRT.  Concomitant changes in muscle mitochondrial function may account for this acute 
loss in fitness. The improvement in mitochondrial function observed with exercise, might 
indicate that a structured intervention immediately after NACRT is necessary to rescue and 
reverse NACRT’s deleterious effect on mitochondrial function and fitness in this patient 
cohort.  
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CHAPTER 1 – Introduction and Thesis Overview 
 
 
1.1 INTRODUCTION 
 
This thesis reports the results of investigations into the effects of preoperative (neoadjuvant) 
chemoradiotherapy (NACRT) and an exercise training programme (SRETP) on objectively 
measured physical fitness (fitness and physical fitness are used interchangeably throughout 
this thesis) in patients with locally advanced rectal cancer who are about to undergo major 
elective oncological resection. It describes the impact of NACRT and SRETP on in vivo 
mitochondrial function in human skeletal muscle using a non-invasive magnetic resonance 
(MR) based approach.  
  
Major abdominal surgery is associated with a substantial burden of postoperative morbidity 
and mortality particularly in the elderly or those with significant co-morbidity. Large audits 
in the United Kingdom reveal 30-day mortality rates of 5.6% for elective colorectal cancer 
surgery (1). A recent study estimated that in the United Kingdom more than 4 million 
surgical procedures are performed annually, 12.3% of which are performed on patients 
classified as “high-risk” (expected mortality >5%) (2). These “high risk” patients can be 
clearly identified by utilizing subjective (e.g. American Society of Anesthesiologists Scores 
- ASA) or objective measures of physical fitness (e.g. cardiopulmonary exercise testing – 
CPET). Patients deemed unfit on preoperative CPET are reliably linked to a higher 
proportion of adverse postoperative surgical outcomes i.e. morbidity or mortality (3–5). This 
group accounts for the large majority of the observed postoperative mortality (83.4%), and 
also has a significantly longer hospital stay which is a surrogate marker of in-hospital 
morbidity. Outcome after major surgery is dependent on both controllable factors, such as 
the medical care received before, during and after surgery, as well as fixed factors, such as 
the patient’s physiological ability to tolerate surgical trauma. Accurate perioperative risk 
assessments allows the multidisciplinary team (MDT) to ensure appropriate modification of 
patients’ preoperative status as well as optimising intra and postoperative management for 
these high risk surgical patients. Therefore, the preoperative identification of patients unable 
to withstand physiological trauma from neoadjuvant cancer treatments or major surgery 
should be a priority. 
 
In the United Kingdom colorectal cancer is the third commonest cause of cancer death (6,7). 
In 2010, 33,218 new cases were registered (58 new cases per 100,000 men and 37 new cases 
per 100,000 women), with 15,776 deaths (6,7). In 2012, of 9000 patients diagnosed with 
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rectal cancer (35% above age of 75 years), 75% underwent major resection (8). Twenty-five 
per cent of cases are locally advanced (TNM stage - T3/T4) cancers considered for NACRT 
to control local disease, improve operability, achieve tumour downsizing and negative 
resection margins (9–13). Only two trials suggest that rectal cancer patients with a lower 
subjective performance status (WHO Score >1) have a worse postoperative outcome after 
combined chemotherapy or chemo-radiation and surgery (14,15). It is therefore important to 
understand quantitatively the impact of NACRT on general physical fitness and also its 
clinical implications on surgical outcome. The mechanism of changing fitness with cancer 
therapies is currently unknown and needs to be explored. Impairment of skeletal muscle 
mitochondrial function will greatly affect muscle bioenergetics, decreasing the efficiency of 
whole body exercise performance and potentially affecting overall patients’ capability in 
dealing with surgical stress. Furthermore, other mechanisms e.g. cancer-induced cachexia, 
cancer related fatigue, oxidative stress (16–18) (which causes muscle weakness and fatigue), 
chemotherapy induced loss of muscle mass (19,20), reactive oxygen species (ROS) (21), 
reduced antioxidant levels (22) and mitochondrial death (23) may be the cause of reduced 
fitness. 
 
Knowledge of the effects of cancer and cancer therapies on physical fitness and 
mitochondrial function is critical in developing interventions to promote recovery of 
physical fitness, especially as these effects may impair fitness for surgical intervention. 
These issues will be addressed in subsequent chapters. To date there is no evidence linking 
the deleterious effects of cancer therapies on physical fitness and surgical outcome, and there 
is only some evidence showing that preoperative exercise training improves surgical 
morbidity and mortality after major surgery. This present thesis originates from a study that I 
led in 2009 whilst undergoing my surgical training in University Hospitals Aintree. This 
consisted of a cohort of colonic surgical patients about to undergo major surgery. CPET was 
in its infancy and I wanted to undertake a study which aimed to investigate any relationship 
between short term in hospital surgical outcomes and objectively measured CPET variables 
in these high risk patients. One hundred and ninety eight patients were recruited in this trial. 
Selected CPET variables were found to be associated with postoperative morbidity and a 
risk stratification model was developed. This trial led to further hypothesis generation 
around the effects of neoadjuvant cancer therapies in colorectal cancer patients and novel 
ways to counteract its effects. Hence this thesis consists of independent studies in which 
objective measures of physical fitness (assessed by means of CPET) and in vivo 
mitochondrial energetics (assessed by means of 31-Phosphorus Magnetic Resonance 
Spectroscopy – 31P MRS) are utilised to derive quantitative measures of the impact of 
NACRT and a preoperative exercise training programme on inter-related global physical 
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fitness and mitochondrial muscle function. These studies will attempt to elucidate the 
complex links between observed changes in whole body cardiopulmonary physiology and 
muscle mitochondrial energetics in rectal cancer patients during NACRT and exercise 
(Figure 1.1). 
 
Figure 1.1 – Gears represent the complex functional interdependence of physiological components 
(musculoskeletal, cardiovascular and respiratory systems) resulting in physical fitness assessment (Wasserman 
and colleagues). 
 
Each study addresses important clinical issues which are largely unexplored in the literature. 
Detailed physiological and pathophysiological background will be presented in Chapter 2, 
whilst the rationale of each study will be presented in the individual chapters. An outline is 
provided here to orientate the reader.  
There are 4 major components presented in this thesis: 
 The first study objectively defines changes in physical fitness after NACRT prior to 
elective surgery for locally advanced rectal cancer. The study hypothesises that long-
course NACRT prior to elective surgery would impair physical fitness as objectively 
assessed by CPET. Secondary aims include determining the relationship of CPET 
variables (Oxygen uptake ( V o2) at estimated lactate threshold ( ˆ L) and V o2 at Peak 
exercise) to Day 5 postoperative in-hospital morbidity, 180-day morbidity and 1 year 
mortality. 
 The second study outlines the development of the iterative process around the 
structured, responsive, exercise training programme (SRETP). It also reports the 
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evaluation of its feasibility, tolerability, safety and adherence amongst patients’ 
immediate post-NACRT and for the subsequent 6 weeks. 
 The SRETP was then applied to a cohort of rectal cancer patients in the third study. 
This is a consecutive, non-randomised, parallel group study to investigate the effects 
of NACRT and a 6-week training programme or standard care (negative control) on 
objectively measured physical fitness and surgical outcomes. Here the aim of this pre-
pilot study was to observe changes in physical fitness and their relationship to 
postoperative outcome after a period of standard care (no intervention) or a 6-week 
SRETP (structured intervention). 
 In the fourth study, physiological methods of measuring physical fitness and 
assessments of in vivo mitochondrial function were applied together in the same 
cohort of patients. Here I describe the relationship between changes in physical fitness 
and changes in mitochondrial function pre- and post-NACRT, as well as, after 
randomization to standard care (no intervention) or a 6-week SRETP (structured 
intervention). The main aim of this study is to identify the biochemical mechanism for 
the observed changes in physical fitness. 
 
 
1.2  GENERAL AIMS OF THIS RESEARCH  
 
The aims of this current research work are: 
 
1. To explore changes in physical fitness after NACRT prior to elective surgery for 
locally advanced rectal cancer using objective CPET methodology, and to 
subsequently attempt to establish a preliminary relationship between change in 
fitness and postoperative morbidity and mortality (Day 5 postoperative in-hospital 
morbidity, 180-day morbidity and 1 year mortality). 
2. To develop a novel post-NACRT training protocol (SRETP) which is feasible, safe 
and tolerable in the pre-operative period of this surgical population. 
3. To explore the changes in physical fitness and surgical outcomes after a period of 
SRETP or routine care (negative control) in a pre-pilot parallel group non-
randomized setting. 
4. Finally, to apply 31P MRS and CPET methods to study in vivo skeletal muscle 
mitochondrial function and whole body physical fitness assessments in an attempt to 
identify a biochemical mechanism for these changes in physical fitness using a 
randomized controlled design (negative control vs. structured intervention). 
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1.3 ORGANIZATION OF THESIS CHAPTERS 
 
This thesis is presented in 8 chapters. 
 
 Chapter 1: The present chapter - this briefly outlines the introduction, general aims 
of this research, organisation of the chapters presented in this thesis, the setting of the 
study and how these integrate into the National Health Service (NHS) colorectal 
cancer care pathway. 
 Chapter 2: Background – Physiology and Pathophysiology – this chapter provides a 
background of the appropriate theory and reviews the literature around all methods 
and techniques used in this thesis. 
 Chapter 3: General Methods and Experimental Setup - this chapter provides a 
description of the general experimental protocols, equipment set-up, as well as data 
acquisition, interpretation and analysis of methods used i.e. Cardiopulmonary exercise 
testing, the exercise training programme and 
31
P MRS. 
 Chapter 4: The Effect of NACRT on Physical Fitness and Morbidity in Rectal 
Cancer Patients – this study explores the changes in objectively measured physical 
fitness using CPET after NACRT in a cohort of locally advanced rectal cancer 
patients. This study also explores the relationship between changes in physical fitness 
and surgical outcome at 5, 180 and 365 days postoperatively. This addresses the novel 
way of observing changes in physical fitness in this homogenous group of patients. 
The physiological and clinical relevance of these observations are further discussed in 
this chapter.  
 Chapter 5: Development of a Structured Responsive Exercise Training Programme 
(SRETP) and Feasibility Study – this study details the iterative processes that led to 
the development of the exercise training programme. Additionally, the feasibility and 
tolerability of the SRETP is explored. 
 Chapter 6: Prehabilitation – A Pre-Pilot Parallel Group Controlled Study – this 
study is designed to further define the effects of neoadjuvant chemoradiotherapy 
(NACRT) and to pilot the SRETP derived in Chapter 5. This chapter specifically 
focuses on a pre-pilot, non-randomised, parallel group controlled study investigating 
the changes in objectively measured CPET derived variables and their relationship to 
in-hospital morbidity. 
 Chapter 7: Effects of Neoadjuvant Chemoradiotherapy and a 6-Week Structured 
Exercise Programme on In Vivo Mitochondrial Function – A Randomised 
Controlled Study – this chapter specifically focuses on a randomised controlled study 
7 
 
investigating the effects of NACRT and SRETP on in vivo mitochondrial muscle 
function and objectively measured physical fitness. 
 Chapter 8: Summary, Conclusion and Future Work – this concluding chapter 
presents a summary of results from each individual study and their implications to 
clinical practice. The strengths and potential methodological limitations are also 
addressed. The conclusions from the research work as well as future studies are 
presented.  
 
 
1.4 STUDY SETTING AND INTEGRATION INTO NHS CANCER PATHWAYS 
 
This thesis deals with rectal cancer patients who are recruited from within NHS cancer care 
pathways. This section is aimed to firstly acquaint the reader with both the previous (Figure 
1.2) and current rectal cancer pathway (Figure 1.3) used at Aintree University Hospitals 
NHS Foundation Trust (AUH is the hospital where these patients are recruited from), and 
secondly, to illustrate the integration of the research investigations/interventions (presented 
in Chapters 4 to 7) into the aforementioned NHS rectal cancer pathway (Figure 1.2 and 1.3).  
 
During the course of my PhD work the standard cancer care pathway for locally advanced 
rectal cancer was changed. Two main changes involved the re-staging scans which were 
moved from week 7 to week 9 post-NACRT, and the surgery which was also moved from 
week 9 to week 15 post-NACRT. These changes were undertaken to be in line with recently 
published evidence illustrating the effects of delaying time of surgery for locally advanced 
rectal cancer patients after neoadjuvant chemoradiotherapy (24–26). The rationale for the 
timing for surgical intervention post-NACRT, as well as the radiobiological sense for using 
NACRT will be discussed in Sections 2.3 and 2.4. 
 
Figures 1.2 and 1.3 show the integration of research investigations and interventions 
presented in Chapters 4-7. These do not alter the standard NHS cancer pathways. All 
research investigations and interventions were specifically designed to fit around the 
standard cancer pathway used at AUH, mainly utilizing the waiting times between standard 
care investigations and the hiatus between end of NACRT and surgery. Ethical approval for 
this project was granted by the Northwest Regional Ethics Committee on the 18
th
 March 
2011(REC Reference Number 11/H1002/12), and further favourable ethical approval was 
given for two amendments on the 20
th
 June 2011 and 30
th
 January 2012 (REC Reference 
Number 11/H1002/12a and 11/H1002/12b). 
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Figure 1.2 – Previous standard rectal cancer pathway at AUH (until October 2011), with the addition of research 
investigations (highlighted in orange) as described in Chapter 4. 
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Figure 1.3 – Current standard rectal cancer pathway at AUH (from October 2011 to date), with the addition of 
research investigations/interventions (highlighted in blue) as described in Chapters 5 to 7. 
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CHAPTER 2 – Background – Physiology and Pathophysiology 
 
 
2.1 ANATOMY OF THE RECTUM 
 
The rectum is continuous with the sigmoid colon at the level of the third sacral vertebra, the 
junction being at the lower end of the sigmoid mesocolon. It descends along the 
sacrococcygeal concavity, with an anteroposterior curve, then curves down and backwards, 
and finally down and forwards to join the anal canal by passing through the pelvic 
diaphragm. The adult rectum is 18-20cm in length and is divided into three equal parts: the 
upper third, which is mobile and has a peritoneal covering; the middle third, which is the 
widest part and is confined within the bony pelvis, covered by peritoneum only on the 
anterior and part of the lateral surfaces; and the lowest third, which lies within the muscular 
floor of the pelvis and has important relations to fascial layers (Figure 2.1). 
 
Figure 2.1 – Anatomy of the rectum; 1 – upper rectum, 2 – middle rectum; 3 – lower rectum 
 
The lowest part of the rectum is separated from the prostate in front by a fascial 
condensation called Denonvilliers’ fascia and from the coccyx and last two sacral vertebrae 
behind by another fascial layer called Waldeyer’s fascia. These layers are surgically 
important as they are a barrier to malignant penetration and are valuable guides at operation. 
Blood supply of the rectum is mainly from the superior rectal artery which is a continuation 
of the inferior mesenteric artery. This divides into anterior and posterior branches and is 
1 
2 
3 
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accompanied by lymphatics which are all kept applied to the back of the rectum by dense 
mesorectal connective tissue. The lymphatic drainage of the mucosal lining of the rectum 
interchanges freely with those of the muscular layers. They flow upwards (only to a limited 
extent laterally and downwards). This is important in surgical excision of malignant disease 
as the surgeon aims to achieve wide clearance of proximal lymph nodes. 
 
 
2.2 ORIGIN OF CARCINOMA  
 
Colorectal cancer is now thought to originate through a multistep process called the 
adenoma-carcinoma sequence, a term that describes the stepwise progression from normal to 
dysplastic epithelium to carcinoma associated with the accumulation of multiple clonally 
selected genetic alterations (27). This concept provides an excellent model to study 
precursor lesions and their transition into invasive cancer. 40% of the western population 
will develop adenomatous polyps, but only 3% will go on to suffer from colorectal cancer. 
The evidence supporting the adenoma-carcinoma sequence can be classified as 
epidemiological, clinicopathological and genetic, with the most recent body of evidence 
relating to molecular genetic events i.e. oncogenes, tumour suppressor genes and DNA 
repair genes and their cellular effects i.e. methylation status and microsatellite instability 
(27), however the origins and precursors of colorectal cancer are beyond the scope of this 
thesis.  
 
 
2.2.1 RECTAL CANCER 
 
In the United Kingdom colorectal cancer is the third commonest cause of cancer death (6,7). 
In 2010, 33,218 new cases were registered (58 new cases per 100,000 men and 37 new cases 
per 100,000 women), with 15,776 deaths (6,7). In 2013, of 9000 diagnosed with rectal 
cancer (35% above age of 75 years), 75% underwent major resection (28). Twenty-five per 
cent of cases are locally advanced (TNM stage - T3/4 N+) cancers considered for long-
course neoadjuvant chemoradiotherapy as these cancers are considered to threaten the 
circumferential resection margins, which is associated with a poor prognosis (9–13,29). 
Different types of histopathological variations exist with the most common being; well-
differentiated adenocarcinomas, moderately differentiated adenocarcinomas and poorly 
differentiated adenocarcinomas. Rectal cancer can spread in 4 ways; local spread, lymphatic 
spread, venous spread and peritoneal dissemination (30).  
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 Local spread: This occurs circumferentially rather than longitudinally. After the 
muscular coat has been penetrated, the growth spreads into the surrounding 
mesorectum, but is still limited by the perirectal fascia. If penetration occurs 
anteriorly, the prostate, seminal vesicles or the bladder may become involved in the 
male, whilst in a female, the vagina or the uterus may become invaded. In either sex, 
with lateral extension, a ureter may become invaded, whilst posterior extension may 
involve the sacrum or the sacral plexus.  
 Lymphatic spread: Rectal cancer above the peritoneal reflection spreads almost 
exclusively upwards, whilst below that level to within 1-2cm of the anal orifice 
lymphatic spread is still upwards, however pararectal lymph nodes of Gerota might 
become involved. The exception to this rule is when the neoplasm lies within the 
field of the middle rectal artery, i.e. between 4 and 8 cm from the anus, in which 
case primary lateral spread along the lymphatics that accompany the middle rectal 
vein might ensue. Metastasis at a higher level than the main trunk of the superior 
rectal artery occurs late in the disease. A radical operation should ensure that the 
highest lying lymph nodes are removed by ligation of the inferior mesenteric artery 
and vein as close to their aortic origin as possible. Surgical technique is discussed in 
Section 2.3.2. 
 Venous spread: Cancer spread via the venous system is a late phenomenon. The 
principal sites for blood-borne metastasis are liver (34%), lungs (22%) and adrenals 
(11%). The remainder is divided among remaining sites.  
 Peritoneal dissemination: This occurs following penetration of the peritoneal coat by 
a high lying rectal cancer. 
  
In 1932, the Dukes classification (Figure 2.2) was introduced to stage colorectal cancers 
(31). This has been subsequently modified by Astler in 1954 (32). Dukes classified 
carcinoma of the rectum into three stages, with the fourth added by Astler: 
 
A The growth is limited to the rectal wall. Prognosis is excellent. 
B The growth is extended to the extrarectal tissues, but no metastasis to the regional 
lymph nodes. Prognosis is reasonable. 
C There are secondary deposits in the regional lymph nodes. These are subdivided into 
C1, in which the local pararectal lymph nodes alone are involved, and C2, in which 
the nodes accompanying the supplying blood vessels are implicated up to the point 
of division. Prognosis is poor. 
D Widespread metastases. 
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Figure 2.2 – Duke’s Classification of the three cardinal stages of colorectal cancer progression 
 
The TNM (Tumour, Node, Metastasis) classification is now the gold standard staging tool 
used by the Royal College of Pathologists (33); T-stage represents the extent of local spread 
and there are four grades – T1 – 4, depending on whether the tumour is confined to the 
mucosa or has penetrated the rectal wall. N-stage describes nodal involvement and M-stage 
describes the presence of distant disease.  
 
 
2.2.2 CLINICAL FEATURES 
 
Signs and symptoms from rectal cancer are often considered insignificant and so patients 
might not seek medical advice for some time. Bleeding is the earliest and most common 
symptom. Tenesmus (a feeling of incomplete emptying) is a very important early symptom 
which is almost invariably present in tumours of the lower half of the rectum. Alteration in 
bowel habit is also a frequent symptom, with patients having a change in stool consistency 
or habit of defecation. Pain is a late symptom, but pain of a colicky character may 
accompany some degree of intestinal obstruction. Infiltration into prostate or bladder may 
cause severe pain, as well as back pain or sciatica if sacral plexus infiltration occurs. Weight 
loss and reduced appetite is suggestive of systemic disease.  
 
 
2.3 MANAGEMENT OF LOCALLY ADVANCED RECTAL CANCER 
 
Locally advanced rectal cancer is defined as tumours which are operable, non-metastatic, 
T3/4 N+ rectal adenocarcinomas and threaten the circumferential resection margins (34). 
The gold standard of treatment for this cancer type is neoadjuvant chemoradiotherapy 
followed by definitive total mesorectal excision surgery (35,36). 
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2.3.1 INVESTIGATIONS 
 
Abdominal examination is negative in early cases, whilst the liver may become palpable 
when metastases occur. In approximately 90% of cases, the tumour may be felt digitally. 
Ulceration, raised and everted edges, together with induration is a frequent and unmistakable 
finding. 
 
A colonoscopy is required in all patients to exclude synchronous tumour and to obtain a 
biopsy of the tumour for pathological assessment. Local and distant assessment of the 
tumour is performed by computed tomography (CT) of the chest, abdomen and pelvis. This 
is usually coupled with MRI of the pelvis. In recent years magnetic resonance imaging 
(MRI) has emerged as the dominant method of pelvic imaging in rectal cancer (37,38). The 
MDT is using MRI to better plan surgical resection and neoadjuvant treatments. With better 
availability of neoadjuvant options, preoperative staging used to differentiate between good- 
versus poor-prognosis tumours is very useful, as this translates into optimized outcomes 
(39). The relationship between the tumour and the sphincter complex and the ability to 
achieve clear radial and distal margins is key to success of rectal cancer surgery (37). MRI 
offers superb soft tissue contrast between tumour and other soft tissues on T2-weighted MRI 
(Figure 2.3) (40–44), while CT has difficulties in this regard (38,44).  
 
 
Figure 2.3 – A T2-weighted sagital MR image of a male with rectal cancer. The image shows a typical 
appearance of the tumour with raised rolled edges (white arrowheads). The lower black arrowhead is the point at 
which the lower most edge of tumour can be measured to the anal verge and the height measured (white dotted 
line) 
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2.3.2 SURGICAL TREATMENT 
 
Radical excision of the rectum, together with the mesorectum and associated lymph nodes is 
the mainstay of rectal cancer surgery (30). When the tumour appears to be locally advanced, 
the administration of a course of preoperative radiotherapy or combination 
chemoradiotherapy may reduce its size and make it more amenable to radical excision. This 
will be reviewed in more detail in Section 2.4.   
 
Patients who are unfit for radical surgery or have wide-spread metastases may still benefit 
from a local procedure such as transanal excision, laser destruction or local radiation to 
control symptoms; however this is outside the scope of this thesis and will not be discussed. 
The main focus of this section is to discuss surgery for locally advanced rectal cancer 
patients.  
 
When a tumour appears to be locally advanced, the administration of neoadjuvant 
(preoperative) radiotherapy or combined chemoradiotherapy has been shown to be beneficial 
in preventing local recurrence. This will be discussed further in Section 2.4. When rectal 
excision is possible, whenever feasible, the aim should be to restore gastrointestinal 
continuity and continence by preserving the anal sphincter. A sphincter-saving operation 
(anterior resection) is usually possible for tumours of the upper two-thirds of the rectum, 
although removal of the rectum with a permanent colostomy (abdominoperineal excision) is 
often required for tumours of the lower third of the rectum. The introduction of the stapling 
gun has enabled many more of these patients to be treated by a sphincter-saving procedure. 
Provided a minimum distal margin of clearance of 2 cm can be secured, it is safe to restore 
gastrointestinal continuity. Because of the much wider degree of local spread by anaplastic 
tumours and the high risk of local recurrence, it has been customary not to perform 
restorative operations when these carcinomas are in the lower third of the rectum. However, 
with the realisation that a preoperative biopsy is often inaccurate with respect to the degree 
of histological differentiation, coupled with the more widespread use of preoperative and 
postoperative radiotherapy, many more anaplastic lesions are being treated by sphincter-
saving procedures.  
 
Low anterior resection (LAR) is now performed in least two-thirds of patients presenting 
with carcinoma of the rectum. The principles of the operation involve radical excision of the 
neoplasm, with at least a 2-cm margin of normal bowel below the lower edge of the tumour, 
removal of all the mesorectum, i.e. total mesorectal excision (TME) (45) and high proximal 
ligation of the inferior mesenteric lymphovascular pedicle. The plane of dissection follows 
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the relatively avascular areolar plane, between the mesorectal fascia surrounding the 
mesorectum and parietal tissues (Figure 2.4). This plane is usually terminated at the pelvic 
floor, having dissected the mesorectum off the levator muscles. However, this plane of 
dissection can be continued into the intersphincteric plane, with low anastomosis to restore 
intestinal continuity. To produce uninvolved margins, the tumour must not extend to ≥1 mm 
of the mesorectal fascia. If the tumour extends into the sphincter complex, then the 
intersphincteric plane should be tumour-free and the tumour should not extend to within 1 
mm of the outer border of the internal sphincter. This plane can be further extended distally 
to perform an intersphincteric abdomino-perineal excision (APE) —essentially the same 
plane as low AR, but intestinal continuity is not maintained. Once the rectum has been 
mobilised adequately, it is removed, and the remaining bowel and rectal stump are washed 
out proximally and distally. Restoration of continuity by direct end-to-end anastomosis 
(manually or by stapling) must be carried out by a meticulous technique to reduce risks of 
suture line breakdown.  
 
 
 
 
Figure 2.4 – A coronal diagram depicting the two anatomical levels (Level 1 and 2) of the distal rectum to help 
define the surgical approach 
 
The main indications for an extra-levator APE procedure are extension of tumour into or 
beyond the levator muscles and/or tumour involving the intersphincteric plane plus or minus 
the external anal sphincter. This operation is typically carried out in two phases and has been 
well described by Holm and colleagues (46).  
 
Finally a pelvic exenteration can be performed when extensive local invasion by a T4 
tumour is found; however this is beyond the purpose of this thesis as all of the patients 
recruited in Chapters 4 to 7 underwent LAR or APE procedures. 
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2.4 EVIDENCE FOR UTILISING CANCER THERAPIES PRIOR TO 
LOCALLY ADVANCED RECTAL CANCER SURGERY 
 
In this next section I will attempt a summary of the evidence for utilizing neoadjuvant cancer 
treatment prior to major rectal cancer surgery. In the 2012 National Bowel Cancer Audit (8), 
4684 patients were diagnosed with rectal cancer and had major surgery, of which 24.2% had 
neoadjuvant long-course radiotherapy and 14.8% had neoadjuvant short-course 
radiotherapy. 7.9% had a positive circumferential resection margin (assuming all missing 
values were negative). The effectiveness of any form of preoperative therapy is dependent 
on the subsequent quality of surgery. As described in 2.3.2, TME is now the accepted 
standard resection for most rectal cancers, whilst an APE may be required for lower rectal 
tumours. The value of neoadjuvant therapy for low rectal tumours is debatable at present and 
requires further evaluation. 
 
The gains in local control from preoperative radiotherapy are well established (47,48) but 
this needs to be balanced against the significant late effects in terms of sexual, urinary and 
bowel dysfunction and also the potential risk of second malignancies. Although preoperative 
chemoradiotherapy and Short-Course Preoperative Radiotherapy (SCPRT) are widely used 
to reduce the risks of local recurrence over surgery alone, and have similar biological 
equivalent radiation doses, there is uncertainty over which schedule to use in which 
particular clinical setting. SCPRT is a brief (typically 5 days) treatment with high dose 
radiotherapy. Short term side effects are minimal though there is some risk from long-term 
morbidity. Chemoradiotherapy involves a protracted (minimum of 5 weeks) course of 
radiotherapy with concomitant chemotherapy. Short term side effects are more marked and 
although long term effects do occur, there are less published data to establish their extent. 
Since this section only addresses preoperative and not postoperative therapy, the results of 
the large MRC CR07/NCIC-CTG C016 trial (49) of preoperative radiotherapy versus 
selective postoperative chemoradiotherapy in patients with rectal cancer are not considered 
in this evidence review. 
 
Three systematic literature searches were conducted to look for available evidence. These 
are presented in Appendix 1 and 2. The literature search found in Appendix 1 relate to 
Sections 2.4.1 and 2.4.2, whereas the literature search found in Appendix 2 relate to Section 
2.4.3. 
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2.4.1 PREOPERATIVE RADIOTHERAPY VERSUS SURGERY ALONE FOR 
OPERABLE RECTAL CANCER 
 
The evidence for this comparison comprised a systematic review (47) and data from long 
term follow-up of randomised trials (48,50,51). In addition there was a systematic review 
(52) which addressed the late adverse effects of preoperative (and postoperative) 
radiotherapy (RT) in patients treated for rectal cancer.  
 
Wong et al. (47) calculated pooled hazards ratios (HR) for overall survival from fourteen 
studies (HR: 0.93 [95%CI: 0.87-1.0] (p=0.04)). They conclude that short-course 
preoperative RT was superior to surgery alone; however this could not be replicated using 
individual patient data. Long term data from the Dutch TME trial also found no significant 
difference in the rate of overall survival between patients who had SCPRT compared with 
those patients who had surgery alone (64.2% versus 63.5%) (51). 
 
Pooled data for disease-specific survival indicated an advantage of SCPRT in improving 
disease-free survival (HR: 0.87 [95%CI: 0.78-0.98] (p=0.02)) but there was high 
heterogeneity between studies so the results may not be reliable. The data for local 
recurrence were highly heterogeneous and were not appropriate for pooling. However, an 
overall reduction in the rate of second malignancies was in favour of SCPRT (HR: 0.89 
[95%CI: 0.82-0.97] (p<0.001). The most common side effect of preoperative RT is 
diarrhoea (20%) (47) and patients in the surgery only group experienced more post-surgical 
toxicity.  
 
Peeters et al. (51) analysed long term data from the Dutch TME trial and found no 
significant difference in the rate of overall survival between patients who had preoperative 
RT compared with those patients who had surgery only (64.2% versus 63.5%). They also 
found no significant difference in 5 year cancer specific survival in irradiated versus non-
irradiated patients (75.4% versus 72.4%). However, there was a 49% reduction in local 
disease recurrence (p<0.001) for irradiated patients but no significant difference in the rate 
of distant recurrence after 5 years of follow-up. Quality of life comparisons showed a non-
significant trend towards worse outcomes in irradiated patients. There was more scarring of 
the anal sphincters in this group (33%) when compared with the non-irradiated group (13%) 
and most also suffered some a degree of incontinence. The maximum resting and squeezing 
pressures were significantly lower in the irradiated group (47). Birgisson et al. (50) observed 
an increased risk of infections among irradiated patients during the first 6 months after 
treatment (RR: 7.67 (95%CI: 1.76-33.39)) and similarly in gastrointestinal diagnoses (RR: 
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2.57 (95%CI: 1.55-4.26)). There was an increase in the risk of non-specific infections (n=10; 
RR: 8.06 (95%CI: 1.02-63.69) in the irradiated group although the risk of cardiac arrhythmia 
was reduced (RR: 0.57 (95%CI: 0.36-0.91). In relation to gastrointestinal diagnoses, 
increased relative risk was observed in irradiated patients for bowel obstruction, nausea and 
non-specific abdominal pain whereas the risk for inguinal hernia was lower. This systematic 
review was the first to collate outcomes post-radiotherapy and rectal cancer surgery. 
 
 
2.4.2 PREOPERATIVE CHEMORADIOTHERAPY VERSUS PREOPERATIVE 
RADIOTHERAPY FOR OPERABLE RECTAL CANCER  
 
Evidence for this comparison arises from four papers (53–56) which report different 
outcomes from the same trial comparing conventionally fractionated neoadjuvant 
chemoradiotherapy (NACRT) with SCPRT. Patients were randomised to receive either 
preoperative 5.5 Gy irradiation with subsequent TME performed within 7 days or NACRT 
(50.4 Gy, 1.8 Gy per fraction plus bolus 5-fluorouracil and leucovorin) followed by TME 
after 4– 6 weeks.  
 
Bujko et al. (53) reported no significant difference in the rate of 4 year survival (HR: 1.01 
(95%CI: 0.69- 1.48) or 4 year disease free survival (HR: 0.96 (95%CI: 0.69-1.35) between 
patients having received NACRT compared with RT. There was also no significant 
difference in the 4 year incidence of local recurrence (HR: 0.65 (95%CI: 0.32-1.28), the 
crude incidence of distant metastases, late toxicity (RR: 1.05 (95%CI: 0.72-1.53) or late 
severe toxicity (RR: 1.43 (95%CI: 0.67-3.07). The same authors in 2004 (54) found no 
significant difference in the rate of sphincter preservation between patients having had RT 
and those having NACRT (61% versus 58%), whilst in 2005 (55) they found no significant 
difference in the rate of postoperative complications or severe complications, including 
death. Unfortunately, as this was not the primary outcome of the trial, the study was 
underpowered to have detected a difference between the interventions had one existed.  
 
Pietrzak et al. (56) specifically addressed quality of life (QoL) and observed no significant 
difference in the mean scores for the global health/quality of life status (p=0.22) or for 
anorectal and sexual function in patients having had NACRT or RT. Approximately two-
thirds of patients complained of faecal and gas incontinence, urgency and inability to 
differentiate between stool and gas. Approximately two-thirds of respondents stated that the 
disturbances in anorectal function had a negative impact on their QoL, with approximately 
20% stating the impact was considerable. There was no significant difference between the 
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two groups in relation to the impact on sexual function (p=0.56 for males; p=0.10 for 
females).  
 
Fiorica et al. (57) presented a systematic review and meta-analysis of long term follow-up 
data from seven trials, including one abstract, comparing NACRT and preoperative RT in 
patients with resectable rectal cancer. The conclusions of the study were that the addition of 
chemotherapy to preoperative radiotherapy reduced the risk of local recurrence (RR: 1.05; 
95%CI: 1.01- 1.10; p=0.02) but did not improve overall survival (RR: 1.02; 95%CI: 0.94-
1.09; p=0.68) or the risk of distant metastases (RR: 0.97; 95%CI: 0.93-1.02; p=0.21). 
Treatment-associated toxicity was also higher with NACRT. 
 
 
2.4.3 PREOPERATIVE RADIOTHERAPY OR PREOPERATIVE 
CHEMORADIOTHERAPY IN LOCALLY ADVANCED RECTAL CANCER 
VERSUS IMMEDIATE SURGERY 
 
This section deals with a large volume of evidence which addresses the issue of preoperative 
treatment (radiotherapy or chemoradiotherapy) versus immediate surgery in locally 
advanced, high risk rectal cancer patients. In relation to preoperative NACRT versus 
preoperative RT alone, two Cochrane reviews (58,59) were available along with a number of 
randomised trials. In relation to preoperative chemoradiotherapy versus surgery alone there 
were a number of case series studies available. One Cochrane review (47) was available to 
provide evidence for preoperative radiotherapy versus surgery alone, which was already 
discussed in Section 2.4.1.  
 
There was no evidence available to address the issue of preoperative chemotherapy versus 
surgery alone, nor were there any studies comparing preoperative chemotherapy with 
preoperative radiotherapy for patients with locally advanced rectal cancer. 
 
 
2.4.3.1 PREOPERATIVE CHEMORADIOTHERAPY VERSUS PREOPERATIVE 
RADIOTHERAPY ALONE 
 
Two Cochrane reviews specifically reviewing this topic found no significant differences 
between the two treatment groups in terms of overall survival (pooled odds ratio, 1.01; 95% 
CI, 0.85-1.20, p=0.88 (59) and odds ratio, 0.79-1.14, p=0.58 (58)) at five years. However, a 
more clinically relevant and significant difference in the rates of local recurrence at 5 years 
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was observed for patients in the RT group compared to patients in the NACRT group (OR 
0.39-0.72, p<0.00001 (58) and OR 0.56, 95% CI 0.42-0.75, p<0.0001 (59)). Using data from 
2 randomised controlled studies, De Caluwe et al. (58) reported no significant difference in 
5-year disease free survival between the radiotherapy and chemoradiotherapy groups (OR 
0.92-1.34, p=0.27). Pooled analysis from the same Cochrane review showed a significant 
difference in pathological complete response in favour of NACRT with an OR of 2.12-5.84, 
p<0.00001. Pooled analysis by McCarthy et al (59) showed significantly higher rates of 
grade III/IV toxicity in the NACRT group (OR 3.96, 95%CI 3.03-5.17, p<0.000001). This 
was confirmed by the updated review by De Caluwe et al. (58) (OR 1.68-10, p=0.002); 
although a limitation of this review is the significant heterogeneity found on data pooling 
from the two reviews. The increased toxicity reported marginally affected postoperative 
overall morbidity (OR 0.67-1.00, p=0.05), whilst it did not affect postoperative mortality and 
anastomotic leak rates.  
 
 
2.4.3.2 PREOPERATIVE CHEMORADIOTHERAPY VERSUS IMMEDIATE 
SURGERY 
 
For this comparison, there was little evidence available. Evidence was drawn from a small 
number of case series, both prospective and retrospective. Patient numbers in these studies 
were relatively small and this was considered to be a major limitation. Chessin et al. (60) 
showed no significant difference in either overall survival (p=0.09) or relapse free survival 
(p=0.10) between patients experiencing major complications and those with no 
complications. From a second case series, Coco et al. (61) observed that the actuarial overall 
survival at 5 years was 75.5%, 7 year survival was 67.8% and 10 year survival was 60.4%; 
actuarial cancer-related survival at 5 years was 77.9%, at 7 years was 70% and at 10 years 
was 65.8%. Mermershtain et al. (62) reported a 5-year overall survival of 70% and 8-year 
overall survival of 58% in a retrospective case series of 30 people. In a retrospective case 
series of 43 patients, Twu et al. (63) compared patients that responded to chemoradiotherapy 
with patients that did not respond and found no significant difference between the two 
groups in relation to overall survival, though a significant difference in local recurrence rate 
was observed in favour of the patients responding to NACRT (p=0.002). They also observed 
that disease-free survival was higher in the group of patients responding to NACRT 
compared with those patients not responding to NACRT (p=0.06). 
 
The largest retrospective review of 390 patients treated for rectal cancer presenting with T3 
or T4 disease and/or involved lymph nodes receiving neoadjuvant chemoradiotherapy (5’-
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FU) before TME compared patients with T1 and T2 disease with no suspicion of involved 
nodes received TME directly. Time to death, local or distant recurrence was not significantly 
different between groups but the prognosis was more unfavourable for those patients who 
had positive nodes regardless of group (64).  
 
Most retrospective case-series (62,63,65) observed pathological complete response rates of 
12-13% in patients treated with NACRT.  
 
 
2.4.3.3 CHEMORADIOTHERAPY UTILISING CAPECITABINE 
 
5-Fluorouracil (5-FU) is a fluorinated analogue of uracil that has been commercially 
available since 1957. 5-FU’s molecular activity is quite complex, showing interference with 
DNA synthesis and mRNA translation. 5-FU is transformed to 5-fluorodeoxyuridine by the 
action of thymidine phosphorylase. This then binds to thymidylate synthetase and to 
tetrahydrofolate, forming a stable complex which prevents the formation of thymidine from 
thymine. Finally DNA synthesis is blocked leading to cell death (66). Because of its 
unpredictable gastrointestinal absorption and degradation 5-FU must be administered 
intravenously. The drawbacks of continuous infusions are hospital and/or home health costs, 
infection risk, and patient burden. To overcome these disadvantages whilst preserving the 
benefits of continuous-infusion doses, and oral pro-drug was developed. Capecitabine is a 
carbonated derivative of doxifluoridine (5’-DFUR) that is absorbed via the intestine in pro-
drug form. This is then activated both in the tumour and in normal tissues, however the 
converting enzyme thymidine phosphorylase is found in higher concentrations in most 
tumour tissues than in normal tissues, hence allows for the theoretical advantage of 
Capecitabine to have a selective activation within the tumour with a lower systemic toxicity.  
 
Numerous phase II trials with a total of 953 patients, all with similar inclusion/exclusion 
criteria, were found (14,67–83). All studies reported grade III/IV toxicity. This was observed 
in 27% (260/953) of patients (range 0-34.5%). The most commonly reported toxicity was 
diarrhoea; other reported toxicities included anaemia, radiation dermatitis and 
leucocytopenia. Sphincter preservation rate was reported in all studies and ranged from 33% 
to 84% (mean 62%). Pathological complete response rate was 17.1% (range 9.1-26%), 
whilst tumour and node down staging was 59.2% (range 32-84%). All studies conclude that 
neoadjuvant Capecitabine and radiation therapy is better tolerated than bolus 5-FU and is 
more effective in the promotion of both down-staging and sphincter preservation in patients 
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with locally advanced rectal cancer. Capecitabine was also shown to be more cost-effective 
than other standard intra-venous treatments.  
 
I conducted a literature search (Appendix 3) looking specifically for an association between 
preoperative markers of physical fitness and surgical outcome in gastrointestinal cancer 
patients treated with RT or NACRT undergoing surgical interventions. Interestingly, only 
Swellengrebel et al. (14) and Cunningham et al. (84) comment on the association of poor 
preoperative World Health Organisation (WHO) performance status and surgical 
complications. Swellengrebel et al. observed that a poor WHO performance status (≥2 at 
diagnosis) and the extent of surgery in locally advanced rectal cancer patients were 
associated with postoperative complications. They make inferences to the role of baseline 
physical fitness on surgical outcome and wound healing. Cunningham et al. also observed an 
association between WHO performance status and death following neoadjuvant 
chemotherapy in operable gastro-oesophageal cancer patients. Although this did not reach 
statistical significance, they demonstrate that less fit patients (WHO PS ≥1) may receive less 
benefit from NAC than fitter patients. 
 
 
2.4.4 CHEMORADIOTHERAPY REGIME USED LOCALLY 
 
All patients recruited to the studies presented in this thesis were recruited from Aintree 
University Hospitals NHS Foundation Trust, via the colorectal MDT. All patients received 
their neoadjuvant chemoradiotherapy at the Clatterbridge Cancer Centre, Wirral, UK, under 
the supervision of one medical oncologist (RS – acknowledged). All recruited patients 
received a standardised NACRT regime. This was kept constant for all recruited patients, in 
an attempt to obtain a homogenous patient sample and to remove any potential treatment 
bias. Patients receiving non-standard NACRT were excluded from the results presented in 
this thesis. 
 
Preoperative radiotherapy consisted of 45 Gy in 25 fractions on weekdays using a three-
dimensional conformal technique with CT guidance. Patients were treated prone (on a belly-
board) to spare small bowel, with a comfortably full bladder. The clinical target volume 
included the primary tumour, the mesorectum and mesorectal lymph nodes, including the 
perirectal, presacral and internal iliac nodes. The upper radiation extent was 3 cm above the 
tumour but no further than the sacral promontory. The perineum was included if an APE was 
planned, while for LAR the lower radiation border was 3 cm below the tumour. A boost 
dose was given (5.4 Gy in 3 fractions) to the primary tumour only. 825 mg.m
-2
 oral 
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capecitabine was given twice daily on radiotherapy days. No patients received 
brachytherapy. Patients recruited in Chapter 4 had their surgery planned on the 9
th
 week 
post-NACRT, whilst patients recruited in Chapters 5-7 had their surgery planned on the 15
th
 
week post-NACRT. 
 
 
2.5 MEASURES OF SURGICAL RISK AND PREOPERATIVE FITNESS FOR 
SURGERY 
 
Major abdominal surgery is associated with a substantial burden of postoperative morbidity 
and mortality particularly in elderly patients and those with co-morbidities. The 2012 the 
UK National Bowel Cancer audit documented 90-day mortality rates of 3.8% for elective 
colon cancer surgery, 4% for recto-sigmoid cancer and 2.5% for elective rectal cancer 
surgery (8). When considering emergency surgery this increased to 13.4% for colonic cancer 
patients and 13.9% for rectal cancer patients. Approximately 4 million surgical procedures 
are performed annually in the UK, 12.3% of which are performed on patients classified as 
“high-risk” (expected mortality >5%) (2,85). In this analysis, the “high-risk” group 
accounted for the majority of postoperative mortality (83.4%), and had a significantly longer 
hospital stay and therefore increased resource usage. These high risk individuals need to be 
risk-assessed preoperatively and have their perioperative management tailored so as to 
reduce avoidable surgical morbidity and mortality. 
 
Outcomes after major surgery are dependent on modifiable factors, such as the medical care 
received before, during and after surgery, as well as more fixed factors, such as the patient’s 
physiological tolerance of surgical trauma. Accurate risk prediction allows the 
multidisciplinary team to ensure appropriate modification of patients’ preoperative status as 
well as optimising intra- and postoperative management for high-risk surgical patients. Such 
risk prediction also facilitates the most efficient use of scarce resources (e.g. intensive care 
beds). Importantly, better risk prediction also provides a higher quality of data to physicians 
and patients thereby enhancing the process of shared decision making before surgery (86). 
So the preoperative identification of patients at high risk of adverse outcome following the 
trauma of major surgery should be a priority.  
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2.5.1 CARDIOPULMONARY EXERCISE TESTING VERSUS OTHER 
METHODS OF ESTIMATING PHYSICAL FITNESS 
 
The advantage of CPET over other methods of preoperative assessment is that it provides an 
integrated assessment of oxygen utilisation under conditions of dynamic exercise stress. It is 
recognised that dynamic tests, in comparison with static tests, are a more effective means of 
evaluating whole-body human physiology. Moreover, patients have an intuitive 
understanding of the concept of being “Fit for Surgery” and therefore the test has good face 
validity. The concept underlying CPET is that the physiological reserve defined by an 
exercise challenge, reflects, at least in part, the reserve available of the patient to meet the 
physiological challenges of the surgical trauma and the perioperative period. These 
challenges include major fluid shifts, acute inflammation and acute catabolism to name a 
few. CPET is also an objective, repeatable, non-invasive, quick, specific and sensitive means 
to detect cardiac failure and myocardial ischaemia at subclinical levels. CPET methodology 
and equipment setup will be discussed in more detail in Section 3.2.  
 
CPET variables can be compared with others methods of assessing exercise tolerance, 
overall fitness and physiological reserve. These range from simple assessments including 
clinical acumen, clinical prediction scores e.g. ASA, Duke’s Activity Scores, Physiological 
and Operative Severity Score for the enUmeration of Mortality and Morbidity (POSSUM), 
colorectal specific POSSUM (CR-POSSUM) (87–89), and assessment of metabolic 
equivalents (METs) to more complex assessments including walk tests (90), plasma 
biomarkers (91) and various measures of cardiac function (92–94).  
 
Simple direct questioning to assess a patient’s cardiorespiratory fitness has long been part of 
the preoperative assessment by the anaesthetist and has been shown to correlate with 
postoperative outcome (95). The European Society of Cardiology (ESC) and the American 
College of Cardiology/American Heart Association (ACC/AHA), both highlight the 
importance of estimating exercise capacity in assessing perioperative risk (96,97). Both 
guidelines recommend estimating functional capacity in METs, using questions derived 
from the DASI. This questionnaire relies on the patient answering 12 questions from which 
an estimated V o2 at Peak exercise can be obtained (98). However, it is patient reported and 
subjective, which may therefore not always correlate with an individual’s true function. 
Predicting risk as a measure of exercise tolerance can also be done by using various risk 
stratification scores, namely the American Society of Anesthesiologists physical status 
(ASA-PS) score (87), the Charleston Age-Comorbidity Index  and the Physiological and 
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Operative Severity Score for the nUmeration of Mortality and morbidity (POSSUM) 
(88,89,99). A recent systematic review identified all risk stratification tools which have been 
validated in heterogeneous patient cohorts, however this concludes that more research is 
needed in the form of impact studies measuring the effect of using risk stratification on 
clinician behavior, patient outcomes and resource utilization (100).  
 
Serological markers of inflammation, such as the high-sensitivity C-reactive protein 
(hsCRP) and plasma N-terminal Pro-Brain Natriuretic Peptide, have also been shown to 
predict cardiovascular complications in elderly patients undergoing non-cardiac and non-
vascular operations however the evidence is not strong (101).  
 
In clinical practice, V o2 Max and the ratio between V o2 Max and resting V o2, named 
METs, is used as an indirect measure of physical and functional performance. The METs 
reached under maximal effort indicate the number of times a subject can increase their 
resting energy expenditure and are considered as an indicator of health and an independent 
predictor of coronary events and mortality (102,103). Adults usually have METs in the range 
of 10–12, while the few studies investigating MET levels during effort in elderly people 
have shown that this number drops to around 6–8 (104,105). This decline in V o2 Max and 
METs with advancing age is due to loss of skeletal muscle mass (106), deterioration in 
muscle oxidation capacity (107) and a reduced cardiovascular efficiency (108). Reilly et al. 
(95) showed the association between perioperative complications and asking if the patient 
would be able to climb two flights of stairs unaided (equivalent to eight METs). This posed 
uncertainty, as patients have different perceptions of work, number of steps and speed at 
which they climbed them.  
 
Incremental shuttle walk tests also offer a mean of estimating fitness. This test involves 
walking incremental ‘shuttles’ of 10m between auditory markers. As the test progresses, the 
markers get closer to each other; thus the time to walk 10m gets shorter. The test continues 
until the patient cannot complete one shuttle between the given markers. Murray et al. (109) 
showed its usefulness to assess perioperative fitness in surgical patients undergoing upper 
gastrointestinal resection. Together with CPET, the shuttle walk test has also been included 
as part of the preoperative work-up of patients undergoing lung cancer surgery, as part of the 
British Thoracic Society algorithm (110). According to Win et al. (111) a distance of 400 m 
on the shuttle walk test would correlate with a peak oxygen consumption of 15 ml.kg
-1
min
-1
 
on a formal exercise test. However, a recent study by Struthers et al. (90) comparing the 
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shuttle walk test, the DASI Questionnaire and CPET shows that the first two discriminate 
poorly between high-risk and low-risk patients in the surgical population.  
 
The current conviction that investigations, such as exercise ECG, Dipyridamole-thallium 
scintigraphy (DTS), dobutamine stress echocardiography and transthoracic 
echocardiography, have a good predictive power to assess fitness prior to major surgery has 
been questioned by various authors (92–94,112). When considering the latter three tests, 
these investigations were considered to be subjective, operator dependent, and costly, 
requiring radioactive substances, patient fasting and highly specialised exercise transthoracic 
echogenicity, which makes them less suitable for the elderly patient as a risk-stratification 
tool when compared to a cardiopulmonary exercise test. Evaluating physical fitness using 
cardiopulmonary exercise testing (CPET) has been used extensively for risk prediction prior 
to thoracic or abdominal surgery. The use of CPET as a risk predictor and its relationship to 
surgical outcome will be discussed in Section 2.5.2.  
 
 
2.5.2 CARDIOPULMONARY EXERCISE TESTING - THE RELATIONSHIP 
BETWEEN PHYSICAL FITNESS AND SURGICAL OUTCOME  
 
Almost two decades ago, Older and colleagues identified an association between low 
physical fitness as determined by CPET, and poor patient outcome following non-
cardiopulmonary surgery (113). Based on this and subsequent published literature, CPET-
derived variables have been increasingly adopted as the objective measure of fitness prior to 
surgery, particularly within the National Health Service in the UK (114). Information 
derived from CPET is now used to inform operative decisions, choice of peri- and 
intraoperative management, as well as to inform discussions of operative risk with patients. 
This section aims to provide the reader with a review of the current literature pertaining to 
the value of CPET as a perioperative risk assessment tool and the relationship between 
CPET variables and surgical outcome in the management of patients undergoing major 
abdominal surgery.  
 
Cardiopulmonary exercise testing is a well tolerated, non-invasive, cost-effective way of 
performing perioperative risk assessment in patients who are scheduled to undergo high-risk 
procedures. It is also useful for those who are at high risk of postoperative complications due 
to advanced age or poor nutritional status, and for those with a history of cardiopulmonary 
morbidity. It provides a global assessment of the integrated response to increasing aerobic 
work involving the cardiovascular, respiratory, neuropsychological and skeletal muscle 
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systems, all of which are activated during the metabolic stress response to surgery (115). It 
allows evaluation of the integrated oxygen delivery system when the demand for oxygen is 
high and the system is required to function near to its maximum capacity. Despite requiring 
a moderate to high level of exertion, CPET is well tolerated by patients and is safe to 
conduct on most patient cohorts (116). Variables derived from CPET, along with the 
physiological basis of those variables, the derivation of the lactate threshold and also the 
methodology of conducting a CPET will be further described in Section 3.2.  
 
Older et al. (117) showed that cardiovascular mortality was virtually restricted to patients 
with a V o2 at estimated lactate threshold ( ˆ L) of less than 11 ml.kg
-1
min
-1
. Since this 
publication in the early 1990s, a large number of studies have addressed the association 
between CPET-derived variables and perioperative outcome in a variety of clinical contexts. 
Several of these have also evaluated the predictive utility of CPET-derived variables as a 
means of describing perioperative risk in clinical practice. This next section reviews this 
literature to evaluate the utility of CPET as a risk stratification tool prior to major abdominal 
surgery. Section 2.5.2.1 is an updated version of a literature review I have published in 2011 
(LL– acknowledged) (4).  
 
 
2.5.2.1 MAJOR INTRA-ABDOMINAL SURGERY 
 
Older et al. (117) recorded the presurgical V o2 at ˆ L of 187 elderly patients undergoing 
major intra-abdominal surgery. They found that an V o2 at ˆ L <11 ml.kg
-1
min
-1 
was 
associated with increased cardiovascular mortality. In patients with a low V o2 at ˆ L and 
preoperative ischaemia, the mortality rate was 42%, in comparison with 4% in patients not 
meeting these criteria. This established the idea of preoperative risk stratification and 
provision of increased postoperative care for high-risk patients. In a latter study and clinical 
review (113,104) Older investigated the impact of triaging patients on the basis of such data. 
If a patient had an V o2 at ˆ L of less than 11 ml.kg
-1
min
-1
, they were assigned to ICU 
preoperatively. This accounted for 28% of the patients. Of the 9 patients who died 
postoperatively from cardiopulmonary complications, 7 had an ˆ L <11 ml.kg
-1
min
-1
, and the 
other two were in the high dependency unit (HDU) category. No deaths were recorded in the 
patients admitted to the ward. 
 
Assessing 843 patients undergoing major colorectal, radical nephrectomy and cystectomy 
surgery, Wilson et al. (120) concluded that a V o2 at ˆ L of 10.9 ml.kg
-1
min
-1 
or less and a 
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ventilatory equivalent for carbon dioxide ( V E/ V CO2) of 34 or more had a sensitivity of 
88% and a specificity of 47% for hospital mortality. Survival at 90 days was significantly 
greater in patients with an ˆ L of greater than 11 (p=0.034), V E/ V CO2 less than 34 
(p=0.021) and in patients without ischaemic heart disease (p=0.02).  
 
Snowden et al. (121) also evaluated the use of CPET in preoperative risk assessment in a 
surgical population (age mean 70 years). They reported the relationship between CPET 
derived variables and morbidity after major intra-abdominal surgery and showed that an ˆ L 
of 10.1 ml.kg
-1
min
-1 
had a sensitivity (88%) and specificity (79%) for the prediction of 
postoperative complications. In a follow up study Snowden et al. (122) studied the 
relationship between cardiorespiratory fitness and age in the context of postoperative 
mortality and morbidity in older people undergoing hepatobiliary surgery. 389 adults with a 
mean age of 66 years (range 26–86 years) were included. They conclude that the anaerobic 
threshold was the most significant independent predictor for postoperative mortality 
(p=0.003 and odds ratio=0.52) in 18 of 389 (4.6%) patients who died during their in-hospital 
stay, and that age was not a significant predictor. Older people with normal cardiorespiratory 
fitness spent the same number of days in the hospital or critical care unit as younger people 
with similar cardiorespiratory fitness (13 vs. 12; p=0.08 and 1 vs. 1; p=0.103 respectively). 
Patients older than 75 years with low cardiorespiratory fitness spent a median of 11 days 
longer in hospital (23 vs. 12; p<0.0001) and 2 days longer in critical care (2.9 vs. 0.9; 
p<0.0001) when compared with patients with adequate cardiorespiratory fitness.  
 
In a smaller study of 32 patients undergoing major intra-abdominal surgery, Hightower et al. 
(87) reported that an ˆ L less than 75% of the predicted value identified those at increased 
risk of complications [area under curve (AUC) 0.72; sensitivity 88%; specificity 79%; 
p=0.016]. A particular strength of the studies by Snowden and Hightower is that clinicians 
were blinded to the CPET results, ensuring that these did not influence patient care or data 
collection based on the CPET results. This should give a more accurate reflection of the true 
magnitude of association between CPET variables and outcome by removing the effect of 
confounding due to clinicians acting on CPET variables, which could influence outcome 
(e.g. choice of level of postoperative care or type of surgery received by the patient) (123).  
 
Junejo et al. (124) evaluated the use of preoperative CPET in predicting outcome following 
major hepatic resection. Two hundred and four patients were assessed for hepatic resection, 
of whom 108 had preoperative CPET. An ˆ L of 9.9 ml.kg
-1
min
-1 
predicted in-hospital death 
and subsequent survival. Below this value, ˆ L was 100% sensitive and 76% specific for in-
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hospital mortality. Age and V E/ V CO2 at ˆ L (34.6 = 84% specificity and 47% sensitivity) 
were also significantly related to postoperative complications. Long-term survival of those 
with an ˆ L of less than 9·9 ml.kg
-1
min
-1 
was significantly worse (Hazard ratio for mortality 
1.81, 95% confidence interval (CI), 1.04–3·17; p = 0.036).  
 
Otto et al. (125) evaluated patients awaiting abdominal and pelvic surgery. Four hundred and 
fourteen patients were studied. They found that V o2 at ˆ L values in Crohn’s disease were 
lower than colorectal cancer (11.4±3.4 vs. 13.2± 3.5 ml.kg
−1
.min
−1
, p=0.03) and for all other 
colorectal disease groups combined (12.6±3.5 ml.kg
−1
.min
−1
, p=0.03). V o2 at ˆ L of 
Ulcerative colitis and Crohn’s disease patients together were reduced compared to 
population reference values (p<0.05). This cohort of patients may impact CPET variables 
differently than standard benign or malignant preoperative patients. The reason for low V o2 
at ˆ L remains to be defined.  
 
Ausania et al. (126) undertook a prospective review of 124 patients who underwent 
pancreaticoduodenectomy and CPET. They found that a low V o2 at ˆ L was significantly 
associated with pancreatic anastomotic leaks, postoperative complications and prolonged 
hospital stay. On multivariable analysis, an V o2 at ˆ L of 10·1 ml.kg
-1
min
-1
 or less was the 
only independent factor associated with pancreatic anastomotic leaks. Chandrabalan et al. 
(127) undertook a similar retrospective review of a hundred patients who underwent 
pancreaticoduodenectomy or total pancreatecomy for pancreatic head lesions. They found 
that an V o2 at ˆ L of <10 ml.kg
−1
.min
−1 
had a significantly greater incidence of postoperative 
pancreatic fistula and major intra-abdominal abscesses (Clavien-Dindo Grade III-IV 22.4% 
vs. 7.8%). These patients were subsequently less likely to undergo adjuvant therapy. Also a 
low V o2 at ˆ L was associated with a prolonged length of hospital stay. Junejo et al. (128) 
conducted a prospective cohort study of patients undergoing pancreaticoduodenectomy. 
Neither V o2 at ˆ L nor V o2 Max predicted morbidity or mortality; however V E/ V CO2 at 
ˆ L with a threshold of 41 was predictive for postoperative mortality (75% sensitive and 95% 
specific).  
 
Colson et al. (129) undertook a review of 1725 patients referred for CPET that subsequently 
underwent major surgery. Thirty-six percent died within 5 years. Death was associated with 
gender, type of surgery (worst for upper gastrointestinal and best for vascular surgery) and 
forced vital capacity.  
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In summary, the above studies agree that selected CPET variables have a predicative value 
in determining postoperative complications and length of hospital stay across a range of 
intra-abdominal surgical procedures. 
 
 
2.5.2.2 VASCULAR SURGERY 
 
A recently published systematic review by Young et al. (130) was performed to assess the 
role of CPET in the preoperative evaluation of patients with abdominal aortic aneurysms or 
peripheral vascular disease requiring surgery. They concluded that there are major 
limitations including small sample sizes, lack of blinding, and an absence of reporting 
standards. They also say that the paucity of robust data precludes routine adoption of CPET 
in risk stratifying patients undergoing major vascular surgery and that the use of CPET 
should be restricted to clinical trials and experimental registries. However, I believe that the 
evidence to date suggests CPET is of valuable prognostic assessment prior to abdominal 
aortic aneurysm surgery and as such merits consideration as a preoperative investigation. 
Young et al. review six studies (90,131–135), with the largest three all reporting that CPET 
was a useful predictor of outcome in patients undergoing abdominal aortic aneurysm repair. 
One of the included studies, by McEnroe and Wilson (135) was actually a retrospective audit 
of 119 patients, published only in abstract form. The other three peer-reviewed studies 
mentioned in the review were all of 30 or fewer patients and were therefore likely to lack the 
power to detect the influence of CPET results on patient outcome. One of the studies, 
Kothmann et al. (132), did not even report outcome data and was designed as a test of inter-
individual (test–retest) variability; it is difficult to understand why such a study was included 
in a systematic review of this nature. Furthermore, all of the ‘grey literature’ articles listed in 
the article (eight studies) supported the use of CPET in the setting of AAA repair.  
 
Carlisle et al. (133) retrospectively studied the association between four CPET markers ( V
o2 at peak, V o2 at ˆ L, V E/ V CO2 and V E/ V O2), four other risk stratification methods 
(revised cardiac risk index (RCRI), POSSUM, simplified acute physiology score (SAPS) II 
and the acute physiology and chronic health evaluation (APACHE) II) and all-cause 
mortality following abdominal aortic aneurysm (AAA) repair. The study differs from other 
CPET articles in non-cardiopulmonary surgery, in that the mortality was not only measured 
in the initial postoperative period, but also up to a median of 35 months. Of the 130 patients 
studied, a total of 29 (22.3%) died by the time of their last follow-up, 14 (10.8%) doing so in 
hospital within 30 days of surgery. All CPET variables correlated with mid-term survival, as 
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did the other four risk stratification methods, although to a lesser degree. The V E/ V CO2 
had the strongest association with mortality rate at 30 days and at mid-term (hazard ratio for 
mortality was 1.14 (95% CI, 1.08–1.20; p<0.001)).  A V E/ V CO2 value of ≥42 and RCRI 
>1 were found to be the optimal thresholds to distinguish patients at increased risk of death. 
Very recent publications by Hartley (136), Prentis (137) and Thompson (134) et al. agree 
that a low V o2 at ˆ L  is associated with postoperative complications, prolonged length of 
hospital stay, prolonged length of critical care stay, and early death following abdominal 
aortic aneurysm surgery. They conclude that CPET has become increasingly important in 
determining the optimum management for these patients and that clinical management, 
patient decision making and risk stratification can be reliably informed by CPET. 
 
 
2.5.2.3 UPPER GASTOINTESTINAL AND BARIATRIC SURGERY 
 
In 1994, Nagamatsu et al. investigated the association between CPET derived variables and 
outcome following upper gastrointestinal (GI) surgery. They analysed data from 52 patients 
who had a right thoracolaparotomy for thoracic oesophageal cancer, and observed significant 
differences in V o2 Max and V o2 at ˆ L (both normalised to body surface area) between 
patients with and without postoperative cardiopulmonary complications. In a follow-up 
study (138), they retrospectively analysed data from 91 patients (mean age 59 years) who 
had undergone an oesophagectomy with three-field lymphadenectomy for squamous cell 
carcinoma and preoperative CPET. Consistent with their original study, V o2 Max values 
(normalised to body surface area) were significantly lower in the cohort of patients that 
experienced cardiopulmonary complications than in those without complications (p<0.001). 
However, no association was observed between complications and V o2 at ˆ L. In a later 
study, Forshaw (139) investigated the capacity of CPET markers to predict patients at 
increased risk of postoperative complications following oesophagectomy. Consistent with 
previous CPET studies in patients undergoing upper GI surgery, ˆ L did not differ between 
those with and without cardiopulmonary complications.  
 
The association between CPET variables and outcome following bariatric surgery was also 
investigated in 109 obese patients (mean body mass index (BMI) 48.1 kg/m
2
) undergoing 
laparoscopic Roux-en-Y gastric bypass surgery (140). Primary outcome variables assessed 
were death, unstable angina, myocardial infarction, deep vein thrombosis, pulmonary 
embolus, renal failure and stroke; secondary outcomes were hospital length of stay (LOS) 
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and readmission. The population was divided into tertiles according to V o2 at peak values 
achieved during treadmill exercise. The rate of complications and length of hospital stay was 
significantly higher for the first tertile. The V o2 at peak threshold value of 15.8 ml.kg
-1
min
-1
, 
(which was the upper boundary of the lowest tertile), had a sensitivity of 75% and a 
specificity of 73% to predict the occurrence of postoperative complications. These results 
indicate that for a morbidly obese population having bariatric surgery, an V o2 at peak less 
than or equal to 15.8 ml.kg
-1
min
-1
 has a reasonable capacity to predict those at increased risk 
of postoperative complications and longer hospital stay.  
 
In a recent paper published by Hennis et al. (141) V o2 at ˆ L was lower in patients with 
postoperative complications than in those without (9.9 (1.5) vs. 11.1 (1.7) ml.kg
-1
min
-1
, 
p=0.049) and in patients with a LOS >3 days compared with LOS ≤3 days (10.4 (1.4) vs. 
11.3 (1.8) ml.kg
-1
min
-1
, p=0.023). Receiver operator characteristic curve (ROC) analysis 
identified V o2 at ˆ L as a significant predictor of LOS >3 days (AUC 0.640, p=0.030). They 
conclude that V o2 at ˆ L, predicts LOS after gastric bypass surgery. 
 
 
2.5.2.4 TRANSPLANT SURGERY 
 
In a study performed by Epstein et al (142) in 2004, symptom-limited CPET conducted at an 
average of 15 months before surgery, was found to be associated with short-term outcome 
after hepatic transplantation. Specifically, they found that reduced aerobic capacity as 
defined by a reduced peak V o2 (% predicted) and reduced V o2 at ˆ L was associated with 
increased mortality during the first 100 days after hepatic transplantation. Non-survivors 
were more likely to have a peak V o2 of less than 60% predicted (p=0.04) and an V o2 at ˆ L 
of less than 50% predicted (p=0.03).  
 
Very recently, Snowden and colleagues (143) assessed the feasibility of preoperative 
submaximal CPET in determining the cardiopulmonary reserve in patients being assessed 
for liver transplantation and its potential for predicting 90-day post-transplant survival. Sixty 
of the 182 patients (33%) underwent liver transplantation, and the mortality rate was 10% 
(6/60). The mean V o2 at ˆ L value was significantly higher for survivors versus non-
survivors (12.0 ± 2.4 versus 8.4 ± 1.3 ml.kg.
-1
min
-1
, p<0.001). Logistic regression revealed 
that V o2 at ˆ L, donor age, blood transfusions and fresh frozen plasma transfusions were 
significant univariate predictors of outcomes. In a multivariate analysis, only V o2 at ˆ L was 
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retained as a significant predictor of mortality. A ROC curve analysis demonstrated 
sensitivity and specificity of 90.7% and 83.3%, respectively, with good model accuracy (CI 
0.82–0.97, p=0.001). The optimal V o2 at ˆ L level for survival was defined as >9 ml.kg
-
1
min
-1
. 
 
 
2.5.3 THE ASSOCIATION OF PHYSICAL FITNESS AND POSTOPERATIVE 
MORBIDITY AFTER MAJOR RECTAL CANCER SURGERY – THE AINTREE 
EXPERIENCE 
 
Between January 2010 and December 2011, I recruited patients as part of a single-centre, 
prospective, observation cohort study to test the hypothesis that CPET variables are related 
to in-hospital morbidity in patients undergoing major rectal cancer surgery (144). This 
follows on a previous study which I initiated in 2009 studying the same hypothesis in 
patients undergoing colonic surgery (145). All patients underwent a CPET at 2 weeks prior 
to starting NACRT or 2 weeks prior to undergoing major surgery. All patients were followed 
prospectively during their postoperative period. Short-term surgical outcome was assessed  
by medical and nursing staff blind to any CPET data using the 9 domains listed in the Post-
Operative Morbidity Survey (POMS) (146) on day 5, Clavien-Dindo Classification (highest 
grade for the most serious sustained in-hospital complication) and in-hospital mortality. In 
the present study, I chose to use a simple score of postoperative morbidity as a primary 
outcome measure, due to the considerable importance this has to early recovery and length 
of stay. The POMS has previously been used in a clinical setting in both the United 
Kingdom and United States and will also be used as the main morbidity measure in 
subsequent chapters of this thesis (Chapters 4 to 7). Length of hospital stay (days) was 
recorded prospectively, and patients were followed up to 1 year for mortality. The colorectal 
MDT (including anaesthetists) and the medical staff collecting the outcome data were blind 
to all CPET data. In this study our primary variable of interest was V o2 at ˆ L (ml.kg
-1
.min
-
1
). Exploratory variables included V o2 at Peak exercise (ml.kg
-1
.min
-1
). Here the primary 
aim was to establish the relationship between postoperative complications (assessed by 
POMS present or absent on day 5) and V o2 at ˆ L. I also aimed to explore the multivariable 
relationship between CPET variables and postoperative in-hospital complications. 
 
One hundred and five patients were recruited, of whom 10 had no surgery (3 due to patient 
choice, 7 due to irresectable metastasis). All 95 patients (72 male and 23 female) who had 
adequate CPET and underwent major elective surgery had complete outcome data. 68 
36 
 
patients (72%) underwent NACRT. 66 patients (70%) underwent an anterior resection, 22 
(23%) an abdominoperineal resection, 4 (4%) a Hartman’s procedure and 3 (3%) other major 
rectal resections. Patient demographics differed significantly in BMI (p=0.003) and 
preoperative heart failure (p=0.008). There was no difference in cancer therapy, clinical or 
pathological staging between patients with and without postoperative morbidity. Patients 
with a complication had significantly lower V o2 at ˆ L (12.7 vs. 9.4 ml.kg
-1
.min
 1
; 
p<0.0005), V o2 at Peak (21.8 vs. 15.8 ml.kg
-1
.min
 1
; p<0.0005), Workload at ˆ L (65 vs. 
45.5W; p<0.0001) and Oxygen pulse at ˆ L (9.4 vs. 8.0 ml.beat
-1
; p=0.004). 
  
Forty-six patients (48%) sustained an in-hospital complication. No 30-day mortality was 
registered. The median number of complications on day 5 (POMS day 5) was 1 (IQ range, 
0–2). Pulmonary, infective, gastrointestinal, cardiovascular and wound complications 
differed between groups (p=0.001, p<0.0005, p=0.014, p=0.019, p=0.01 respectively).  
 
Independently V o2 at ˆ L and V o2 at Peak were significantly associated with in-hospital 
morbidity (p<0.0001). For V o2 at ˆ L, AUC was 0.87 (CI 0.78-0.95), whilst the optimal cut-
point was 10.6 ml.kg
-1
.min
-1
, giving a sensitivity of 84% and a specificity of 92%. For V o2 
at Peak AUC was 0.85 (CI 0.77-0.93), whilst the optimal cut-point was 18.6 ml.kg
-1
.min
-1
, 
giving a sensitivity of 82% and a specificity of 80%.  
 
For multivariable logistic regression, from the 5 candidate variables, V o2 at ˆ L and V o2 at 
Peak were retained in the final model. However, since neither variable meaningfully 
contributed to the other (they are highly correlated), univariate models were used instead. 
Due to the dichotomisation this resulted in two identical models. As a result, the odds of 
POMS day 5 surgical morbidity were reduced by 93% for patients above the median 
compared with those below the median (OR 0.07, CI 0.03-0.19, p<0.0001). The medians 
were 11.2 ml.kg
-1
.min
-1
 and 18.8 ml.kg
-1
.min
-1
 for V o2 at ˆ L and V o2 at Peak respectively. 
Additionally a sensitivity analysis was conducted whereby the same multivariable selection 
procedure was used with NACRT (yes/no) as an additional covariate. NACRT was not 
retained in the final model which was unsurprising given a univariate logistic regression p-
value of 0.963.  
 
Overall median length of stay was 9 days (IQ range 6–16 days). Patients with no POMS 
defined morbidity on Day 5 had a median length of stay of 7 days (IQ range 6–9) compared 
with 15 days (IQ range 7–24) in patients with POMS-defined morbidity on Day 5 
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(p<0.0001). All patients were followed up to 1 year postoperatively for mortality. 7 patients 
died within 1 year of their operation; all had an V o2 at ˆ L of <10.6 ml.kg
-1
.min
-1 
and 
suffered from postoperative in-hospital morbidity.  
 
This study further supports the literature presented in Section 2.5.2.1. Here, I have shown 
that CPET variables namely V o2 at ˆ L and V o2 at Peak are the best prognostic markers of 
postoperative complications for this cohort, with a high sensitivity and specificity when 
compared to other studies (113,121,124). The identification of V o2 at ˆ L and V o2 at Peak 
as a predictor for short term outcome in rectal cancer surgery is novel. This study inspired 
future work which is presented in Chapter 4 where the effect of NACRT on physical fitness 
and postoperative morbidity will be explored in the same patient cohort. Furthermore, in 
Chapter 5 and 6, I endeavour to study the effects of NACRT and a novel prehabilitation 
exercise programme on objectively measured physical fitness and postoperative outcome in 
locally advanced rectal cancer patients. 
 
 
2.6 IMPROVING PHYSICAL FITNESS WITH PREOPERATIVE EXERCISE IN 
ABDOMINAL CAVITY CANCER PATIENTS 
 
Traditionally, efforts have been made to improve the postoperative recovery process by 
intervening after major surgery. The preoperative period may be a more emotionally salient 
time to intervene with regard to the factors that contribute to recovery as, beyond the 
physical benefits, active engagement of the individual in the preparation process is likely to 
alleviate some of the emotional distress surrounding the anticipation of surgery and the 
recovery process. 
 
We now know that aerobic exercise training is beneficial in improving physical fitness in a 
variety of patient populations (147–150), even over a short time period. Aerobic training 
augments cardiac, respiratory and musculoskeletal functions, therefore implementing a 
preoperative training intervention to improve physical fitness prior to major cancer surgery 
would appear plausible. Preoperative conditioning before a stressful event (i.e. surgical 
trauma) is termed prehabilitation (151). The goal of prehabilitation is to improve 
preoperative physical fitness through an exercise intervention programme in an attempt to 
accelerate postoperative recovery.    
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There is nascent literature in this area suggesting that, notwithstanding the time constraints 
imposed by the surgical timetable, exercise training may provide benefit in this patient 
group. In this systematic review of the literature I concentrated on attempting to answer 
several key questions, namely: Can pre- and postoperative exercise training improve fitness? 
Does any improvement in fitness translate into an improvement in outcome? Do patients 
benefit from this approach? What are the key elements of perioperative training 
interventions – modality, frequency, duration, intensity and pattern?  
 
Whilst I have already discussed the predictive utility of CPET derived variables in Section 
2.5, there is now convincing evidence that physical fitness is associated with outcome 
following major surgery; i.e. less fit patients having a greater risk of complications and death 
postoperatively. This has led to the hypothesis that prehabilitation would improve physical 
fitness and thereby reduce the incidence of adverse surgical outcomes. There is emerging 
evidence that such ‘prehabilitation’ may also improve HRQL and fitness levels, however, 
there have been few adequately powered randomised trials in this field and there is little 
current evidence to support the benefits of prehabilitation in terms of improving surgical 
outcome. On the other hand, rehabilitation following other acute stressors has been 
extensively used and is now common NHS practice e.g. following cardiac events (cardiac 
rehabilitation) (150) and also following chronic obstructive pulmonary disease exacerbations 
(pulmonary rehabilitation) (152).  
 
 
2.6.1 PREOPERATIVE AEROBIC EXERCISE TRAINING IN ELECTIVE 
INTRA-CAVITY SURGERY: A SYSTEMATC REVIEW 
 
I recently published a literature review (153) on perioperative exercise training in elderly 
subjects, this was then followed up by a systematic review of preoperative aerobic exercise 
training in elective intra-cavity surgery (154) which I co-authored. In this section I will 
provide an overview of this systematic review. Appendix 4 provides full details about 
methodology, search strategy, inclusion and exclusion criteria, data extraction and analysis 
details, details regarding the quality assessment tool used, as well as a list of excluded 
studies. Ten studies were included in this review. Table 2.1 includes characteristics of these 
included studies. The search identified studies using preoperative aerobic exercise training 
interventions with reported measures of physical fitness having been performed in patients 
undergoing gastrointestinal (5 studies, 219 patients),(155–159) thoracic (4 studies, 59 
patients),(160–163) and cardiac (1 study, 246 patients) (164) surgery. All studies were 
single-centre and the median number of patients recruited was 20.5; only 2 studies recruited 
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more than 100 patients.  Two studies employed a control group (158,164) and two employed 
a sham intervention (156,157).  Seven of the 10 studies were published within the last 5 
years. Mean patient age ranged from 55-71 years across the studies.  
 
Patient outcome measures following surgery were reported in 7 studies and are presented in 
Table 2.2.  Arthur et al. reported a significantly shorter hospital and intensive care unit 
length of stay in the intervention group (164). Asoh et al. reported that of the 4 patients 
deemed “unfit” at surgery, despite aerobic exercise training, all developed postoperative 
complications and 2 died of heart failure within 30 days of their operation. In the group 
deemed to be “fit”, 12% developed postoperative complications and one died within one 
year of the operation due to inoperable gastric cancer (155). Two studies found no 
differences between the intervention and sham intervention group in postoperative clinical 
outcome measures (156,157).  
 
The measures of physical fitness before and after the exercise intervention are presented in 
Table 2.3. Eight studies reported a significant improvement in at least one measure of 
physical fitness. Four studies showed significant improvement in V o2 at Peak with aerobic 
exercise training. In the next sections I will review the characteristics of the exercise 
interventions adopted in various trials included in this review (Section 2.6.1.1), the 
feasibility and safety of such interventions (Section 2.6.1.2) and I shall also give a brief 
summary of each of the included trials (Section 2.6.1.3).    
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Study Country Journal Study design Number 
of 
Centres 
N Mean 
Age 
(Years) 
Patient 
Surgery Group 
Exercise Intervention 
Arthur et al. 
(164) 
Canada Annals of Internal 
Medicine 
RCT with 
concealed 
randomisation 
Single 246 
(37F) 
I: 62            
C: 64 
Coronary Artery 
Bypass Graft 
Aerobic Interval 
         Asoh et al.  
(155) 
Japan The Japanese 
Journal of Surgery 
Observational Single 29 
(NR) 
68 GI Aerobic Continuous 
         Bobbio et al. 
(161) 
 
Italy European Journal of 
Cardio-Thoracic 
Surgery 
Observational 
pilot 
Single 12 
(2F) 
71 Lung Cancer       
( V o2 at Peak 
<15ml/kg/min) 
Aerobic Continuous, 
Strength, Breathing 
Exercises 
         Carli et al. 
(156) 
Canada British Journal of 
Surgery 
RIT Single 112 
(47F) 
I: 61            
SI: 60 
Colorectal Aerobic Continuous, 
Strength 
         Cesario et al. 
(162) 
Italy Lung Cancer Observational 
pilot 
Single 8 
(NR) 
NR Lung Cancer 
(deemed unfit 
for surgery) 
High Intensity 
Continuous, Breathing & 
Abdominal Exercise 
         Debigaré et 
al. (163) 
Canada Journal of 
Cardiopulmonary 
Rehabilitation 
Observational Single 19 
(7F) 
61 Lung Volume 
Reduction 
(emphysema) 
Aerobic Continuous, 
Strength 
         Dronkers et 
al. (157) 
Holland Clinical 
Rehabilitation 
Single blind RIT Single 42 
(11F) 
I: 71          
SI: 69 
GI Cancer Aerobic Continuous, 
Strength, Breathing 
Exercises 
         Jones et al. 
(160) 
Canada Cancer Observational Single 20 
(14F) 
65 Lung Cancer 
(NSCLC) 
Aerobic Continuous and 
Interval 
         Kim et al. 
(158) 
 
Canada The Tohoku Journal 
of Experimental 
Medicine 
RCT (2:1, I:C) Single 21 
(8F) 
I: 55          
C: 65 
Colorectal Aerobic Continuous 
         Timmerman 
et al. (159) 
Holland Physiotherapy 
Theory and Practice 
Observational Single 15 
(3F) 
59 GI Aerobic Continuous 
                   
Table 2.1 – Preoperative Aerobic Exercise Training Study Characteristics. RCT, randomised controlled trial; RIT, randomised intervention trial comparing intervention with sham 
intervention; F, female; I, intervention; C, control; SI, sham intervention; NR, no record; NSCLC, non-small cell lung cancer; GI, Gastrointestinal.
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Table 2.2 – Preoperative Aerobic Exercise Training Clinical Outcomes. * denotes a statistically significant 
difference (P<0.05); 1 group allocation not reported; NR, No record; Fit, achieved plateau in HR during a 
constant load exercise test; Unfit, did not achieve plateau in HR during a constant load exercise test; I, 
Intervention; C, Control; SI, Sham intervention. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study Postoperative 
complications 
(patients) 
Length of 
hospital stay 
(Days (SD)) 
In-hospital 
mortality 
(patients) 
Long-term mortality (patients) 
     Arthur et al. 
(164) 
NR I: 5 * 
C:6 
NR 1 (within 6 months)
1
 
     Asoh et al. 
(155) 
“Fit”- 3/25, 
“Unfit” - 4/4 
NR 
NR 
"Fit" - 0/25, 
“Unfit” - 2/4 
“Fit”- 1/25 (Within 3 months) 
“Unfit” – 3/4 (within 3 months) 
     Bobbio et al. 
(161) 
8 of 11 17.5 ±14.8 NR 0 (follow up period not stated) 
     Carli et al. 
(156) 
NR I: 11.9 ±34.6 
SI: 6.6 ±3.6 
NR NR 
     Cesario et al. 
(162) 
2/8 NR NR 0 (follow up period not stated) 
     Dronkers et al. 
(157) 
I: 9 
SI:8 
I: 16.2 ±11.5 
SI: 21.6 ±23.7 
NR 
NR 
NR 
NR 
     Jones et al. 
(160) 
7 of 20 NR NR NR 
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Table 2.3 - Changes in objective measures of fitness; I, Intervention; C, Control; SI, Sham Intervention; N, no; Y, 
yes; HR, heart rate; Unfit, unable to achieve a plateau in HR during a constant load exercise test; TTE, time to 
exhaustion during a constant load exercise test; V o2  Submax,  oxygen consumption during a constant load sub 
maximal exercise test 
 
Study N Measure Group Baseline  
(mean ±SD) 
Post 
Intervention 
(mean ±SD) 
Improvement 
       Arthur et al. 
(164) 
246 
(37F) 
V o2 at Peak 
(ml.min
-1
) 
I 
C 
1327.6 ±320 
1201.2 ±288 
NR 
NR 
N 
N 
       Asoh et al. 
(155) 
11  
(NR) 
Achieved steady 
state HR 
I 11 of 29 "unfit" 4 of 29 
"unfit" 
7 of 11 
       Bobbio et 
al. (161) 
 
12  
(2F) 
V o2 at Peak 
(ml.kg.
-1
min
-1
) 
I 13.5 ±1.3 16.3 ±1.9 Y (P<0.001) 
  V o2 at ˆ L 
(ml.kg.
-1
min
-1
) 
I 10.1 ±1.9 13.4 ±3.3 Y (P<0.02) 
  WR peak (W) I 65 ±14 79 ±19 Y (P<0.001) 
       Carli et al. 
(156) 
 
112 
(47F) 
6 MWD (m) 
I 
SI 
474.3 ±15.1 
494.1 ±15.5 
463.6 ±18.5 
502.8 ±15.8 
N 
N 
  
V o2 at Peak 
(ml.min
-1
) 
I 
SI 
1395 ±76 
1400 ±71 
1529 ±88 
1511 ±84 
Y (P=0.003) 
Y (P=0.007) 
       
Cesario et 
al. (162) 
8  
(NR) 
6MWD (m) I 261 ±97 340 ±66 Y (P<0.05) 
       Debigaré et 
al. (163) 
19  
(7F) 
V o2 at Peak 
(ml.min
-1
) 
I 630 ±172 698 ±207 Y (P<0.05) 
  WR peak (W) I 37.6 ±12.1 44.7 ±16.2 Y (P<0.05) 
  6MWD (m) I 354 ±116 425 ±110 Y (P<0.01) 
  TTE (s) I 201 ±162 710 ±668 Y (P<0.01) 
       Dronkers et 
al. (157) 
42  
(11F) 
Predicted V o2 
at Peak (ml.kg.
-
1
min
-1
) 
I 
SI 
29.4 ±9.5 
31.6 ±6.5 
27.6 ±6.5 
32.9 ±6.9 
N 
N 
       Jones et al. 
(160) 
20  
(14F) 
V o2 at Peak 
(ml.kg.
-1
min
-1
) 
I 15.7 ±3.7 18.0 ±3.4 Y (P=0.002) 
  6MWD (m) I 438 ±77 478 ±75 Y (P=0.03) 
  WR peak (W) I 82 ±24 91 ±30 N (P=0.055) 
       Kim et al. 
(158) 
21  
(8F) 
V o2 at Peak 
(ml.kg.
-1
min
-1
) 
I 
C 
21.5 ±10.1 
20.3 ±4.6 
20.9 ±8.7 
19.9 ±5.6 
N 
N 
  WR peak (W) I 
C 
103 ±57 
109 ±39 
117 ±57 
109 ±39 
Y (P<0.05) 
N 
  V o2 Submax 
(ml.kg.
-1
min
-1
) 
I 
C 
18.9 ±8.5 
17.5 ±4.7 
16.9 ±7.4 
17.0 ±4.7 
Y (P<0.05) 
N 
  6MWD (m) I  
C 
436 ±64 
478 ±99 
467 ±80 
504 ±103 
N 
N 
       Timmerman 
et al. (159) 
15  
(3F) 
Predicted  V o2 
at Peak (ml.kg.
-
1
min
-1
) 
I 25 ±0.5 33 ±0.9 Y (P=0.002) 
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2.6.1.1 CHARACTERISTICS OF EXERCISE INTERVENTIONS 
 
Characteristics of the interventions (frequency, intensity and duration) are reported in Table 
2.4. The frequency of the exercise sessions ranged from 2 to 14 sessions per week and lasted 
between 20 and 180 minutes per session.  The duration of the interventions ranged from 1 to 
12 weeks. Nine of the aerobic exercise training studies utilised continuous aerobic exercise 
for part or all of the exercise session, one study used only interval aerobic exercise (164). 
Strength training, involving weight lifting, was incorporated into 4 of the training 
interventions (156,157,161,163). Breathing exercises were incorporated into three of the 
training interventions (157,161,162).  
 
The intensity of the aerobic exercise training component of the interventions varied across 
studies. One study required patients to exercise continuously, keeping heart rate below 
130bpm (155).  Seven studies used intensities based on an initial exercise test (156,160–
164). Intensities between 40% and 85% of maximum heart rate (HRmax), heart rate reserve 
(HRR); HRmax minus resting heart rate, Work load at peak, functional capacity and V o2 at 
Peak were used. Two studies used a combination of the Borg score (between 11-16) and 40-
65% HRR or 55-75% HRmax (157,158). One study included one interval exercise session 
per week in addition to 4 continuous exercise sessions per week. The interval exercise 
session involved exercise at 100% V o2 at Peak for 30 seconds followed by a 60 second rest, 
repeated 10-15 times (160).  
 
The aerobic exercise training sessions were performed in-hospital for six of the studies, at 
home for three of the studies and a combination of hospital and home aerobic exercise 
training for one of the studies.  
 
 
2.6.1.2 FEASIBILITY AND SAFETY OF EXERCISE INTERVENTIONS 
 
The dropout rate for the primary aerobic exercise training intervention, excluding control 
arms, ranged from 0-17%. Reasons for drop out included; fatigue, sickness, no longer having 
surgery, having surgery at another institution, myocardial infarction, undergoing a surgical 
procedure not related to the study, COPD exacerbation, death of spouse, unable to 
participate due to work commitments. Adherence was reported in six of the studies. In five 
of the studies, adherence was reported as a percentage of the total number of exercise 
sessions completed and ranged from 72 to 97%. One study reported a 16% adherence rate, 
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this was calculated by the number of patients that completed the proposed 3.5 hours per 
week of physical activity for every week of their training program.  
 
There were 2 exercise related adverse events (AEs); drop in systolic blood pressure 
>20mmHg. There were 15 AEs reported that occurred outside of aerobic exercise training. 
Twelve were in patients awaiting CABG surgery; eight AEs were in the control group and 4 
AEs were in the intervention group. The AEs were; unstable angina (5 control, 1 
intervention), myocardial infarction (2 control, 1 intervention), undiagnosed worsening 
status (1 control, 2 intervention). Three AEs were in patients awaiting lung volume reduction 
surgery and were due to exacerbation of COPD. 
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Table 2.4 - Frequency, duration, intensity, adverse events and adherence of the exercise intervention 
Study Intervention 
(N) 
Intervention 
Duration 
(weeks) 
Frequency 
(per week) 
Duration 
(min per 
session) 
Hospital / 
Home 
intervention 
Intensity  Exercise 
adverse 
Events 
Non-exercise 
Adverse 
Events 
Adherence Dropout 
           Arthur et al. 
(164) 
 
123  
(16F) 
8 2 90 Hospital 30 mins: 40-70% 
functional capacity 
NR 12  NR 10 
           Asoh et al. 
(155)  
11  
(NR) 
1-3 14 20 Hospital 20 mins: 
HR<130bpm 
0 NR NR 0 
           Bobbio et 
al. (161) 
 
12  
(2F) 
4 5 90 Hospital 30mins:50-80% 
WRpeak 
NR NR NR 0 
           Carli et al. 
(156) 
 
58  
(24F)* 
7.7 ±7.6 7 20-45 Home 20-30mins: >50% 
HRpeak 
NR NR 16% fully 
adhered 
9 
           Cesario et 
al. (162) 
8  
(NR) 
4 5 180 Hospital 80% WRpeak NR NR NR 0 
           Debigaré et 
al. (163) 
19  
(7F) 
10-12 5 36 ±8 Home 15-45 mins:  ≥50% 
V o2 at Peak 
0 3 97% 4 
           Dronkers et 
al. (157) 
22  
(7F) 
2-4 7 60 Hospital  
(2 sessions) 
and Home  
(5 sessions) 
20-30mins: 55-75% 
HRmax / Borg  
11-13 
0 NR In hospital 
was 97% 
3 
           Jones et al. 
(160) 
 
20  
(14F) 
4-6 5 30-40 Hospital Continuous 20-
30mins: 60-65%  
V o2 at Peak; 
Interval 15 x 30:60s 
100% V o2 at Peak  
2 NR 72% 2 
           Kim et al. 
(158) 
14  
(5F) 
3.8 ±1.2 7 20-30 Home 20-30mins: 40-65% 
HRR / Borg 11-16  
0 NR 74% 2 
           Timmerman 
et al. (159) 
15  
(3F) 
5 2 120 Hospital 30-50mins:  
65-85%HRR 
0 NR 84% 0 
      
# 
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2.6.1.3 SUMMARY OF INCLUDED TRIALS 
 
Arthur et al. (164) 
A single centre randomised controlled trial (RCT) (n=246) investigating the effects of an 8 
week individualised preoperative aerobic exercise training intervention compared with usual 
care in patients awaiting coronary artery bypass graft surgery (CABG). The intervention 
involved aerobic interval exercise training on a cycle ergometer, treadmill or cross trainer 
(Table 2.4). Physical fitness ( V o2 at Peak) was not different between groups after 8 weeks 
of training. Functional status, measured by questionnaire, was higher in the intervention 
group at the time of surgery. Hospital length of stay and Intensive Care Unit (ICU) length of 
stay were 1 day fewer in the intervention group.  
 
Asoh and Tsuji (155) 
A single centre observational study (n=29) in patients with cardiovascular disease awaiting 
major intra-abdominal surgery. Fitness levels were identified through a constant load 
treadmill test. Those who reached a plateau in heart rate were considered to have adequate 
fitness (n=18) and those who did not were considered to have inadequate fitness (n=11). The 
inadequate fitness group were exercise trained in-hospital (Table 2.4) and then reassessed for 
fitness. Seven of 11 patients gained adequate fitness following aerobic exercise training. 
There was one death due to unresectable cancer and 3 postoperative complications in the 
adequate fitness group (n=25). All patients with inadequate fitness (n=4) had postoperative 
complications and 3 patients died. Two deaths were within 30 days of surgery due to cardiac 
failure, the third was due to metastatic cancer 3 months following surgery.  
 
Bobbio et al. (161) 
A single centre observational study (n=12) investigating the effects of preoperative 
pulmonary rehabilitation in patients awaiting lung resection surgery for stage 1 or 2 non-
small cell lung cancer with V o2 at Peak <15 ml kg
-1
 min
-1
. The intervention involved five 90 
minute in-hospital sessions of pulmonary rehabilitation per week for 4 weeks and twice-
daily breathing exercises at home. The in-hospital pulmonary rehabilitation involved aerobic 
exercise training (Table 2.4), muscle stretching exercises and free weight exercise training. 
There were improvements in V O2 peak, AT, maximum work rate (WR peak) and oxygen 
pulse (V O2/heart rate). Eight of 11 patients had postoperative pulmonary complications 
following surgery and one patient did not have surgery.  
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Cesario et al. (162) 
A single centre prospective observational study (n=8) investigating the effects of 
preoperative pulmonary rehabilitation in patients with operable lung cancer who were denied 
surgery due to poor pulmonary function. The intervention involved five 3 hour rehabilitation 
sessions per week for 4 weeks. Each session included incremental cycling or treadmill 
exercise at 80% of maximum workload, abdominal muscle activities, breathing exercises, 
and educational sessions. Lung function and 6MWD significantly improved and all patients 
became eligible for surgery following preoperative pulmonary rehabilitation. There were no 
deaths and two patients had complications in the immediate postoperative period.  
 
Carli et al. (156) 
A single centre randomised intervention trial (n=112) investigating the effects of a 
preoperative bike and strengthening exercise intervention (intervention) compared with a 
walking and breathing exercise intervention (sham intervention) in patients awaiting 
colorectal surgery. The intervention involved daily cycling exercise (Table 2.4), and strength 
training 3 times per week with upper and lower body exercises using free weights and own 
body weight exercises. The sham intervention group was encouraged to walk for 30 minutes 
per day, and perform breathing exercises and leg exercises. Adherence to the exercise 
interventions was low, particularly in the bike and strengthening exercise group. 6MWD, the 
primary outcome measure, did not change after exercise training. V o2 at Peak improved 
significantly in both groups. Outcome was measured by assessing 6MWD at approximately 
10 weeks post-surgery. A greater number of patients showed an improvement in 6MWD 
post-surgery in the Control group.   
 
Debigaré et al. (163) 
A single centre observational study (n=23) investigating the effects of a preoperative 
exercise intervention in patients with severe emphysema awaiting lung volume reduction 
surgery. Patients were tested for aerobic exercise capacity, aerobic endurance, 6MWD, 
muscle strength, and quality of life before and after an exercise training intervention. The 
exercise intervention involved 5 sessions per week for 10-12 weeks with a strength and 
aerobic component to every session.  Strength training involved leg, arm and abdominal 
exercises using resistance bands, with between 10 and 30 reps per exercise. Aerobic exercise 
training is described in Table 2.4. V o2 at Peak, WR peak, peak lactate, peak time to 
exhaustion, 6MWD, muscle strength and quality of life were significantly improved 
following preoperative exercise training.  
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Dronkers et al. (157) 
A single centre RIT (n=42) investigating the effects of a preoperative exercise intervention 
in patients aged ≥60 years awaiting elective colon surgery. The intervention involved a 
warm-up, strength exercises, breathing exercises, aerobic exercise (Table 2.4), training in 
functional activities and a cool down. The sham intervention group were encouraged to walk 
or cycle for >30minutes per day and were given a pedometer and weekly feedback on 
number of steps achieved. Inspiratory muscle endurance improved significantly in the 
intervention group. There were no changes in fitness measures between groups and 
postoperative lengths of stay were similar. Number of steps travelled in the preoperative 
period was similar between groups. Patients in either group who travelled fewer steps had an 
increased incidence of postoperative complications following surgery.  
 
Jones et al. (160) 
A single centre observational study (n=20) investigating the effects of preoperative aerobic 
exercise training in patients awaiting lung resection surgery for malignant lung lesions. The 
intervention is described in Table 2.4. There were two adverse events during aerobic 
exercise training. V o2 at Peak and 6MWD increased significantly after aerobic exercise 
training, however pulmonary function did not. Adherence was good, those with >80% 
adherence had significantly greater improvements than those with <80% adherence. Seven 
patients had postoperative complications.  
 
Kim et al.(158) 
A single centre randomized controlled trial (n=21), randomised 2:1 (intervention : control), 
investigating the effects of a preoperative aerobic exercise training intervention in patients 
awaiting colorectal surgery. The intervention is described in Table 2.4. The control group 
were given no formal exercise prescription but were encouraged to perform breathing and 
circulatory exercises. WR peak improved significantly in the intervention group. V o2 at 
Peak did not change in either group. V o2, heart rate and minute ventilation were lower at 
the same submaximal intensity following the aerobic exercise training program in the 
intervention group. There were small improvements for 6MWD in both groups.  
 
Timmerman et al. (159) 
A single centre observational study (n=39) investigating the effects of preoperative exercise 
training in patients with intra-abdominal or thoracic cancer awaiting resection surgery. 
Exercise training involved cycling exercise (Table 2.4), and resistance training of large 
muscle groups with 3 sets of 12-20 repetitions per muscle exercise at 60-80% of their 1 
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repetition maximum. Intensity of the resistance training was increased throughout. Predicted 
V o2 at Peak and muscle strength significantly improved following exercise training.  
 
 
2.6.1.4 DISCUSSION 
 
The principle finding of this review was that preoperative aerobic exercise training was 
associated with reduced postoperative length of stay in one study of patients undergoing 
cardiac surgery. However, it remains uncertain whether this intervention is effective in 
improving postoperative clinical outcome for other intra-thoracic or intra-abdominal 
surgeries. The secondary findings identified that preoperative aerobic exercise training 
improved at least one measure of physical fitness in the majority of studies and improved or 
maintained preoperative HRQL. Moreover, preoperative aerobic exercise training appeared 
to be a feasible and safe intervention.   
 
The largest (n>100) randomized controlled trial included in this review reported clinical 
outcome measures and found a reduced hospital and a reduced intensive care length of stay 
in the intervention group. As such, no conclusions regarding the primary objective of this 
review could be made, other than in cardiac surgery where preoperative aerobic exercise 
training was associated with a reduced length of hospital stay. Moreover, eight of 10 studies 
reported improvement in at least one reported measure of physical fitness following aerobic 
exercise intervention. These data are promising; however, control groups were employed in 
only 2 studies, thus limiting the strength of the findings. Several CPET variables were used 
to quantify improvement in physical fitness. V o2 at Peak and V o2 at ˆ L are probably the 
most widely accepted measures of fitness used for physical fitness assessment and 
preoperative risk assessment. However, only 6 studies reported V o2 at Peak and 4 used V o2 
at Peak for primary assessment of change in physical fitness, no studies reported V o2 at ˆ L.  
 
The frequency, duration and intensity of preoperative aerobic exercise training programs 
varied significantly between studies; however, the majority of studies showed an 
improvement in physical fitness. Furthermore, aerobic exercise training was feasible, well 
tolerated and showed an acceptable adherence with only few dropouts from the intervention 
groups.  In one study, greater adherence was associated with larger improvements in 
physical fitness (160).  
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Carli and Zavorsky (151) first reviewed the concept of prehabilitation for intra-abdominal 
and orthopaedic surgery. Only two preoperative aerobic exercise training studies were 
identified (155,164). The authors acknowledged the limited number of studies and 
concluded that preoperative aerobic exercise training appeared beneficial in patients 
awaiting cardiac and abdominal surgery. More recently, Valkenet et al. and Singh et al. 
(165,166) reviewed the effects of preoperative interventions on surgical outcome. These 
reviews included a broader range of preoperative interventions including aerobic exercise, 
breathing exercise and limb strength training, and also included urological and pelvic floor 
continence surgery. The author’s drew similar conclusion in recommending further research 
into prehabilitation as exercise interventions seemed to improve surgical outcomes. 
Prehabilitation for joint replacement and for urological/pelvic floor continence surgery was 
excluded in my present review because prehabilitation, in this context, is predominantly 
focused on strength, mobility, pelvic floor and biofeedback exercises which is conceptually 
different to that of aerobic exercise training to improve whole-body physical fitness during 
the perioperative period.  
 
This section provides an up-to-date review of the current prehabilitation literature 
incorporating aerobic exercise training in patients awaiting major intra-abdominal and intra-
thoracic surgery. The systematic review I carried out was conducted in a rigorous manner 
using specific search terms to identify relevant articles (seen in Appendix 4). Bias was 
minimized by having two investigators independently screening candidate articles using 
predefined criteria. Prehabilitation is a broad term encompassing various interventions with 
different theoretical underlying mechanisms but have a common goal to improve 
postoperative clinical outcome. Narrowing the focus to a specific area of prehabilitation, 
aerobic exercise training, provided meaningful analysis of the practicalities of the 
intervention and a clearer understanding of its effectiveness.  
 
In conclusion, preoperative aerobic exercise training appears to be beneficial in patients 
awaiting cardiac surgery; however the effect in patients prior to major intra-thoracic and 
intra-abdominal surgeries is uncertain. In general, most studies showed the intervention to be 
effective in improving physical fitness. Preoperative aerobic exercise training was safe, 
feasible and well tolerated. The optimal design of a preoperative exercise training program 
however remains unclear. Future studies should report appropriate measures of clinical 
outcome, physical fitness and cost effectiveness and be adequately powered to determine the 
effects of aerobic exercise training on postoperative clinical outcome. In a very recently 
published paper Li et al. (167) show improved postoperative function capacity after 1-month 
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of trimodal prehabilitation, however this is only pilot data and their randomised controlled 
trial is still ongoing (NCT01356264).  
 
In an attempt to introduce prehabilitation to rectal cancer patients post-NACRT, I will 
endeavour to illustrate the methodology behind my structured, responsive, exercise, training 
programme in Chapter 3 (Section 3.3). In Chapter 5, I will explain the iterative process 
around the SREPT and will also apply it to an unselected cohort of patients as a feasibility 
and tolerability trial, with an adequately powered non-randomised pre-pilot parallel group 
study to follow in Chapter 6.  
 
 
2.7 MECHANISMS OF EXERCISE TOLERANCE OR INTOLERANCE IN 
HEALTH AND DISEASE 
 
This next section provides an overview of the potential mechanisms of exercise tolerance 
and potential limitation in health and cancer states. 
  
The mechanisms of exercise intolerance in individuals who are healthy, ageing, athletic, or 
who have a chronic disease like cancer have been studied (116). A sound scientific 
knowledge of the underlying limitations of exercise tolerance exists. This information 
should be used to guide effective exercise training and rehabilitation programmes to improve 
clinical outcomes. Exercise intolerance has received comparably little attention in 
individuals diagnosed with cancer. The prevailing dogma was that unlike other chronic 
diseases, the pathophysiology of most cancer diagnoses, other than lung cancer, does not 
directly impact on the functional or structural integrity of the systems associated with 
oxygen transport and utilisation. Given the recent increased interest in exercise therapy as a 
component of cancer management, it has become apparent that cancer patients have 
markedly reduced cardiorespiratory fitness (168) which might have implications for acute 
and late-occurring cancer-related toxic effects and for clinical outcome especially in the 
postoperative period.  
 
An individual’s cardiorespiratory fitness is the efficiency with which oxygen is transported 
from the atmosphere into mitochondria in muscle cells. Maximum, or peak, oxygen 
consumption is the gold standard measurement of cardiorespiratory fitness and is strongly 
and inversely related to risk of death (102,169). Cardiorespiratory fitness is determined by 
the transport of oxygen from the environment to the skeletal muscle mitochondria via a 
series of convective and diffusive steps involving a sequential reduction in the partial 
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pressure of oxygen commonly termed the oxygen cascade. This involves several 
components of the pulmonary and cardiovascular systems, including the blood, blood 
vessels, and skeletal muscles all of which might be implicated in the process of exercise 
intolerance. During inspiration, oxygen from the environment, at a partial pressure of about 
160 mm Hg, is delivered to the alveoli where partial pressure of oxygen is around 105 mm 
Hg. Oxygen diffuses across the blood–gas barrier, at an arterial partial pressure of about 100 
mm Hg, into the blood in the pulmonary capillaries and binds to haemoglobin. Through the 
cardiovascular system acting as a pump, oxygen is convectively transported throughout the 
arterial system to the capillaries. In the capillaries, partial pressure of oxygen drops as 
oxygen diffuses out of the capillaries and moves into the intracellular space; this forces 
haemoglobin to off-load oxygen. Diffusion occurs throughout the length of the capillary 
with mean capillary partial pressure of oxygen estimated to be about 40 mm Hg (170). 
Inside the muscle cell, oxygen is transported to the mitochondria via myoglobin but this may 
also occur independent of myoglobin through a mechanism that may be dependent on a 
partial pressure gradient between cytosolic partial pressure of oxygen (estimated at about 3 
mm Hg) and mitochondrial partial pressure of oxygen (commonly assumed to be close to 0 
mm Hg). 
 
During intense exercise, ATP requirements of metabolically active skeletal muscle increase 
substantially from resting values. This increase in ATP requirement is accompanied by 
comparative responses in cardiac output (to increase convective oxygen delivery) and 
pulmonary oxygen diffusion capacity. In humans, aerobic metabolism is the most efficient 
method for ATP resynthesis and oxygen consumption in the muscles is closely matched by 
oxygen supply by the heart, lungs, and vasculature. In healthy individuals (at sea level), the 
ability of the lungs to increase diffusion capacity far exceeds that of the other components of 
the oxygen cascade in all but the fittest individuals. Thus, lung diffusion capacity continually 
increases up to maximal oxygen consumption without reaching an upper limit. Similarly, 
mitochondria appear to maintain a relatively large reserve for increasing oxidative 
phosphorylation, as physiological manipulations that increase convective oxygen delivery or 
intracellular partial pressure of oxygen have been shown to augment mitochondrial maximal 
oxygen consumption. As such, convective oxygen delivery to the muscle capillary and 
diffusive oxygen delivery into the muscle cell have been identified as primary sites of 
limitation to maximal oxygen consumption peak in healthy individuals although all steps 
within the oxygen cascade integratively determine cardiorespiratory fitness. 
 
As seen in Figure 2.5, multiple causes of exercise limitation exist. A summary of these 
causes are detailed hereunder. 
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 Age-related exercise limitation - more than 50% of all cancer diagnoses and 71% of 
cancer deaths are in individuals older than 65 years. 
 Cardio-respiratory fitness is reduced in both women and men by around 10% per 
decade of life (171). This decrease in fitness is caused by unfavourable changes in 
diastolic filling and in ventricular compliance and relaxation, and losses in systolic 
function, lung elastic recoil, mechanical ventilation, vascular conductance, and 
oxidative capacity (Figure 2.5) (172). 
 Co-morbid disease adversely affects the oxygen cascade and contributes to ageing 
effects.  
 Physical inactivity (often neglected as a cause of exercise intolerance). Inactivity as 
a result of pain, weakness, locoregional or systemic therapy might exacerbate the 
loss of cardiorespiratory fitness in patients with cancer (173–175). In the seminal 
Dallas Bed Rest study, 3 weeks of inactivity led to a substantial reduction in cardiac 
output, oxidative capacity, and muscle cross-sectional area. An update of this study 
found that 30 years of ageing led to a reduction in peak oxygen uptake of about 
20%, with physical inactivity thought to account for as much as 40% of the decline. 
In fact, peak oxygen uptake was lower after 30 days of bed rest than after 30 years 
of ageing, showing the devastating effect of inactivity on exercise tolerance (172). 
Dozens of interventional studies have tested the feasibility and potential benefits of 
exercise in cancer survivors. Recent meta-analyses of randomised trials involving 
exercise interventions after cancer, encouragingly demonstrate that the benefits of 
exercise spanned across several common cancer types and following a range of 
treatments including surgery, radiotherapy, chemotherapy, hormones and even the 
newer biological therapies. The most recent meta-analysis of 34 randomised trials 
published in the BMJ in 2012 involving patients exercising after cancer, 
demonstrated a benefit for a number of troublesome symptoms particularly fatigue, 
mood, anxiety and depression; muscle power, hand grip, exercise capacity and 
quality of life (148). The American College of Sports Medicine also published a 
comprehensive review of exercise intervention studies in cancer populations which 
included data from 85 RCT’s of exercise in cancer survivors. Evidence consistently 
demonstrated that exercise could be performed safely in adjuvant and post-treatment 
settings. Exercise led to significant improvements in aerobic fitness; increased 
flexibility and strength; quality of life; anxiety and depression; fatigue, body image, 
size and composition. Interestingly the concept that exercise counteracts fatigue has 
been around for a long while, however the concept of deconditioning after a cancer 
diagnosis or the recognition that cancer patients get deconditioned as a results of 
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their cancer treatment is novel. Deconditioning is frequently seen in ill patients, 
elderly, and the obese. Fatigue has many factors including chemical reactions, such 
as that of tumor necrosis factor, Interleukin-1, -6, and others, as well as cognitive, 
emotional and physiological components. It has been estimated to be present in 40% 
of cancer patients. When a person becomes partially or fully incapacitated with a 
loss of independence it can be looked upon as a rapid aging process, leading to 
frailty, which also goes along with the loss of vital capacity. It becomes harder to 
maintain daily functions, such as ambulation, with an altered oxygen capacity and 
increased lactic acid production affecting muscle strength and function. Normal 
activities of daily living, such as walking, increase the demands of oxygen 
consumption, leading to fatigue through deconditioning. In the specific rectal cancer 
cohort described in this thesis, it is hypothesised that physical inactivity might lead 
to acute deconditioning with neoadjuvant cancer treatment. This might be a 
substantial contributor to a declining physical fitness, however the biological 
mechanisms of increased tumour burden, acute deconditioning and other whole 
body effects i.e. reduction in mitochondrial efficiency etc. resulting in a decline in 
physical fitness need disentangling. 
 The pathophysiology of certain cancers might also directly affect the functional or 
structural integrity of components of the oxygen cascade. Tumours in the lungs, 
from either primary or metastatic lung cancer, are thought to disrupt pulmonary 
mechanics and gas exchange, however most cancers are typically accompanied by 
weight loss, anorexia, anaemia, protein catabolism, and muscle wasting; however in 
the specific rectal cancer cohort described in this thesis these factors were not 
thought to be the main factors for a reduction in physical fitness. 
 Cancer treatments – chemotherapy, radiotherapy or both are considered highly toxic 
and exert massive physiological stresses on cancer patients especially in the 
preoperative setting prior to the further physiological stressor of elective surgical 
trauma. These cancer treatments are discussed in Section 7.6.2, with specific relation 
to their effects on mitochondrial function. 
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Figure 2.5 – Proposed causes of reduced exercise tolerance in patients with cancer that are mediated by adverse changes in the components of the oxygen cascade (176). 
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Within this thesis, different approaches were adopted to probe different parts of the whole 
lungs-heart-muscle system to investigate changes in physical fitness and the causes of 
exercise intolerance. Whole body function/capacity during exercise was tested by using 
cardiopulmonary exercise testing. As reviewed previously (Sections 2.5.1 and 2.5.2 and data 
presented in Chapters 4 to 7) this allows in depth objective testing of the cardiopulmonary 
system at rest and under stress and is now widely used to measure preoperative physical 
fitness. CPET can be usefully combined with 
31
P MRS (177,178) to probe in vivo 
mitochondrial metabolism and skeletal muscle function during rest and exercise in selected 
peripheral muscle groups (Section 2.9). With this two pronged approach most of the 
components of the oxygen cascade illustrated above will be investigated with rigorous and 
robust methodology using validated techniques. 
 
 
2.8 THE ASSESSMENT OF MITOCHONDRIAL FUNCTION  
 
The next section will provide a review of the functional aspects of mitochondria in relation 
to muscle energy production, mitochondrial ATP synthesis and the assessment of 
mitochondrial function as a measure of physical fitness. The principles behind 31-
phosphrous magnetic resonance spectroscopy (
31
P MRS) for studying skeletal muscle 
mitochondrial energetics are also reviewed. 
 
 
2.8.1 ROLE OF MITOCHONDRIA IN SKELETAL MUSCLE ENERGETICS 
 
Mitochondria are cellular organelles which have a primary role of high energy production of 
adenosine triphosphate (ATP) through aerobic metabolism. The efficiency of mitochondria 
is particularly important in skeletal muscle, as muscle is metabolically very active and 
requires high rates of ATP turnover during exercise states. ATP is crucial in the contractile 
process as it is directly involved in ion transportation, action potential propagation and 
myofilament sliding. Reduction in ATP generation may contribute to premature muscle 
fatigue and a reduction in physical fitness.  
 
Energy metabolism by the mitochondria involve several pathways of energy transfer which 
may be summarised as: 1) reactions generating Acetyl-co-enzyme A from oxidation of the 
pyruvate dehydrogenase reaction (glucose substrate) and the β-oxidation system (fatty acid 
substrate); 2) the reactions of the tricarboxylic acid (TCA) or the Krebs cycle; 3) the 
oxidation of electron carriers (NADH and FADH2) generated from the TCA cycles in the 
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electron transport chain, and finally; 4) ATP synthesis from ADP and phosphate (processes 
summarised in figure 2.6) (179). The coupling of electron transport and ATP synthesis is 
called oxidative phosphorylation. This is a critical function of mitochondria and is 
represented by the following equation: 
 
NADH + ½O2 + H
+ + 3ADP + 3Pi → 3ATP + NAD+ + H2O 
 
Hence, ATP production is regulated by any of the 4 aforementioned substrates. These could 
act as a primary regulator for oxidative phosphorylation during muscle rest-to-work 
transitions; however this remains controversial despite extensive research. 
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Figure 2.6 – Summary of energy producing pathways in the 
mitochondrion: The Krebs cycle shows input from fatty acids and 
carbohydrates which ultimately generate NADH and FADH2. These 
donate electrons to iron-containing compounds (Fe-S) within complexes 
I and II. Electrons than pass on to complex III via ubiquinone (UQ) and 
then to cytochrome C (Cyt.c), which finally is transferred to complex IV 
to reduce O2 to H2O. Protons are pumped out of the matrix into the 
intermembrane space at complexes I, II, and IV generating an 
electrochemical gradient used to drive ATP synthesis by complex V. 
(Adapted from (179)). 
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2.8.2 REGULATION AND MODULATION OF MITOCHONDRIAL OXIDATIVE 
PHOSPHORYLATION  
 
Computational models of oxidative phosphorylation in intact skeletal and heart muscle have 
led to the concept of ‘parallel activation’ or ‘step-activation’ mechanisms for tighter control 
of ATP supply and demand (180). This model advances the idea that there is no single 
primary regulator for controlling the rate of ATP synthesis, but instead, all components of 
ATP synthesis reactions are directly activated by some cytosolic factor (still unknown) in 
parallel with the activation of ATP consumption during muscle work. Mitochondrial 
capacity for oxidative ATP synthesis is a function of both the structural and functional 
aspects of the organelle. The structural aspect of mitochondria is determined by the 
mitochondrial content of the cells (i.e. volume and density of mitochondrial proteins and 
enzymes) and their morphological profiles, while mitochondrial functional integrity is 
reflected in the capacity for ATP production per unit of mitochondria (181). The functional 
properties of mitochondria may be affected by various factors including enzyme and 
structural functionality, availability of substrates driving the metabolic reactions (e.g. ADP) 
and other factors, in particular oxygen availability.  
 
Much interest has been raised over the years on the relationship between oxygen availability, 
ATP demand and ATP production in view of the potential role of oxygen as an important 
modulator of muscle metabolism (179–181). Oxygen is an indispensible substrate of 
mitochondrial oxidative ATP synthesis with a primary function as the terminal electron 
acceptor within the electron transport chain (ETC). Therefore, reduced availability of 
oxygen conceptually attenuates maximal rate of oxidative ATP synthesis in mitochondria. 
Mitochondrial oxygenation is determined by the capillary O2 driving pressure (convective 
oxygen transport) and the local diffusion capacity (diffusive oxygen transport), interacting 
with the rate of O2 utilization (182). Both muscle blood flow and O2 dissociation from 
haemoglobin determine convective O2 delivery, and improvement in one or both would, 
therefore, be expected to elevate intracellular PaO2. The change in diffusion capacity for O2 
from the red blood cell into the myocyte is a function of diffusion distances and surface area, 
both of which are dependent on capillary recruitment. The key question is whether oxygen 
has a role in limiting the rate of mitochondrial respiration (i.e. a potential controller of 
mitochondrial ATP synthesis), or, whether it is a substrate which merely modulates rather 
than controls mitochondrial ATP synthesis rate. Historical work done on isolated 
mitochondrial preparation suggested that the maximal rates of mitochondrial respiration 
could be maintained at a very low levels of oxygen, as intracellular oxygenation level must 
be reduced to a very low level compared to the arterial or venous PaO2 to have an effect on 
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mitochondrial respiration (183). The available oxygen in the tissues even in hypoxic 
conditions is thought to still remain in excess of that required to limit mitochondrial 
respiration.  
 
In intact tissues however, there has been a suggestion that the affinity of cytochrome c 
oxidase for oxygen molecules may be much lower compared to in vitro conditions, implying 
that even normoxic oxygen tension could potentially be rate limiting for mitochondrial 
oxidative phosphorylation (184). However, more recent in vivo studies support the concept 
that oxygen is not a direct controller of  oxidative phosphorylation, but rather has an indirect 
regulator of signals such as ADP, Pi, phosphorylation potential (i.e. [ATP]/[ADP][Pi]) and 
PCr (185–187). The in vivo effect of oxygen availability on muscle bioenergetics has been 
studied by several investigators, mainly by 
31
P MRS methods, through observation of the 
changes in the muscle metabolites considered as surrogate markers of mitochondrial 
oxidative capacity in conditions during which manipulations of inspired oxygen levels 
(FiO2) were implemented. For instance, presuming that phosphocreatine (PCr) hydrolysis is 
one of the signals for mitochondrial respiration, as proposed by Haseler and colleagues 
(185), after a random switching of the FiO2 in 3 different conditions (normoxia, hypoxia and 
hyperoxia), the PCr levels were raised or declined in accordance to the increased or 
decreased FiO2, suggesting a role of oxygen is modulating one of the proposed regulators of 
tissue respiration (i.e. PCr) during steady state exercise. This observation has been supported 
by an animal study showing that when oxygen delivery to working muscle was reduced by 
either ischaemia or hypoxaemia, the relationship between the rates of tissue respiration (as 
reflected by measurement of muscle oxygen consumption i.e. V o2) and the measured 
variables believed to regulate respiration (i.e. ADP, Pi and PCr) was altered such that a 
greater regulatory signal was required to drive mitochondrial respiration to elicit a given V
o2 (187). These findings are however, not universal. A recent study combining a novel 
optical spectroscopic method to measure intracellular PaO2 with 
31
P MRS technique yielding 
PCr and pH measurement (used to calculate phosphorylation state i.e. [ATP]/[ADP][Pi]) in 
mouse skeletal muscle seems to indicate a constant phosphorylation state despite the decline 
in intracellular PaO2 to a low level thought to affect the regulation of mitochondrial 
respiration. Based on the dissociation between intracellular PaO2 and the observed level of 
the regulatory signal ([ATP]/[ADP][Pi]), the authors rejected the hypothesis that oxygen has 
a regulatory role in cellular respiration through direct coupling with metabolic signals 
driving mitochondrial respiration (188). Thus, the role of oxygen in modulating 
mitochondrial function remains to be further elucidated. The hypothesis of a potential 
reduction in mitochondrial energetics due to an alteration of intracellular PaO2 or a reduction 
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in mitochondrial function post-NACRT in this rectal cancer patient cohort is an interesting 
one. This however, has never been illustrated in any patient population and might be novel 
findings relating preoperative changes in mitochondrial function to whole body physical 
fitness. This is further discussed in Chapter 7. 
 
 
2.8.3 METHODS OF ASSESSMENT OF MITOCHONDRIAL FUNCTION 
 
The assessment of mitochondrial function can be performed by using a variety of 
techniques, each with its distinct advantages and limitations. Functional characterisation of 
mitochondria using ex vivo approach has the advantage of permitting detailed assessment of 
specific components of the ATP-synthesis pathways in addition to allowing enormous 
complementary data to be obtained from the same sample of biopsied tissue (e.g. 
morphometric and histological analysis, quantification of mitochondrial DNA copy number, 
mRNA and protein expressions and activities of various mitochondrial enzymes). However, 
it has the inherent limitation of being invasive and thus impractical for multiple sampling 
particularly during study protocols such as the study presented in Chapter 7.  In addition, it 
allows a very limited sampling volume which may not be a representative portion of the 
whole muscle considering the heterogeneity of muscle tissue. Lastly, the ex vivo 
experimental conditions may not reflect normal physiological conditions. In contrast, an in 
vivo method such as magnetic resonance spectroscopy (MRS) is able to investigate 
mitochondrial functional properties from a large tissue sample in normal physiological 
conditions (i.e. intact circulatory and regulatory systems), and allows frequent sampling 
intervals due to its completely non invasive nature. These advantages, together with the 
readily available expertise and technology available at the University of Liverpool were the 
reasons why MRS was utilized in this thesis. MRS however also has limitations, these 
include the inability of distinguishing the functional status of specific enzyme complexes, 
thus only reflecting the overall oxidative capacity of the mitochondria or mitochondrial 
energetics. In addition, due to its inherent relatively low sensitivity, this method does not 
provide information at the level of a single fibre, but instead records metabolic changes from 
a mixture of fibres with different metabolic characteristics. The basic principles and 
relevance of tissue biopsy, whole body oxygen consumption and MRS for the assessment of 
skeletal muscle mitochondrial function is further described below. 
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2.8.3.1 EX-VIVO MITOCHONDRIAL ANALYSIS BY TISSUE EXCISION BIOPSY 
 
Analysis of mitochondrial properties ex vivo could be performed either on isolated 
mitochondria or permeabilized fibres preparation from biopsied tissue samples. The general 
approach is to obtain muscle tissue sample via a biopsy technique (e.g. Bergström procedure 
or open biopsy). Following adequate sample preparation, materials are then subjected to 
further analysis for quantitative assessment of mitochondrial oxidative capacity. Various 
approaches have been taken to provide quantitative information of mitochondrial energetic 
function. The conventional ex vivo approach involves measurements of maximal activities of 
key mitochondrial enzymes such as citrate synthase (which is a common enzyme marker of 
mitochondrial matrix) as well as succinate dehydrogenase and/or cytochrome c oxidase 
(both of which are the representative enzymes from inner mitochondrial membrane) via 
spectrophotometric based enzyme activity assays (189).  
 
Two other approaches which have been widely utilised for a more comprehensive ex vivo 
analysis of mitochondrial oxidative capacity include polarographic measurement of 
mitochondrial oxygen consumption (183) and direct measurement of ATP production rates 
using a bioluminescence approach (190). Both quantitative and qualitative aspects of 
mitochondrial respiration could be assessed by this method. 
 
 
2.8.3.2 MITOCHONDRIAL FUNCTION DERIVED FROM OXYGEN 
CONSUMPTION DURING EXERCISE 
 
The oxidative phosphorylation reaction for ATP synthesis is heavily dependent on the 
availability of oxygen to mitochondria as previously discussed in Section 2.8.2. This in turn, 
relies on the efficiency of muscle oxygen consumption. Thus, measurement of muscle 
oxygen consumption ( V o2 muscle) could be used to reflect the extent of mitochondrial oxygen 
utilisation for ATP synthesis i.e. a marker of mitochondrial function. Muscle oxygen 
consumption could either be indirectly ascertained from measurement of pulmonary oxygen 
consumption at maximal or peak exercise (reflecting whole body oxygen consumption) 
measured from expired gas concentration at the mouth using CPET, or, inferred from 
measurement of local oxygen consumption using near infrared spectroscopy (NIRS). A more 
direct measurement of V o2 muscle could be obtained from a relatively invasive procedure 
such as thermodilution method with subsequent arterial-venous blood sampling which 
provides measurement of the difference in oxygen content between the arterial and venous 
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compartment, reflecting the extent of oxygen extraction by the muscle. In this section I shall 
concentrate on the derivation of mitochondrial function from oxygen consumption measured 
by CPET as this technique is utilized extensively in the assessment of physical fitness in this 
thesis (Chapters 4 to 7). This technique and its methodology are discussed in more detail in 
Chapter 3, Section 3.2.  
 
Measurement of maximal oxygen consumption ( V o2 Max or V o2 Peak) during maximal or 
peak exercise is an indicator of an individual’s ability to sustain muscular activities, and 
represents a marker of physical fitness which is closely related to surgical risk stratification 
and surgical outcome as described in Section 2.5. V o2 Max can be defined as the failure of 
the V o2 to increase despite an increase in work rate (191). It is physiologically governed by 
the capacity of the cardiovascular system to provide adequate oxygen supply to the skeletal 
muscle (i.e. cardiac output), as well as the capacity of the muscle to extract and utilize the 
supplied oxygen (represented by arteriovenous difference in O2 content) which is largely 
determined by muscle metabolic factors. V o2 Max is thus universally represented by the 
following Fick equation:  
 
V o2 Max = Cardiac Output x Arteriovenous O2 difference. 
 
Although the absolute value of this measurement is not conventionally used to specifically 
reflect mitochondrial oxidative capacity, it could be used to infer measurement of V o2 in 
the exercising legs, which could in turn be converted into measurement of maximal ATP 
synthesis rate. This is based on the assumption that as work increases, the principal site of 
greater oxygen utilization is presumed to be the working muscle, and therefore, the changes 
in whole body V o2 are expected to be a reflection of the increasing muscle V o2.  
 
Another method of studying mitochondrial function is by magnetic resonance spectroscopy. 
This is a non-invasive technique which allows in vivo detection of various biologically 
relevant metabolites within a tissue of interest. Amongst the various MR visible nuclei, the 
31-phosphorus (
31
P) nucleus is the principle metabolite involved in energy transduction. Its 
detection is therefore very useful for studying skeletal muscle energetics. The two MR-
spectroscopic approaches involving 
31
P nuclei detection which can be used to study muscle 
energy metabolism and mitochondrial function are 
31
P magnetic resonance saturation 
transfer technique, and 
31
P magnetic resonance spectroscopy (
31
P MRS).  The latter has been 
extensively used for non- invasive measurement of mitochondrial energy metabolism. This 
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technique is utilised in this current thesis (Chapter 7) to study mitochondrial function in vivo 
and will therefore be described in a greater detail in the next section (Section 2.9). To permit 
further understanding of this MR approach, a review of the physical basis of the MR method 
is necessary. The next section provides the introductory background to the general principles 
of the MR method, and outlines the basis of the 
31
P MRS technique for studying skeletal 
muscle bioenergetics in vivo.  
 
 
2.9 31-PHOSPHORUS MAGNETIC RESONANCE SPECTROSCOPY (
31
P MRS) 
 
Nuclear magnetic resonance (NMR) is a phenomenon initially described independently by 
Bloch and Purcell (192,193), in which particular atomic nuclei with nuclear spin respond to 
the application of magnetic fields by absorbing energy in the radiofrequency range of the 
electromagnetic spectrum, and re-emit this energy in the form of radio signals when the 
nuclei transfer to their original state.  MRI and MRS are the two major clinical applications 
of NMR techniques. The MRS technique has been adapted for acquiring biochemical 
information in vivo from a defined volume of tissue. It complements MRI as a non-invasive 
means for tissue characterization. The two techniques are fundamentally similar, with the 
exception of the originating atomic nucleus generating the signals and the manner in which 
the data is displayed. MRS obtains resonance signals from specific metabolites (e.g. 
13
C, 
31
P, 
1
H) within tissues, which are subsequently displayed as a function of frequency (a 
spectrum). These signals are normally obtained in the absence of a magnetic field gradient. 
On the other hand, MR imaging obtains resonance signals originating from 
1
H nuclei in the 
intra- and extracellular water and some lipids in the presence of a field gradient, which in 
turn, are presented as anatomical images. MRS techniques have evolved from a simple 
application for studying the chemical properties of solids and solutions, to the studies of 
biochemical and metabolism properties of isolated tissue in vivo.  
 
31
P MRS has been extensively used for evaluating muscle bioenergetics in healthy and 
pathological conditions  (194–198). This method allows for detection of changes in 31P 
nuclei within various energy-related compounds such as PCr, ATP and Pi during exercise 
and recovery. 
31
P MRS measurements can be made to yield quantitative estimates of ATP 
turnover, mitochondrial oxidative capacity, and proton handling in skeletal muscle 
(199,200). 
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2.9.1 GENERAL PRINCIPLES OF MAGNETIC RESONANCE  
 
The phenomenon of nuclear magnetic resonance can be induced in atomic nuclei that 
contain either an odd number of protons or neutrons. The odd particle imparts a net angular 
momentum or ‘spin’ to the nucleus, creating a magnetic moment for that nucleus. Such 
nuclei may therefore be considered as small magnets spinning on their axes (Figure 2.7 i). 
When placed in a homogenous magnetic field of high intensity, these nuclei precess (circle 
in an orbit) about the field and tend to align in specific ways depending on their spin states 
(Figure 2.7 ii).  Nuclei lining up against the external magnetic field (anti-parallel) are 
considered to have relatively higher energy state compared to those in parallel alignment 
with the external magnetic field lines (Figure 2.7 iii). In a typical NMR experiment, 
resonance (i.e. transitions between the nuclear orientations, thus energy states), can be 
induced repeatedly in a controlled manner by irradiation with radiofrequency (rf) energy, 
which is typically applied as a short pulse at a specific resonance frequency. At a given 
magnetic field, each of these various magnetically active nuclei (e.g. 
1
H, 
31
P,
13
C) will absorb 
the radiation and precess at very different frequencies (Larmor frequency), the relationship 
of which being expressed by the following equation:  
 
v = γ B0/2π 
 
where v , the absorbed frequency (hertz), depends on the strength of the external magnetic 
field, B0 (Tesla unit) and γ (the gyromagnetic ratio) which is a constant of proportionality 
reflecting the characteristic property of the specific nucleus. This relationship allows a 
spectrometer and coil probe to be tuned onto the frequency of a selected nucleus (e.g. 63.5 
MHz for hydrogen at 1.5 Tesla, and 25.8 for phosphorus at 1.5 Tesla). Although the nuclei 
can assume only two orientations with respect to the static/external magnetic field, B0 (i.e. 
along Z-axis), they are free to rotate around B0, and thus, their projections may occupy any 
position in a circle on the X-Y plane (Figure 2.7 iv). Therefore, in the presence of B0, the 
typical slight excess of nuclei in the lower energy level (but random in X-Y plane) results in 
a net magnetization vector, M, parallel to B0 (Figure 2.7 iii).  
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Figure 2.7 – Diagram of a magnetic resonance imaging scanner showing the NMR phenomenon (i): random 
alignment of the nuclei spin in the absence of external magnetic field, (ii): In the presence of external magnetic 
field (B0), nuclei spin precess and tend to align themselves either parallel or anti-parallel to B0 (Note that nuclei 
in anti-parallel position have relatively higher energy state). (iii): The relative balance between ‘spin-up’ and 
‘spin-down’ nuclei reflects the magnetization in longitudinal plane (iv): The nuclei are also free to rotate around 
B0 occupying any position in the X-Y plane. The combination of (iii) and (iv) will result in the net magnetization 
vector of the nuclei, M. 
 
Application of a short, broad bandwidth pulse of radiofrequency energy tuned to the nucleus 
precession frequency causes the specific nucleus to absorb this energy (i.e. more nuclei will 
be in the anti-parallel/ high energy state), and change its angle of precession (i.e. rotation of 
M away from the Z axis). The angle to which M moves out of alignment is referred to as the 
flip angle (Figure 2.8 v). The largest signals are obtained after a 900 pulse, because in that 
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phase, Mxy is at its maximum. In addition to movement of the nuclei’s net magnetization in 
the transverse plane, excitation of nuclei induced by the RF pulse also results in individual 
nuclear magnetic moment to move in phase with each other (coherent) i.e. nuclei are in the 
same place on the precession path around B0 at any given time (Figure 2.8 vi). 
 
 
 
Figure 2.8 - Application of radiofrequency (rf) energy in the presence of external magnetic field leads to 2 main 
effects: (v) – rotation of M away from Z-axis towards the XY plane (caused by more nuclei being transferred into 
a higher energy state position following absorption of energy induced by the rf pulse); and (vi) – nuclei move 
around B0 in a coherent pattern / in phase with each other (i.e. nuclei are in the same place on the precession path 
at any given time). 
 
 
During the interval between the excitation waves, the nucleus reverts back into its original 
alignment and emits energy, which is detected by a receiver coil (Figure 2.9 vii). The return 
of M to its original state with concurrent release of energy is called relaxation. The 
resonance signal generated by transverse relaxation of nuclei following RF pulse is captured 
by the receiver coil in the form of sinusoidal wave, termed free-induction decay (FID) 
(Figure 2.9 viii). This represents an exponential decrease of resonance signal from the 
nucleus over time. The initial intensity of the signal is proportional to the number of the 
nuclei it originates from (Figure 2.9 ix). 
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Figure 2.9: When the RF pulse is turned off, the nuclei spin give up the absorbed energy into their surrounding 
and M reverts back to its original position (vii). The rate at which M recovers to its original position represents T1 relaxation. At the same time, the nuclei also experience loss of coherent 
transverse magnetization (de-phasing) resulting from the loss of energy into the neighbouring nuclei (viii). MR raw signal (in the form of free induction decay/ FID) is produced when coherent 
magnetization cuts across the coil producing magnetic field fluctuations inside the coil which induce an electrical voltage in the coil (ix); The FID signal could then be mathematically 
transformed to produce either an MR image or MR spectra. 
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In MR imaging, the free-induction delay (FID) signal is mathematically transformed into a 
two- or three-dimensional image (Figure 2.9ix MR imaging/spectroscopy). The relaxation 
properties of hydrogen atom in different tissues determine the image contrast in MR 
Imaging. In MR spectroscopy, the recording of FID from various nuclei/compounds can be 
translated into a display of peak intensities versus frequencies (spectra) by using the Fourier 
transformation. Since MRS is a relatively insensitive technique, many radiofrequency 
impulses have to be applied and the resulting FID have to be signal-averaged in order to 
obtain MR spectra with sufficient “signal-to-noise-ratio’. In a MR spectrum, the relative 
frequency position of the metabolite signal, known as the ‘chemical shift’, is influenced by 
the local magnetic environment of the nucleus, which in turn, is dependent on the chemical 
properties of the nucleus. Therefore, different nuclei have different signature peaks at a 
specific chemical shift, which is useful for their identification. Signals from different 
chemicals containing the same nuclei are also separated by the nuclei chemical shift. The 
chemical shift is measured using the dimensionless units, parts per million (ppm), i.e. ppm = 
(observed frequency – reference frequency)/Larmor frequency x 106. The positions of 
resonance peaks are measured relative to a standard/reference material, i.e., in vivo reference 
(internal standard) includes water at 4.7 ppm for 
1
H spectroscopy or creatine phosphate at 0 
ppm for 
31
P spectroscopy. 
 
 
2.9.2 
31
P MRS – IN-VIVO BIOENERGETICS AND ASSESSMENT OF 
MITOCHONDRIAL FUNCTION IN HUMAN SKELETAL MUSCLE 
 
31
P MRS is an increasingly recognized non-invasive technique mainly used for evaluating 
skeletal muscle metabolism in vivo (196,201). Unlike direct biochemical and histochemical 
analyses which are generally designed to show the activity of a single enzyme or complex 
under conditions of maximal activity, 
31
P MRS provides information about the entire 
enzymatic pathway such as glycolysis in the cytoplasm and/or oxidative metabolism within 
the skeletal muscle mitochondria. This method offers the opportunity of continuously 
measuring the phosphorylated compounds involved in muscle bioenergetics in real time and 
in a totally non-invasive manner. However, only metabolites in human muscle which are 
unbound and present at concentration of at least 1 mM result in the 
31
P MRS spectral peaks 
that are sufficiently narrow and have adequate signal-to-noise ratio to be ‘visible’. It is a 
fortunate property of 
31
P MRS that this includes some metabolites of key bioenergetic 
significance.
 31
P MRS probes in vivo mitochondrial metabolism during rest and exercise in 
selected muscle groups. These findings in skeletal muscle can be usefully combined with 
CPET (177,178) corroborating whole body measurements. Furthermore, good correlations 
70 
 
have been shown to exist between in vivo and in vitro measurement of mitochondrial 
function in health and chronic conditions (e.g. type-2 diabetes). This makes the estimation of 
mitochondrial function by 
31
P MRS an attractive and reliable modality when repeated 
measurements need to be undertaken (178,202,203), which is why this modality has been 
chosen to assess mitochondrial function in this cohort of patients (Chapter 7).   
 
 
2.9.3 
31
P MRS SPECTRUM 
 
An example of a 
31
P MRS spectrum can be seen in Figure 2.10. This spectrum obtained from 
muscle is characterized by peaks due to PCr, the three (α, β and γ) phosphate moieties of 
ATP, unbound inorganic phosphate, and mono- and di-phosphoesters (PME, PDE). With the 
exception of ADP, which is present in too low a concentration to be observed in resting 
muscle, the principal metabolites involved in energy transduction can be observed, which 
makes in vivo 
31
P MRS particularly useful for studying muscle energetics. Phosphodiesters 
such as glycerophosphocholine and glycerophosphoethanolamine, which is also detected as 
a small peak in normal muscle spectra, are indicative of membrane breakdown and has been 
shown be elevated in disorders of muscle necrosis and atrophy such as muscle dystrophy, 
but it also increases as a result of normal aging (197). 
 
 
Relative resonance frequency/ chemical shift (ppm) 
 
Figure 2.10- An example of a 31P magnetic resonance spectrum of human calf muscle in vivo. Resonances are 
visible for adenosine triphosphate (ATP), phosphocreatine (PCr), phosphodiesters (PDE), and inorganic 
phosphate (Pi). Adapted from Befroy et al. (197) 
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In addition, three more pieces of information that are of functional relevance can be 
retrieved from the 
31
P spectra, albeit indirectly, i.e. the intracellular pH, the free 
concentration of ADP and Magnesium (Mg
2+
) ions. Tissue pH can be deduced from the 
chemical shift of Pi. The 
31
P MRS pH measurement makes use of the fact that the basic and 
acidic species of Pi that coexist at physiological pH have different chemical shifts and are in 
rapid chemical exchange (204). The relative proportion of the two species and the actual 
resonance position is determined by pH. Following proper calibration, the measured Pi 
resonance frequency can thus be used to estimate the intracellular pH. Secondly, the CK 
equilibrium can be used to calculate the free levels of ADP in the cell. The concentration of 
ADP in resting and moderately active muscle is typically in the tens of micromoles range, 
which is too low to allow direct detection by 
31
P MRS. Knowledge of ADP levels is highly 
relevant, since ADP is an important regulator of the mitochondrial ATP synthesis. This use 
of the CK reaction is based on the fact that total CK activity exceeds the ATP utilizing and 
delivering fluxes several fold, implying that dynamic changes in PCr levels can be used 
indirectly to quantify changes in the ADP (and ATP) levels (205). Therefore, quantitative 
analysis of the changes in the concentration of phosphorylated compound and intracellular 
pH derived from the 
31
P MR spectra obtained during transition from rest-exercise-recovery 
period have been applied to characterise skeletal muscle energy metabolism and 
mitochondrial function in vivo (206). 
 
 
2.9.4 
31
P MRS METABOLIC CHANGES DURING EXERCISE AND RECOVERY 
 
31
P MRS has opened a window on bioenergetics during skeletal muscle exercise and 
recovery in a non-invasive manner and with a time resolution typically of the order of 
seconds. This has made a major contribution to the understanding of mammalian cell energy 
metabolism, its control and the way in which it can be affected in disease. This is of 
particular interest as this approach will be implemented in this thesis. I will attempt to show 
changes in mitochondrial function in vivo at three different time points in rectal cancer 
patients: at diagnosis, after standardised NACRT treatment and also after a period of 
structured exercise or control (no intervention) (Chapter 7). This is novel as an 
interventional 
31
P MRS randomized controlled study in a cancer patient cohort has never 
been attempted.  
 
Figure 2.11 shows a typical dynamic time series of 
31
P MR spectra of human muscle 
acquired serially at rest, during exercise and subsequent recovery. At rest the intramuscular 
concentration of ATP is relatively low (averaging 6-8 mmol.kg
-1
 wet weight) compared to its 
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turnover rate during exercise. In a recent 
31
P MRS investigation on human medial 
gastrocnemius, the maximal total ATP flux was found to be approximately 217 mmol.ATP
-
1
.min
-1
 during high intensity exercise (207). Despite large increase in ATP demand during 
muscular activity, it has been widely demonstrated that ATP concentration remains constant 
throughout the transition from rest to exercise (208). The continuous re-synthesizing of ATP 
to closely match its utilization rate during exercise is being provided by activation of three 
major metabolic pathways in the skeletal muscle: 1) the net hydrolysis of muscle’s PCr 
stores through the creatine kinase reaction; 2) breakdown of glycogen to lactate in anaerobic 
glycolysis; and 3) oxidative metabolism of carbohydrates and lipids in mitochondria. 
 
At the start of the energy challenge, hydrolysed ATP is resynthesized from PCr breakdown 
and depending on conditions, from anaerobic glycogenolysis. Thus, PCr levels decrease and 
Pi levels increase, while ATP levels remain constant. PCr hydrolysis consumes protons and 
generally results in a small rise in cellular pH (alkalinization) at the start of exercise. During 
aerobic exercise, most of the energy is subsequently provided by oxidative metabolism. 
Anaerobic glycogenolysis produces protons via lactate production and typically results in 
cellular acidification. After the energy challenge, the PCr buffer is restored and Pi levels 
normalize. The ATP used for resynthesis of PCr is mostly derived from oxidative 
phosphorylation. The relative contribution of these ATP-producing pathways is dependent 
on the intensity of the exercise, such that oxidative ATP synthesis dominates during low- 
and moderate-intensity exercise. During exercise, the 
31
P MRS spectrum shows declining 
levels of PCr with stoichiometric increase in Pi level, while ATP level remains unchanged 
(Figure 2.11). The total PCr change over the entire duration of exercise (i.e. -Δ[PCr]/Δt) is a 
measure of average failure of oxidative ATP synthesis to meet the ATP demand in purely 
aerobic exercise. An increase in this parameter (either due to increased PCr depletion, 
reduced exercise duration, or both) may reflect either increased ATP demand or impaired 
oxidative ATP supply (209). The initial rate of PCr depletion at the onset of exercise (-Δ 
[PCr]/ Δ t) is a measure of the ATP turnover rate (i.e. rate of ATP hydrolysis), reflecting the 
ATP demand during exercise. This measurement divided by force output per unit cross-
sectional area reflects the contractile efficiency, which measures how well ATP is used to 
generate force (209).  
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Figure 2.11 – Dynamic 31P MRS time series of human quadriceps muscle at rest, during knee flexion exercise 
and subsequent recovery. The subject performed 2.5 min of single-legged knee flexion exercise at 70% maximal 
voluntary contraction. Note that PCr levels decline during exercise with a corresponding increase in Pi. PCr then 
returns to baseline during recovery. ATP remains constant throughout the workload transition.   
 
With the cessation of exercise, the anaerobic metabolic pathways are immediately 
deactivated, but mitochondrial oxidative phosphorylation continues at an accelerated rate to 
replenish high-energy phosphate stores utilized during exercise. PCr re-synthesis is carried 
out by the reversed creatine kinase reaction, which transfers a high energy phosphate group 
from ATP (produced entirely from oxidative phosphorylation in mitochondria) to creatine. 
In a concurrent event, the ADP levels that had increased during exercise (via ATP 
hydrolysis) recovers to their low resting level, as oxidative phosphorylation converts ADP to 
ATP. Since oxidative phosphorylation reaction occurs exclusively in the mitochondria, the 
post-exercise PCr and ADP recovery rates are valuable indices of mitochondrial function. 
Therefore, aspects of mitochondrial function obtained from 
31
P MRS can be expressed in 
various ways:  
 
PCr recovery kinetics: i) the half-time of PCr recovery (PCr t½), denoting the time it takes 
for the depleted amount of PCr to recover to half of its pre-exercise level, or, ii) PCr 
recovery rate constant (kPCr), i.e. 0.693/t½ PCr assuming monoexponential kinetics (as in the 
present experiments – Chapter 7).  
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ADP recovery kinetics: i) the half-time of ADP recovery (ADP t½), denoting the time for 
half of ADP concentration to be depleted, being utilized in mitochondrial oxidative 
phosphorylation reaction to re-synthesize ATP), or ii) rate constant of ADP recovery 
(kADP), i.e. 0.693/t½ADP. These variables are not going to be utilized in this thesis.  
 
The initial rate of PCr re-synthesis, V (i.e. d[PCr]/dt) calculated from [PCr] at the end of 
exercise and the initial data point in recovery. This represents a direct estimate of the end 
exercise rate of ATP synthesis that is purely oxidative. This variable is not going to be 
utilized in this thesis.  
 
The simplest analysis is by using pure aerobic exercise (that is exercise below the V o2 at ˆ
L, where glycolytic ATP synthesis can be neglected) and recovery. During this type of 
exercise PCr kinetics are monoexponential, and at least in the early stages, so are pulmonary 
V o2 kinetics (210). Since PCr recovery has been shown to follow a monoexponential time 
course, the parameters related to the recovery kinetics of PCr are derived from a typical least 
square regression fit, based on the following equation:  
 
[PCr]t = [PCr]0 + (Δ[PCr] (1 – e(-t/τ)) 
 
where [PCr]t is the PCr concentration at a given time point during recovery, [PCr]0 is the 
PCr level at the onset of recovery, Δ[PCr] is the change in PCr concentration from rest to the 
onset of recovery, t = time, and τ is a time constant. So the monoexponential PCr kinetics 
imply a linear steady-state relationship of oxidative ATP synthesis to the fall in PCr, and 
vice versa (211). A similar relationship is seen between oxidative ATP synthesis rates and 
ATP hydrolysis rate. This predicts that post-exercise PCr resynthesis will be exponential, 
and that the absolute PCr resynthesis rate measures suprabasal oxidative ATP synthesis rate. 
Therefore kPCr is taken to be a surrogate marker of in vivo mitochondrial function (212).   
 
Figure 2.12 shows an example of oxidative exercise described above. Mitochondrial 
function can thus be derived using PCr recovery kinetics. Figure 2.13 plots PCr synthesis 
against the relative fall in [PCr] (Δ[PCr]). The slope from the origin to the end-exercise point 
is an apparent rate constant; if PCr kinetics are monoexponential the data will lie on a 
straight line whose slope is the exponential rate constant kPCr.   
 
All of the 
31
P MRS- derived parameters above provide essentially the same information and 
are rooted from the concept that PCr is recovered solely through mitochondrial oxidative 
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phosphorylation, therefore kPCr or τ PCr can be used as a relative for mitochondrial function.  
Good correlations between the above mentioned MRS measurements and biochemical 
markers of mitochondrial function (citrate synthase activity) have been previously 
demonstrated, validating the use of this method for non-invasive assessment of 
mitochondrial function in vivo (178,202).  
 
 
 
Figure 2.12 – PCr (a) and ADP (b) recovery curves for an individual subject deduced from dynamic 31P MRS. 
 
 
 
 
Figure 2.13 – Derivation of the monoexponential rate constant kPCr by linear fit.
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CHAPTER 3 – General Methods and Experimental Setup 
 
 
3.1 INTRODUCTION  
 
The studies described in this thesis demonstrate a combination of non-invasive methods 
utilised to study whole body physical fitness and mitochondrial function. These methods 
were used to assess changes in fitness and mitochondrial function in locally advanced rectal 
cancer patients who were recruited from within NHS cancer care pathways. In Chapter 1 the 
reader was acquainted with both the previous (Figure 1.2) and current colorectal cancer 
pathways (Figure 1.3) used at Aintree University Teaching Hospitals NHS Foundation Trust. 
In Figures 3.1 and 3.2, I attempt to illustrate the integration of the research 
investigations/interventions (presented in Chapters 4 to 7) into the aforementioned NHS 
rectal cancer pathways (Figure 1.2 and 1.3).  
 
As one can observe in Figures 3.1 and 3.2 the integration of research investigations and 
interventions presented in Chapters 4-7 does not alter the standard NHS cancer pathways. 
All research investigations and interventions were specifically designed to fit around the 
standard cancer pathway used at AUH, utilizing the waiting times between standard care 
investigations and the hiatus between the end of NACRT and surgery. Ethical approval for 
this project was granted by the Northwest Regional Ethics Committee on the 18
th
 March 
2011 (REC Reference Number 11/H1002/12), and further favourable ethical approval was 
given for two amendments on the 20
th
 June 2011 and 30
th
 January 2012 (REC Reference 
Number 11/H1002/12a and 11/H1002/12b). All studies presented in this thesis were 
registered with the clinicaltrials.gov website (Chapter 4 – NCT 01334593, Chapter 6 – 
NCT01325909 and Chapter 7 – NCT01859442).  
 
Methodological approaches described in this chapter include the cardiopulmonary exercise 
testing protocol, the structured responsive exercise training programme protocol and the 31-
Phosphorus Magnetic Resonance Spectroscopy (
31
P MRS) methodology. This chapter 
describes the general experimental protocols and set up for the methods detailed above, all 
of which have been implemented in Chapters 4 to7. 
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Figure 3.1 – Previous standard rectal cancer pathway at AUH (until October 2011), with the addition 
of research investigations (highlighted in orange) as described in Chapter 4. 
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Figure 3.2 – Current standard rectal cancer pathway at AUH (from October 2011 to date), with the 
addition of research investigations/interventions (highlighted in blue) as described in Chapters 5 to 7. 
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3.2 CARDIOPULMONARY EXERCISE TESTING 
 
As described in Section 2.5.1, the advantage of CPET over other methods of preoperative 
assessment is that it provides an integrated assessment of oxygen utilisation under conditions 
of dynamic exercise stress. CPET has already been validated for the assessment of advanced 
cancer patients (168,173). CPET is an objective, repeatable, non-invasive, quick, specific 
and sensitive means of assessing physical fitness in the preoperative setting. The relationship 
between fitness variables derived from CPET and surgical outcome is described in Section 
2.5.2. The equipment and test setup (Section 3.2.1), exercise protocol (Section 3.2.2), 
derived variables, their physiological basis and definitions (Section 3.2.3) and the 
determination of the estimated lactate threshold by the V-slope method (Section 3.2.3.4) are 
all discussed hereunder in more detail. 
 
 
3.2.1 EQUIPMENT AND SETUP 
 
CPET followed the American Thoracic Society/ American College of Chest Physicians 
recommendations (116) and the CPET in clinical oncology practice recommendations by 
Jones and colleagues (168) . All patients were assessed for CPET contraindications (Table 
3.1) by accessing their electronic health care records at AUH (116). 
 
Absolute Contraindications Relative Contraindications 
Acute myocardial infarction Left main coronary stenosis 
Unstable angina Moderate stenotic valvular heart disease 
Uncontrolled arrhythmias causing 
symptoms or haemodynamic compromise 
Severe untreated arterial hypertension at rest 
(systolic > 200mmHg, 120mm Hg diastolic) 
Syncope Tachyarrhythmia or bradyarrhythmia 
Active endocarditis Hypertrophic cardiomyopathy 
Acute myocarditis or pericarditis Significant pulmonary hypertension 
Uncontrolled heart failure Advanced or complicated pregnancy 
Thrombosis of lower extremity Electrolyte abnormalities 
Suspected dissecting aneurysm  
Uncontrolled asthma  
Pulmonary oedema  
Room air desaturation at rest <85% if no 
known lung pathologies 
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Respiratory failure  
Acute non-cardiopulmonary disorder that 
may affect exercise performance  
 
Mental impairment leading to inability to 
co-operate 
 
 
Table 3.1 – Absolute and relative contraindications to CPET 
 
CPET was conducted on an electromagnetically braked cycle ergometer (Ergoline 2000) 
with the patient breathing through a facemask. Attached to the facemask is a flow sensor 
(Geratherm Respiratory GmbH), which is a device that measures differences in flow stream 
pressures across a variable orifice membrane. The flow sensor is connected to a gas analyzer 
via a 2 meter gas-sampling tube. The gas analyzer measures concentrations of O2 and CO2 
separately. Gas transport delay (time required for gas to traverse the distance from the 
sampling site to the analyser) and analyzer response (the kinetics of response to a change in 
gas composition introduced into the analyzer) generally of the order of 0.2 to 0.4 seconds 
was compensated for by the computer software used (Blue Cherry version 1.1.4.0 – 
Geratherm Respiratory GmbH). Part of the gas-sampling tube is made of a Nafion polymer 
which reduces the water vapour content in the analysed gas, in order to reduce the partial 
pressure of water vapour in the sampled gas which may introduce substantial errors in the 
metabolic rate calculations if left uncorrected (213). Ambient temperature, pressure and 
humidity were recorded in real time (Ambi Stick - Geratherm Respiratory GmbH). The flow 
sensor was calibrated for flow (L/s) prior to each test with a standard 3L syringe. A range of 
flow rates were performed to simulate the wide range of flow rates that occur in going from 
rest to heavy exercise. Agreement in calculated volumes to within ±3% signified adequate 
calibration. Gas calibrations for O2 and CO2, together with their respective delays was also 
performed prior to each test. Gas calibrations were performed (two point calibration) with 
ambient O2 and CO2 with standard, gravimetrically weighed, bottled calibration gas of know 
concentrations (BOC gases, accurate to ±1%). A typical CPET setup is shown in Figure 3.3. 
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Figure 3.3 – CPET set-up showing a metabolic cart with two video monitors showing real time respiratory 
variables and full 12-lead ECG, a study patient who is fitted with a flowsensor and mask and an 
electromagnetically braked cycle ergometer 
 
Prior to testing a cardiac arrest trolley was checked and available. The patient’s 
demographics were entered into the software. This included date of birth, hospital 
identification, trial anonymization code, gender, height (cms), and weight (kg). Calculations 
for body mass index (BMI – kg.m-2) and body surface area (BSA – m2) were performed. 
Electrocardiography electrodes were placed in the usual 12-lead positions. Skin preparation 
and sweat-resistant adhesives were used to reduce noise on the ECG tracing. The leads were 
attached to the electrodes and to the ECG analyzer (AMEDTEC). Heart rate was measured 
from the R-R interval of the ECG. Electrodes and ECG detection software were configured 
to reject movement artifact. Baseline spirometry was then performed by utilizing the flow-
volume loop icon on the Blue Cherry software (Figure 3.4). The mouthpiece and flow-sensor 
was placed in the patients’ mouth with a good air tight seal and a nose-peg was placed 
appropriately. A face mask was used if the mouthpiece was poorly tolerated by the patient. 
The patient was then asked to breathe in as deeply as possible (full inspiration). The patient 
held their breath long enough to seal their lips with the mouthpiece, and then was instructed 
to blow out forcibly as hard and as fast as possible, until their lungs were empty. All patients 
were given consistent encouragement to keep blowing out (end expiration). Three attempts 
which were within 100ml or 5% of each other were performed and saved (Figure 3.4). 
 
A ramp exercise protocol was then calculated and selected (more details on protocol in 
Section 3.2.2). The correct size facemask was selected for the patient. The facemask was 
Mask and  
Flow 
Sensor 
Blood 
Pressure 
Cuff 
Cycle 
Ergometer 
Gas 
Analyser 
Metabolic 
Cart 
ECG 
Output 
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placed on the patients face ascertaining a good seal around the mask cushion, with no leaks 
on air tightness testing. The patient was then coached to give their “best effort”, however 
they were also told to stop if any adverse events were encountered (described in Section 
3.2.2). The patient was then asked to climb onto the stationary cycle ergometer. The height 
of the seat was assessed, adjusted and recorded with the patient not overextending at the 
knee joint on the descending pedal stroke. Patients were instructed to pedal between 55 and 
65 rpm for the duration of the test until volitional termination. 
 
 
 
Figure 3.4 – Three consistent flow volume curves 
 
A non-invasive blood pressure (BP) cuff was fitted to the patients’ right arm, and an 
automated BP was measured at rest, and every 2 minutes during exercise and recovery. 
Patients were also monitored with continuous pulse oximetry via an ear probe.  
 
 
3.2.2 RAMP EXERCISE PROTOCOL 
 
All patients were tested at the same time of day and time to ensure consistency and eliminate 
bias. Baseline measurements included resting heart rate, blood pressure, SpO2, and ECG 
were undertaken. The test protocol included four phases; an initial rest phase (three minutes) 
is employed to establish baseline values. Baseline CPET measurements of VE, V o2, end-
tidal PO2 and PCO2 were noted and allowed to stabilise. This was followed by three minutes 
of unloaded cycling (zero watts) to allow the patient to become familiar with the cycling 
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motion and to reduce the influence of the lag present between increased work rate (WR) and 
the V o2 response. Following this, the incremental exercise phase begins. A ramp 
incremental protocol was used, during which the set work rate was increased linearly with 
time, with a corresponding increase in the intensity of the exercise. The ramp incremental 
protocol was determined for each patient by using a formula by Wasserman et al. (214): 
 
V o2 unloaded pedaling (mls.min
-1
) = 150 + (6 x Weight in kg) 
Peak V o2 (mls.min
-1
) = Height (cms) – Age (years) x 20 (sedentary males) 
Peak V o2 (mls.min
-1
) = Height (cms) – Age (years) x 14 (sedentary females) 
Work rate increment/min = Peak V o2 – V o2 unloaded pedaling/ 100 
 
The patient was given verbal feedback and encouragement throughout the test; this was kept 
as constant as possible with a lot of encouragement given towards the end of the test. The 
test was terminated by the patient at volitional exhaustion or symptoms (e.g. shortness of 
breath, chest pain etc.). Specific criteria for stopping were: 
 
 The patient stops pedalling due to leg fatigue, dyspnoea, pain or light headedness, 
and, 
 The patient fails to maintain an RPM of greater than 40 RPM for more than 1 
minute and does not respond to encouragement. 
 
An exercise period of between 8 to 12 minutes was ideal. All patients were coached to give 
their “best effort” all throughout the test. Following test completion, a recovery period (five 
minutes) of low intensity exercise was performed to maintain venous return, thereby 
reducing the risk of pooling of blood in the leg veins which can be associated with 
symptomatic hypotension (e.g. light-headedness, faint). The patient was observed 
throughout recovery until physiological variables including heart rate, blood pressure, 
ventilation, and oxygen saturation, returned close to baseline levels and any exercise induced 
ECG changes had resolved. The test was stopped if the patient experienced any adverse 
symptoms namely (96,116,215); 
 
 Angina 
 2mm ST depression if symptomatic or 4mm if asymptomatic or > 1mm ST 
elevation 
 Significant arrhythmias 
 Fall in systolic pressure > 20mmHg from the highest value during the test 
85 
 
 Hypertension > 250mm Hg systolic; > 120 mm Hg diastolic 
 Severe desaturation: SpO2 < 80% accompanied by limiting hypoxaemia 
 Sudden pallor 
 Loss of coordination  
 Mental confusion 
 Signs of respiratory failure 
 
Test data was displayed in both numerical and graphical formats by the software. ˆ L 
derivations were done using the V-slope methods described in Section 3.2.3.5. CPETs were 
reported by myself and LL (Clinical Exercise Physiologist - acknowledged) in an unblinded 
fashion; however these were then dually reported by an experienced consultant clinical 
scientist (SJ - acknowledged) who was blinded to all CPET data points, clinical data and 
patient allocation. All reported CPET data is defined in Section 3.2.3. 
 
 
3.2.3 VARIABLES AND DEFINITIONS 
 
A number of important physiological variables are recorded during CPET. These are briefly 
defined in Table 3.2, however a more detailed description of the physiological basis of these 
variables will be provided in Section 3.2.3.1. Some of these variables, as described in 
Section 2.5, have been used to identify patients at high risk of perioperative morbidity and 
mortality: Estimated Lactate Threshold ( ˆ L ) (113,117,120,121), V o2 Peak (140), and V E/
V CO2 (120,133). These three variables are most commonly used to stratify risk for non-
cardiopulmonary surgery (3–5,114,119).  
 
Estimated Lactate Threshold  
( ˆ L) 
The exercise V o2 above which anaerobic high-energy 
phosphate production supplements aerobic high-energy 
phosphate production, with consequential lowering of 
the cellular redox state, increase in lactate/pyruvate 
ratio, and net increase in lactate production at the site of 
anaerobiosis. Exercise above the ˆ L is reflected in the 
muscle effluent and central blood by an increase in 
lactate concentration, lactate/pyruvate ratio and 
metabolic acidosis.  
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Oxygen Uptake ( V o2) The amount of oxygen extracted from the inspired gas 
in a given period of time (ml/L.min
-1
). 
Oxygen Pulse (02 pulse) The V o2 divided by the heart rate. This represents the 
amount of oxygen (O2) extracted by the tissues from the 
O2 carried in each stroke volume. This variable can be 
calculated at ˆ L and at peak exercise (ml.beat
-1
). 
Heart Rate Reserve (HRR) The difference between the predicted highest heart rate 
attainable during maximum exercise and the actual 
highest heart rate. 
Peak Oxygen Uptake  
( V o2 Peak) 
The highest oxygen uptake achieved during a maximum 
work rate test, calculated as the average V o2 in the last 
30 seconds of exercise. 
Work rate  The rate at which work is performed in Watts.  
Ventilatory Equivalents for 
CO2 and O2  
( V E/ V CO2 and V E/ V O2) 
The ventilatory equivalents for CO2 and O2 are 
measurements of the ventilatory requirement for a given 
metabolic rate. Both variables can be calculated at ˆ L 
and at peak exercise. 
Minute Ventilation (VE) The volume of gas exhaled divided by the time of 
collection in minutes. 
Forced Expiratory Volume in 1 
Second (FEV1) 
Volume that has been exhaled at the end of the first 
second of forced expiration 
Forced Vital Capacity (FVC) The determination of the vital capacity from a 
maximally forced expiratory effort 
FEV1/FVC A calculated proportion of a person’s vital capacity that 
they are able to expire over one second 
End tidal PCO2 (PET CO2) Partial pressure of CO2 (PCO2) of respired gas, 
determined at the end of an exhalation. This is 
commonly the highest PCO2 measured during the 
alveolar phase of the exhalation. It is expressed in 
mmHg. 
End tidal PO2 (PET O2) Partial pressure of O2 (PO2) of respired gas, determined 
at the end of an exhalation. This is commonly the 
highest PO2 measured during the alveolar phase of the 
exhalation. It is expressed in mmHg. 
 
Table 3.2: Cardiopulmonary Exercise testing variable definitions 
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Other variables recorded during a CPET include: heart rate (HR), blood pressure (BP), 
oxygen saturation (SaO2). 
 
 
3.2.3.1 PHYSIOLOGICAL BASIS OF CPET VARIABLES AND TEST 
INTERPRETATION 
 
This section will review the physiological basis of important CPET derived variables, noting 
there normal response to exercise. Although the meaning and limitations of each variable 
will be considered individually, for the purposes of optimal test interpretation, the greatest 
diagnostic potential and impact on clinical decision-making does not rest on the utility of 
one variable alone, but rather on their integrated use. Their integrated use has been used in 
risk stratification and fitness assessment in this thesis.   
 
 
3.2.3.2 OXYGEN UPTAKE 
 
Oxygen uptake ( V o2) is determined by cellular O2 demand up to the point where it equates 
to the maximal rate of O2 transport. V o2 can be computed from blood flow and O2  
extraction by the tissues expressed in the Fick equation: 
 
Q = (SV x HR) = V o2 /[C(a–v)O2] 
 
Where Q indicates cardiac output, SV indicates stroke volume, and [C(a–v)O2] indicates the 
arteriovenous O2 content difference, which is related to the O2 extraction. Factors that can 
influence O2 availability are oxygen carrying capacity of the blood, dissociation curve shift 
(with temperature, CO2 and pH), cardiac function, redistribution of peripheral blood flow, 
and extraction by the tissues (influenced by capillary density, mitochondrial 
function/density, adequacy of perfusion and tissue diffusion).  
 
V o2 normally increases nearly linearly as external work increases. The slope of V o2 vs. 
external work rate reflects the efficiency of the metabolic conversion of chemical potential 
energy to mechanical work and the mechanical efficiency of the musculoskeletal system. 
Change in V o2 divided by change in work rate is normally about 8.5-11 ml/min/watt and is 
independent of gender, age or height (214). Obese individuals may show an increased in V
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o2 for a given external work rate, but the rate of rise in V o2 with increasing external work 
should be normal. A reduction in this often indicates inadequacies of O2 transport or 
abnormal O2 utilization.  
 
With increasing V o2 and work rates, patients begin to approach volitional termination of 
exercise, or a clear plateau in V o2, which is described as the V o2 Max. V o2 Max is the best 
index of aerobic capacity and the gold standard of cardiorespiratory fitness. It represents the 
maximal achievable level of oxidative metabolism involving large muscle groups. However, 
in clinical practice, this is very hard to achieve before symptom limitation. Consequently V
o2 Peak is often used as an estimate for V o2 Max. V o2 Peak is dependent on the quantity of 
exercising muscle, age, sex and body size an can be affected by training. V o2 is usually 
reported as absolute or adjusted for body weight. V o2 can also be referenced to lean body 
mass (fat free mass), however its routine measurement is difficult. A reduced V o2 Peak may 
reflect problems with oxygen transport i.e. cardiac or pulmonary limitations, tissue oxygen 
extraction, neuromuscular or musculoskeletal limitations and of course is effort dependent.
V o2 Peak is always reported as the highest V o2 achieved during CPET averaged over last 
30 seconds of loaded exercise data. A formula for estimating V o2 Peak reported by 
Wasserman and Whipp (214) is as follows : 
 
Predicted V o2 during unloaded pedalling (ml.min
-1
) = (5.8 x weight in kg) + 151 
V o2 Peak (ml.min
-1
) = Height (cm) – age (years) x 20 (sedentary males) or x 14 (sedentary 
females) 
 
 
3.2.3.3 CARBON DIOXIDE OUTPUT 
 
Carbon dioxide output ( V co2) during exercise is determined by factors similar to those that 
govern V o2 , i.e. cardiac output, CO2 – carrying capacity of the blood, and tissue exchange. 
However, because CO2 is much more soluble in tissues and blood, CO2 output measured at 
the mouth is more strongly dependent on ventilation than V o2. In addition because CO2 is a 
weak acid, the body uses CO2 regulation to compensate for acute metabolic acidosis, which 
affects the pattern of V co2 as work increases above anaerobic metabolism. During short 
duration exercise, glycogen is used primarily by muscle for energy, and the relation between 
O2 consumption and CO2 production is almost equimolar. As such, during progressive 
exercise, V co2 increases nearly as much as V o2 over low work rates, with an average 
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relationship of slightly less than 1 (Figure 3.5, slope S1). There is then a relatively sharp 
change in slope toward the midrange of the V o2 response (Figure 3.5, AT (anaerobic 
threshold) or V o2 at ˆ L – red line). This results in a steeper, but linear profile over the upper 
work rate range (Figure 3.5, slope S2). The steeper slope reflects the CO2 generated in excess 
of that produced by aerobic metabolism due to bicarbonate buffering of increased lactic acid 
production. With anaerobic metabolism, V co2 increases as a result of the chemical reaction 
between hydrogen ions (from lactate) and dissolved CO2: 
 
[H
+
] + [HCO3
-] ↔ [H2CO3] ↔ [CO2] + [H2O] 
 
 
 
Figure 3.5 – Graph depicting V co2 vs. V o2 increasing with a ramp incremental protocol (actual patient data) 
 
As tissue lactate production increases [H
+
], the reaction is driven to the right, producing 
extra CO2 above that produced aerobically. The excess CO2 may also come from reduction 
in the body CO2 stores as a result of hyperventilation (manifested as arterial hypocapnia). 
CO2 output needs to be measured accurately as it is the basis for the calculation of several 
derived variables, including, the respiratory exchange ratio, the respiratory quotient, alveolar 
ventilation etc.  
 
The ratio of V co2 / V o2 is called the respiratory exchange ratio (RER). Under steady state 
conditions, the RER equals the respiratory quotient (RQ), whose value is determined by the 
fuels used for the metabolic processes. An RQ of 1.0 indicates a mixture of carbohydrates, 
whereas an RQ of less than 1.0 indicates a mixture of carbohydrate with fat (about 0.7) or 
S1 
S2 
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protein (about 0.8). If true steady state exists, the blood and gas transport systems are 
keeping pace with tissue metabolism; thus the RER can replace the RQ. An RER of greater 
than 1.0 could be caused by CO2 derived from lactic acid or hyperventilation because of the 
20-fold or higher tissue solubility of CO2 compared with O2, therefore when testing both 
these sources of CO2 must be considered when the RER is above 1.0.  
 
 
3.2.3.4 LACTATE THRESHOLD 
 
The lactate threshold ( ˆ L) is considered an estimator of the onset of metabolic acidosis 
caused predominantly by the increased rate of rise of arterial lactate during exercise. After 
30 years the physiological mechanism underlying the increase in muscle and blood lactate 
that occurs at the ˆ L still remain controversial (216).  
 
Energy for muscle contraction is provided by high-energy phosphate groups supplied in the 
form of adenosine triphosphate (ATP). ATP is supplied by the breakdown of glycogen to 
pyruvate, which enters the tricarboxylic acid (TCA) cycle via acetyl-coA, and breakdown of 
fats to produce acetyl-coA. Further processing of acetyl-coA in the TCA cycle and electron 
transport chain produces ATP needed for muscle contraction. If processing occurs only in 
the glycolytic pathway, a smaller amount of ATP is formed along with lactic acid (described 
in Section 2.7.1). The extra acid produced causes an increase in V co2 by buffering of CO2 
in the blood. Controversy persists as to whether a deficiency of oxygen delivery versus 
oxidative capacity also contributes to the onset of lactic acid production, hence the term 
“anaerobic threshold.” It is possible that both processes, that is, the pattern of muscle fibre 
recruitment and a potential imbalance between oxygen supply and oxidative metabolism, 
contribute to the increase in lactic acid as exercise intensity increases.  
 
In normal individuals, the ˆ L occurs at about 50–60% V o2 Max predicted in sedentary 
individuals, with a wide range of normal values. The ˆ L determination is age, modality and 
protocol specific. The ˆ L derived from arm exercise is lower than that derived from leg 
exercise, and that derived from cycle ergometry is lower than that derived from treadmill. 
This reflects differences in exercising muscle mass and possibly differences in the dominant 
fibre type of exercising muscle. The ˆ L demarcates the upper limit of a range of exercise 
intensities that can be accomplished almost entirely aerobically. Whereas work rates below 
the ˆ L can be sustained essentially indefinitely until fatigue, a progressive increase in work 
rate above ˆ L is associated with a progressive decrease in exercise tolerance. So in patients 
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who become symptom limited with premature cessation of exercise, the ˆ L is an effort-
independent measurement may represent a sub-maximal variable that may assist in clinical 
decision making (3–5). 
 
 
3.2.3.5 V-SLOPE METHOD OF LACTATE THRESHOLD DERIVATION AND 
TEST INTERPRETATION 
 
Several methods are available for the determination of ˆ L. These include invasive methods 
(arterial lactate, bicarbonate) or non-invasive methods (ventilatory equivalents, V-slope or 
modified V-slope). All ˆ L derivations and their corresponding CPET variables reported in 
this thesis were performed using the modified V-slope method described hereunder.    
 
As work rate increases, V o2 and V co2 increase linearly until exercise lactic acidosis 
develops.  This changing relationship was used to identify the lactate threshold using a 
technique known as the “V-slope” method. V co2 is plotted against V o2 with the former on 
the y-axis and the latter on the x-axis (Figure 3.5). To confirm that this change of slope is 
not occasioned by hyperventilation, monitoring ventilatory equivalents and end-tidal Pco2 is 
necessary. Consequently, the ventilatory equivalents for O2 and end-tidal O2 reach their 
nadir and begin to rise in concert with the S1–S2 transition, without an increase in the 
ventilatory equivalent for CO2 and/or decrease in end-tidal Pco2. The intercept of these two 
slopes is the ˆ L as measured by gas exchange (Figure 3.6). The technique of derivation of 
the ˆ L is referred to as the V-Slope method (214,217). The modified V-Slope method 
identifies the ˆ L as the tangential breakpoint in the V co2- V o2 relationship from the line of 
unity (‘line of one’) during the incremental stage of the exercise test (Figure 3.7). Because 
inappropriate increases in V co2 disproportionate to increases in metabolic rate V o2 due to 
acute hyperventilation invalidate the non-invasive determination of the ˆ L, the V-slope and 
ventilatory equivalents were used together with the RER (approaching 1.0) to more 
accurately identify the ˆ L.  
 
The V-slope methods depend solely on the physicochemical reaction of lactate with 
bicarbonate and thus the occurrence of the breakpoint is independent of chemoreceptor 
sensitivity and the ventilatory response to exercise - although the magnitude of the response 
is (217,218). However, the physiological basis for this variable remains controversial (216), 
but the inter-observer variability for experienced clinicians is very acceptable (219).  
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Figure 3.6 - An example trace showing V o2 at ˆ L determination (actual patient data) as described in the 
section above. A mixture of the tangential breakpoint seen in the V co2- V o2 relationship (first panel), together 
with the ventilatory equivalents (second panel) and the end tidal graph (third panel) is used in the modified V-
slope technique. 
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Figure 3.7 - The modified V- Slope method of ˆ L determination. At the ˆ L the gradient of the V o2 - V co2 
relationship will increase above 1.  The breakpoint - marked by the red vertical line is the ˆ L (actual patient 
data) 
 
 
3.3 STRUCTURED RESPONSIVE EXERCISE TRAINING PROGRAMME 
 
Between Week 0 and 6 post-NACRT, patients in the exercise group underwent a structured, 
responsive, exercise training programme (SRETP). An iterative process was undertaken 
prior to implementation of this exercise programme based on the systematic review outlined 
in Section 2.6. This iterative process led to the development of the final training programme 
which will be summarised in Chapter 5. 
 
 
3.3.1 SETUP AND TRAINING PROGRAMME CALCULATION 
 
The SRETP encompassed a: 
- Structured: 3 times a week for a duration of 6 weeks (18 sessions in total – including 3 
CPETs). 
- Responsive: Informed by a CPET at week 3 (mid-exercise programme).  
- Exercise: Interval training including moderate and severe intensity aerobic exercise. 
- Training: Undertaking a course of exercise in preparation for a major stressor. 
- Programme: A series of goals to be accomplished.  
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Patients participated in a 6 week in-hospital, supervised exercise training program on a 
computer controlled, electromagnetically braked, cycle ergometer (Ergoline 200, Germany) 
(Figure 3.8). Severe and moderated intensity interval training, consisting of repeated short 
periods of severe and moderate intensity work and recovery which was directed by changes 
in work rates at V o2 at ˆ L and V o2 Peak was undertaken. 
 
 
 
Figure 3.8 – A computer controlled electromagnetically braked exercise training bike (Courtesy of Love Medical 
Ltd, Manchester, UK)  
 
The training program was individually set/ tailored to be responsive to each patients’ 
changing fitness. This was set following the initial CPET test post-NACRT (Week 0). Each 
session was 4 to 5 repeats of: a) 3 minutes severe intensity cycling immediately followed by, 
b) 2 minutes of moderate intensity (20 minutes total in total for the first 3 sessions, then 30 
minutes for the following sessions). 5 minutes of unloaded cycling was performed at the 
start and end of all training sessions for a warm-up and cool down. Moderate intensity 
exercise (80% ˆ L) was set at a power output equivalent to 80% of the work rate at V o2 at 
ˆ L and severe intensity was set at a power output that is half-way between work rates at V
o2 at ˆ L and V o2 Peak (termed 50%∆). This is illustrated by the formula below: 
 
Moderate intensity exercise – (Work load at V o2 at ˆ L – ⅔ of work ramp) x 80% 
Severe intensity exercise – ((Work load at V o2 Peak - Work load at V o2 at ˆ L - ⅔ of work 
ramp) x 50%) + Work load at V o2 at ˆ L 
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Patients attend 3 exercise sessions per week for 6 weeks. Each exercise session lasted 30 
minutes in total for the first 3 sessions and then the duration was increased to 40 minutes in 
total for the next 12 sessions. Patients were screened prior to each session to ensure that it 
was safe to perform exercise. Blood pressure was monitored throughout the exercise and 
heart rate was recorded continuously from the R-R interval (Polar FT7, Warwick, UK). 
Sessions 0, 7 and 18 (Weeks 0, 3, and 6) were standard CPETs (protocol as per Section 
3.2.2) included to make the exercise programme responsive to the patients individual needs 
and monitor the progression of training-induced changes in physical fitness. The absolute 
power output for subsequent training sessions was adjusted according to the outcome of the 
CPET test. 
 
Exercise and CPET sessions could be terminated by the patient or the exercise supervisor at 
any time if any of the criteria to stop the session are met. This was based on the ATS CPET 
safety guidelines as per Section 3.2.2. A schematic of the training programme is illustrated 
in Figure 3.9 hereunder. A screen shot of the graphical result which is visible to the patient 
on the exercise bike at the end of each training session is illustrated in Figure 3.10. This is 
considered to be a valuable help for both the patient and the exercise supervisor and aids 
monitoring of the session’s progress. Variables recorded during the exercise training 
programme included: 
 
 Blood pressure 
 Heart Rate 
 Power output (Watts) 
 
 
Week 1 (sessions 1-3)      
3 min 
80% ˆ L 
2 min 
50%∆ 
3 min 
80% ˆ L 
2 min 
50%∆ 
3 min 
80% ˆ L 
2 min 
50%∆ 
3 min 
80% ˆ L 
2 min 
50%∆ 
Week 2-6 (sessions 4-17, excluding 7 and 18)             
3 min 
80% ˆ L 
2 min 
50%∆ 
3 min 
80% ˆ L 
2 min 
50%∆ 
3 min 
80% ˆ L 
2 min 
50%∆ 
3 min 
80% ˆ L 
2 min 
50%∆ 
3 min 
80% ˆ L 
2 min 
50%∆ 
 
Figure 3.9 – Schematic of exercise training programme 
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Figure 3.10 – Screen shot of the display on exercise ergometer at the end of a 40 minute exercise session. This 
shows workload (W) and heart rate (beats.min-1) on the y-axis vs. time (min) on the x-axis. The square wave 
pattern on the background is the preloaded exercise training programme. The sinusoidal pattern on the 
foreground is the variation in heart rate with the different training intensities recorded over time. 
 
 
3.4 31-PHOSPHORUS MAGNETIC RESONANCE SPECTROSCOPY (
31
P MRS) 
  
This section describes the general experimental protocol and set up for the 
31
P MRS 
implemented in chapter 7 of this thesis. All experiments were conducted in a whole-body 3.0 
Tesla MR scanner (Magnetom TRIO, Siemens, Erlangen, Germany) at the Magnetic 
Resonance and Image Analysis Research Centre (MARIARC), University of Liverpool. All 
patients were screened using standard pre-experimental questionnaires to ensure no 
contraindications to exercising inside the MR scanner were found. All subjects were 
requested to abstain from heavy exercise at least 24 hours prior to the experiment. Subjects 
were also advised not to consume any caffeinated beverages and to refrain from smoking at 
least 6 hours prior to testing.  
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3.4.1 SETUP AND EXERCISE EQUIPMENT 
 
31
P MRS assessments of peripheral muscle mitochondrial function in quadriceps muscle was 
carried out using an isometric knee extension exercise protocol similar to a study published 
by Kemp et al. using a plantar flexion exercise protocol (209). All patients had repeat tests 
on the same day and time as their previous tests to avoid bias. Subjects lay supine (secured 
with a Velcro strap across the hips) with the right knee flexed over a rigid foam support in a 
custom-built rig permitting isometric knee extension exercise against a strap across the 
anterior lower shin/ankle connected to an aluminum bar fitted with a strain gauge (Figure 
3.11). The quadriceps exercise rig is composed of a knee support system which is attached to 
a flattened sturdy hardwood base and an ankle brace which is secured to the hardwood base 
via the aluminum bar. The knee support system is constructed from two pieces of medium 
density fibre board screwed on to two other pieces of triangular chip boards, forming a 
triangular wedge which supports the knee in a flexed position at an angle of ~130 degrees at 
rest (~ 50 degrees from terminal extension). Construction of a more acute angle of flexion 
was not possible due to height restriction in the magnet bore. The force produced during 
muscle contraction is detected by a strain gauge attached to the exercise rig, and is fed back 
to the light emitting diode (LED) display unit placed above the patient’s head. To allow 
viewing of the LED, a flexibly adjusted mirror-mounted head-gear is strapped to the 
patient’s head. Patients used real-time visual and auditory feedback from the LED display 
and from an audible metronome to achieve their target workloads during the exercise 
protocol.  
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Figure 3.11 – A patient on the MR table attached to the quadriceps exercise rig in the scanner room. The right leg 
is mounted on the scanner bed. The coil is attached on the right thigh with Velcro straps. The patient is fitted with 
a head gear which has a mirror mounted on the inner surface so as to be able to look at an LED display unit 
placed at the top of the scanner table. A non-extensible strap is placed over the patient’s lower abdomen to 
minimise the back muscles contributing to the exercise 
 
 
 
 
Figure 3.12 - A close up of the exercise rig setup on the scanner table with the patient’s leg strapped in the 
exercising position 
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31
P MRS data were acquired from right quadriceps muscle (vastus lateralis) using a dual-
tuned 18cm/15cm diameter 
31
P/
1
H surface coil (RAPID Biomedical, Rimpar, Germany), 
Velcro-strapped to the anterior thigh (midway between anterior superior iliac spine and 
patella) as shown in Figure 3.12. The level of maximum voluntary contraction (MVC) in this 
rig was used as a functional measure of maximal power output during exercise. In isometric 
exercise, power output (i.e. work rate = force x distance x rate) is formally zero (since there 
is no change in muscle length during contraction), but the force-time integral can be used as 
an analogue of work. The patient’s MVC was determined prior to initiation of every exercise 
session. The patient was instructed to extend their knee and attempt to ‘snap’ the Velcro 
strap at their ankle with maximum effort. The sensitivity of the force transducer was 
manually adjusted until the subject’s MVC levelled at number 10 in the LED display scale, 
and the patient was able to sustain his/her MVC at that level for at least 1 second. Three 
consecutive MVCs were performed separated by at least 15 seconds of rest. The highest 
value of the 3 maximum forces was used as 100% MVC for the individual. Force output data 
during exercise was recorded on a personal computer running Chart software (version 5) via 
the PowerLab data acquisition system (AD Instruments, Hastings, UK). Force was measured 
in voltage units after multiplication with the instrument’s sensitivity level (Figure 3.13). A 
5cm wide non-distensible strap was placed over the patients lower abdomen and secured the 
patient to the scanner table to minimise the contribution of the back muscles throughout the 
exercise. To ensure accuracy and consistency in both the timing and duration of 
contractions, an audible cue was provided to the subject by means of an electronic 
metronome set at the same contraction frequency. The patient was instructed to contract at 
the start of the tone, maintain contraction during the tone and release the contraction upon 
the disappearance of the audible cue, such that a square-wave pattern of exercise was 
achieved (i.e. constant workload) (Figure 3.13). 
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Figure 3.13 – Chart software tracing with patient performing the exercise protocol (Voltage on y-axis and time on 
x-axis) 
 
 
3.4.2 EXERCISE PROTOCOL, DATA PROCESSING AND INITIAL ANALYSIS 
 
After an automated set-up and manual shimming using tissue water, a 4-scan fully relaxed 
(TR=10s) spectrum and a 32-scan partially saturated (TR=2s) resting spectrum were 
collected (Figure 3.14).  
 
 
 
Figure 3.14 – Manual shimming with anatomical localization done in multiple planes (axial, coronal and sagital) 
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The exercise protocol consisted of 5 min rest followed by 2 bouts of isometric exercise each 
followed by 7 min recovery periods, while spectra were collected (TR=2s) every 8 s paced at 
0.25 Hz (2 seconds on, 2 seconds off) by an audible cue. Two exercise intensities were used, 
corresponding to 70% and 90% of MVC established in 3 brief trials prior to MRS 
acquisition (in pilot experiments these intensities were found to give acceptable PCr 
depletion with minimal acidification in typical subjects). Block MRS data output files from 
exercise-recovery acquisitions were converted to text using a specially-written MATLAB 
routine. All 
31
P MRS data were processed using the java-based Magnetic Resonance User 
Interface (jMRUI v.3.0), using the AMARES (Advanced Method for Accurate, Robust and 
Efficient Spectral fitting) time-domain fitting algorithm (Figure 3.15). Data were fitted 
assuming Lorentzian lineshapes for PCr, Pi, PDE, PME, NADP and ATP (β-ATP a 1:2:1 
triplet, α-ATP and γ-ATP both 1:1 doublets) based on prior knowledge of the metabolite 
peaks (prior knowledge file kindly provided by Dr Damian Tyler, University of Oxford). 
The chemical shift of the inorganic phosphate (Pi) peak relative to PCr (σ parts per million) 
was used by standard means to determine intracellular pH. PCr recovery time courses were 
fitted to a monoexponential function to estimate the recovery rate constant (k min
-1
). In the 
absence of appreciable changes in pH, this is accepted as a measure of effective muscle 
mitochondrial function, the latter being a system property which reflects cardiovascular 
oxygen supply and mitochondrial oxygen usage (220). As the PCr recovery rate constant did 
not differ significantly between the two exercise intensities, and as pH changes were small 
throughout, values of k are presented as mean of the two intensities to reduce variability 
(209).  
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Figure 3.15 - Examples of MRUI output from the AMARES fitting of: (top panel) resting 31P MR spectra and 
(bottom panel) exercise spectra (at 60% MVC) obtained from the right quadriceps muscle of a young healthy 
male volunteer. Four sections were generated from the output: 1) the ‘original’ section displayed the original 
spectra transformed from the raw FID data; 2) the ‘estimate’ section displayed the pre-specified peaks (i.e. prior 
knowledge), 3) the integration of the 2 previous sections (i.e. fitting of the peaks) resulted in the fitted peak 
metabolites which were displayed in the ‘individual component’ section, and lastly, 4) any residual unfitted peaks 
were displayed in the ‘residue’ section. Note that the amplitude of Pi peak has increased considerably by this 
point of the exercise. A good fit is generally indicated by the absence of any residual amplitude in the ‘residue’ 
column, as shown above. As expected, the signal-to-noise ratio was relatively poorer in the exercise compared to 
resting spectra due to leg movement during exercise
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Time course data were edited for occasional outliers by replacing the amplitude under 
question with the average value of amplitude before and after the suspected data point: these 
can include spurious transient large fluctuations in metabolite amplitudes unrelated to the 
underlying physiological observation (probably arising due to the alteration in signal-to-
noise properties of the 
31
P MRS technique), and spurious unphysiological pH values due to 
failure of fit to small Pi peaks. 
 
The 
31
P MRS data processing and analysis steps are briefly summarized as follows: 
 
 Raw data from the scanner were processed by MRUI software (AMARES fitting 
procedure) to generate measurements of metabolites peak amplitudes. 
 
 The 3 separate MRUI outputs (i.e. fully relaxed, partially saturated and saturated 
spectra) from each individual subject were exported and combined into a single data 
output Excel spreadsheet for the respective subject.  
 
 An analysis workbook was constructed to automate the data analysis procedure in 
order to save labour and minimise human error in manual input of the data (courtesy 
of Prof. Graham Kemp). The analysis workbook was linked to the individual 
subject’s data output spreadsheet to enable direct extraction of the MRUI-processed 
data. Various additional data processing steps were taken including expressing the 
metabolite amplitudes in relative terms (i.e. relative to resting baseline), calculation 
of pH and calculation of ADP concentration. 
 
 Various parameters were calculated from analysis of the recovery data related to PCr 
and ADP recovery time courses. In the initial analysis of the recovery data, PCr and 
ADP recovery time courses were fitted to a monoexponential function to determine 
their respective recovery kinetics i.e. rate constant values (kPCr).  
 
 All curve fitting was performed using Microsoft Excel solver function to execute 
least squares regression.  
 
 Analysis was performed in a blinded fashion, with the assessor blind to individual 
patients’ clinical details, CPET variables, group allocation (i.e. exercise or control) 
and MR time points (i.e. baseline (pre-NACRT), Week 0 and Week 6 (post-
NACRT)).  
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Analysis of the post-exercise kPCr in the vastus lateralis muscle quantified the in vivo 
mitochondrial oxidative capacity of skeletal muscle because, during recovery from exercise, 
PCr is resynthesized purely as a consequence of oxidative ATP synthesis. These measures 
correlate with ex vivo measurements of muscle mitochondrial function and whole-body 
measures of aerobic fitness in healthy controls (178) and were taken as surrogate markers of 
mitochondrial function in vivo. 
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Physical Fitness and Morbidity in Rectal Cancer 
Patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
108 
 
CHAPTER 4 – The Effect of Neoadjuvant Chemoradiotherapy on Physical Fitness and 
Morbidity in Rectal Cancer Patients 
 
 
4.1 INTRODUCTION 
 
This chapter defines the effects of neoadjuvant chemoradiotherapy on objectively measured 
physical fitness determined by CPET with specific focus on (1) the changes in objectively 
measured V o2 at ˆ L pre- and post-NACRT, (2) changes in other CPET-derived variables 
measured pre- and post-NACRT, and (3) the relationship of CPET variables to in-hospital 
morbidity and medium term follow-up.  
 
In 2012, the UK National Bowel Cancer Audit reported that the ASA score (a categorical 
descriptor of fitness for surgery) was the strongest predictor of death within 30 days of 
surgery (8). Twenty-five per cent of audited cases in 2013 were locally advanced (T3/T4 
N+) cancers considered for long-course neoadjuvant chemoradiotherapy (NACRT) to 
control local disease, improve operability, and achieve tumour downsizing and negative 
resection margins (9,10,12,13,28) (Section 2.4). However, standard NACRT based on 
external beam radiation and oral or intravenous fluoropyrimidines causes dose-limiting 
toxicity (most commonly diarrhoea, hand-foot syndrome, cardiotoxicity and haematological 
toxicity) reaching Grade 3–5 in 20% (Common Terminology Criteria for Adverse Events, 
Version 3.0) (14). It is less clear whether there are further metabolic adverse effects from 
cancer therapies which could impact outcome after surgery.  
 
As described in previous sections (2.5.2) cardiorespiratory fitness, assessed by 
cardiopulmonary exercise testing (CPET), correlates well with outcome following major 
surgery. Knowledge of the effects of cancer and cancer therapies on physical fitness is 
critical in developing interventions targeted at improving preoperative fitness and promoting 
recovery of muscle mass. Subjective assessment tools have been used to predict surgical 
outcomes, however there is little evidence linking objectively-measured physical fitness and 
surgical outcome in this group. Meta-analyses of randomized trials along with few published 
randomized controlled trials suggest that neoadjuvant chemotherapy and/or radiation therapy 
slightly increase the risk of morbidity and mortality (221,222), however these meta-analyses 
deal with oesophageal cancer patients. Nordlinger et al. (223) evaluated the effect of 
preoperative chemotherapy on hepatic metastasis and showed a 36% increase in 
complications with chemotherapy. Other studies though, failed to show any association 
between neoadjuvant chemotherapy and increased postoperative morbidity and mortality 
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(224–226). In a very large recently published patient dataset the use of neoadjuvant 
chemotherapy in cancer patients undergoing resection surgery was not associated with a 
higher rate of early postoperative morbidity and mortality (227). 
 
In rectal cancer only a few trials suggest that patients with a lower subjective performance 
status (WHO Score >1) have worse postoperative outcome after combined chemotherapy or 
chemo-radiation and surgery (14,15,228,229). To my knowledge the assessment of changes 
in objectively measured physical fitness and its relation to postoperative outcome in this 
cohort of patients has never been attempted before.  
 
 
4.2 STUDY OBJECTIVES 
 
In this chapter I set out to test the hypothesis that NACRT prior to elective locally advanced 
rectal cancer surgery would impair objectively measured physical fitness ( V o2 at ˆ L). 
Secondary aims include: (1) studying the change of other CPET derived variables post-
NACRT, (2) determining the relationship of CPET variables to Day 5 postoperative in-
hospital morbidity, (3) and to report 180-day morbidity and 1 year mortality.  
 
 
4.3 PATIENTS AND STUDY METHODS 
 
This single-centre, prospective, observational cohort study was based at Aintree University 
Teaching Hospitals, Liverpool, UK. Ethics approval was sought from the Northwest 
Research Ethics Committee (11/H1002/12) and the study was registered with 
ClinicalTrials.gov (NCT01334593). Written informed consent was obtained from all 
patients. From July 2011 to end of October 2011, I recruited consecutive patients referred to 
the Colorectal Multi-Disciplinary Team (MDT), age ≥18 years, with locally advanced 
(circumferential resection margin threatened) electively resectable rectal cancer, who were 
scheduled for standardized NACRT on the basis of Tumour, Node, Metastasis (TNM) 
classification >T2/N+ with no distant metastasis (230) and a WHO Performance Status <2 
(231). Patients were excluded if they were diagnosed with non-resectable disease, were 
unable to perform CPET (due to mechanical reasons e.g. unable to pedal), declined surgery 
or NACRT, received non-standard NACRT or were unable to give informed consent. CPET 
was performed 2 weeks before and 7 weeks post-NACRT (prior to surgery at 9 weeks post-
NACRT). TNM staging investigations involved flexible sigmoidoscopy for histological 
diagnosis, colonoscopy, chest, abdomen and pelvis computer-aided tomography (CT) and a 
110 
 
1.5 Tesla (Magnetom Aera, Siemens, Erlangen, Germany) pelvis magnetic resonance 
imaging (MRI). 
 
Eligible patients then underwent NACRT for 5 weeks. Preoperative radiotherapy consisted 
of 45 Gy in 25 fractions on weekdays using a three-dimensional conformal technique with 
CT guidance. Patients were treated prone (on a belly-board) to spare small bowel, with a 
comfortably full bladder. The clinical target volume included the primary tumour, the 
mesorectum and mesorectal lymph nodes, including the perirectal, presacral and internal 
iliac nodes. The upper radiation extent was 3 cm above the tumour but no further than the 
sacral promontory. The perineum was included if an abdomino-perineal resection (APR) 
was planned, while for low anterior resection (LAR) the lower radiation border was 3 cm 
below the tumour. A boost dose was given (5.4 Gy in 3 fractions) to the primary tumour 
only. 825 mg.m
-2
 oral capecitabine was given twice daily on radiotherapy days (Section 
2.4.4). No patients received brachytherapy.  
 
Acute toxicity and adverse events were discussed at the weekly colorectal multidisciplinary 
meeting (MDT). Adverse events were graded according to the National Cancer Institute 
Common Terminology Criteria (version 3.0), and the acute radiation-induced skin toxicity 
using the Radiation Therapy Oncology Group scoring system.  
 
Patients completing NACRT went on to have CPET (for protocol refer to Section 3.2), 
spirometry and a re-staging chest, abdomen and pelvic CT and pelvic MRI at 7 weeks post-
NACRT. All patients underwent total mesorectal excision (TME) surgery (232,233) after 
completing NACRT. A defunctioning stoma was constructed at the discretion of the 
surgeon. The colorectal MDT, anaesthetists and medical staff collecting outcome data were 
blind to CPET results. 
 
Patients were assessed pre- and postoperatively by the Colorectal Physiologic and Operative 
Severity Score for the Enumeration of Mortality and Morbidity (CR-POSSUM) (234), and 
postoperatively by the Post-Operative Morbidity Survey (POMS) (146) and the Clavien-
Dindo Classification of Surgical Complications (235) by staff blind to CPET data at day 5 
postoperatively. Patients were followed up by telephone consultation at 180-days 
postoperatively for morbidity and up to 1 year for mortality using hospital records. 
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4.4 STATISTICAL ANALYSIS 
 
Continuous variables are presented as mean and standard deviation (SD) or as medians and 
interquartile range (IQR), depending on their distribution. Categorical variables are 
presented as frequency and/or proportion. Pre- and post-NACRT data were compared using 
paired t-tests. Relationships between the change in haemoglobin concentration and the 
change in V o2 at ˆ L and V o2 Peak (ml.kg
-1
min
-1
) were assessed using the Pearson 
correlation coefficient. Statistical significance was accepted at p<0.05; no corrections were 
made for multiple comparisons. Descriptive analysis was used to compare baseline 
characteristics of patients pre- and post-NACRT (Table 4.1), to document in-hospital 
complications using POMS day 5 and Clavien-Dindo classification, together with 180-day 
morbidity using Clavien-Dindo classification, loco-regional recurrence rates (Table 4.4) and 
1 year mortality. 
 
The primary outcome variable was V o2 at ˆ L (ml.kg.
-1
min
-1
). Secondary outcome variables 
included V o2 Peak (ml.kg.
-1
min
-1
), oxygen pulse (ml.beat
-1
), V E/ V co2 at ˆ L and Peak 
exercise and the relationship of V o2 at ˆ L to postoperative in-hospital morbidity. 
 
Logistic regression models were used to assess in-hospital complications, converting the 
continuous CPET variable of V o2 at ˆ L and Peak into a categorical one (coded as 0 if 
below median and 1 if equal to or greater than the median value). Receiver operator 
characteristic (ROC) curves were constructed for V o2 at ˆ L and Peak. From these the 
optimal cut-point was identified by minimising the distance to the top-left corner. 
 
I aimed to recruit 22 patients who would undergo NACRT and elective rectal surgery as an 
intention to treat for rectal cancer. This estimate was based on a two-sample t-test with 90% 
power to detect an estimated mean (SD) minimum clinically relevant difference in V o2 at ˆ
L of 1.5 (1.0) ml.kg.
-1
min
-1
). A drop-out rate of 10% was assumed (based on a previous pilot 
study). 
 
 
4.5 RESULTS 
 
Thirty-five patients were eligible for surgery, of whom 5 did not consent and 3 were 
recruited into a different trial; 27 patients were recruited and underwent CPET prior to 
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NACRT; 2 withdrew their consent before undergoing the post-NACRT CPET, the 
remaining 25 (17 males and 8 females, mean age 68 years) completed NACRT and 
underwent elective rectal cancer surgery (Figure 4.1 illustrates a CONSORT diagram 
depicting patient flow for this study).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 – Consort diagram 
 
Table 4.1 describes patient characteristics and Table 4.2 describes tumour and treatment 
characteristics. There were no significant changes in WHO performance status, haemoglobin 
or lung function following NACRT. CPET was performed at 2.0 ± 0.8 weeks pre-NACRT 
and at 7.0 ± 1.0 weeks post-NACRT. Eighty-four per cent of diagnosed rectal cancers were 
T3, with 52% having a good response to NACRT determined by MRI. All patients 
underwent CT and MR-directed staging, then total mesorectal excision (TME) surgery 
(complete resection (R0)) at median of 63 (range 51-78) days post-NACRT. The 
circumferential resection margin (CRM) was >5mm in all cases. No patients had complete 
pathological response. 
 
 
35 patients reviewed at MDT 
and considered eligible 
- 5 patients not consented 
- 3 patients recruited in 
another clinical trial 
 
 
27 patients recruited  
27 patients completed CPET 
27 patients completed 
NACRT 2 patients did not 
complete 2
nd
 CPET 
 
25 patients completed 2
nd
 CPET  
Surgery n= 25  
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 Total Pre-
NACRT 
Post-
NACRT 
Mean Difference 
(95% CI) 
p-value 
Age (years)
1 
67.7(9.2)  
Gender M:F (%)
1
 17(68) : 8(32) 
CR-POSSUM- Operative 
Severity Score* 
11.2(1.2) 
CR-POSSUM-
Physiological Score* 
9(1.8) 
CR-POSSUM- Predicted 
Mortality (%)* 
7.8(4.5) 
Weight (kg)
1
  75 
(16.9) 
75.3 
(17.4) 
0.30 
(-1.2, 0.6) 
0.54 
Height (m)
1 
 166.4 
(8) 
166.6 
(8.1) 
0.20 
(-0.6, 0.1) 
0.16 
BMI (kg.m-
2
)
1
  27.0 
(5.5) 
27.0 
(5.6) 
0.01 
(-0.3, 0.4) 
0.94 
WHO Performance 
Status
3 
 1 
(0-2) 
1 
(0-2) 
  
FEV1 (L)
 1
  2.5 
(0.8) 
2.5 
(0.7) 
0 
(-1.2,1.2) 
0.92 
FVC (L)
 4
  3.7 
(2.9-4.4) 
3.7 
(3.0-4.5) 
0.04 
(-0.1, 0.1) 
0.36 
FEV1/FVC (%)
1
  67.2 
(10.5) 
67.0 
(11.5) 
-0.02 
(-2.0, 1.6) 
0.79 
Haemoglobin (g.dl
-1
)
1
  13.6 
(1.5) 
13.5 
(1.6) 
-0.03 
(-0.5, 0.4) 
0.87 
Clinical TNM 
classification
2# 
  
cT2  1(4) 3(12)  
cT3  21(84) 19(76) 
cT4  3(12) 3(12) 
cN0  7(28) 13(52) 
cN1  13(52) 9(36) 
cN2  5(20) 3(12) 
cM0  25 25 
 
Table 4.1 – Patient characteristics; * Mean (SD) CR-POSSUM components # with percentages in parentheses; 1 
Values presented as mean (SD); 2 International Union against Cancer tumour node metastasis (TNM); 3 Median 
(range) World Health Organisation (WHO) Performance Status; 4 Values presented as median (IQR) 
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 Number of Patients 
(n=25)
#
 
Tumour distance from anal verge 
<5 cm 6(24) 
6-10cm 14(56) 
>10cm 5(20) 
Operation Type 
Open 14 (56) 
Laparoscopic 11(44) 
Surgery 
Low Anterior Resection and diverting stoma 15 (60) 
Abdomino-perineal resection and end stoma 7 (28) 
Hartmann procedure 3 (12) 
Pathological TNM 
pT1 4 (16) 
pT2 5 (20) 
pT3 11 (44) 
pT4 5 (20) 
pN0 15 (60) 
pN1 6 (24) 
pN2 4 (16) 
Dukes Staging 
A 8 (32) 
B 7 (28) 
C 0/1 10 (40) 
Resection margins 
R0 25 (100) 
 
Table 4.2 – Patient tumour and treatment demographics; # With percentages in parentheses 
 
 
4.5.1 CHEMORADIOTHERAPY AND ACUTE TOXICITY 
 
The mean cumulative dose of capecitabine was 96% (range 84-100%); 3 patients needed 
dose reduction. 96% of patients (all but 1) received at least 45Gy radiotherapy, and all 
completed the full 25 fractions. Seven patients (28%) (including 3 patients receiving a 
diverting stoma because of obstructive symptoms prior to NACRT) experienced grade 3 
toxicity, notably diarrhoea and radiation dermatitis, but no grade 4 toxicity.  
 
 
4.5.2 THE EFFECT OF NACRT ON PHYSICAL FITNESS 
 
Table 4.3 shows CPET-derived variables pre- and post-NACRT. Post-NACRT, both 
absolute (ml.min
-1
) and relative (ml.kg.
-1
min
-1
) V o2 at ˆ L and Peak exercise were reduced 
(p<0.0001). Figure 4.2 and 4.3 show a pair-plot of individual patients’ V o2 at ˆ L and Peak 
pre- and post-NACRT.  
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Table 4.3 – CPET variables pre- and post-NACRT. 1 Values presented as mean (SD); 2 Values presented as 
median (IQR) 
 
 
 Pre-NACRT Post-NACRT Mean Difference 
(95% CI) 
P-value 
V o2 at ˆ L   
(ml.kg
-1
.min
-1
)
2
 
12.1 
(9.4-13.0) 
10.6 
(8.2-12.0) 
-1.5 
(-1.7, -1.2) 
<0.0001 
V o2 at ˆ L  
(ml.min
-1
)
1
 
905.2 
(343.4) 
803.0 
(323.5) 
-102.2 
(-75.7,-128.7) 
<0.0001 
V o2 Peak  
(ml.kg
-1
.min
-1
)
2
 
18.1 
(15.7-20.4) 
16.7 
(12.1-19.2) 
-1.4 
(-3.1, -1.0) 
<0.0001 
V o2 Peak  
(ml.min
-1
)
1
 
1370 
(710) 
1180 
(690) 
-190 
(-86.7, -252.1) 
<0.0001 
O2 pulse at ˆ L  
(ml.beat
-1
)
1
 
8.7 
(2.9) 
8.0 
(2.7) 
-0.7 
(-1.2, -0.2) 
0.005 
O2 pulse at Peak 
(ml.beat
-1
)
1
 
11.2 
(3.6) 
10.1 
(3.0) 
-1.1 
(-1.8, -0.4) 
0.002 
V E/ V co2 at ˆ L 1 33.5 
(5.1) 
33.1 
(5.1) 
-0.4 
(-1.7, 0.9) 
0.54 
V E/ V co2 at Peak1 35.8 
(5.5) 
35.8 
(6.1) 
0 
(-1.2, 1.2) 
0.99 
Baseline heart rate 
(beats.min
-1
)
2
 
85 
(68-91) 
83 
(70-88) 
-2 
(-4.7, 2.1) 
0.43 
Peak heart Rate 
(beats.min
-1
)
2
 
124 
(103-144) 
122 
(110-139) 
2 
(-6.4, 10.5) 
0.62 
Work load at ˆ L  
(W)
2
 
46 
(35-56) 
41 
(24-55) 
-5 
(-10.0, 0.1) 
0.06 
Work load at Peak 
(W)
2
 
104 
(66-122) 
96 
(60-116) 
-8 
(-13.4, -2.7) 
0.005 
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Figure 4.2 – Pair-plot of V o2 at ˆ L (ml.kg.-1min-1) pre and post-NACRT 
 
 
 
 
Figure 4.3 - Pair-plot of V o2 at Peak (ml.kg.-1min-1) pre- and post-NACRT 
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Oxygen pulse (ml.beat
-1
) decreased at both ˆ L (p=0.005) and Peak (p=0.002). V E/ V co2 
did not change. There was a trend towards (however statistically non-significant) a change in 
median workload at ˆ L (p=0.06), but a significant reduction in maximum power (p=0.005) 
was found. There was no change in resting or peak heart rate, spirometry and haemoglobin, 
and no relationship was found between changes in V o2 at ˆ L and change in haemoglobin 
with NACRT (r=0.18; p>0.05). 
 
 
4.5.3 RELATIONSHIP BETWEEN PHYSICAL FITNESS AND SURGICAL 
OUTCOME 
 
The median WHO performance status of 1 (0-2) pre-NACRT did not change post-NACRT. 
CR-POSSUM was calculated using variables collected immediately pre- and 
postoperatively, with patients having a mean operative severity score of 11.2 (1.2), 
physiological score of 9 (1.8) and predicted mortality of 7.8% (4.5). No in-hospital mortality 
was observed.  Two patients (8%) were dead at 1 year follow up due to radiologically 
documented liver and brain metastasis; both had an V o2 at ˆ L of ≤10.7ml.kg.
-1
min
-1 
post-
NACRT, and suffered from postoperative anastomotic leaks (Grade IIIa). 15 of 25 patients 
(60%) experienced ≥1 postoperative complications (Grade ≥1). 10 of 15 patients with an in-
hospital complication (67%) had a V o2 at ˆ L less than 10.7ml.kg.
-1
min
-1
. The mean (SD) 
V o2 at ˆ L pre- vs. post-NACRT in patients with POMS 0 at day 5 was 13.1±4.1 vs. 
10.8±1.9 ml.kg.
-1
min
-1
 respectively, compared with 11.8±3.9 vs. 9.3±2.0 ml.kg.
-1
min
-1
 in 
patients with POMS ≥1. Table 4.4 shows complication grade as described by Clavien-Dindo 
classification, as well as POMS at day 5 and at 180-days.  
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Complication Type In-Hospital Morbidity 180-day Morbidity 
 CD POMS at Day 5 CD Observed Episodes 
LT ≤10.7 * 
(n=13) 
LT >10.7 
*
 
(n=12) 
LT ≤10.7 * 
(n=13) 
LT >10.7 
*
 
(n=12) 
Pulmonary 
Pneumonia 
 
II 
 
2 
 
0 
 
II 
 
0 
 
2 
Infection 
Febrile requiring 
Antibiotics 
Anastomotic Leak 
requiring re operation  
 
II 
 
IIIb 
 
3 
 
2 
 
1 
 
1 
 
II 
 
0 
 
1 
 
0 
 
3 
 
0 
Renal 
Acute Kidney Injury 
 
I 
 
1 
 
0 
 
0 
 
0 
 
0 
Gastrointestinal 
Ileus 
Total Parenteral Nutrition 
High Output stoma 
Abdominal Collection 
Bowel Obstruction 
 
I 
II 
0 
0 
0 
 
4 
5 
0 
0 
0 
 
0 
1 
0 
0 
0 
 
0 
II 
II 
IIIa 
IIIb 
 
0 
1 
1 
0 
1 
 
0 
0 
0 
2 
0 
Cardiovascular 
Arrhythmias 
 
II 
 
1 
 
0 
 
0 
 
0 
 
0 
Neurological 0 0 0 0 0 0 
Haematological II 1 0 II 1 0 
New Postoperative Pain I 0 1 0 0 0 
Wound Dehiscence 
Abdominal 
Perineal  
 
II 
II 
 
1 
3 
 
0 
2 
 
0 
I 
 
0 
1 
 
0 
2 
 
Table 4.4 – Total postoperative in-hospital morbidity assessed by Clavien-Dindo Classification (CD) and POMS 
at Day 5 dichotomized at the ROC cut-off for V o2 at ˆ L post-NACRT (10.7 ml.kg.-1min-1). 180-day morbidity 
assessed by Clavien-Dindo Classification and number of observed POMS morbidity episodes dichotomized at the 
ROC cut-off V o2 at ˆ L post-NACRT. 
 
ROC curves were constructed to discriminate between patients with and without 
postoperative in-hospital complications based on their pre- and post-NACRT V o2 at ˆ L and 
Peak. An optimal V o2 at ˆ L and Peak of 12.0 and 18.1 ml.kg.
-1
min
-1
 respectively (Figure 
4.4A and B) predicted those at risk of increased postoperative complications; this was 77% 
sensitive and 75% specific ( V o2 at ˆ L - Area under curve (AUC) = 0.71, 95% CI 0.50-0.93; 
V o2 at Peak – AUC = 0.75, 95% CI 0.55-0.95) for both ˆ L and Peak variables. Repeating 
the ROC analysis with the post-NACRT variables (Figure 4.5A and B), optimal cut-off 
points were 10.7 and 16.7 ml.kg.
-1
min
-1
 respectively; this was 77% sensitive and 83% 
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specific for V o2 at ˆ L (AUC = 0.72, 95%CI 0.50-0.94) and 85% sensitive and 83% specific 
for V o2 at Peak (AUC = 0.80, 95% CI 0.60-1.00). 
 
 
 
 
Figure 4.4A – ROC curve for V o2 at ˆ L pre-NACRT 
 
 
 
 
Figure 4.4B – ROC curve for V o2 Peak pre-NACRT 
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Figure 4.5A – ROC curve for V o2 at ˆ L post-NACRT 
 
 
 
 
Figure 4.5B – ROC curve for V o2 Peak post-NACRT 
 
A logistic regression model was used to investigate the association of CPET variables with 
in-hospital complications. Complication episodes were dichotomized around the ROC cut-
off values of 12.0 ml.kg.
-1
min
-1
 for pre-NACRT and 10.7 ml.kg.
-1
min
-1
 for post-NACRT V
o2 at ˆ L. A 90% reduction in the odds of complications was observed respectively (pre-
NACRT – OR 0.10, 95% CI 0.16-0.63; p=0.01, post-NACRT – OR 0.09, 95% CI 0.01-0.61; 
p=0.01). Fitting the same model for pre- and post- V o2 Peak (Cut-off 18.1 ml.kg.
-1
min
-1
 pre-
NACRT and 16.7 ml.kg.
-1
min
-1
 post-NACRT), the odds of complications reduced by 85% 
and 94% respectively (pre-NACRT – OR 0.15, 95% CI 0.03-0.87; p=0.04; post-NACRT – 
OR 0.06, 95% CI 0-0.44; p=0.006).  
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4.6 DISCUSSION 
 
This work reports three important novel findings. Firstly, in patients with resectable locally 
advanced rectal cancer, NACRT prior to surgery impairs objectively measured physical 
fitness (significant reduction in V o2 and oxygen pulse both at ˆ L and Peak exercise and 
significant reduction in peak work rate). This reduction in fitness following NACRT is 
consistent across a broad range of levels of baseline fitness (Figures 4.2 and 4.3). Secondly, 
reduced physical fitness ( V o2 at ˆ L and Peak) is associated with an unfavourable 
postoperative in-hospital outcome. Lastly, using cut-off values derived from the ROC 
analysis for V o2 at ˆ L and Peak exercise, postoperative in-hospital morbidity can be 
predicted with a good accuracy. Taken together these findings suggest that physiological 
reserve (the ability to increase V o2 in response to a stressor) is important for rectal cancer 
patients exposed to the dual challenges of NACRT and major surgery. Furthermore, the 
decline in physical fitness objectively determined by CPET in this cohort is associated with 
postoperative outcome. This has obvious clinical implications. 
 
The main motive for this present work is that the effects of cancer therapies on objectively 
measured physical fitness have not previously been explored in any patient cohort. The 
benefits of NACRT in rectal cancer are improved local disease control (12) and possibly 
overall and cancer-specific survival (236). Although it may seem unsurprising that NACRT 
impairs physical fitness, only Swellengrebel and colleagues (14) clearly link poor 
performance status at diagnosis (a subjective measure of fitness assessment) and the extent 
of surgery to postoperative morbidity.  
 
The mechanism of this decline in fitness has not been explored in this cohort. However, it is  
know that cancer-induced cachexia may cause loss of up to 75% of skeletal muscle (237), 
resulting in fatigue and higher mortality (238). In this cohort, cancer progression is not a 
contributing factor as tumours on average were downstaged (Table 4.2). Equally 
haemoglobin, BMI, and weight remained stable during NACRT which makes cachexia or 
anemia an unlikely cause for this acute reduction in fitness. Chemotherapy, particularly 
capecitabine may also directly contribute (239–241), by mechanisms which are not fully 
understood. It is known that oxidative damage (16–18) (which causes muscle weakness and 
fatigue) caused by doxorubicin-based chemotherapy causes loss of muscle mass (19,20), up-
regulation of E3 ubiquitin-ligase/MAFbx (242) and causes mitochondrial death (23). 
Moreover, drugs with a quinone moiety can directly interact with oxygen to generate 
reactive oxygen species (ROS) (21), while other chemotherapeutic agents decrease 
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antioxidant levels. The effects of capecitabine in relation to oxidative damage and 
mitochondrial damage are currently unknown. However, it is known that chemotherapy 
affects cardiorespiratory and microcirculatory function (243), physical activity (240,244), 
and mitochondrial and other cellular metabolism (245), but cellular/physiological 
mechanisms of this type of chemoradiotherapy used in this population remain elusive. The 
link between neoadjuvant cancer therapies and postoperative outcome is not clear. A large 
retrospective study in a diverse cancer populations has shown that the odds of mortality or 
composite 30-day postoperative morbidity appears not to differ in patients who were or were 
not given chemotherapy within 30 days before surgery (227).  
 
The mechanism of reduced fitness due to NACRT is currently unknown. This appears to be 
the first study in which a reduction in objectively measured physical fitness and its link to 
short and medium term postoperative outcome has been explored using validated and robust 
methodology. A recent study has explored the impact of neoadjuvant chemotherapy (NAC) 
on physical fitness in upper gastrointestinal cancer patients prior to elective surgery. This 
used self-paced exercise tests in resectable oesophageal squamous cell cancer and found that 
NAC had no impact on physical fitness and activity (defined by 6-minute walking distance 
and the International Physical Activity Questionnaire); however objective measures such as 
CPET or activity monitoring were not used (246). A recently published observational study 
has observed the same decline in fitness with NAC in upper gastrointestinal cancer patients 
with a significant association between objectively measured fitness (using CPET) and 1-year 
survival (43).    
 
Apart from the novelty of the observation, the strengths of this study include the low risk of 
confounding by indication (44), the consistently blinded objective physiological evaluation, 
the standardization of the NACRT regime, the homogenous cancer cohort and a 
comprehensive short- and medium-term follow up. Limitations lie in the observational 
design, the small sample size and the recall bias introduced by the telephone 180-day follow-
up. Whilst this study was adequately powered (90%) to detect a 1.5 ml.kg.
-1
min
-1
 difference 
in V o2 at ˆ L, it was not ‘powered’ (i.e. designed to have a sufficient sample size) to detect a 
link between change in physical fitness and postoperative outcome: a larger, adequately 
powered, prospective studies will be required to achieve this goal.    
 
A reduction in CPET variables observed could be a consequence of factors including 
anaemia, progression of disease, inactivity or poor nutritional intake: however, haemoglobin, 
weight and BMI were unchanged and tumours were on average downstaged in our cohort 
(Table 4.1 and 4.2).  
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The findings presented in this chapter have potentially important clinical implications. A 
seen in Section 2.5.2, reduced physical fitness is associated with increased perioperative 
morbidity and mortality. These data presented here provide the first direct evidence that the 
benefits of NACRT in tumour downsizing may be at least partly offset by increased 
perioperative risk due to reduced physical fitness. Further, these data show that standardised 
and objective measurements of fitness allow an accurate preoperative assessment with some 
predictive power for short term postoperative morbidity; however a more definitive study is 
needed to validate these findings. A detailed understanding of the pre-treatment state is 
particularly important in patients with borderline baseline fitness, where a further fitness 
decline may be linked to adverse postoperative outcomes. This relationship merits further 
investigation, as does the possibility of intervention by exercise training during NACRT or 
in the preoperative period to attenuate these deleterious effects of NACRT on physical 
fitness. This will be investigated in my feasibility and tolerability pilot study (Chapter 5) and 
in the ensuing prehabilitation parallel group, non-randomized controlled trial (Chapter 6) 
investigating the improvements in physical fitness resulting from a 6-week structured 
responsive exercise training programme.  
 
In conclusion, NACRT before major rectal cancer surgery significantly reduces physical 
fitness objectively assessed by CPET. Furthermore, the observed association between 
reduced physical fitness and unfavourable postoperative outcome relating to both in-hospital 
and 180-day morbidity merits further study. These effects should influence the perioperative 
management of locally advanced rectal cancer patients, with special emphasis on an 
intervention to improve physical fitness using a preoperative tailored exercise training 
programme as will be illustrated in Chapter 5 and 6. 
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Chapter 5 
 
 
Development of the Structured Responsive 
Exercise Training Programme and a Feasibility 
Study 
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CHAPTER 5 – Development of the Structured Responsive Exercise Training 
Programme and a Feasibility Study 
 
 
5.1 INTRODUCTION 
 
Aerobic exercise training is known to be beneficial in improving physical fitness in a variety 
of clinical populations (147–150,247). Exercise training has been shown to improve 
objectively measured physical fitness over a short time period, with significant augmentation 
of cardiac (248), respiratory (249) and musculoskeletal function (250). The decrease in 
physical fitness post-NACRT described in the previous chapter (Section 4.5.2), together 
with the unfavourable postoperative outcome (Section 4.5.3) highlights the need for an 
intervention, in the form of an exercise programme, to improve physical fitness prior to 
major surgery and potentially improve postoperative surgical outcome.  
 
The implementation of an aerobic exercise training intervention between diagnosis and 
surgery already appears to be feasible in the preoperative period, however the evidence to 
support this and the possibility of improving postoperative outcome is currently very limited 
(151,153,154). As seen in Section 2.6, systematic reviews of the literature on preoperative 
exercise interventions are limited by the number of available studies and the large 
heterogeneity of the exercise techniques and surgical patient cohorts.   
 
In this next chapter I will detail the iterative processes that led to the development of the 
proposed exercise training programme presented in Section 3.3. Additionally, this 
intervention will then be tested for its feasibility and tolerability in Section 5.3 of this 
chapter.  
 
 
5.2 DEVELOPMENT OF THE EXERCISE TRAINING PROGRAMME 
 
Recent guidance published by the American Heart Association and the American College of 
Sports Medicine (ACSM) (118,251) have helped clarify public health recommendations for 
physical activity in adults and the elderly with chronic conditions. These have been 
subsequently incorporated into the recently published position statement published by the 
ACSM (252). They conclude that the benefits of exercise outweigh the risks in most adults. 
A programme of regular exercise that includes cardiorespiratory, resistance, flexibility, and 
neuromotor exercise training in addition to activities of daily living is essential for most 
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adults to improve and maintain physical fitness and health. The ACSM also recommends 
that most adults engage in moderate-intensity cardiorespiratory exercise training for more 
than 30 minutes per day on an average of 5 days per week for a total of approximately 150 
minutes per week, or vigorous-intensity cardiorespiratory exercise training for more than 20 
minutes per day for 3 days per week. A combination of moderate- and vigorous-intensity 
exercise should aim to achieve a total energy expenditure of approximately 500–1000 
METs/min/week. Bearing all these recommendations in mind, I set out to review the 
literature around preoperative exercise training (discussed in Section 2.6 and published in 
the British Journal of Anaesthesia 2013 (154)). Due to the rigorous nature of the quality 
tools applied when conducting the systematic review, some important studies reporting 
exercise programmes in different settings may have not been included. I now revisit this 
literature in Section 5.2.1 and detail how these studies also contributed to the iterative 
process and design of the final exercise training programme.  
 
My aim was to set up an exercise training programme which was achievable, tolerable and 
feasible for locally advanced rectal cancer patients immediately after NACRT. An obvious 
challenge was the time constraint of undertaking this exercise programme in an NHS target-
driven rectal cancer pathway. The exercise programme was designed to improve physical 
fitness (meeting patients’ needs, goals and initial abilities) in the time period following 
NACRT and prior to surgery. The intensity of the exercise training programme was designed 
to be tailored and responsive to each patient’s initial and evolving abilities by using CPET as 
an objective measure of physical fitness. All exercise training programmes in cancer patients 
have been undertaken either during or following adjuvant cancer therapies, designing such a 
new programme required focus and emphasis placed on individual patient abilities post-
NACRT. This proved challenging as patients following such treatment often present with 
treatment-related side effects and are by default high-risk due to the nature of the tumour and 
cancer therapies they receive. Furthermore, to my knowledge this was never attempted 
before in this cohort of patients.  
 
 
5.2.1 REVIEW OF EXERCISE TRAINING INTERVENTIONS 
 
The role of exercise in cardiac (253) and pulmonary rehabilitation (152) is well established. 
A recent meta-analysis investigated the effects of different levels of training intensity (high 
vs. low) and type (continuous vs. interval) on exercise capacity and health-related quality of 
life for chronic obstructive pulmonary disease (COPD) patients (254). They concluded that 
comparisons between the higher and lower training intensities were limited due to the small 
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number of included studies and participants. Furthermore, comparisons between continuous 
and interval training, appear to be equally effective in improving exercise capacity. Intensity, 
duration and exercise modality are important determinants of the physiological adaptations 
that occur in response to training. In COPD, these have not been explored in great detail; 
however there seems to be greater physiological benefits obtained through high-intensity 
compared to moderate-intensity training programmes (255,256). However, high-intensity 
exercise training in a continuous fashion may not be applicable to certain types of patient 
cohorts. Implementation of exercise type is also crucial; interval training in pulmonary 
rehabilitation has been advocated as an alternative to continuous exercise. Interval and 
continuous training can both be applied safely and effectively within the context of 
pulmonary rehabilitation (152), however the choice of interval or continuous training will be 
a matter of patient and/or therapist preference. Interval training may require a higher 
therapist to patient ratio to ensure adequate work rate and rest intervals are achieved 
compared with continuous training; however interval training has been found to be more 
acceptable to patients (257,258) and can also be used to deliver higher intensity training 
which is easily tolerable (254).  
 
Section 2.6 answered several related questions using a systematic review of preoperative 
exercise programmes; however this review excluded (see Appendix 4 for exclusion criteria) 
several studies which were nevertheless considered important and were utilised in the 
derivation of the exercise programme detailed in Section 3.3. This literature will be 
presented briefly in Table 5.1. 
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*- cancer survivors  
 
Table 5.1 – Training programme characteristics of studies exclude by the systematic review presented in Section 
3.3. HRR – Heart Rate Response, min – minutes, RPE – rating of perceived exertion scale, Max HR –maximum 
heart rate, HIT – high intensity training, LIT – low intensity training. 
 
Various exercise training programmes have been used in a variety of pre- or post- operative 
settings as seen in the table above and in Section 2.6. Most of these training programmes 
have been associated with improvement in exercise variables with minimal adverse effects. 
Study Population Exercise 
Intervention 
Frequency Intensity Duration 
      Myers et al. 
(259) 
Abdominal 
Aortic 
Aneurysm 
Resistance 3/week 60% HRR up to 80% 10 min 
      Kothmann et al. 
(260) 
Abdominal 
Aortic 
Aneurysm 
Continuous 2/week 12-14 BORG RPE 30 min 
      Adamsen et al. 
(261) 
Cancer 
patients 
undergoing 
chemotherapy 
High intensity 
resistance and 
interval 
3/week 85-95% Max HR 90 min 
      Courneya et al. 
(262)* 
Colorectal 
cancer 
Walking 3-5/week 65-75% Max HR 20-30 
min 
      Courneya et al. 
(263)* 
Lymphoma Aerobic 
training 
3/week 60-75% V o2 Peak 
and 1 session 
interval training at 
100% V o2 Peak 
 
15-45 
min 
Segal et al. 
(264)* 
Prostate 
cancer 
Aerobic vs. 
resistance 
training 
3/week 50-75% V o2 Peak 15-45 
min 
      Courneya et al. 
(265) 
Breast cancer Aerobic vs. 
resistance 
training 
3/week 60-80% V o2 Peak 15-45 
min 
Herrero et al. 
(266)* 
Breast cancer Combined 
aerobic and 
resistance 
3/week 70-80% Max HR 20-30 
min 
Courneya et al. 
(267)* 
Breast cancer Aerobic 
training 
3/week 70-75% V o2 Peak 15-35 
min 
      
Burnham et al. 
(268)* 
Cancer 
patients 
High vs. low 
intensity 
aerobic 
training 
3/week HIT – 40-60% HRR 
LIT – 25-40% HRR 
14-32 
min 
Jones et al. 
(269) 
Breast cancer Moderate vs. 
moderate-high 
intensity 
aerobic 
150min/ 
week 
Moderate – 60-75% 
V o2 Peak 
High – 60-100% V
o2 Peak 
20-45 
min 
      
Dimeo et al 
(270)* 
Cancer 
patients 
Interval 
training 
5/week Week 1 5x3 min 
Week 2 4x5 min 
Week 3 3x8 min 
80% Max HR 
30 min 
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The literature presented above as well as that presented in Section 2.6 was carefully 
presented to a Steering Group of exercise training experts (acknowledged). Taking 
everything I have discussed into consideration, this led to the development of an iterative 
process, which resulted in the final training programme presented in Section 3.3. In the next 
section (Section 5.2.2) I will attempt to deconstruct the training programme, justify the 
rationale behind the individual components and detail how these come together to make up 
the final exercise intervention.  
 
 
5.2.2 EXERCISE PRESCRIPTION 
 
During the iterative process that led to the final design of the exercise training protocol, 
myself and the Steering Group considered: 
 
 Planning and integration into a standard NHS cancer pathway 
 Training setting (home based, hospital based or a combination) 
 Programme duration 
 Session duration 
 Session frequency 
 Programme modality (bike vs. treadmill) 
 Training modality (continuous, interval, resistance, etc.) 
 Exercise intensity (high, moderate, low etc.) 
 Monitoring response (session and whole programme) 
 Tailoring training intensity to individual ability 
 Primary and secondary exercise variables to serve as endpoints  
 
 
Planning and Integration into a Standard NHS Cancer Pathway 
The training programme was planned to take place in the hiatus between the end of NACRT 
(i.e. Week 0) and the re-staging scans at Week 9 (Figure 3.2; Chapter 3). Due to the rigor 
and time constrains of the standard NHS cancer pathway, the patients only had a maximum 
of 14 weeks to train prior to surgery. A decision was taken to start the training immediately 
after NACRT (usually the following Monday after completion of NACRT) as it was agreed 
that the patients would anecdotally be at their weakest physical fitness immediate after 
NACRT, and exercise could potentially halt the deleterious effects of NACRT on their 
fitness (based on the findings presented in Section 4.5). The Steering Committee 
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immediately identified the need for a feasibility and tolerability (F&T) study, as this would 
test two important aspects of the training protocol i.e. that patients immediately post-
NACRT are able to sit on a static ergometer and cycle effectively, and also that patients 
could complete an exercise training programme.  
 
Training Setting 
Due to the novelty of the training programme, the specialised equipment needed and the 
unknown risk to the population pertaining to exercise training immediately after NACRT, 
the Steering Group decided to offer a supervised, in-hospital training programme, which 
would be delivered by me with the help of an exercise physiologist, with full resuscitation 
equipment immediately available.  
 
Programme Duration 
As discussed in the integration section above, the maximum length of the training 
programme (until the date of surgery) could have been up to 14 weeks, however the time to 
rectal cancer surgery post-NACRT is quite long at AUH and is not common practice in other 
NHS hospitals. The usual time to surgery post-NACRT is approximately 6-8 weeks, 
therefore the steering committee decided to implement a 6 week programme of exercise, as 
this is the absolute minimum time window that any NHS hospital would wait post-NACRT 
prior to surgery, thus the exercise programme can be easy implemented in other NHS trusts 
without the need to change their standard cancer care pathway. 
 
Session Duration 
ACSM guidance was used to decide the duration of the exercise sessions (252). A 30 minute 
exercise session for the first 3 sessions, increasing to 40 minutes for the next 12 sessions was 
deemed to be appropriate. This was also based on the level of exercise intensity that the 
patients will be doing, as well as the average age of the population and concomitant medical 
co-morbidities. The F&T study was to investigate whether this was appropriate. 
 
Session Frequency 
Again, the ACSM guidelines were used to arrive to the conclusion that 3 sessions per week 
(usually Monday, Wednesday and Friday), preferably at the same time of day was optimal. 
The F&T study was to investigate whether this was appropriate (252). 
 
Programme Modality 
A cycle ergometer was chosen by the Steering Group as the modality for exercise delivery. 
The stationary ergometer has the advantage of providing weight-supported exercise to the 
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patients, albeit with the discomfort of having to sit down on a seat. The seat tolerability was 
a source of concern for the steering committee particularly in this patient cohort, however as 
these patients would be monitored by CPET using a cycle ergometer it was felt that cycle 
training would provide the safest and most accurate way of quantifying work rates 
prescribed (214). Moreover, the exercise training ergometers purchased had the function of a 
fully programmable chip and pin card which drove the exercise training programme and a 
screen (Figure 3.9) which guided the patient through the programme. This provides help, 
guidance and self-monitoring for the patient as they progress through the exercise sessions.       
 
Training Modality 
Various training modalities have been employed in both preoperative and postoperative 
exercise training programmes as well as in cardiac or pulmonary rehabilitation. The largest 
body of evidence is around interval and continuous training within the context of pulmonary 
rehabilitation (152).  
 
Interval exercise was chosen for this cohort of patients as it has been found to be more 
acceptable to high risk patients (257,258) and to deliver higher intensity training which was 
easily tolerable (254). Moreover, interval exercise training has been successfully used in 
colorectal cancer patients (270) and in various other high risk groups. Meyer et al. (271) 
used interval training (80% max heart rate) in patients post-coronary bypass surgery, which 
increased fitness and lowered baseline heart rates. Moholdt et al. (272) randomized patients 
post-coronary bypass surgery to an interval (4 min at 90% max heart rate and 3 min 70% 
max heart rate) or continuous exercise (70% max heart rate for 46 min). They showed 
significant improvements in V o2 Peak in both groups within 4 weeks, however at 6 months 
the interval group shows a better long-term effect. Freyssin et al. (273) randomized chronic 
heart failure patients to high-intensity interval (12 repetitions of 30 seconds at 50% and 80% 
max workloads during the first 4 weeks and the last 4 weeks respectively and 60 seconds of 
complete rest) vs. continuous training (45 min of heart rate at V o2 at ˆ L ). Both types of 
exercise were deemed safe and tolerable for this population. The interval group significantly 
increased their V o2 Peak and 6-min waking time when compared to the continuous group. 
Wisloff et al. (274) randomized post-infarction heart failure patients to moderate continuous 
training (70% of peak heart rate) or aerobic interval training (95% of peak heart rate) 3 times 
per week for 12 weeks. V o2 Peak increased more with aerobic interval training than 
moderate continuous training (46% vs. 14%, p<0.001). Left ventricular end-diastolic and 
end-systolic volumes declined with aerobic interval training only, by 18% and 25%, 
respectively; left ventricular ejection fraction increased 35%, and pro-brain natriuretic 
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peptide decreased 40%. Of interest, mitochondrial function in lateral vastus muscle 
increased with aerobic interval training only. No changes occurred in the control group (38).  
 
Gloeckl et al. (275) randomized lung transplant candidates to interval (100% V o2 Peak work 
rate for 30 seconds alternating with 30 seconds rest) vs. continuous training (60% V o2 Peak 
work rate) during a 3-week inpatient rehabilitation program. This was well tolerated and 
both groups achieved similar clinically relevant improvements in 6-minute walking distance; 
however patients in the interval group had lower dyspnoea and had fewer unintended breaks.   
In a mechanistic study, Daussin et al. (276) studied the effects of continuous vs. interval 
training (4 min work load at V o2 at ˆ L followed by 1 min at 90% work load at V o2 Max) 
on skeletal muscle and cardiorespiratory adaptations in sedentary subjects. An 8-week 
training program in a cross-over design, separated by 12 weeks of detraining, was 
conducted. Maximal oxygen uptake ( V o2 Max) increased after both trainings, whereas only 
the interval group was associated with faster V o2 kinetics (τ: 68.0 ± 1.6 vs. 54.9 ±0.7 s, P 
<0.05) measured during a test to exhaustion. Skeletal muscle mitochondrial oxidative 
capacities (V max) were only increased after interval training (3.3 ±0.4 before and 4.5 ±0.6 
μmol O2.min
-1
.g dw
-1
 after training; P <0.05). The gain of V max was correlated with the 
gain of V o2 Max with interval training. These results suggest that fluctuations of workload 
and oxygen uptake during training sessions, rather than exercise duration or global energy 
expenditure, are key factors in improving muscle oxidative capacities. In this study, interval 
training seems to be optimal in maximizing both peripheral muscle and central 
cardiorespiratory adaptations, permitting significant physical fitness improvement. 
 
As seen above both modalities can be applied safely and effectively, however the choice of 
interval or continuous training will usually be down to the patient and/or therapist 
preference. Both interval and continuous training require patient supervision, however as the 
equipment used in this study enabled the training programme to be fully automated, the level 
of input from the person supervising the exercise programme was minimal. The tolerability 
of the derived interval training programme will be assessed in the F&T study. 
 
Exercise intensity 
Historically, the rationale for interval exercise training has been the ability to impose very 
high power outputs from peripheral muscles without overloading the cardiorespiratory 
capacity. In healthy young people, high-intensity interval training induces greater 
improvement in oxygen consumption (277), work rate, ventilatory and lactate thresholds 
(278) compared to continuous training. Studies on muscle fibre metabolism during interval 
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exercise in healthy subjects have shown that glycogen depletion is similar between type I 
and II fibres, suggesting that both fibre types are recruited to a similar degree. Although, 
heavy intensity continuous exercise induces high blood lactate levels (due to the depletion of 
phosphocreatine and the use of myoglobin-bound oxygen reserves), interspersed periods of 
sub-lactate threshold work rates may facilitate lactate removal and partially restore the 
phosphocreatine levels (279).  
 
Compared with the same total amount of work performed continuously, interval exercise 
imposes maximal loads on both peripheral muscles and oxygen-transporting organs without 
significant engagement of anaerobic processes. In moderate exercise with short exercise 
periods (< 30 sec) healthy young subjects can endure very high rates of aerobic exercise 
thereby yielding very little lactate production. This type of high intensity periodic activity is 
shown to be effective not only in athletic training but also in COPD (257,280) and chronic 
heart failure (274,281).  
 
A moderate alternating with high intensity exercise programme was chosen (3 min moderate 
intensity alternating within 2 min severe intensity exercise) for this study. The literature is 
equivocal when considering the intensity of exercise training programmes; however, levels 
of intensity were used which coincided to the work rate at V o2 at ˆ L  (282,283) and V o2 
Peak (284) as this has been shown to be an adequate training stimulus for sedentary adults 
(118,251) and in a preoperative setting (154,260). Moderate intensity exercise will be 
defined as an intensity equivalent to 80% of the work rate at V o2 at ˆ L. This will ensure 
that during this bout the patient is exercising in the moderate intensity domain. Severe 
intensity exercise will be defined as a work rate intensity equivalent to 50% of the difference 
between the V o2 at ˆ L and V o2 Peak. This severe exercise intensity was selected to 
approximate intensities used in studies that utilize maximal heart rate or maximal workload 
intensities approaching 70-80% (156,159,162,259,261,263–266,270,285). Defining exercise 
training intensities using the workloads derived by CPET is reliable, accurate and objective. 
The tolerability of the interval training programme intensity and intervals will be assessed in 
the F&T study.  
 
Monitoring Training Response 
The patients’ training response will be monitored by CPET, so the steering committee 
decided to include a further CPET at session 7 (mid-exercise). This allows monitoring and 
tailoring individual patient’s training programme in response to their mid-exercise CPET. 
  
134 
 
Intensity Tailoring 
Work rates at moderate and severe intensity will be tailored to the patients’ individual needs 
as assessed by CPET. At session 7 (mid-exercise), the work rates at V o2 at ˆ L and V o2 
Peak are re-derived and the moderate and severe intensity domains are changed accordingly 
(see formula Section 3.3.1). If no change or a decline in workloads is found, the same 
workloads as the first 5 training sessions will be maintained. The tolerability of changes in 
intensity will be assessed in the F&T study. 
 
Primary and Secondary Exercise Variable Endpoints 
The Steering Committee decided that the primary end point was to study the changes in V o2 
at ˆ L as this was felt to be a clinically relevant outcome variable which is non-volition 
dependant and reliably identified by CPET. The steering committee was guided by the 
results from Section 4.5 which show a -1.5 ml.kg
-1
.min
-1 
significant change between V o2 at 
ˆ L pre- and post NACRT. This was felt to be clinically relevant and important. Kothmann 
and colleagues (286) established a minimum clinically significant difference of 2.0 ml.kg
-
1
.min
-1 
in V o2 at ˆ L in patients undergoing major intra-abdominal surgery, hence an 
improvement of this magnitude was considered clinically relevant and significant in this 
population. If the F&T proves successful (i.e. attaining a clinically significant change in V
o2 at ˆ L), a change of 2.0 ml.kg
-1
.min
-1 
in V o2 at ˆ L will be used to provide a sample size 
calculation for the prehabilitation study (detailed in Chapter 6). Secondary outcome 
variables which the F&T study, together with the definitive prehabilitation study will 
investigate include changes in: V o2 Peak, work rates at V o2 at ˆ L and V o2 Peak, O2 pulse 
at ˆ L and Peak, V E/ V co2 at ˆ L
 
and Peak, and baseline and peak heart rates. 
 
 
5.3 FEASIBILITY AND TOLERABILITY STUDY 
 
This section is aimed to study the effects of the structured, responsive, exercise training 
programme (SRETP) detailed in Section 5.2.2 in patients immediately after a standardized 
period of neoadjuvant chemoradiotherapy. This study is designed to test the feasibility and 
tolerability of a 6-week SRETP with specific focus on; (1) the changes in the primary 
outcome variable ( V o2 at ˆ L), (2) the changes in the secondary outcome variables (as 
above), (3) the feasibility of a 6 week SRETP, (4) the patient’s ability to tolerate the SRETP 
immediately after standardized NACRT, (5) the tolerability of the exercise session duration, 
(6) the tolerability of the exercise session frequency, (7) the tolerability of performing 
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exercise on a cycle ergometer immediately post-NACRT, (8) the tolerability of the interval 
training schedule, (9) the tolerability of the exercise intensity and, (10) the tolerability of the 
change in exercise intensity at session 8. 
 
 
5.3.1 PATIENTS AND STUDY METHODS 
 
This single-centre, prospective, interventional feasibility and tolerability study was based at 
Aintree University Teaching Hospitals, Liverpool, UK. Written informed consent was 
obtained from all patients. From October to November 2011, I recruited consecutive patients 
referred to the Colorectal Multi-Disciplinary Team (MDT), age ≥18 years, with locally 
advanced electively resectable rectal cancer, who were scheduled for standardized NACRT 
on the basis of Tumour, Node, Metastasis (TNM) classification >T2/N+ with no distant 
metastasis (230) and WHO Performance Status < 2 (231). Patients were excluded if they 
were diagnosed with non-resectable disease, were unable to perform CPET (due to 
mechanical reasons e.g. unable to pedal), declined surgery or NACRT, underwent a non-
standardized NACRT regime or were unable to give informed consent.  
 
CPET was performed 2 weeks before, immediately post-NACRT (week 0), at week 3 and 6 
weeks post-NACRT (prior to surgery at 15 weeks post-NACRT) (see Figure 3.2; Chapter 3). 
TNM staging investigations involved flexible sigmoidoscopy for histological diagnosis, 
colonoscopy, chest, abdomen and pelvis computer-aided tomography (CT) and a 1.5 Tesla 
(Magnetom Area, Siemens, Erlangen, Germany) magnetic resonance imaging (MRI) of the 
pelvis. Eligible patients then underwent a standardized NACRT regime for 5 weeks. The 
standardized neoadjuvant radiotherapy regime consisted of 45 Gy in 25 fractions on 
weekdays using a three-dimensional conformal technique with CT guidance. Patients were 
treated prone (on a belly-board) to spare small bowel, with a comfortably full bladder. The 
clinical target volume included the primary tumour, the mesorectum and mesorectal lymph 
nodes, including the perirectal, presacral and internal iliac nodes. The upper radiation extent 
was 3 cm above the tumour but no further than the sacral promontory. The perineum was 
included if an abdominoperineal excision (APE) was planned, while for low anterior 
resection (LAR) the lower radiation border was 3 cm below the tumour. A boost dose was 
given (5.4 Gy in 3 fractions) to the primary tumour only. 825 mg.m
-2
 oral capecitabine was 
given twice daily on radiotherapy days (Section 2.4.4). No patients received brachytherapy. 
Acute toxicity and adverse events were discussed at the weekly colorectal multidisciplinary 
meeting (MDT). Adverse events were graded according to the National Cancer Institute 
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Common Terminology Criteria (version 3.0), and the acute radiation-induced skin toxicity 
using the Radiation Therapy Oncology Group scoring system.  
 
All patients went on to have CPET (for protocol refer to Section 3.2), spirometry and re-
staging chest, abdomen and pelvic CT and pelvic MRI at 9 weeks post-NACRT. The 
Colorectal MDT, anaesthetists and medical staff collecting outcome data were blind to all 
CPET results. All patients underwent the SRETP immediately after finishing NACRT (see 
Figure 3.2; Chapter 3). This was undertaken as a feasibility and tolerability trial, in an 
attempt to study the effect of the SRETP in this patient population. Details of the SRETP 
protocol are given in Section 3.3. All patients underwent rectal cancer surgery with a total 
mesorectal excision (TME) (232,233) at week 15. A defunctioning stoma was constructed at 
the discretion of the surgeon.  
 
Continuous variables are presented as mean and standard deviation (SD) or as medians and 
interquartile range (IQR), depending on their distribution. Categorical variables are 
presented as a frequency and/or proportion. The primary outcome variable was V o2 at ˆ L 
(ml.kg.
-1
min
-1
). Secondary outcome variables included V o2 Peak (ml.kg.
-1
min
-1
), work rates 
at V o2 at ˆ L and V o2 Peak, oxygen pulse at ˆ L and Peak (ml.beat
-1
), V E/ V co2 at ˆ L and 
Peak and baseline and peak heart rates. Although no formal statistical analysis is performed 
in this feasibility and tolerability study, a change in V o2 at ˆ L of +2.0 ml.kg
-1
.min
-1 
was 
considered clinically significant (286). Furthermore, this study is only aimed at answering 
specific questions addressed in the aims section above; hence no statistical testing is 
undertaken.  
 
For this study I aimed to recruit 5 patients who completed a course of standardised NACRT 
and were listed to have elective surgery as an intention to treat for rectal cancer.  
 
 
5.3.2 RESULTS  
 
Five consecutive patients were recruited. Table 5.2 describes the patient characteristics and 
Table 5.3 describes tumour characteristics. CPET was performed at 2.0 ± 0.5 weeks pre-
NACRT (Baseline), then immediately post-NACRT (week 0 ± 0.5 weeks), at session 7 
(week 3 ± 0.5 weeks) and at session 18, the end of the exercise programme (week 6 ± 0.5 
weeks). All patients underwent CT and MR-directed staging, then TME surgery at a median 
of 105 (range 100-111) days post-NACRT.  
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Patient Characteristics Total 
Age (years)
1 
74.6 (4.2) 
Gender M:F (%)
1
 5 (100) : 0 (0) 
Past Medical History
#
 
Heart Failure 
Diabetes 
Ischaemic heart Disease 
Cerebrovascular Disease 
 
1 (20%) 
1 (20%) 
1 (20%) 
0 
ASA
2
 2 (2-2) 
WHO Performance Status
2
 0 (0-0) 
Clinical MRI TNM classification
3# 
cT3 
cT4 
cN1 
cN2 
cM0 
 
4 (80%) 
1 (20%) 
3 (60%) 
2 (40%) 
5 (100%) 
 
Table 5.2 – Patient characteristics; # with percentages in parentheses, 1 Values presented as mean (SD); 2 Median 
(range) World Health Organisation (WHO) Performance Status and American Society of Anaesthesiologists 
Score (ASA); 3 International Union against Cancer tumour node metastasis (TNM) MRI pre-NACRT staging 
 
 
Tumour Characteristics Total 
#
 
Tumour distance from anal verge 
<5 cm 1(20) 
6-10cm 0 
>10cm 4(80) 
Pathological TNM 
pT1 1 (20) 
pT2 0 
pT3 3 (60) 
pT4 1 (20) 
pN0 4 (80) 
pN1 1 (20) 
pN2 0 
Dukes Staging 
A 1 (20) 
B 2 (40) 
C 0/1 2 (40) 
Resection margins 
R0 4 (80) 
 
Table 5.3 – Patient tumour and treatment characteritcs; # with percentages in parentheses 
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The mean cumulative dose of capecitabine was 100%; none of the patients needed dose 
reduction. 100% of patients received at least 45Gy radiotherapy, and all completed the full 
25 fractions. None of the patients experienced grade 3 or 4 toxicity. All patients successfully 
underwent 18 sessions of the SRETP set out in Section 3.3, with no adverse events. The 
adherence to the full 18 sessions (3 sessions per week) was 98%, with only 2 patients not 
attending 1 session each. On questioning about the length and tolerability of the training 
programme immediate after completing NACRT, all patients thought this was achievable. 
All patients completed the full exercise sessions (30 or 40 minute sessions) in the pre-
determined order (3 sessions per week for 6 weeks, usually on Monday’s, Wednesday’s and 
Friday’s) and none of the patients had to stop due to adverse events. When asked about the 
tolerability of the length and frequency of the individual sessions all the patients agreed that 
this was achievable. Three out of 5 patients complained of saddle soreness after completing 
the exercise sessions, especially at the end of the week or when the exercise intensity was 
increased. This did not impede the patients from completing any individual session. The 
patients preferred the seat to be more comfortable, so gel cushions were fitted to the training 
bikes. All patients completed an interval training schedule and found this acceptable, 
although one patient found the change in intensities difficult at first. All the patients 
commented on the advantage of tailored, supervised exercise, and found it re-assuring that 
the exercise was undertaken in a hospital setting. All patients found the training intensity 
challenging during the first 3 sessions (rating the first 3 sessions as very hard on the rating of 
perceived exertion (RPE) scale), however this got better as the sessions progressed (with the 
RPE’s decreasing to somewhat hard). Only 2 out of 5 patients noticed a change in work rate 
intensity at session 8.  
 
Table 5.4 shows CPET-derived variables (primary and secondary outcome variables) pre-
NACRT, and at week 0, 3 and 6 post-NACRT. Figures 5.1 and 5.2 show the changes over 
time for all 5 patients (plotted in grey) and median changes (plotted in red) for V o2 at ˆ L 
and V o2 peak respectively. 
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Table 5.4 – CPET variables at all four study time points. Values presented as 1mean (SD) and 2median (IQR) 
 
 
 
 Baseline Week 0 Week 3 Week 6 
BMI (kg.m
-2
)
1 
29 (4.3) 28.6 (4.8) 30.1 (5.3) 29.3 (5.0) 
FEV1 (L)
 1
 2.9 (1.0) 2.9 (1.0) 3.3 (0.7) 2.9 (1.0) 
FVC (L)
 1
 4.2 (1.0) 4.3 (0.9) 4.6 (0.8) 4.3 (0.9) 
FEV1/FVC (%)
1
 66.1 (13.9) 66.0 (12.6) 71.5 (6.1) 66.4 (12.2) 
Haemoglobin (g.dl
-1
)
1
 13.7 (1.5) 13.6 (1.2) n/a 13.5 (1.0) 
V o2 at ˆ L   
(ml.kg
-1
.min
-1
)
2
 
10.3 
(9.5-12.4) 
9.2 
(7.7-10.6) 
10.8 
(10.0-12.0) 
12.5 
(12.1-12.5) 
V o2 at ˆ L (L.min
-1
)
2
 1.0 
(0.9-1.0) 
0.9 
(0.7-1.0) 
1.1 
(1.0-1.1) 
1.2 
(1.2-1.2) 
V o2 Peak  
(ml.kg
-1
.min
-1
)
2
 
17.2 
(15.6-19.9) 
14.3 
(10.8-15.5) 
19.0 
(18.4-19.7) 
20.1 
(19.0-21.1) 
V o2 Peak (L.min
-1
)
2
 1.6 
(1.6-1.7) 
1.3 
(1.0-1.4) 
1.8 
(1.7-1.9) 
1.9 
(1.7-2.1) 
O2 pulse at ˆ L   
(ml.beat
-1
)
2
 
8.6 
(8.5-10.1) 
8.2 
(6.3-8.6) 
10.4 
(9.3-11.4) 
10.8 
(10.7-11.2) 
O2 pulse at Peak  
(ml.beat
-1
)
2
 
11.1 
(11.1-13.9) 
9.9 
(7.1-10.7) 
13.4 
(12.1-13.5) 
13.9 
(12.9-14.2) 
V E/ V co2 at ˆ L
 2
 29.6 
(28.9-35.5) 
31.6 
(31.4-32.4) 
33.2 
(31.0-37.0) 
32.9 
(29.0-34.4) 
V E/ V co2 at Peak
2
 30.6 
(30.1-35.9) 
34.4 
(31.3-35.1) 
32.7 
(32.0-36.6) 
34.2 
(28.8-37.5) 
Baseline heart rate 
(beats.min
-1
)
2
 
89 (88-92) 82 (79-84) 80 (76-80) 80 (75-84) 
Peak heart Rate 
(beats.min
-1
)
2
 
139 
(119-146) 
123 
(114-137) 
132 
(121-142) 
132 
(132-135) 
Work rate at ˆ L (W)
2
 58 (44-62) 56 (56-58) 60 (56-62) 70 (68-72) 
Work rate at Peak (W)
2
 120 
(116-120) 
118 
(112-120) 
136 
(116-138) 
138 
(138-140) 
140 
 
 
 
Figure 5.1 – Line graph of V o2 at ˆ L (ml.kg.-1min-1) showing changes over time. Individual patients plotted in 
grey and median change plotted in red. 
 
 
 
 
 
 
Figure 5.2 – Line graph of V o2 Peak (ml.kg.-1min-1) showing changes over time. Individual patients plotted in 
grey and median change plotted in red. 
 
 
 
0 
2 
4 
6 
8 
10 
12 
14 
16 
Baseline Week 0  Week 3 Week 6 
V
O
2
 a
t 
L
T
 (
m
l.
k
g
-1
.m
in
-1
) 
0 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
Baseline Week 0  Week 3 Week 6 
V
O
2
 P
ea
k
 (
m
l.
k
g
-1
.m
in
-1
) 
141 
 
5.3.3 DISCUSSION 
 
This feasibility and tolerability study yielded important novel findings. Firstly and most 
importantly, that the exercise programme can improve objectively measured physical fitness 
in this cohort of patients’ between week 0 and week 6. A similar decline in physical fitness 
post-NACRT (baseline vs. week 0) is observed in the results above (Figure 5.1 and 5.2) as 
seen in Section 4.5.2. Here V o2 at ˆ L and V o2 Peak declined by -1.1 and -2.9 ml.kg
-1
.min
-1
 
respectively after standardised NACRT (baseline vs. week 0), however the SRETP (week 0 
vs. week 6) improved both V o2 at ˆ L and V o2 Peak by +3.3 and +5.8 ml.kg
-1
.min
-1
 
respectively. Although no formal statistical analysis was applied, the +3.3 ml.kg
-1
.min
-1
 
improvement in V o2 at ˆ L is considered to be a clinically relevant finding. As seen in 
Figures 5.1 and 5.2 all patients sustained a reduction in physical fitness variables post-
NACRT and an improvement in these variables after a structured exercise programme. The 
benefit of the intervention was sufficient to reverse the deleterious effects of NACRT. This 
change in objectively measured physical fitness will be further studied with the addition of a 
parallel control group in Chapter 6, so as to validate these changes in physical fitness and 
compare them to a control group assigned to standard care (negative control, no exercise). 
The volume of exercise prescribed to these individuals, (i.e. frequency x duration x 
intensity) together with the length of the training programme produced a large improvement 
in physical fitness. Moreover, the 98% adherence rate to the exercise programme provides 
initial proof of concept that the SRETP is feasible and tolerable in its duration, setting, 
frequency, intensity and schedule in this cohort of patients. Of note, no problems or adverse 
events were encountered by starting the exercise programme immediately after finishing 
NACRT, even though one of the patients tumours was <5cm from the anal verge (these 
patients in particular tend to suffer from perineal burns post-NACRT). To my knowledge no 
other study reports an exercise training programme that starts immediately after neoadjuvant 
cancer treatment in any preoperative cancer population. The intensity of the training 
programme was chosen because it best approximates the published literature that uses 
maximal heart rate or maximal work rate intensities approaching 70-80%. Furthermore, this 
interval intensity was already shown to be safe in other patient cohorts 
(156,159,162,259,261,263–266,270,285). Work rate at V o2 at ˆ L and V o2 Peak were 
utilised because they were felt to be reliably identified by CPET, and most importantly 
because they can be reliably implemented using the exercise training bikes. I believe that 
these points remain valid, especially in the light of the results of this F&T study. With 
regards to appropriate primary outcome measures to gauge physical fitness improvement, V
o2 Max or V o2 Peak may prove to be more valid. These measurements, however, depend on 
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pushing patients to volitional exhaustion and consequently raise safety concerns in these 
high-risk individuals. V o2 Peak measurements also depends on an individual’s motivation 
during exercise testing, raising some concerns in relation to repeatability in other patient 
groups. In contrast, V o2 at ˆ L measurement can be safely achieved during sub-maximal 
exercise and is independent of subject motivation. These considerations, and the fact that the 
evidence base for improved surgical outcome is founded on this measurement make the 
combination of V o2 at ˆ L and V o2 Peak appropriate outcome measures of physical fitness 
as tested above.  
 
From a clinical stand-point, the patients who achieved the largest improvement in V o2 at ˆ L 
could change their perioperative risk classification from high risk to intermediate or else 
from intermediate to low risk, therefore it would be reasonable to assume (based on the 
current evidence base presented in Section 2.5.2) that such a shift might equate to improved 
surgical outcome in this high-risk population. This however, needs to be tested in a larger 
cohort of patients in a randomized controlled fashion.  
 
The steering committee felt that if such an improvement in physical fitness using a SRETP is 
attained in 6 weeks after NACRT in a feasibility setting, this would merit further 
investigation in a pre-pilot setting to inform a larger, definitive randomized controlled trial.    
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CHAPTER 6 – Prehabilitation – A Pre-Pilot Parallel Group Controlled Study 
 
 
6.1 INTRODUCTION 
 
This chapter aims to further define the effects of neoadjuvant chemoradiotherapy (NACRT) 
and to pilot the structured, responsive exercise training programme (SRETP) developed in 
Chapter 5. This chapter specifically focuses on a pre-pilot, non-randomised, parallel group 
controlled study investigating; (1) the changes in objectively measured V o2 at ˆ L and V o2 
Peak over the study period (Figure 3.2, Chapter 3), (2) changes in other CPET derived 
variables over the study period, (3) the relationship of CPET variables to in-hospital 
morbidity in the exercise and control groups, and (4) the extended safety and tolerability of 
the exercise programme.  
 
Traditionally, efforts to improve recovery and outcome from surgery have used interventions 
in the intra-operative and the postoperative periods (287,288), mainly with the adoption of 
enhanced recovery programmes in major colorectal surgery. However, this might be too late 
in high risk populations like locally advanced cancer patients following neoadjuvant cancer 
therapies. With poor objectively measured physical fitness being clearly linked to poor 
postoperative outcomes (4,120,122,133,289), the preoperative period is thought to offer a 
more emotionally salient and opportune time to intervene and actively engage patients in 
preparation for major surgery and postoperative recovery. The process of enhancing physical 
fitness to enable individuals to withstand the stress of a major traumatic event has been 
termed as prehabilitation (156,290). There is however a paucity of literature around pre-
surgical exercise interventions (154) especially in cancer patients (166,291). This has 
already been discussed in Section 2.6 of this thesis (154). Preoperative aerobic exercise 
training appears to be beneficial in patients awaiting cardiac surgery, but the effect in 
patients prior to major intra-thoracic and intra-abdominal surgeries still remained uncertain. 
The reviewed literature however shows that an intervention prior to surgery is safe, feasible, 
well tolerated and appears to improve objectively measured physical fitness. In Section 5.2, 
the iterative process around the structured, responsive, exercise training programme 
demonstrated a reassuring feasibility and tolerability profile in this patient cohort.  
 
The concept of preoperative intervention with exercise training is a new one in this cohort of 
patients; therefore, there is a need to identify prehabilitation programmes that can be used to 
optimise patients’ fitness following the insult of NACRT prior to major surgical trauma. Due 
to the improvements in patients’ objective physical fitness in the feasibility study (Section 
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5.3), a larger, adequately powered pre-pilot study investigating the improvements in physical 
fitness with the exercise training programme derived in Chapter 5 was performed. This will 
be the main focus of the chapter hereunder.  
 
 
6.2 STUDY OBJECTIVES 
 
The objective of this pre-pilot non-randomised, parallel group interventional study is to 
evaluate, in patients scheduled for rectal cancer surgery following NACRT, the extent to 
which a 6-week structured exercise programme carried out preoperative may be used to 
improve objectively measured physical fitness.  
 
The primary end point was to investigate changes in V o2 at ˆ L and V o2 Peak between week 
0 and week 6 in both the exercise and control groups to assess the impact of the exercise 
intervention on physical fitness. Further exploratory end points were to investigate the: 
 
 changes in V o2 at ˆ L and V o2 Peak with NACRT (between baseline and week 0),  
 changes in other selected CPET variables with the exercise intervention (between 
week 0 and week 6), 
 continued safety, tolerability and patient adherence to the exercise intervention 
(number of adverse events and adherence recorded with CPET or exercise training 
sessions),   
 relationship of selected CPET variables to in-hospital morbidity, and 
 differences in length of hospital stay, 1 year mortality and 1 year disease free 
survival in between groups.  
 
 
6.3 PATIENTS AND STUDY METHODS 
 
Approval by the North West – Liverpool East Research and Ethics Committee 
(11/H1002/12) was sought and the trial was registered with clinicaltrials.gov 
(NCT01325909). Written informed consent was obtained from all patients. We recruited 
consecutive patients between October 2011 and February 2013 who were referred to the 
Colorectal Multi-Disciplinary Team (MDT), age ≥18 years, with locally advanced 
(circumferential resection margin threatened) resectable rectal cancer, scheduled for 
standardized NACRT on the basis of Tumour, Node, Metastasis (TNM) classification 
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>T2/N+ with no distant metastasis (230) and WHO Performance Status < 2 (231). 
Predefined exclusion criteria were: inability to give informed consent, non-resectable 
disease, inability to perform CPET or bicycle exercise due to leg dysfunction, patients who 
declined surgery or NACRT, or who received non-standard NACRT.  
 
TNM staging involved flexible sigmoidoscopy for histological diagnosis, colonoscopy, 
chest, abdomen and pelvis computer-aided tomography (CT) and a 1.5 Tesla (Magnetom 
Area, Siemens, Erlangen, Germany) pelvic magnetic resonance imaging (MRI). All patients 
then underwent NACRT for 5 weeks. Standardized radiotherapy consisted of 45 Gy in 25 
fractions on weekdays using a 3-dimensional conformal technique with CT guidance. A 
boost dose was given (5.4 Gy in 3 fractions) to the primary tumour only. Oral capecitabine 
(825 mg.m
-2
) was given twice daily on radiotherapy days. No patients received 
brachytherapy. When patients completed NACRT they were restaged using chest, abdomen 
and pelvic CT and pelvic MRI at 9 weeks post-NACRT. The colorectal multidisciplinary 
team (MDT) was blind to the CPET results and patient allocation, which therefore did not 
influence perioperative management. All patients underwent total mesorectal excision 
(TME) surgery (232). A defunctioning stoma was constructed at the discretion of the 
surgeon.  
 
Any acute toxicity whilst undergoing NACRT was discussed at the weekly colorectal MDT 
meeting. Toxicity events were graded according to the National Cancer Institute Common 
Terminology Criteria (version 3.0), and the acute radiation-induced skin toxicity using the 
Radiation Therapy Oncology Group scoring system.  
 
CPET followed our standard protocol described in Section 3.2. Recorded patient 
characteristics included age, gender, height, weight, cancer staging, surgical procedure 
planned, WHO classification and ASA-PS, as well as established diagnosis of diabetes, 
ischaemic heart disease, cerebrovascular disease, or heart failure. Resting flow-volume loops 
were used to derive Forced Expiratory Volume over 1 second (FEV1) and Forced Vital 
Capacity (FVC). All patients underwent CPET 2 weeks before NACRT (baseline) and 
immediately post-NACRT (Week 0). Patients in both groups then underwent CPET at 
Weeks 3, 6, 9 and 14 before surgery at Week 15. Patients in the exercise group undertook 
the intervention continuously between Week 0 and Week 6. The study schedule is 
summarised in Chapter 3, Figure 3.2 and in more detail in Figure 6.1. CPET data were 
reported by two experienced assessors blind to patient characteristics, group allocation and 
outcome data. Any CPET-related adverse events were discussed at the weekly colorectal 
MDT meeting.  
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After completing NACRT, all patients were allocated to the exercise training group by 
default. If patients were unable to commit to the predefined exercise schedule for any reason 
(residing >20 miles from hospital or have carer responsibilities), they were asked to act as 
contemporaneously recruited controls (no exercise intervention) with the same CPET 
follow-up as the exercise group. Patients in the exercise group attended an in-hospital 
exercise training programme which was supervised (by a team member trained in advanced 
life support), structured (3 sessions/week for 6 weeks) and responsive (informed by 
measured work rates at V o2 at ˆ L and V o2 Peak at Week 3). The exercise schedule is 
described in Section 3.3. Patients exercised in groups of two (for camaraderie), each patient 
being prescribed a programme tailored to individual fitness (based initially on CPET results 
at Week 0). After session 7 (Week 3), work rates were individually adjusted in line with 
mid-programme CPET results. 
 
Patients were assessed pre- and postoperatively using the Colorectal Physiologic and 
Operative Severity Score for the Enumeration of Mortality and Morbidity (CR-POSSUM) 
(234). Patients were assessed postoperatively on days 3,5,8 and 15 using the Post-Operative 
Morbidity Survey (POMS) (146) and the Clavien-Dindo Classification of Surgical 
Complications (235) by members of the research team blind to CPET data and group 
allocation. Patients were followed up for local/distant radiologically documented metastasis 
and mortality at 1 year postoperatively. 
 
 
6.4 STATISTICAL ANALYSIS 
 
Our aim was to recruit 30 patients (15 patients in the exercise group and 15 in the control 
group) who would undergo standardised NACRT and surgery as an intention to treat for 
rectal cancer. This sample size was based on an unpaired t-test with 90% power to detect an 
estimated minimum difference in V o2 at ˆ L of 1.5 ml.kg
-1
.min
-1
 and an SD of 1.1 ml.kg
-
1
.min
-1
, and allowed for 20% patient drop-out (based on a previous pilot study (292)). 
Descriptive statistics are reported as mean (SD) or median and inter-quartile range (IQR) 
and categorical statistics as frequency (percentage). A statistical comparison of patient 
characteristics between groups was undertaken. A two-sample t-test was used for continuous 
variables when relevant distributional assumptions were met, and the Mann-Whitney U test 
otherwise. Categorical variables were compared using Chi-Square tests or, when cell counts 
were insufficient, Fishers Exact test. p <0.05 was taken as indicating a statistically 
significant difference.  
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For the primary analysis, compound symmetry covariance pattern linear mixed models were 
used to model V o2 at ˆ L and V o2 Peak exercise over the 3 time-points: baseline (pre-
NACRT), Week 0, and Week 6 post-NACRT. Both group (exercise/control) and visit 
(baseline, Week 0 and Week 6) were included as main effects in addition to the interaction 
between them i.e. there was sufficient statistical evidence to suggest that the effect of visit 
differed between the two groups. Formal comparisons were considered to be statistically 
significant at a Bonferroni-corrected significance level of p<0.008. Model selection was 
based on Akaike’s Information Criterion (AIC) and residuals and model fit were assessed 
using QQ plots and residual versus predicted mean plots. The impact of potential 
confounders on between-group comparisons was assessed by incorporating variables listed 
in Table 6.0 into the final models as sensitivity analyses. All mixed model statistical 
analyses were conducted using SAS 9.3 (SAS Institute, Cary NC). Length of stay for the 
exercise and control groups were estimated using the Kaplan-Meier method and compared 
using the Log rank Test. The univariate association between in-hospital complications 
(yes/no) with other variables was assessed using logistic regression. These analyses were 
conducted using Stata version 12 (StataCorp. 2011. Stata Statistical Software: Release 12. 
College Station, TX: StataCorp LP.) 
 
 
6.5 RESULTS 
 
A total of 39 patients were recruited, of whom 22/22 and 13/17 completed the study in the 
exercise and control groups respectively (4 patients having dropped out before baseline 
CPET after allocation to the control group). Figure 6.1 illustrates a CONSORT diagram 
depicting detailed patient flow for this study.  
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Figure 6.1 – Consort diagram 
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Patient characteristics are shown in Table 6.1. There were significant baseline differences 
between the groups in age, ASA, WHO performance status and CR-POSSUM predicted 
morbidity scores, with the control group being older and having poorer subjective 
performance.  
 
 
Table 6.1 - Patient characteristics; Smoking status assessed as currently smoking - yes (1) vs. no (0) 1Values 
presented as mean (SD); 2Number of patients (%). World Health Organisation (WHO) Performance Status and 
American Society of Anaesthesiologists Score (ASA); *Values are mean (SD) for CR-POSSUM components – 
Exercise n=17 and Control n=11. Four patient drop outs immediately before 1st CPET (dropouts not included). 
 
Table 6.2 shows changes in BMI, spirometry variables (FEV1, FVC, FEV1/FVC) and 
haemoglobin over the whole study period in the exercise and the control groups, along with 
MRI tumour staging and re-staging post-NACRT (Week 9). There were no significant 
baseline differences in these variables between the two groups.  
 
 
 
 
 
 Exercise (n=22) Control (n=13) p-value 
Age (years)
1 64 (9.6) 72 (7.3) 0.015 
Gender M:F (%) 14 (64) :8 (36) 9 (69) : 4 (31) 1 
Smoking (%) 10 (45) 4 (31) 0.617 
Past Medical History
2
 
Heart Failure 
Diabetes 
Ischaemic heart Disease 
Cerebrovascular Disease 
 
3 (14) 
2 (9) 
5 (23) 
0 
 
1 (8) 
1 (8) 
5  (38) 
0 
 
1 
1 
0.444 
1 
ASA
2 
1 
2 
3 
 
11 (50) 
9 (41) 
2 (9) 
 
0 
11 (85) 
2 (15) 
 
 
 
0.003 
WHO Performance 
Status
2 
0
 
1 
2 
 
 
18 (82) 
4 (18) 
0 
 
 
8 (62) 
3 (23) 
2 (15) 
 
 
 
 
0.035 
CR-POSSUM-
Physiological Score* 
8.0 (1.8) 9.3 (2.3) 0.162 
CR-POSSUM- Predicted 
Mortality (%)* 
3.2 (1.1) 9.4 (8.9) 0.003 
CR-POSSUM- Operative 
Severity Score* 
9.8 (2.0) 11.4 (0.5) 0.236 
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Table 6.2 - Patient characteristics; # with percentages in parentheses; 1 Values presented as mean (SD); 2 
International Union against Cancer tumour node metastasis (TNM) MRI staging. 4 patient drop outs immediately 
after 1st CPET (dropouts not included in demographics). 
 Exercise (n=22) Control (n=13) p-value 
BMI (kg.m
-2
)
1 
Baseline 
Week 0 
Week 3 
Week 6 
Week 9 
Week 14 
 
27.4 (5.1) 
27.3 (5.0) 
27.6 (5.2) 
27.8 (5.6) 
27.0 (5.6) 
27.7 (6.0) 
 
24.9 (3.9) 
25.1 (3.9) 
29.0 (3.1) 
25.1 (3.4) 
27.0 (4.6) 
26.5 (5.3) 
 
0.121 
 
FEV1 (L)
 1 
Baseline 
Week 0 
Week 3 
Week 6 
Week 9 
Week 14 
 
2.8 (0.8) 
2.7 (0.8) 
2.9 (0.7) 
2.8 (0.8) 
2.8 (0.8) 
2.8 (0.8) 
 
2.5 (0.6) 
2.5 (0.6) 
3.0 (0.4) 
2.6 (0.6) 
3.1 (0.3) 
3.0 (0.4) 
 
0.232 
 
FVC (L)
 1 
Baseline 
Week 0 
Week 3 
Week 6 
Week 9 
Week 14 
 
3.8 (1.0) 
3.8 (1.0) 
3.8 (1.0) 
3.8 (0.9) 
3.5 (0.9) 
3.6 (1.0) 
 
3.8 (0.7) 
3.9 (0.7) 
4.3 (0.6) 
3.9 (0.7) 
4.3 (0.6) 
4.5 (0.7) 
 
0.898 
 
FEV1/FVC (%)
1 
Baseline 
Week 0 
Week 3 
Week 6 
Week 9 
Week 14 
 
72.6 (12.1) 
72 (11.7) 
73.3 (9.8) 
73.0 (11.6) 
74.4 (10.7) 
74.5 (11.4) 
 
66.6 (8.1) 
66.2 (9.7) 
71.3 (9.0) 
66.7 (9.8) 
71.7 (5.2) 
67.3 (5.0) 
 
0.051 
 
Haemoglobin (g.dl
-1
)
1 
Baseline 
Week 0 
Week 6 
 
13.7 (1.4) 
13.4 (1.4) 
13.6 (1.5) 
 
13.2 (1.2) 
13.0 (1.4) 
13.3 (1.3) 
 
0.303 
 
Clinical MRI 
TNM 
classification
2# 
 
Baseline 
cTx 
cT2 
cT3 
cT4 
cN0 
cN1 
cN2 
cM0 
0 0 1 
2 (9) 1 (8)  
17 (77) 10 (77)  
3 (14) 2 (15)  
2 (9) 2 (15) 0.892 
12 (55) 7 (54)  
8 (36) 4 (31)  
22 (100) 13 (100) 1 
Clinical MRI 
TNM 
classification
2# 
 
Week 9 
cTx 
cT2 
cT3 
cT4 
cN0 
cN1 
cN2 
cM0 
2 (9) 2 (15) 0.321 
3 (14) 4 (31)  
15 (68) 5(38)  
2 (9) 2 (15)  
14 (64) 3 (23) 0.100 
6 (27) 9 (69)  
2 (9) 1 (8)  
20 (91) 13 (100) 0.519 
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Table 6.3 shows tumour and cancer treatment characteristics for both groups. A significant, 
large difference was found between the groups in the response to NACRT (defined as 
mrTRG response with standardised NACRT). All patients completed NACRT. One patient 
needed capecitabine dose reduction, while 4 patients (3 in the exercise group and 1 control) 
sustained perineal radiation skin changes (maximum score 2 out of 4).  
 
 
Table 6.3 - All values are presented as number of patients (frequency). MRI Tumour Regression Grading 
(mrTRG) – Favourable = T0-3a, Not Favourable T3b>. #28 out of 35 patients had surgery (exercise n=17 and 
control n=11). 
 
 
 
 
 
 Exercise (n=22) Control (n=13) p-value 
Tumour distance from anal verge  
<5.0 cm 
5.1-10.0cm 
>10.1cm 
 
10 (45) 
10 (45) 
2 (9) 
 
9 (69) 
3 (23) 
1 (8) 
 
0.395 
Response to NACRT (mrTRG) 
Favourable 
Not Favourable 
Complete Clinical Response 
 
19 (86) 
0 
3 (14) 
 
6 (46) 
5 (38) 
2 (15) 
 
0.006 
Operation Type 
#
 
Open 
Laparoscopic 
 
11 (65) 
6 (35) 
 
8 (73) 
3 (27) 
 
1 
Surgery Type 
#
 
Low anterior resection 
Abdomino-perineal excision 
Hartmann procedure 
 
12 (71) 
5 (29) 
0 
 
5 (45) 
5 (45) 
1 (9) 
 
0.299 
Pathological TNM 
#
 
pT1 
pT2 
pT3 
pT4 
 
pN0 
pN1 
pN2 
 
1 (6) 
3 (18) 
10 (59) 
3 (18) 
 
9 (53) 
6 (35) 
2 (12) 
 
1 (9) 
2 (18) 
7 (64) 
1 (9) 
 
7 (64) 
2 (18) 
2 (18) 
 
1 
 
 
 
 
0.651 
Dukes Staging 
#
 
A 
B 
C  
 
4 (24) 
4 (24) 
9 (53) 
 
3 (27) 
4 (36) 
4 (36) 
 
0.701 
153 
 
6.5.1 CHANGES IN PHYSICAL FITNESS WITH NACRT AND EXERCISE 
 
The median time to starting the exercise programme after completion of NACRT was 2 
working days (IQR 1-7 days). The mean (SD) % adherence to the exercise programme 
(defined as % of the total of 18 sessions completed) was 96 (5) %. The mean (SD) % 
adherence to CPETs (defined as % of the total of 6 CPETs attended) was 92 (14) % in the 
exercise group vs. 60 (5) % in the control group. There were no adverse events recorded 
following CPET or exercise. Table 6.4 shows changes in all CPET-related variables at the 
different time points.  
 Exercise (n=22) Control (n=13) 
Adherence to exercise programme 
(%)
1
 
96 (5.3) n/a 
Adherence to CPETs (%)
1
 92 (14.2) 60 (5.1) 
V o2 at ˆ L (ml.kg
-1
.min
-1
)
1
 
Baseline 
Week 0 
Week 3 
Week 6 
Week 9 
Week 14 
 
12.0 (2.5) 
10.3 (2.6) 
11.3 (2.5) 
12.4 (2.7) 
12.1 (3.6) 
11.7 (3.0) 
 
12.2 (2.3) 
10.1 (3.4) 
10.5 (0.6) 
9.5 (2.9) 
10.7 (3.4) 
8.1 (2.1) 
V o2 at ˆ L (L.min
-1
)
1
 
Baseline 
Week 0 
Week 3 
Week 6 
Week 9 
Week 14 
 
0.9 (0.3) 
0.8 (0.2) 
0.9 (0.2) 
1.0 (0.2) 
1.0 (0.4) 
0.9 (0.2) 
 
0.8 (0.2) 
0.7 (0.2) 
0.8 (0.1) 
0.7 (0.2) 
0.8 (0.1) 
0.7 (0.1) 
V o2 Peak (ml.kg
-1
.min
-1
)
1
 
Baseline 
Week 0 
Week 3 
Week 6 
Week 9 
Week 14 
 
18.9 (5.1) 
16.0 (4.3) 
18.0 (3.8) 
18.7 (4.3) 
18.0 (5.3) 
18.1 (4.7) 
 
17.9 (3.1) 
15.7 (5.0) 
14.1 (1.6) 
14.4 (4.5) 
14.4 (5.4) 
12.4 (5.0) 
V o2 Peak (L.min
-1
)
1
 
Baseline 
Week 0 
Week 3 
Week 6 
Week 9 
Week 14 
 
1.4 (0.4) 
1.2 (0.4) 
1.4 (0.4) 
1.5 (0.4) 
1.4 (0.4) 
1.4 (0.4) 
 
1.2 (0.3) 
1.1 (0.3) 
1.2 (0.1) 
1.1 (0.2) 
1.2 (0.3) 
1.1 (0.2) 
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O2 pulse at ˆ L (ml.beat
-1
)
1
 
Baseline 
Week 0 
Week 3 
Week 6 
Week 9 
Week 14 
 
8.7 (2.4) 
7.6 (2.1) 
8.6 (2.3) 
8.9 (2.3) 
8.4 (2.8) 
8.3 (2.1) 
 
8.5 (2.1) 
7.0 (1.7) 
8.7 (1.7) 
7.4 (1.7) 
8.7 (1.0) 
7.8 (1.0) 
O2 pulse at Peak (ml.beat
-1
)
1
 
Baseline 
Week 0 
Week 3 
Week 6 
Week 9 
Week 14 
 
10.5 (2.9) 
9.4 (2.7) 
10.9 (2.8) 
10.7 (2.9) 
9.8 (3.7) 
10.0 (2.7) 
 
10.3 (2.6) 
8.9 (1.9) 
9.4 (1.3) 
9.3 (2.1) 
9.9 (1.3) 
9.3 (1.5) 
V E/ V co2 at ˆ L 1 
Baseline 
Week 0 
Week 3 
Week 6 
Week 9 
Week 14 
 
30.5 (4.7) 
31.8 (4.4) 
31.9 (5.0) 
31.0 (5.0) 
30.2 (4.4) 
30.4 (4.5) 
 
34.6 (4.2) 
33.8 (5.1) 
35.9 (4.0) 
34.1 (4.1) 
35.0 (3.4) 
34.8 (4.0) 
V E/ V co2 at Peak1 
Baseline 
Week 0 
Week 3 
Week 6 
Week 9 
Week 14 
 
31.9 (4.3) 
33.6 (4.8) 
33.0 (4.6) 
34.1 (4.4) 
33.4 (4.8) 
33.1 (4.3) 
 
36.7 (4.5) 
37.0 (6.7) 
38.0 (4.8) 
37.9 (6.0) 
37.7 (5.7) 
34.8 (2.7) 
Baseline heart rate (beats.min
-1
)
3
 
Baseline 
Week 0 
Week 3 
Week 6 
Week 9 
Week 14 
 
84.0 (71.3, 91.0) 
82.5 (71.3, 89.0) 
77.0 (70.0, 86.0) 
77.5 (70.3, 84.8) 
78.0 (71.3, 84.3) 
86.0 (69.0, 89.0) 
 
83.0 (74.0, 88.0) 
83.0 (70.0, 93.0) 
81.0 (77.0, 87.5) 
87.0 (81.0, 93.0) 
88.5 (82.8, 90.3) 
72.0 (62.0, 77.5) 
Peak heart Rate (beats.min
-1
)
3
 
Baseline 
Week 0 
Week 3 
Week 6 
Week 9 
Week 14 
 
139.0 (124.0, 145.0) 
134.0 (122.0, 145.0) 
139.0 (125.0, 145.0) 
138.0 (132.0, 147.0) 
142.0 (132.0, 159.0) 
145.0 (136., 156.0) 
 
136.0 (113.0, 142.0) 
122.0 (110.0, 142.0) 
114.0 (108.0, 114.0) 
121.0 (115.0, 142.0) 
119.0 (112.0, 128.0) 
112.0 (112.0, 129.0) 
Work rate at ˆ L (W)
3
 
Baseline 
Week 0 
Week 3 
Week 6 
Week 9 
Week 14 
 
58.0 (44.5, 70.0) 
53.0 (34.8, 63.0) 
60.0 (47.0, 80.0) 
72.0 (48.5, 80.0) 
69.0 (45.3, 79.0) 
68.0 (44.0, 76.0) 
 
 
 
46.0 (42.0, 50.0) 
35.0 ( 25.0, 50.0) 
42.0 (36.0, 53.0) 
34.0 (30.0, 42.0) 
48.0 (42.0, 58.5) 
52.0 (47.5, 71.0) 
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Table 6.4 – CPET variables reported at each study time point. 1 Values presented as mean (SD). 2 Values 
presented as mean (CI). 3Values presented as median (IQR). V o2 at ˆ L , Oxygen uptake at estimated lactate 
threshold; V o2 Peak, Oxygen uptake at peak exercise; O2 pulse at ˆ L, Oxygen pulse at estimated lactate 
threshold; O2 pulse at Peak, Oxygen pulse at peak exercise;  V E/ V co2 at ˆ L, Ventilatory equivalents for 
carbon dioxide at estimated lactate threshold; V E/ V co2 at ˆ L, Ventilatory equivalents for carbon dioxide at 
peak exercise; Work rate at ˆ L, Work rate at estimated lactate threshold; Work rate at Peak, Work rate at peak 
exercise. 
 
V o2 at ˆ L and V o2 Peak were the primary outcome variables.  There was a significant 
reduction in V o2 at ˆ L (-1.91 ml.kg
-1
.min
-1
; 95%CI -1.27 to -2.55; p<0.0001) and V o2 at 
Peak (-2.52 ml.kg
-1
.min
-1
; 95%CI -1.33 to -3.71; p<0.0001) post-NACRT (Week 0). The 
exercise group showed a significant improvement in both primary endpoints during the 
intervention period (Week 0 to Week 6), in contrast to the worsening physical fitness in the 
control group (Figure 6.2 A and B). The exercise group improved V o2 at ˆ L by +2.12 
ml.kg
-1
.min
-1
 (95%CI +1.34 to +2.90; p<0.0001), while the control group showed a non-
significant decline in V o2 at ˆ L by -0.65 ml.kg
-1
.min
-1
 (95% CI: -1.66 to +0.37; p=0.204). A 
direct comparison of V o2 at ˆ L between groups at week 6, correcting for differences in V o2 
at ˆ L between the groups at Week 0, shows a difference of +2.77 ml.kg
-1
.min
-1 
(95%CI 
+1.49 to +4.05; p<0.0001). V o2 Peak shows similar changes in the exercise group: +2.65 
ml.kg
-1
.min
-1 
(95%CI +1.19 to +4.10; p=0.0005), while the control group worsened  by -1.25 
ml.kg
-1
.min
-1 
 (95% CI: -3.14 to +0.64; p=0.19). A similar direct comparison of V o2 Peak 
between groups at Week 6, correcting for differences in V o2 Peak at Week 0, shows a 
change of +3.90 ml.kg
-1
.min
-1 
(95%CI +1.52 to +6.28; p=0.0017). Adjusting for potential 
confounders had negligible effect on these analyses (not shown). A secondary analysis of V
o2 at ˆ L and V o2 Peak, including all time-points, was conducted and the results are shown in 
Figure 6.3 A and B.  
 
 
 
Work rate at Peak (W)
3
 
Baseline 
Week 0 
Week 3 
Week 6 
Week 9 
Week 14 
 
118.0 (92.5, 130.0) 
109.0 (82.5, 124.0) 
122.0 (96.0, 136.0) 
131.0 (95.5, 143.0) 
123.0 (88.0, 146.0) 
116.0 (85.0, 146.0) 
 
104.0 (74.0, 112.0) 
80.0 (62.0, 102.0) 
112.0 (102.5, 113.0) 
85.0 (70.0, 95.0) 
109.0 (95.3, 124.5) 
112.0 (93.5, 129.0) 
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 (A) 
 
 
(B) 
 
 
Figure 6.2A and B – Line diagram showing fitted means and 95%CI for V o2 at ˆ L (ml.kg-1.min-1) (A) and V
o2 Peak (ml.kg
-1.min-1) (B) at baseline (pre-NACRT), week 0 (post-NACRT) and Week 6 for the exercise 
(dashed line) and control groups (solid line) 
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Figure 6.3A and B – Line diagram showing fitted means and 95%CI for V o2 at ˆ L (ml.kg-1.min-1) (A) and V
o2 Peak (ml.kg
-1.min-1) (B) for the exercise group and the control group over the whole study period (baseline 
pre-NACRT to week 14 pre-surgery – secondary analysis) 
 
Changes in individual patients’ V o2 at ˆ L (Figures 6.4 and 6.5) and V o2 Peak (Figures 6.6 
and 6.7) were plotted on point-to-point graphs as seen on Figures 6.4A (baseline to Week 0) 
and B (Week 0 to Week 6) for the exercise group and Figures 6.5A (baseline to Week 0) and 
B (Week 0 to Week 6) for the control group. V o2 Peak  data were plotted on Figures 6.6A 
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(baseline to Week 0) and B (Week 0 to Week 6) for the exercise group and Figures 6.7A 
(baseline to Week 0) and B (Week 0 to Week 6) for the control group. 
 
 
(A) 
 
 
(B) 
 
 
Figure 6.4 – (A) Point-to-point graphs of V o2 at ˆ L for patients between pre-NACRT (baseline) and post-
NACRT (Week0); and (B) between post-NACRT and Week 6 in the exercise group 
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(A) 
 
 
(B) 
 
 
Figure 6.5 – (A) Point-to-point graphs of V o2 at ˆ L for patients between pre-NACRT (baseline) and post-
NACRT (Week0); and (B) between post-NACRT and Week 6 in the control group 
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(A) 
 
 
(B) 
 
 
Figure 6.6 – (A) Point-to-point graphs of V o2 at Peak for patients between pre-NACRT (baseline) and post-
NACRT (Week0); and (B) between post-NACRT and Week 6 in the exercise group 
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(A) 
 
 
(B) 
 
 
Figure 6.7 – (A) Point-to-point graphs of V o2 at Peak for patients between pre-NACRT (baseline) and post-
NACRT (Week0); and (B) between post-NACRT and Week 6 in the control group 
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6.5.2 OUTCOMES FROM PREOPERATIVE RE-STAGING INVESTIGATIONS 
 
Five patients (14%) from the total cohort had a complete clinical response on re-staging 
investigations at Week 9 (2 in the control group (15%) vs. 3 in the exercise group (14%)). 
These patients did not undergo surgery and were allocated to a watch and wait follow-up 
program. The control group had a significantly poorer tumour response to NACRT on re-
staging MRI (mrTRG) (p=0.006), however there was no evidence of a statistical difference 
in TNM re-staging between the two groups (p=0.822). 11 patients (85%) in the control 
group and 17 patients (77%) in the exercise group underwent surgery. Unfortunately 2 
patients (9%) in the exercise group were deemed palliative on re-staging investigations (one 
patient developed liver metastasis, while another developed local tumour progression). Both 
patients completed the exercise programme however both patients were unable to improve 
their fitness post-NACRT.  
 
 
6.5.3 RELATIONSHIP BETWEEN PHYSICAL FITNESS AND SURGICAL 
OUTCOME 
 
Surgical outcome and post-operative follow up until 1 year is shown in Table 6.5. Figure 6.8 
shows that there was no significant differences in the median length of hospital stay between 
the groups (p=0.848).   
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 Exercise (n=17) Control (n=11) 
Length of Stay (days)
 1
 9 (6-16) 9 (8-15) 
Total Parenteral Nutrition (days)
 1
 0 (0-0) 0 (0-0) 
Level 2/3 Care (days)
 1
 0 (0-0) 0 (0-2) 
 POMS Day POMS Day 
 
3 5 8 15 3 5 8 15 
 
Discharge rate (%)
#
 
In Hospital Morbidity positive
#
 
In Hospital Morbidity negative
#
 
 
POMS
#          
                         
Pulmonary 
Infectious 
Renal 
Gastrointestinal 
Cardiovascular 
Neurological 
Haematological 
Wound  
Pain 
 
0 
5 (29) 
12(71) 
 
 
0 
2 (12) 
2 (12) 
4 (24) 
1 (6) 
0 
0 
0 
1 (6) 
 
2 (12) 
7 (41) 
8 (47) 
 
 
2 (12) 
4 (24) 
0 
5 (29) 
0 
0 
0 
0 
1 (6) 
 
7 (41) 
7 (41) 
3 (18) 
 
 
2 (12) 
3 (18) 
1 (6) 
4 (24) 
0 
0 
0 
0 
0 
 
12(71) 
5 (29) 
0 
 
 
0 
2 (12) 
1 (6) 
4 (4) 
0 
0 
1 (6) 
1 (6) 
0 
 
0 
6 (55) 
5 (45) 
 
 
0 
1 (9) 
1 (9) 
3 (27) 
1 (9) 
1 (9) 
0 
0 
1 (9) 
 
0 
6 (55) 
5 (45) 
 
 
2 (18) 
2 (18) 
1 (9) 
4 (36) 
1 (9) 
0 
0 
0 
1 (9) 
 
4(36) 
5 (45) 
2 (19) 
 
 
2 (18) 
3 (27) 
1 (9) 
5 (45) 
0 
0 
0 
2 (18) 
1 (9) 
 
8 (73) 
3 (27) 
0 
 
 
0 
2 (18) 
0 
3 (27) 
0 
0 
0 
2 (18) 
1 (9) 
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Table 6.5 – Tables showing postoperative outcome until 1year follow up. Post-operative follow up at day 3,5,8 and 15 was undertaken using the post-operative morbidity survey. Further follow 
up was then undertaken at 30-days for mortality, morbidity (Clavine-Dindo score) and hospital readmission and at 1 year for radiologically documented recurrence or distant metastasis, and 
mortality. 1 Values presented as median (interquartile range). # Values are presented as number of patients (frequency).
 Exercise (n=17) Control (n=11) 
Clavine-Dindo Score
#
 
Grade I 
Grade II 
Grade IIIa 
Grade IIIb 
Grade IVa 
Grade IVb 
 
3 (18) 
2 (12) 
0 
2 (12) 
1 (6) 
0 
 
2 (18) 
2 (18) 
0 
3 (27) 
1 (9) 
0 
30-day Mortality (%)
#
 0 0 
30-day Readmission (%)
#
 2 (12) 8 (73) 
1 year mortality (%)
#
 4 (24) 2 (18) 
1 year recurrence rates (%)
#
 7 (41) 2 (20) 
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Figure 6.8 – Kaplan-Meier curve comparing length of hospital stay in days between the exercise and control 
groups 
 
73% of the control group developed in hospital complications vs. 53% of the exercise group. 
On univariate logistic regression age, group allocation, operation method (Laparoscopic vs. 
Open), gender, V o2 at ˆ L and V o2 Peak were tested (Table 6.6). None of the selected 
variables were found to be significantly associated with postoperative complications. 
 
 OR (95% CI) p-value 
Age 1.04 (0.95, 1.12) 0.388 
Exercise/Control 0.42 (0.08, 2.16) 0.300 
Laparoscopic/Open 1.37 (0.27, 6.87) 0.701 
Gender 1.11 (0.21, 6.01) 0.903 
V o2 at ˆ L (Week 14) 0.87 (0.63, 1.21) 0.413 
V o2 at Peak (Week 14) 0.83 (0.66, 1.05) 0.128 
 
Table 6.6 – Univariate associations between in-hospital complications (yes/no) and selected variables. OR – 
Odds Ratio; CI – Confidence Interval 
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None of the patients died within 30-days of surgery. 73% of the patients in the control group 
were readmitted to hospital within 30-days of being discharged. 24% of patients in the 
exercise group vs. 18% in the control group died within 1 year of their surgery. 41% of 
patients in the exercise group vs. 20% in the control group developed radiological 
documented distant or local metastasis within 1 year of their surgery. No statistical analysis 
was undertaken for 30-day or 1-year outcomes.  
 
 
6.6 DISCUSSION 
 
This interventional pilot study shows that a 6-week structured exercise programme improves 
objectively measured physical fitness ( V o2 at ˆ L as determined by CPET) in patients 
scheduled for rectal cancer surgery following standardised NACRT. There was a significant 
mean benefit in V o2 at ˆ L of +2.12 ml.kg
-1
.min
-1
 (95%CI +1.34 to +2.90; p<0.0001) in the 
exercise group at the end of the intervention period. V o2 Peak showed similar changes in the 
exercise group: +2.65 ml.kg
-1
.min
-1 
(95%CI +1.19 to +4.10; p=0.0005). These changes are 
similar to those found in the feasibility and tolerability study (Section 5.3.2) where patients 
improved both V o2 at ˆ L and V o2 Peak by +3.3 and +5.8 ml.kg
-1
.min
-1
 respectively. The 
control group showed a non-significant decline in V o2 at ˆ L by -0.65 ml.kg
-1
.min
-1
 (95% 
CI: -1.66 to +0.37; p=0.204). V o2 Peak shows similar changes in the control group 
worsening  by -1.25 ml.kg
-1
.min
-1 
 (95% CI: -3.14 to +0.64; p=0.19). A direct comparison of 
V o2 at ˆ L between groups at week 6, correcting for differences in V o2 at ˆ L between the 
groups at Week 0, shows a difference of +2.77 ml.kg
-1
.min
-1 
(95%CI +1.49 to +4.05; 
p<0.0001).  
 
In this study the training programme was still deemed safe and feasible (96% adherence to 
the intervention) in this group of patients immediately post-NACRT, with no recorded 
adverse events after CPET or exercise sessions.  
 
A similar deleterious effect of NACRT on physical fitness was observed, with all patients 
showing a significant decline in V o2 at ˆ L between baseline and Week 0 of -1.91 ml.kg
-
1
.min
-1 
(95%CI -1.27 to -2.55; p<0.0001) consistent with results in Sections 4.5.2 (-1.5 
ml.kg
-1
.min
-1 
(95%CI -1.7 to -1.2); p<0.0001) and 5.3.2 (-1.1 ml.kg
-1
.min
-1
), which reinforces 
results seen in previous pilot work (292) and with recently published data from Chapter 4 
(293).  
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This study reinforces the concept of successful prehabilitation with exercise training to 
improve physical fitness after the deleterious effects of NACRT and prior to an added 
physiological insult of major cancer surgery. We know that poor preoperative physical 
fitness, reflecting poor physiological reserves, is associated with postoperative morbidity (3–
5), and that rehabilitation following acute or chronic stressors (chronic obstructive 
pulmonary disease, chronic heart failure or myocardial infarction) (147,149,150) can 
improve fitness and quality of life. It therefore seems reasonable that an exercise 
intervention (prehabilitation) should be aimed at restoring physical fitness back to baseline 
levels (pre-NACRT) prior to another acute stressor (major cancer surgery). Section 2.6 of 
this thesis (154) concludes that preoperative aerobic exercise training is feasible, safe and 
tolerable in several surgical patient groups, and improves at least one measure of physical 
fitness. However, because of the small number of published studies, limitations in study 
design (few randomised controlled trials or interventional trials without a control group) and 
the heterogeneous reporting of interventions and outcomes, evidence is lacking on the 
benefits of prehabilitation on physical fitness and surgical outcome. This study strengthens 
this evidence with an adequately powered, controlled, blinded study which shows a 
clinically significant improvement in physical fitness in a high risk homogenous group of 
preoperative patients. This study also reports on in-hospital postoperative surgical outcomes, 
and length of hospital stay in both the exercise and the control groups (no significant 
differences found). Furthermore, none of the variables selected for univariate logistic 
regression (Table 6.6) were found to be significantly associated with postoperative 
complications. Patients in the exercise group had a better response to NACRT as opposed to 
the control group on re-staging mrTRG. Also, interestingly when looking at the 30-day 
readmission rates, 73% of the control group was readmitted to hospital (median length of 
readmission stay 10 days). Only 12% of the exercise group were readmitted (National Bowel 
Cancer Audit 2013 data for 30-day readmission rates = 24% (28)). Furthermore, long term 
data from this study shows an average 1 year survival (76% in the exercise group vs. 82% in 
the control group) (National Bowel Cancer Audit 2013 data 2 year survival rate = 86% (28)), 
however 1 year radiologically documented local/distant recurrence rates (41% in the 
exercise group vs. 20% in the control group) especially in the exercise group were deemed 
to be high. No statistical analysis was carried out on the out of hospital outcome measures, 
as this was outside the scope of this study and is only reported for completeness.   
 
To my knowledge, this study is the first to show a significant decline in objectively 
measured physical fitness post-NACRT and a clinically meaningful improvement in 
physical fitness by using a structured, responsive, exercise training programme in patients 
following NACRT prior to rectal cancer surgery. Comparison of this study to similar 
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prehabilitation studies found in the literature is difficult, however in a randomized controlled 
trial of colorectal cancer patients, Carli and colleagues (156) found no differences between a 
structured bike and strengthening regime vs. simple walking and breathing exercises. In a 
subsequent observational study of a trimodal prehabilitation programme they demonstrated 
better postoperative walking capacity (6 min walking distance) in the intervention group 
(167). Other randomised studies on aerobic training in patients undergoing colonic resection 
showed improvement in subjectively measured oxygen uptake, peak power output and heart 
rate (157,158). Kothmann and colleagues (286) undertook an interventional training study in 
abdominal aortic aneurysm patients under surveillance. They define a minimum clinically 
important difference (MCID) in V o2 at ˆ L of +2.0 ml.kg
-1
.min
-1
. Although Kothmann 
significantly improved objectively measured physical fitness ( V o2 at ˆ L) of this high risk 
cohort using a moderate intensity continuous exercise training programme, they were unable 
to attain MCID, possibly because of too low an exercise duration and intensity (286). My 
aim was to return patients fitness back to pre- NACRT levels, therefore the sample size 
estimate was based on the changes in fitness between baseline and week 0 ( V o2 at ˆ L of -
1.5 ml.kg
-1
.min
-1 
observed in my previous pilot work and in Chapter 4 of this thesis 
(292,293)) using an unpaired comparison with 90% power to detect a mean minimum 
relevant difference in V o2 at ˆ L of 1.5 ml.kg
-1
.min
-1
. Using a MCID of V o2 at ˆ L of 2.0 
ml.kg
-1
.min
-1 
as per Kothmann at el. the sample size was estimated at 9 patients in each 
group, which was deemed to be a small patient cohort. However, using a higher intensity, 
interval training regime of longer duration, as suggested by Kothmann and colleagues (286) 
a between group difference in V o2 at ˆ L at week 6 of +2.77 ml.kg
-1
.min
-1 
(95%CI +1.49 to 
+4.05; p<0.0001) was attained which is considered to be a substantial clinically significant 
difference.   
 
Another interesting finding is the clear difference between individual patient response to the 
exercise training programme. By examining figures 6.4B and 6.6B, we can observe a clear 
responder vs. non-responder difference. The mechanism of this is yet unknown. This is not 
to say that if a patient is a non-responder he/she is unable to improve oxygen uptake 
variables irrespective of the intervention. A non-responder to interval training may be a 
responder to continuous or resistance training with a different stimulus, however this needs 
to be ascertained using a multimodal exercise RCT. This observation is not novel. Carli 
(156) and Kothmann (286) and colleagues have described this phenomenon in their 
prehabilitation papers, however to date no biological mechanism has been put forward. 
Moreover, if the exercise group is split into responders ( V o2 at ˆ L at week 6 of ≥2.0 ml.kg
-
1
.min
-1
) and non-responders ( V o2 at ˆ L at week 6 of <2.0 ml.kg
-1
.min
-1
) and then compared 
169 
 
to their respective mrTRG outcomes a trend towards better oncological response when 
patients are exercise responders is noted. This phenomenon needs further evaluation due to 
its potential clinical significance as this study was not powered to investigate this. 
 
These findings have important clinically significant implications. Over time (Figure 6.2) a 
sharp change in fitness was observed in the first 6 weeks in the exercise group, whilst the 
control group was unable to recover from the physiological insult of NACRT, showing a 
sustained decline from Week 3 to Week 14. Moreover, the exercise group overshoots their 
baseline fitness ( V o2 at ˆ L pre-NACRT) at Week 6, with their fitness thereafter slowly 
declining to baseline (pre-NACRT) levels. Thus, by Week 6 patients in the exercise group 
have completely recovered from the effects of NACRT on fitness, while those in the control 
group are now at a higher risk of adverse surgical outcome on the basis of conventional risk 
stratification cut-off points for V o2 at ˆ L of around 10.1 ml.kg
-1
.min
-1
 to 10.9 ml.kg
-1
.min
-1
 
(120,121,144,145). Moreover, this illustrates an important point; in surgical units where 
CPET is part of the routine perioperative cancer pathway, rectal cancer patients usually 
undergo CPET prior to NACRT and not upon re-staging. Thus, fitness for surgery 
assessments made using pre-NACRT V o2 at ˆ L and other CPET variables might be 
incorrect as changes in fitness post-NACRT are not accounted for.  
 
Strengths of this study include the homogenous nature of the study population (only 
operable locally advanced rectal cancer patients were included), the blinded reporting of 
objectively measured CPET outcome variables (blind to patient characteristics, group 
allocation and timeline), the blinded collection of postoperative outcomes, the prospective 
nature of the study, the rigorous conduct of the exercise intervention, the standardization of 
the NACRT regime and the statistical modeling undertaken. 
 
Potential weaknesses include the single-centre design, the baseline differences between the 
exercise and the control groups in age and performance status, CR-POSSUM predicted 
mortality, response to NACRT, and lower peak work rates and less efficient ventilatory 
equivalents. Another weakness is the non-randomized design of the study. Due to the lack of 
randomization, the observed changes in physical fitness between the groups may be due to 
other group differences. Although a sensitivity analyses was performed here, this is no 
substitute for randomization, however, the main objective of this study was to satisfy study 
objectives listed in 6.2 and provide initial pilot evidence to further investigate the safety and 
feasibility of the exercise intervention which is useful to inform a larger multicentre 
randomized controlled study in the same patient cohort. 
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In conclusion, this study reinforces findings described elsewhere in this thesis (Sections 
4.5.2 and 5.3.2, and previous published work (19,20)) showing that there is an acute 
significant reduction in physical fitness with NACRT. Furthermore, this study also shows 
that an objective improvement in physical fitness, with a clinically significant difference in 
V o2 at ˆ L in the exercise group at week 6 of +2.12 ml.kg
-1
.min
-1
 (95%CI +1.34 to +2.90; 
p<0.0001) can be attained with a structured exercise programme immediately post-NACRT 
prior to surgery. Moreover, this continues to be safe and feasible in this high risk cancer 
patient cohort. The exercise intervention was aimed at returning patients to a pre-NACRT 
level of fitness; however at week 6 baseline fitness was improved. Unfortunately, the control 
group, sustained the same deleterious insult of NACRT as seen in previous Sections (4.5.2 
and 5.3.2), but these patients continued to register a decline in physical fitness that remained 
uncorrected due to the lack of a preoperative intervention. This is a novel finding in a high 
risk surgical cohort; however the need for a randomised controlled trial to validate these 
findings is now apparent. Furthermore, a larger randomised controlled trial is also necessary 
to investigate the role of prehabilitation on postoperative surgical and tumour outcomes. 
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CHAPTER 7 – Effects of Neoadjuvant Chemoradiotherapy and a 6-Week Structured 
Exercise Programme on In Vivo Mitochondrial Function – A Randomised Controlled 
Trial 
 
 
7.1 INTRODUCTION 
 
Given the reduction in objectively measured physical fitness found in locally advanced 
rectal cancer patients following a period of standardized neoadjuvant chemoradiotherapy 
(Section 4.5 and 6.5) and the clinically significant improvement with a SRETP (as opposed 
to a period of no intervention in the contemporaneously recruited control group (Section 
6.5)), the logical next step was to explore potential mechanisms that might account for these 
changes in physical fitness. Mitochondrial function as an aspect of in vivo skeletal muscle 
function was an obvious starting point (see Section 2.7 and 2.8 for background) , as no 
change in CPET markers of cardiac, respiratory or circulatory function were observed in this 
patient cohort in prior experiments presented in this thesis (Section 4.5, 5.3, 6.5) which 
would account for the exercise intolerance observed. Skeletal muscle function and 
mitochondrial energetics have been explored in chronically ill patient groups (e.g. chronic 
obstructive pulmonary disease (COPD), heart failure and type-2 diabetes) but not in cancer 
patients especially following neoadjuvant cancer treatments. Thus using similar validated, 
non-invasive techniques to assess in vivo mitochondrial function would be an acceptable and 
interesting pilot study in these cancer patients.  
 
Magnetic resonance spectroscopy (MRS) methods can give information about cellular 
metabolism in vivo which is difficult to obtain by other ways. Section 2.8 of this thesis 
reviews the role of mitochondria in skeletal muscle energetics, while Sections 2.8.3 and 2.9 
review the ex vivo and in vivo assessment methods of measuring mitochondrial function. 
31
P 
MRS measurements of the post-exercise recovery kinetics of cytosolic pH and the cytosolic 
concentrations of phosphocreatine (PCr), orthophosphate (Pi) and ADP contain much 
information about muscle mitochondrial function (ATP synthesis, its regulation and 
abnormalities) and what might be called cellular pH homeostasis in vivo; however, 
quantitative interpretation depends on understanding the physiological basis of these 
measurements (196,199,212,294). 
31
P MRS probes in vivo mitochondrial metabolism during 
rest and exercise in selected muscle groups, where the PCr recovery time constant (kPCr) is 
taken to be a marker of in vivo mitochondrial function.  
 
A different approach to probe whole body function/capacity during exercise is the use of 
cardiopulmonary exercise testing (reviewed in Sections 2.5.1 and 2.5.2 and data presented in 
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Chapters 4,5 and 6) which can be usefully combined with 
31
P MRS (177,178) to probe 
different parts of the whole lungs-heart-muscle system. Furthermore, good correlations exist 
between in vivo and in vitro measures of mitochondrial function in health and in many 
chronic conditions (e.g. type-2 diabetes). This makes the estimation of mitochondrial 
function by 
31
P MRS an attractive, non-invasive and reliable modality when repeated 
measurements need to be undertaken (178,202,203).  
 
The pathogenesis of cancer related fatigue and reduction in fitness is complex (295,296), and 
the actual muscle metabolism mechanism of subjective weakness, reduced physical fitness 
and lack of energy remains elusive. The mechanism of the reduction in objectively measured 
physical fitness with NACRT (Section 4.5.2 and 6.5.1) and its improvement with structured 
exercise (Section 5.3.2 and 6.5.1) in this cohort of patients has never been explored prior to 
these experiments presented in this thesis. The work described in this chapter is designed to 
characterise the dynamic interrelationships between changes in whole body physical fitness 
(due to neoadjuvant chemoradiotherapy, structured exercise training or control periods i.e. 
no intervention) and in vivo mitochondrial function. This chapter specifically focuses on a 
randomised controlled study investigating; (1) the effects of NACRT on in vivo 
mitochondrial muscle function and physical fitness, and (2) the effects of a 6-week 
structured responsive exercise training programme or a control period (no intervention) on in 
vivo mitochondrial muscle function and physical fitness. 
 
 
7.2 STUDY OBJECTIVES 
 
The aims of this randomised controlled pilot study are to evaluate:  
 the effects of NACRT on in vivo mitochondrial muscle function (kPCr) and selected 
CPET variables ( V o2 at ˆ L and V o2 at Peak exercise) between baseline and Week 
0; and  
 the effects of a 6-week structured responsive exercise training programme or a 
control (no intervention) on in vivo mitochondrial muscle function (kPCr) and 
selected CPET variables ( V o2 at ˆ L and V o2 Peak) (between Week 0 and Week 
6). 
 
Primary variables of interest are V o2 at ˆ L, V o2 Peak (ml.kg
-1
.min
-1
), and mean PCr 
recovery rate constant (kPCr min
-1
). 
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7.3 PATIENTS AND STUDY METHODS 
 
Approval by the North West – Liverpool East Research and Ethics Committee 
(11/H1002/12b) was sought and the trial was registered with clinicaltrials.gov 
(NCT01859442). Written informed consent was obtained from all patients. We recruited 
consecutive patients between January 2013 and October 2013 who were referred to the 
Colorectal Multi-Disciplinary Team (MDT), age ≥18 years, with locally advanced resectable 
rectal cancer (circumferential resection margin threatened), scheduled for standardized 
NACRT on the basis of Tumour, Node, Metastasis (TNM) classification >T2/N+ with no 
distant metastasis (230) and WHO Performance Status < 2 (231). Predefined exclusion 
criteria were: inability to give informed consent, non-resectable disease, inability to perform 
CPET or bicycle exercise due to leg dysfunction, patients who declined surgery or NACRT, 
patients who received non-standard NACRT and patients who failed the MR safety 
screening.  
 
TNM staging involved flexible sigmoidoscopy for histological diagnosis, colonoscopy, 
chest, abdomen and pelvis computer-aided tomography (CT) and a 1.5 Tesla pelvic MRI 
(Magnetom Aera, Siemens, Erlangen, Germany). All patients then underwent standardised 
NACRT for 5 weeks. Standardized radiotherapy consisted of 45 Gy in 25 fractions on 
weekdays using a 3-dimensional conformal technique with CT guidance. A boost dose was 
given (5.4 Gy in 3 fractions) to the primary tumour only. Oral capecitabine (825 mg.m
-2
) 
was given twice daily on radiotherapy days. No patients received brachytherapy. The 
colorectal multidisciplinary team (MDT) was blind to CPET results and patient allocation, 
which therefore did not influence perioperative management. All patients underwent total 
mesorectal excision (TME) surgery (232). A defunctioning stoma was constructed at the 
discretion of the surgeon.  
 
Any acute toxicity whilst undergoing NACRT was discussed at the weekly colorectal MDT 
meeting. Toxicity events were graded according to the National Cancer Institute Common 
Terminology Criteria (version 3.0), and the acute radiation-induced skin toxicity using the 
Radiation Therapy Oncology Group scoring system.  
 
CPET followed a standard protocol described in Section 3.2. 
31
P MRS scanning followed a 
standard protocol described in Section 3.4. Recorded patient characteristics included age, 
gender, height, weight, diagnosis, TNM staging, surgical procedure planned, WHO 
classification and ASA-PS, as well as established diagnosis of diabetes, ischaemic heart 
disease, cerebrovascular disease, or heart failure. Resting flow-volume loops were used to 
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derive Forced Expiratory Volume over 1 second (FEV1) and Forced Vital Capacity (FVC). 
All patients underwent CPET and a 
31
P MRS scan at 2 weeks before NACRT (baseline) and 
immediately post-NACRT (Week 0). Patients were randomised 1:1 to an exercise group or 
control group using a random number generating software. Patients in both groups then 
underwent CPET at Weeks 3, and 6. Patients underwent a final 
31
P MRS scan at Week 6. 
Patients in the exercise group undertook the exercise intervention continuously between 
Week 0 and Week 6. The study schedule is summarised in Chapter 3; Figure 3.2 and in more 
detail in Figure 7.1 below. CPET data were reported by two experienced assessors blind to 
patient characteristics and group allocation. Any CPET or exercise-related adverse events 
were discussed at the weekly colorectal MDT meeting. 
31
P MRS scan analysis was 
performed in a blinded fashion, with the assessor blind to individual patients’ clinical details, 
CPET variables, group allocation and MR time points (i.e. baseline (pre-NACRT), Week 0 
and Week 6 (post-NACRT)). 
 
Patients in the exercise group attended an in-hospital exercise training programme which 
was supervised (by a team member trained in advanced life support), structured (3 
sessions/week for 6 weeks) and responsive (informed by measured work rates at V o2 at ˆ L 
and V o2 Peak at Week 3). The exercise schedule is described in Section 3.3. Patients 
exercised in groups of two (for camaraderie), each patient being prescribed a programme 
tailored to individual fitness (based initially on CPET results at Week 0). After session 7 
(Week 3), work rates were individually adjusted in line with mid-programme CPET results. 
 
 
7.4 STATISTICAL ANALYSIS 
 
Our aim was to recruit 12 patients (6 patients in the exercise group and 6 in the control 
group) who would undergo standardised NACRT, CPET and 
31
P MRS scans at baseline 
(pre-NACRT), at Week 0 (immediately post-NACRT) and Week 6. Descriptive statistics are 
reported as mean (SD) or median and inter-quartile range (IQR) and categorical statistics as 
frequency (percentage). No statistical comparisons of patient characteristics between groups 
were undertaken. Randomization was performed by randomly assigning patients to one of 
the two groups (exercise vs. control) in a 1:1 fashion, using a computer-based random 
number generator. Randomization was done on completion of NACRT. The central 
investigator performed the randomization; however personnel who reported CPET and 
31
P 
MRS tests were blind to the randomization sequence.  
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For the primary analysis, baseline and Week 0 measurements for V o2 at ˆ L, V o2 Peak and 
kPCr were compared using a paired t-test. Week 6 variables were compared between exercise 
and control groups using ANCOVA. Correction for Week 0 variables was done. Spearman 
correlations were performed between changes in haemoglobin and V o2 at ˆ L (baseline vs. 
Week 0). Spearman correlations were also performed between V o2 at ˆ L, V o2 Peak and 
kPCr at each time point. Formal comparisons were considered to be statistically significant at 
p<0.05. These analyses were conducted using Stata version 12 (StataCorp. 2011. Stata 
Statistical Software: Release 12. College Station, TX: StataCorp LP.) 
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7.5 RESULTS 
 
A total of 12 patients were recruited, all of whom completed the study period. Figure 7.1 
illustrates a diagram depicting detailed patient flow for this study.  
 
 
Patient characteristics are reported in Table 7.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1 – Consort diagram 
Control Group 
n=6 
Exercise Group 
n=6 
Cardiopulmonary exercise test (CPET) and 
31
P MRS scan– Baseline (n=12) 
 
Standardised Neoadjuvant 
chemoradiotherapy (n=12) 
 
CPET and 
31
P MRS scan – Week 0 
Recruited 
(n=12) 
 
 Exercise Programme –  
Week 0 to Week 6 
 
Randomisation 
CPET and 
31
P MRS scan – Week 0 
CPET – Week 3 CPET – Week 3 
CPET and 
31
P MRS scan – Week 6 
n=6 
CPET and 
31
P MRS scan – Week 6 
n=6 
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Table 7.1 – Patient characteristics; Smoking status assessed as currently smoking - yes (1) vs. no (0). 1Values 
presented as mean (SD); 2 Number of patients (%). World Health Organization (WHO) Performance Status and 
American Society of Anaesthesiologists Score (ASA). 
 
Table 7.2 shows changes in BMI, spirometry variables (FEV1, FVC, FEV1/FVC) and 
haemoglobin over the whole study period in the exercise and the control groups, along with 
MRI tumour staging at baseline.  
 Exercise (n=6) Control (n=6) 
Age (years)
1 
67 (12.2) 70 (7.8) 
Gender M:F (%)
2
 4 (67) : 2 (33) 6 (100) : 0 
Smoking (%)
2
 0 2 (33) 
Past Medical History
2
 
Heart Failure 
Diabetes 
Ischaemic heart Disease 
Cerebrovascular Disease 
 
0 
0 
0 
0 
 
0 
1 (17) 
2 (33) 
0 
ASA
2 
1 
2 
 
3 (50) 
3 (50) 
 
3(50) 
3(50) 
WHO Performance 
Status
2 
0
 
1 
 
 
4 (67) 
2 (33) 
 
 
5 (83) 
1 (17) 
 Exercise (n=6) Control (n=6) 
BMI (kg.m
-2
)
1 
Baseline 
Week 0 
Week 3 
Week 6 
 
27.5 (3.6) 
27.1 (3.3) 
27.2 (3.1) 
27.7 (3.7) 
 
26.2 (4.3) 
25.5 (3.2) 
26.4 (4.2) 
26.6 (4.4) 
FEV1 (L)
1 
Baseline 
Week 0 
Week 3 
Week 6 
 
3.0 (0.8) 
2.9 (1.0) 
3.3 (0.6) 
2.9 (0.8) 
 
3.1 (0.6) 
2.9 (0.8) 
3.1 (0.6) 
2.8 (0.6) 
FVC (L)
1 
Baseline 
Week 0 
Week 3 
Week 6 
 
4.6 (0.9) 
4.6 (0.9) 
4.3 (0.9) 
4.3 (0.8) 
 
4.2 (0.7) 
3.9 (0.9) 
3.8 (0.7) 
3.8 (0.6) 
FEV1/FVC (%)
1 
Baseline 
Week 0 
Week 3 
Week 6 
 
71 (8.2) 
73 (8.5) 
77 (6.2) 
71 (14.4) 
 
73 (6.9) 
73 (6.7) 
74 (6.4) 
73 (7.6) 
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Table 7.2 – Patient and tumour characteristics; # with percentages in parentheses; 1 Values presented as mean 
(SD); 2 International Union against Cancer Tumour Node Metastasis (TNM) MRI staging. 
 
 
7.5.1 CHANGES IN PHYSICAL FITNESS WITH NACRT AND EXERCISE 
 
The median time to starting the exercise programme after completion of NACRT was 2 
working days (IQR 1-6 days). The mean (SD) % adherence to the exercise programme 
(defined as % of the total of 18 sessions completed) was 89 (5) %. The mean % adherence to 
CPETs (defined as % of the total of 6 CPETs attended) was 97% in the exercise group vs. 
100 % in the control group. There were no adverse events recorded following CPET or any 
of the exercise sessions. One patient in the exercise group only completed 5 of 18 exercise 
sessions. This patient sustained severe (grade 3 of 4) perineal burns and was unable to sit for 
prolonged periods of time, therefore was unable to adhere with the exercise programme. 
Table 7.3 shows changes in all CPET related variables that were measured.  
 
 
 
 
 
 
 
 
Haemoglobin (g.dl
-1
)
1 
Baseline 
Week 0 
Week 6 
 
12.8 (1.5) 
12.6 (1.6) 
12.8 (1.2) 
 
13.7 (1.4) 
13.1 (1.5) 
13.1 (1.6) 
Tumour distance from 
anal verge 
1
 
<5.0 cm 
5.1-10.0cm 
>10.1cm 
 
 
4 (67) 
2 (33) 
0 
 
 
2 (33) 
3 (50) 
1 (17) 
Clinical MRI 
TNM 
classification
2# 
 
Baseline 
cTx 
cT2 
cT3 
cT4 
cN0 
cN1 
cN2 
cM0 
0 0 
0 0 
5 (83) 5 (83) 
1 (17) 1 (17) 
2 (33) 1 (17) 
1 (17)  3 (50) 
3 (50) 2 (33) 
6 (100) 6 (100) 
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 Exercise (n=6) Control (n=6) 
kPCr  (min
-1
) 
Baseline 
Week 0 
Week 6 
 
1.47 (0.5) 
1.05 (0.4) 
1.83 (0.6) 
 
1.45 (0.5) 
1.18 (0.3) 
1.33 (0.7) 
V o2 at ˆ L (ml.kg
-1
.min
-1
)
1
 
Baseline 
Week 0 
Week 3 
Week 6 
 
12.8 (4.6) 
9.5 (3.0) 
12.9 (3.0) 
12.9 (4.1) 
 
11.7 (1.9) 
10.4 (1.9) 
9.4 (0.8) 
10.1 (1.5) 
V o2 at ˆ L (L.min
-1
)
1
 
Baseline 
Week 0 
Week 3 
Week 6 
 
1.0 (0.4) 
0.7 (0.3) 
1.0 (0.3) 
1.0 (0.3) 
 
0.9 (0.2) 
0.8 (0.2) 
0.7 (0.1) 
0.7 (0.1) 
V o2 Peak (ml.kg
-1
.min
-1
)
1
 
Baseline 
Week 0 
Week 3 
Week 6 
 
19.3 (8.4) 
14.2 (4.9) 
19.2 (4.7) 
18.8 (6.7) 
 
18.1 (3.4) 
15.3 (3.1) 
14.3 (2.7) 
15.3 (1.9) 
V o2 Peak (L.min
-1
)
1
 
Baseline 
Week 0 
Week 3 
Week 6 
 
1.5 (0.7) 
1.1 (0.4) 
1.5 (0.5) 
1.5 (0.5) 
 
1.3 (0.3) 
1.1 (0.3) 
1.0 (0.3) 
1.1 (0.2) 
O2 pulse at ˆ L (ml.beat
-1
)
1
 
Baseline 
Week 0 
Week 3 
Week 6 
 
9.0 (3.8) 
7.1 (2.9) 
9.4 (2.6) 
9.3 (3.2) 
 
8.8 (2.2) 
8.4 (1.1) 
8.1 (1.2) 
8.3 (1.2) 
O2 pulse at Peak (ml.beat
-1
)
1
 
Baseline 
Week 0 
Week 3 
Week 6 
 
10.5 (4.9) 
7.8 (2.8) 
10.7 (3.2) 
10.7 (4.3) 
 
10.5 (2.0) 
9.6 (0.8) 
9.3 (1.6) 
9.9 (0.9) 
V E/ V co2 at ˆ L 1 
Baseline 
Week 0 
Week 3 
Week 6 
 
35.7 (7.8) 
34.4 (5.7) 
33.7 (2.3) 
33.8 (5.5) 
 
33.3 (5.0) 
33.9 (2.7) 
35.0 (3.7) 
34.2 (4.2) 
V E/ V co2 at Peak1 
Baseline 
Week 0 
Week 3 
Week 6 
 
36.2 (5.9) 
38.3 (6.1) 
37.0 (2.8) 
38.5 (5.6) 
 
35.7 (3.2) 
35.9 (3.3) 
35.3 (2.7) 
35.3 (4.0) 
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Table 7.3 – Exercise and 31P MRS variables presented at all study time points. 1 Values presented as mean (SD). 
2Values presented as median (IQR). kPCr, Phosphocreatine recovery time constant; V o2 at ˆ L , Oxygen uptake at 
estimated lactate threshold; V o2 Peak, Oxygen uptake at peak exercise; O2 pulse at ˆ L, Oxygen pulse at 
estimated lactate threshold; O2 pulse at Peak, Oxygen pulse at peak exercise;  V E/ V co2 at ˆ L, Ventilatory 
equivalents for carbon dioxide at estimated lactate threshold; V E/ V co2 at ˆ L, Ventilatory equivalents for 
carbon dioxide at peak exercise; Work rate at ˆ L, Work rate at estimated lactate threshold; Work rate at Peak, 
Work rate at peak exercise. 
 
V o2 at ˆ L and V o2 Peak were the primary outcome CPET variables.  There was a 
significant reduction in V o2 at ˆ L (-2.36 ml.kg
-1
.min
-1
; 95%CI -3.78 to -0.93; p<0.0039) and 
V o2 at Peak (-3.95 ml.kg
-1
.min
-1
; 95%CI -6.79 to -1.11; p<0.0108) post-NACRT (Week 0). 
The exercise group showed a significant improvement in both primary endpoints during the 
intervention period (Week 0 to Week 6), in contrast to the worsening physical fitness in the 
control group (Figure 7.2 A and B). 
 
 
 
 
 
 
Baseline heart rate (beats.min
-1
)
2
 
Baseline 
Week 0 
Week 3 
Week 6 
 
84 (77,92) 
77 (71,87) 
76 (71,93) 
84 (76,88) 
 
71 (64,75) 
61 (60,64) 
61 (60,64) 
63 (60,70) 
Peak heart Rate (beats.min
-1
)
2
 
Baseline 
Week 0 
Week 3 
Week 6 
 
142 (136,145) 
141 (134,151) 
140 (133,144) 
135 (130,146) 
 
126 (121, 133) 
113 (106, 125) 
109 (101, 127) 
108 (99,126) 
Work rate at ˆ L (W)
2
 
Baseline 
Week 0 
Week 3 
Week 6 
 
54 (36,82) 
56 (43,72) 
74 (70,94) 
75 (62,88) 
 
55 (43,71) 
52 (37,70) 
57 (39,67) 
58 (51,60) 
Work rate at Peak (W)
2
 
Baseline 
Week 0 
Week 3 
Week 6 
 
109 (70,156) 
113 (87, 135) 
126 (116, 172) 
126 (108, 161) 
 
109 (80,123) 
99 (70,123) 
99 (69,124) 
110 (91,128) 
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(A) 
 
 
 
(B) 
 
Figure 7.2A and B – Line diagram showing fitted means and SD for V o2 at ˆ L (ml.kg-1.min-1) (A) and V o2 
Peak (ml.kg-1.min-1) (B) at baseline (pre-NACRT), week 0 (post-NACRT) and Week 6 for the exercise (dashed 
line) and control groups (solid line) 
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During the intervention period, the exercise group improved V o2 at ˆ L by +3.43 ml.kg
-
1
.min
-1
 (95%CI +1.96 to +4.91), while the control group showed a further decline in V o2 at 
ˆ L by -0.25 ml.kg
-1
.min
-1
 (95%CI: -1.53 to +1.03). A direct comparison of V o2 at ˆ L 
between groups at week 6, correcting for differences in V o2 at ˆ L between the groups at 
Week 0, shows a clinically significant difference of +3.85 ml.kg
-1
.min
-1 
(95%CI +2.12 to 
+5.59; p=0.001). V o2 Peak shows similar changes in the exercise group: +4.53 ml.kg
-1
.min
-1 
(95%CI +0.31 to +8.76), while the control group worsened  by -0.03 ml.kg
-1
.min
-1 
 (95%CI: 
-2.00 to +1.93). A similar direct comparison of V o2 Peak between groups at Week 6, 
correcting for differences in V o2 Peak at Week 0, shows a change of +4.49 ml.kg
-1
.min
-1 
(95%CI +0.14 to +8.84; p=0.044). Figure 7.3 displays individual patient data between 
baseline and week 0 for V o2 at ˆ L and V o2 Peak, while data for individual patient data in 
the exercise and control groups between week 0 and week 6 for V o2 Peak and V o2 at ˆ L is 
displayed in Figure 7.4 and Figure 7.5 respectively.  
 
 
Figure 7.3: CPET variables ( V o2 at ˆ L and V o2 at Peak) Baseline (before NACRT)) and at Week 0 (post-
NACRT): lines link data-points (closed circles) for individual patients, and open circles show overall mean±SEM 
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Figure 7.4: Changes in individual patient data for V o2 at Peak between Week 0 (post-NACRT) and Week 6 
(after 6 weeks of structured exercise or control): lines link data-points (closed circles) for individual patients, and 
open circles show overall mean±SEM 
 
 
V o2 at ˆ L 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.5: Changes in individual patient data for V o2 at ˆ L between Week 0 (post-NACRT) and Week 6 (after 
6 weeks of structured exercise or control): lines link data-points (closed circles) for individual patients, and open 
circles show overall mean±SEM 
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7.5.2 CHANGES IN MITOCHONDRIAL FUNCTION WITH NACRT AND 
EXERCISE 
 
All 
31
P MRS scans were undertaken at a minimum of 48 hours following the CPET (median 
time following CPET is 2+0.5 days). All 12 patients were adherent to all three 
31
P MRS 
scans. There were no adverse events recorded following any of the scans. Figure 7.6 shows a 
complete time course of pH and kPCr at baseline and during the whole of the exercise and 
recovery periods. Figures 7.7A and B show the mean fractional PCr recovery at baseline (A 
- pre-NACRT) and at Week 0 (B - post-NACRT) with exponential fitting. The mean 
fractional PCr recovery with exponential fitting has been repeated for Week 6 data however 
this is not shown. 
 
 
 
Figure 7.6 – Line graph showing time course of changes in the group mean data of kPCr and pH (relative to 
baseline) during the experimental protocol (exercise and recovery) in response to the 2 workloads with associated 
kinetic fits. MVC – Maximal Voluntary Contraction 
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Figure 7.7A shows the mean fractional PCr recovery (min-1) at baseline (pre-NACRT) showing exponential fit 
against time 
 
 
 
 
Figure 7.7B shows the mean fractional PCr recovery (min-1) at Week 0 (post-NACRT) showing exponential fit 
against time 
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A statistically significant decline in kPCr of -0.34 (95%CI -0.51, -0.17; p=0.0009) was found 
in all patients post-NACRT (between baseline and Week 0) (Figure 7.8). During the 
intervention period, the exercise group improved kPCr by +0.78 (95%CI +0.26 to +1.31), 
while the control group also showed a small improvement in kPCr of +0.15 (95%CI: -0.32 to 
+0.62). A direct comparison of kPCr between groups at week 6, correcting for differences in 
kPCr between the groups at Week 0, shows a significant difference of +0.66
 
(95%CI 0 to 
+1.31; p=0.049) (Figure 7.9A (exercise group) and Figure 7.9B (control group). A line 
diagram showing changes in kPCr over the whole study period is shown in Figure 7.10.  
 
 
 
 
Figure 7.8: Line diagram linking data-points (closed circles) for individual patients, and overall mean±SEM 
(open circles) showing changes in kPCr between baseline (before NACRT) and Week 0 (post-NACRT) 
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Figure 7.9A: Line diagram linking data-points (closed circles) for individual patients, and overall mean±SEM 
(open circles) showing changes in kPCr between Week 0 (post-NACRT) and Week 6 in the exercise group 
 
 
 
 
 
 
Figure 7.9B: Line diagram linking data-points (closed circles) for individual patients, and overall mean±SEM 
(open circles) showing changes in kPCr between Week 0 (post-NACRT) and Week 6 in the control group 
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Figure 7.10 – Line diagram showing fitted means and SD for kPCr at baseline (pre-NACRT), week 0 (post-
NACRT) and Week 6 for the exercise (dashed line) and control groups (solid line) 
 
No significant relationship was found between the change in V o2 at ˆ L and change in 
haemoglobin between baseline and Week 0 (Figure 7.11); r=0.27; p=0.396.  
 
 
 
 
Figure 7.11 – Correlation plot showing changes in V o2 at ˆ L (ml.kg-1.min-1) vs. changes in haemoglobin (g.dl-
1) between baseline (pre-NACRT) and week 0 (post-NACRT) 
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No significant relationship was found for the whole group (SRETP plus control) between V
o2 at ˆ L and kPCr at the two time points before and after NACRT (Baseline - r=0.37, p=0.23; 
Week 0 – r=0.13, p=0.67), and between V o2 at Peak and kPCr (Baseline - r=0.37, p=0.24; 
Week 0 – r=0.06, p=0.84) between baseline and Week 0 (Figure 7.12A and B). 
 
 
(A) 
 
 
(B) 
 
 
 
Figure 7.12A and B - Correlation plots showing changes in V o2 at ˆ L (ml.kg.-1min-1) (A) and V o2 Peak 
(ml.kg.-1min-1) (B) vs. changes in kPCr (l.min
-1) between baseline (Pre) and Week 0 (Post). Blue circles represent 
baseline whilst red circles represent Week 0 measurements. 
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Furthermore, no significant  relationship was found for the whole group at the two later time 
points between the change in V o2 at ˆ L and change in kPCr (Post - r=0.001, p=1.00; Week 6 
– r=0.38, p=0.23), and between the change in V o2 at Peak and change in kPCr (Post - r=-
0.07, p=0.82; Week 6 – r=0.45, p=0.14) between Week 0 and Week 6 relative to baseline 
(Figure 7.13A and B). 
 
 (A) 
 
(B) 
 
 
Figure 7.13A and B - Correlation plots showing relative (i.e. no change = 1.0) changes in V o2 at ˆ L (ml.kg.-
1min-1) (A) and V o2 Peak (ml.kg.-1min-1) (B) vs. changes in kPCr (l.min-1) between Week 0 (Post) and Week 6. 
Red circles represent Week 0 whilst pink squares represent Week 6 measurements. 
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When assessing the relationship between the changes in V o2 at ˆ L and V o2 at Peak and the 
changes in kPCr  across the 3 time points in the exercise group alone, a strong relationship 
was found for baseline ( V o2 at ˆ L r=0.84, p=0.04 and V o2 at Peak r=0.86, p=0.03) and 
Week 6 ( V o2 at ˆ L r=0.82, p=0.04 and V o2 at Peak r=0.74, p=0.08) measurements (Figure 
7.14A and B). No relationship was found for Week 0 measurements.  
 
(A) 
 
 
(B) 
 
 
Figure 7.14A and B - Correlation plots showing changes in V o2 at ˆ L (ml.kg.-1min-1) (A) and V o2 Peak 
(ml.kg.-1min-1) (B) vs. changes in kPCr (l.min
-1) between all 3 time points for the exercise group alone. Blue 
circles represent baseline, red circles represent Week 0, whilst pink circles represent Week 6 measurements. 
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7.6 DISCUSSION 
 
This randomized controlled pilot study shows significant reductions in V o2 at ˆ L (-2.36 
ml.kg
-1
.min
-1
) and V o2 at Peak (-3.95 ml.kg
-1
.min
-1
) between baseline and Week 0 (post-
NACRT) in locally advanced rectal cancer patients consistent with findings observed in 
Section 6.5. Furthermore, also consistent with results from the study in Chapter 6, a 6-week 
structured exercise intervention period is shown to improve objectively measured physical 
fitness in patients scheduled for rectal cancer surgery following standardised NACRT. A 
clinically significant mean improvement in V o2 at ˆ L of +3.85 ml.kg
-1
.min
-1
 was seen in the 
exercise group, as opposed to the control group who showed a decline in V o2 at ˆ L by -0.25 
ml.kg
-1
.min
-1
. Similar changes were found in V o2 at Peak.  
 
The main objective of this chapter was to attempt to define changes in in vivo mitochondrial 
function measured by 
31
P MRS which might underlie changes in physical fitness measured 
objectively by whole body measurements (using CPET). This was done in an attempt to 
elucidate a potential mechanistic link driving the changes in objectively measured whole 
body physical fitness with NACRT and the structured exercise programme. Between 
baseline and Week 0, a significant reduction in kPCr of -0.34 was found in all patients (Figure 
7.8). Between Week 0 and Week 6, the exercise group showed a significant improvement in 
kPCr as opposed to the control group of +0.66 (Figure 7.9 A and B). These are important, 
novel, potentially clinically relevant findings which show changes in whole body measures 
of physical fitness (CPET variables) consistent with previous results in Section 4.5 (decline 
in fitness with NACRT), Section 5.3 (improvement in fitness with SRETP) and Section 6.5 
(decline in fitness with NACRT, with an improvement in fitness in the exercise group 
compared with the control group). These changes in whole body measures of fitness are now 
seen to be consistent with changes in mitochondrial function seen in peripheral muscle. 
Therefore, the acute decline in mitochondrial function with NACRT (-34%) may account for 
the acute loss in fitness over the neoadjuvant treatment period. Moreover, over the next 6 
weeks, the acute improvement in mitochondrial function observed with exercise (+71%) as 
opposed to no intervention (+21%), might indicate that a structured intervention 
immediately after NACRT arrests and ameliorates the deleterious effect of NACRT on 
mitochondrial function. 
 
This pilot study was not powered to detect between-individual correlations between 
31
P 
MRS and CPET measurements either at baseline, after NACRT or after SRETP (Figure 7.12 
for the whole group, and Figure 7.14 for the exercise group only), or between changes in 
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these measurements from baseline at the latter two time points (Figure 7.13 for the whole 
group, and Figure 7.14 for the exercise group only). There is perhaps a suggestion of such 
relationships in the whole-group (Figures 7.12 and 7.13), but this fails to reach statistical 
significance. In the exercise group alone, however, the baseline and post-exercise data do 
show a significant correlation, which is not seen post-NACRT, when both variables shows a 
notably reduced range. The mechanism proposed here would predict such correlations in all 
groups, but clearly a larger study would be required to define these precisely. 
 
 
7.6.1 MITOCHONDRIAL FUNCTION ALTERATION IN CHRONIC DISEASE  
 
31
P MRS studies of this kind have never been attempted in cancer patients. Mitochondrial 
function has been shown to be impaired in patients with exercise intolerance (cramping, 
fatigue, muscle pain, stiffness or burning) during mild muscular exertion (297) and in 
chronic disease states such as cardiac failure (298) and peripheral arterial occlusive disease 
(209,299). 
31
P MRS findings from chronic disease states reveal abnormalities in skeletal 
metabolism during exercise, more specifically in heart failure patients kPCr concentrations 
were lower with respect to matched controls, which would indicate reduced ATP and kPCr 
resynthesis despite a lower ATP utilization rate due to substantial lower work rates carried 
out by the patients. Furthermore, a lower kPCr suggested impaired oxidative phosphorylation, 
which is hypothesised to be due to an acidic change in pH or an intrinsic change in skeletal 
muscle fibre type. When considering other chronic disease states such as patients with 
arterial insufficiency or claudication similar trends emerge; slower kPCr at the end of the 
exercise protocol in the claudication group with respect to healthy controls, and no changes 
in pH indicating altered mitochondrial function (299). This was further elucidated by Kemp 
and colleagues (209) who found that peripheral vascular disease patients have normal 
muscle cross-sectional area, maximal voluntary contraction, ATP turnover and contractile 
efficiency (ATP turnover per force/area), larger PCr changes during exercise (i.e. increased 
shortfall of oxidative ATP synthesis) and slower kPCr recovery (47% ± 7% [mean ± SEM] 
decrease in functional capacity for oxidative ATP synthesis, p=0.001), faster deoxygenation 
during exercise and slower post-exercise reoxygenation (59% ± 7% decrease in rate 
constant, p=0.0009). Results from this cohort of patients have been consistent however; 
arguments for the reduction in kPCr have been inconsistent with interpretations ranging from 
a simple direct impairment of oxygen supply to exercising muscle to a more complex 
multifactorial interplay of intrinsic mitochondrial defects; such as change in fibre type, 
change in oxidative enzymes and mitochondrial damage due to oxidative stress.  
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Mitochondrial dysfunction has also been described in patients with COPD (300,301). These 
patients exhibit decrease in oxidative capacity and an excessive production of reactive 
oxygen species (ROS). Oxidative capacity can be directly assessed by measuring the activity 
of key enzymes, such as those of the citric acid cycle (Krebs cycle) (i.e., citrate synthase and 
succinate dehydrogenase) and β-hydroxyacyl-CoA dehydrogenase (an enzyme involved in 
β-oxidation of fatty acids), the concentrations of which are typically lower in patients with 
COPD than in healthy controls (302). Consistent with these results, the recovery time for 
kPCr after exercise, measured by 
31
P-MRS, is significantly prolonged (i.e., reduced oxidative 
capacity) in these patients (303). Reasons for this are still unclear, however causes for the 
overall decreased oxidative capacity and mitochondrial respiration might be due to reduced 
mitochondrial density (found to be lower in COPD patients than in age-matched, healthy 
controls (304)). The reduced mitochondrial density and oxidative capacity found in COPD 
patients are likely a consequence of the shift from type I fibers (slow, oxidative) to type IIx 
fibers (fast twitch, glycolytic) that is consistently observed in the peripheral skeletal muscle 
of COPD patients (304). While such muscle atrophy and loss of oxidative capacity is the 
typical physiological response to muscle disuse/deconditioning (305) and can be corrected 
with training (302,306), mechanisms for skeletal muscle dysfunction other than inactivity 
(i.e., inflammation, hypoxia, oxidative stress, nutrition) have been postulated and are still 
under debate (307,308). Similar mechanisms as the ones described above might mediate the 
decline in physical fitness with cancer therapies in cancer patients.  
 
 
7.6.2 MITOCHONDRIAL FUNCTION ALTERATION WITH CANCER AND 
CANCER THERAPIES 
 
Cancer and cancer treatments can potentially induce lean tissue degradation and 
abnormalities in the metabolic system in cardiac and skeletal muscle, resulting in loss of 
muscular weakness in cancer survivors which may resemble the muscle dysfunction 
discussed above. Multiple factors appear to contribute to muscle wasting and cellular 
dysfunction, such as generation of cytokines (tumor necrosis factor-a, interleukin 1, 
interleukin 6, interferon-c), fatty acid-derived eicosanoids and reactive oxygen (ROS) and 
nitrogen species (RNS). When generation of ROS/RNS exceeds cellular adaptive and repair 
capacities – a condition of oxidative stress is known to exert damaging effects to biological 
molecules such as nucleic acids, proteins, membrane phsopholipds etc. which may lead to 
deregulation of cell function or of sub cellular structures e.g. mitochondria or even whole 
cell death. Many cancer therapies exert an oxidative stress effect on non-targeted tissues 
leading to “normal tissue injury” (21). This collateral damage from cancer therapies leads to 
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impairment of normal tissue function, which is hypothesised to account for a reduction in 
fitness in our cancer cohort due to a deregulation of normal mitochondrial function. A 
review by Chen et al (21) suggests that a better understanding of the mechanisms involved in 
oxidative injury to normal tissues is essential to design intervention strategies that will 
attenuate the toxicity of chemotherapeutic agents without compromising their anticancer 
effects. This was the aim of the structured exercise training programme (SRETP) which was 
implemented in this chapter as well as in Chapters 5 and 6, in an attempt to attenuate the 
deleterious effects of NACRT on physical fitness seen consistently throughout this thesis 
(Chapters 4 to 7). 
  
Another potential factor involved in cellular harm is proteolysis-inducing factor (PIF). PIF 
activates the ubiquitin–proteasome proteolytic pathway, which may be the proteolytic 
pathway for muscle breakdown in cancer patients. The interaction of tumour products, 
hormones and inflammatory mediators promotes gluconeogenesis, limits anabolism and 
increases catabolism, which contributes to the poor performance status (closely associated 
with fitness) of cancer survivors and threatens cancer survival (309). The loss of lean muscle 
mass occurs due to a decline in protein synthesis in conjunction with enhanced protein 
catabolism. Cancer survivors experience the decline in protein synthesis due to physical 
inactivity (deconditioning) coupled with a possible reduction in the supply of amino acids in 
protein production, while protein degradation appears to be due to an increased expression 
of components in the ubiquitin–proteasome proteolytic pathway. The major adaptations that 
occur as a result of a decline in protein synthesis and protein degradation include (a) a 
reduction in muscle and muscle fibre cross-sectional area as a result of a loss of myofibrils 
and myofilaments; (b) a loss of muscle extensibility; and (c) a decrease in proteins necessary 
for metabolism, especially the oxidative enzymes in the Krebs cycle and electron transport 
chain, leading to a reduction in the muscles’ oxidative potential (309,310).  
 
In this cohort of patients receiving both neoadjuvant chemotherapy and radiotherapy, 
mechanisms for the reduction in fitness might be multifactorial. It is known that in patients 
receiving ionising radiation as a means of thoracic cancer treatment causes excessive 
fibrosis, or non-healing wound responses, characterised by upregulation of a 
proinflammatory cascade in local tissue (311). Together with the perturbation of 
homoeostatic control of reactive oxygen species, this cascade of events leads to excessive 
deposition of extracellular matrix and collagen, vascular damage, and ischaemia. Incidental 
radiation damage to the heart and lungs is especially relevant to exercise tolerance; however 
this is not immediately evident in this cohort of locally advanced rectal cancer patients. In a 
prospective study of patients who received radiotherapy for left-sided breast cancer between 
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1998 and 2005, subclinical abnormalities in myocardial perfusion were noted in more than 
50% of patients (312). Radiation can also cause pulmonary damage. Symptomatic shortness 
of breath following radiation occurs in about 1% of patients treated with tangents alone, but 
can occur in up to 5% of patients who receive local and regional (i.e. nodal) irradiation along 
with systemic chemotherapy (313). These adverse effects of radiation on the heart and lungs 
might contribute to exercise intolerance by reducing pulmonary diffusion capacity and 
convective oxygen delivery. No study has addressed whether radiation directly reduces 
cardiorespiratory fitness in patients with cancer. Miller and colleagues (314) found that 6 
min walk distance, a measure of functional capacity and a common surrogate of 
cardiorespiratory fitness in patients with respiratory disease, was associated with pulmonary 
toxicity in 31 patients who received radiation treatment for inoperable lung cancer. Higher 
walking distance was associated with lower radiation-induced lung injury. In the patient 
cohort studied in this thesis, NACRT has not been shown to affect lung function as 
measured by spirometry or CPET ( V E/ V co2 at ˆ L or V E/ V co2 at Peak) or cardiac 
function (O2 Pulse at ˆ L or O2 Pulse at Peak). 
 
Haemoglobin concentration is another component of oxygen delivery known to be affected 
by chemotherapy. Anaemia can affect 30–100% of patients as a result of bone-marrow 
damage and lowered production of red blood cells (315). Lower haemoglobin concentrations 
were found to be independently associated with a lower oxygen uptake during the 
preoperative CPET (316). Haemoglobin was measured at baseline, Week 0 and Week 6 
before CPET. None of the patients in this cohort was found to be anaemic at any time point 
and there were no significant differences between time points, so a reduction in oxygen 
delivery/uptake due to anaemia was deemed to be unlikely in this patient cohort.  
 
Breast cancer patients receiving chemotherapy are known to suffer from acute or long-term 
cardiovascular complications (317). Although many of the complications do not persist after 
completing chemotherapy, cardiac toxicity is considered permanent and leads to reduced 
systolic function and diastolic filling, leaving patients at a high risk of age-related cardiac 
disorders in the future (318). The generation of reactive oxygen species and induction of 
cardiac myocyte apoptosis are thought to have a central role in this process (319). Mercuro 
and colleagues (320) prospectively examined early myocardial dysfunction among 16 
patients undergoing anthracycline (epirubicin)-containing chemotherapy using conventional 
echocardiography with tissue doppler imaging integrated with biochemical markers of 
myocardial damage and inflammation/reactive oxygen species. Levels of inflammation and 
reactive oxygen species increased significantly during chemotherapy and were correlated 
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with change in myocardial strain. Unfavorable alterations in myocardial tissue result in 
impaired left ventricular ejection fraction (LVEF) and cardiac output, which in turn would 
reduce convective oxygen delivery. Molecular and cellular mechanism affecting cardiac 
muscle have been postulated to be as a result of myocyte death, myocyte injury due to 
reactive oxygen species, sarcomere “sarcopenia”, sarcomere structure disruption, 
myofilament degradation due to degradation of Titin (an entopic spring element in the 
sarcomere that regulates length-dependent calcium sensitivity), suppression of transcription 
sarcomere proteins, and most importantly disruption of specific growth factors e.g. 
neuregulin which regulates cardiac muscle myocyte sarcomere turnover  (319).  
 
Similarly, oxidative stress produced by other chemotherapies (e.g. anthracyclines – cysplatin 
and epirubicin used commonly in clinical oncology practices) (21) show similar oxidative 
stress-mediated injury to cardiac muscle, kidneys and brain tissue. At subcellular levels, 
mitochondria are the main targets of chemotherapy induced oxidative stress. Electron 
micrographs clearly demonstrate profound damage is caused to the organelle, including 
mitochondrial vacuolization, mitochondrial degeneration, and disruption of the 
mitochondrial membrane. Mitochondrial DNA (mtDNA) is an important target for oxidative 
stress. Compared with nuclear DNA, mtDNA is more susceptible to oxidative damage, 
owing to its proximity to the site of ROS generation, its lack of introns and histones, and the 
limited DNA repair capacities in mitochondria (321). The heightened, oxidation sensitive 
mutability of mtDNA has obvious implications for cellular energy production.  
 
The chemotherapy component of the NACRT is oral capecitabine which is known as a 
cytotoxic antimetabolite, which is converted into 5-fluorouracil (5-FU) and highly expressed 
in cancer cells, thus giving less toxicity than intravenous 5-FU, however oral Capecitabine is 
still known to cause hand-foot syndrome, diarrhoea, nausea, vomiting, and muscle fatigue 
(322). Similar mechanisms as the ones described above might be implicated in the 
deregulation of mitochondrial function in this cohort of patients. The only study that 
investigates the role of chemoradiotherapy bystander effects in tissue explants models from 
colorectal cancer patients is by Gorman and colleagues (323). In this study, bystander cells 
were exposed to media from radiation (2Gy and 5Gy) and FOLFOX (Folinic acid, 
fluorouracil and oxaliplatin) treated tumour and matching normal tissue. Gorman showed a 
significant reduction in telomere lengths and an increase in bridge formations compared to 
bystander cells treated with media from un-irradiated tissue (0 Gy) at 24 h. Bystander cells 
exposed to media from 2Gy irradiated tumour tissue showed significant depolarisation of the 
mitochondrial membrane potential and an increase in reactive oxygen species levels. In this 
study bystander cells overexpressing a mitochondrial antioxidant manganese superoxide 
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dismutase (MnSOD) was examined. The hypothesis being that this antioxidant could rescue 
the mitochondrial changes and subsequently influence nuclear instability events. Gorman 
found that in MnSOD treated cells, ROS levels were significantly reduced and mitochondrial 
membrane potential significantly increased. These events were coupled with a significant 
reduction in percentage of cells with anaphase bridges and also a reduction in the number of 
cells undergoing telomere length shortening. Using a human colorectal cancer explant tissue 
model, this study has demonstrated that radiation and chemotherapy bystander responses 
induce early genomic instability events such as telomere shortening and bridge formations 
coupled with mitochondrial dysfunction. These results support results found in Section 7.5.2 
of this chapter, where mitochondrial function was seen to decline with NACRT and was 
found to improve in the exercise group as opposed to the control group. Similar cellular 
bystander harm may be operating in this patient cohort leading to a reduction in fitness. For 
our purposes exercise is likened to the antioxidant effects of MnSOD. In a review by 
Clarkson and colleagues (324) physical training was thought to enhance the antioxidant 
defense system to offset ROS induced damage by severe exercise or in this case cancer 
treatments which mimic these ROS.  
 
 
7.6.3 EXERCISE AND MITOCHONDRIAL FUNCTION 
 
More than 70 studies have investigated the effects of structured exercise training with a wide 
range of psychosocial and physiological outcomes among individuals diagnosed with cancer 
(325–327). The association between exercise training and improvement in quality of life, 
exercise capacity, physical functioning and fatigue has already been reviewed by Doherty 
and West, Burke and West (154,328) and in Section 2.6 of this thesis.  
 
The effects of exercise on sequential steps within the oxygen cascade (Figure 7.15) and the 
molecular mechanisms that regulate exercise adaptations within each step have not yet been 
investigated. Cardiorespiratory fitness in oncology patients is determined by the integrative 
responses of all components of the oxygen cascade. Nevertheless, the relative importance of 
each component governing exercise tolerance may differ considerably across cancer 
populations according to primary site, stage, current cancer therapies, and co-morbid 
disease. In the largest study so far, about 17 weeks of aerobic training did not improve peak 
oxygen consumption among women receiving anthracycline-containing chemotherapy for 
early breast cancer, although peak oxygen consumption did decline by about 5% among 
women randomly assigned to the sedentary control group (265).  
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Figure 7.15 – Illustration showing sequential reduction in the partial pressure of oxygen throughout the oxygen 
cascade, from the air to mitochondria in muscle cells. 
 
Similarly, Jones and colleagues found that aerobic training was associated with substantial 
improvements in peak oxygen consumption among postsurgical patients with non-small-cell 
lung cancer, but these effects were confined to those not receiving cisplatin-based adjuvant 
chemotherapy (329). These results suggest that either the direct or secondary effects of 
chemotherapy might suppress exercise-induced adaptations in components of the oxygen 
cascade.  
 
Aerobic training is known to lead to improvements in cardiac morphology, including 
increases in ventricular mass and volume, and diastolic relaxation and filling, which increase 
the stroke volume and maximum cardiac output (330). Aerobic training also increases blood 
volume; an initial increase in plasma volume is followed by a delayed increase in red-blood-
cell mass to normalise the haematocrit. The subsequent increase in haemoglobin 
concentration, combined with an enhanced cardiac output, will increase convective oxygen 
delivery independent of a change in lung diffusion capacity - assuming no diffusion 
limitation exists. In skeletal muscle, aerobic exercise leads to substantial augmentation of 
mitochondrial size and number, activity and number of aerobic enzymes, and capillary 
surface area. Exercise also induces a change in muscle morphology towards a more 
oxidative phenotype. These changes vastly improve the oxidative capacity of skeletal muscle 
and its ability to resynthesise ATP (176,331,332).  
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Cancer cells have dramatically altered cellular metabolism and have increased rates of 
glycolysis relative to normal cells (333). Both insulin and IGF-1 are cellular survival factors. 
Exercise is considered a cornerstone intervention for metabolic control. Skeletal muscle is 
the major tissue responsible for insulin-stimulated glucose uptake and fat oxidation and 
accounts for about 80% of glucose disposal under insulin-stimulated conditions. Exercise 
can increase glucose uptake by 20–100 times in the muscle via insulin-independent 
mechanisms (334). Central to this response are activation of hypoxia inducible factor-1 
(HIF-1), peroxisome proliferator-activated receptor co-activator (PGC)-1a, and AMP-
activated protein kinase (AMPK) which likely act in concert to stimulate mitochondrial 
biogenesis, oxidative phosphorylation, and cellular respiration (335). Because altered 
tumour-cell metabolism is strongly linked with cancer, (333) the modifying effects of 
exercise on metabolic control in patients with cancer, either alone or in conjunction with 
drugs, is an exciting avenue for future investigation.  
 
 
7.6.4 STRENGHTS, WEAKNESSES AND CONCLUSION 
 
Particular strengths of this study are the low risk of confounding by indication (123), the 
blinded physiological evaluations (both CPET and 
31
P MRS reporters were blind to group 
allocation, timeline and data resulting from both tests), the standardization of the NACRT 
and the homogenous cancer cohort. Limitations lie in the small sample size (albeit only pilot 
in nature) and the inherent limitations in the MRS measurement. These include low signal 
sensitivity, limited spatial localisation, and less accurate determination of tissue metabolite 
concentrations in absolute terms. The ‘pulse-and-acquire’ (non-localised) sequence which 
has been used in this study offers very good temporal resolution (i.e. 8 seconds), but at the 
expense of limited spatial resolution. The surface coil only enables spectral collection within 
~ 8 mm depth of muscle from the surface. There is no means of distinguishing between the 
different muscle fibre types or variations in fibre recruitment. Thus, the acquired spectra are 
representative of a heterogeneous pool of fibres within a sampled area which vary in their 
oxidative capacities and ability to produce maximal tension. Another limitation of MRS is 
the difficulty of determining absolute concentrations of phosphorus metabolites. There are 
several methods which have been used to quantify phosphorus-containing metabolites by 
31
P 
MRS, briefly summarized in a recent review by Kemp and colleagues (200). In essence, kPCr 
could be estimated by any of the following approaches: 1) from the signal ratio of PCr/ATP 
(making appropriate correction for saturation effect), using [ATP] (assumed from literature 
value) as an internal standard; 2) to use water as an internal standard, measured by 
1
H MRS; 
and 3) to use external standards (phantom) in a defined sample of volume either measured in 
202 
 
the same experiment, or in a separate experiment but with the same volume of interest after 
correction for coil loading and sensitivity. In the present thesis, the first approach was 
adopted for the ease of implementation.  
 
In conclusion, this randomized controlled pilot study shows a significant reduction in V o2 at 
ˆ L (-2.36 ml.kg
-1
.min
-1
) and V o2 at Peak (-3.95 ml.kg
-1
.min
-1
) between baseline and Week 
0). Furthermore, a clinically significant mean improvement in V o2 at ˆ L of +3.85 ml.kg
-
1
.min
-1
 was seen in the exercise group, as opposed to the control group who showed a 
decline in V o2 at ˆ L by -0.25 ml.kg
-1
.min
-1
. Moreover, a significant, novel reduction in 
mitochondrial function (kPCr) with NACRT (between baseline and Week 0) was found in the 
vast majority of patients. Mitochondrial function was significantly improved with a period of 
structured interval exercise training as opposed to the control group where no intervention 
was carried out between Week 0 and 6 post-NACRT. These important, novel, clinically 
relevant findings closely mirror changes in whole body measures of physical fitness 
objectively derived by CPET, which may account for the acute loss in fitness with NACRT 
and improvement in fitness with the SRETP. In conjunction these two novel findings, 
together with the potential mechanistic links explored above, make a rational case for a 
tentative link between changes found in mitochondrial function and physical fitness 
observed with cancer therapies and exercise in this thesis. Finally, the changes in 
mitochondrial function observed in this study need to be correlated with potential clinical 
patient benefit and surgical outcome so as to determine whether the change in mitochondrial 
function with exercise is associated with improved surgical outcomes. 
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CHAPTER 8 – Summary, Future Work and Conclusion 
 
 
8.1 INTRODUCTION 
 
Major surgery carries substantial morbidity and mortality, particularly in advanced cancer 
patients with co-morbidities (28,336–338). Outcomes after major surgery are a significant 
public health issue and depend on modifiable factors such as perioperative medical care, as 
well as fixed factors like the patients’ physiological tolerance to iatrogenically induced 
trauma; in the form of neoadjuvant cancer treatments or major surgery. The study of 
physical fitness and mitochondrial function in cancer patients is novel. With recent advances 
in objectively measured fitness assessments (i.e. CPET), a link between poor fitness and 
poor surgical outcome is now clear especially in major surgical patients (3,4,144,145). 
Accurate perioperative fitness assessments and risk prediction allows the multidisciplinary 
team to ensure appropriate modification of patients’ preoperative status as well as optimising 
intra- and postoperative management for high-risk surgical candidates. Such risk prediction 
also facilitates the most efficient use of scarce hospital resources, enhances the process of 
shared decision making before surgery (86), permits personalised (or at least stratified) 
patient care, and most importantly ensures the best outcome to avoid unnecessary 
postoperative morbidity and mortality. The assessment of patients’ fitness in the 
perioperative setting has never been more topical, however this has never been objectively 
undertaken in patients undergoing neoadjuvant cancer therapies i.e. a high risk surgical 
cohort. Therefore, the individual needs of these patients in terms of fitness and physiological 
preparation for surgery has never been addressed. This thesis specifically attempts to 
identify and address these important fitness changes in advanced rectal cancer patients 
undergoing NACRT. The novel observations found in the experiments summarised below 
show clinically important changes in objectively measured physical fitness with neoadjuvant 
cancer treatment and an exercise programme. Furthermore, an interesting link between 
physical fitness (measured by whole body measurements) and in vivo mitochondrial function 
(measured by 
31
P MRS) is also explored. All the experiments carried out in this thesis 
highlight the urgent need for accurate preoperative risk assessment as well as a tailored 
intervention in patients at high risk of adverse outcome following the physiological trauma 
of neoadjuvant cancer therapies prior to major cancer surgery. 
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8.1 SUMMARY AND IMPLICATIONS 
 
In Chapter 4, 27 locally advanced rectal cancer patients were recruited. 25 patients 
completed CPET evaluation at baseline and post-NACRT as well as a 180-day morbidity 
and 1 year mortality follow up. V o2 at ˆ L (Figure 4.2) and Peak exercise (Figure 4.3) were 
reduced (-1.5 and -1.4 ml.kg
-1
.min
-1
 respectively; p<0.0001). Oxygen pulse decreased at both 
ˆ L (-0.7 ml.beat
-1
; p=0.005) and Peak (-1.1 ml.beat
-1
; p=0.002). V E/ V co2 did not change. 
There was no change in median workload at ˆ L (p=0.06), however a reduction in maximum 
power (-8W; p=0.005) was observed. There was no change in resting or peak heart rate, 
spirometry and haemoglobin, and no relationship was found between changes in V o2 at ˆ L 
and changes in haemoglobin with NACRT (r=0.18; p>0.05). Optimal ROC cut-off values for 
V o2 at ˆ L and Peak of 12.0 and 18.1 ml.kg.
-1
min
-1
 respectively (Figure 4.4A and B) 
predicted those at risk of increased postoperative complications; this was 77% sensitive and 
75% specific ( V o2 at ˆ L - Area under curve (AUC) = 0.71, 95% CI 0.50-0.93; V o2 Peak – 
AUC = 0.75, 95% CI 0.55-0.95) for both variables. Repeating the ROC analysis with the 
post-NACRT variables (Figure 4.5A and B), optimal cut-off points were 10.7 and 16.7 
ml.kg.
-1
min
-1
 respectively; this was 77% sensitive and 83% specific for V o2 at ˆ L (AUC = 
0.72, 95% CI 0.50-0.94) and 85% sensitive and 83% specific for V o2 at Peak (AUC = 0.80, 
95% CI 0.60-1.00). A logistic regression model was used to investigate the association of 
CPET variables with in-hospital complications. A 90% reduction in the odds of 
complications was observed respectively (pre-NACRT – OR 0.10, 95% CI 0.16-0.63; 
p=0.01, post-NACRT – OR 0.09, 95% CI 0.01-0.61; p=0.01). Fitting the same model for 
pre- and post- V o2 Peak (Cut-off 18.1 ml.kg.
-1
min
-1
 pre-NACRT and 16.7 ml.kg.
-1
min
-1
 
post-NACRT), the odds of complications reduced by 85% and 94% respectively (pre-
NACRT – OR 0.15, 95% CI 0.03-0.87; p=0.04; post-NACRT – OR 0.06, 95% CI 0-0.44; 
p=0.006). These data provide the first direct evidence that the benefits of NACRT in tumour 
downsizing may be at least partly offset by increased perioperative risk due to a reduction in 
physical fitness. Further, these data show that standardized and objective measurements of 
fitness allow an accurate preoperative assessment with high predictive power for 
postoperative morbidity. This chapter concludes that NACRT before rectal cancer surgery 
significantly reduces physical fitness (293). The observed association between reduced 
physical fitness and unfavourable postoperative outcome relating to both in-hospital and 
180-day morbidity as well as 1-year mortality merits further study. Taken together these 
findings suggest that physiological reserve (the ability to increase V o2 in response to a 
stressor) is important for rectal cancer patients exposed to the dual challenges of NACRT 
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and major surgery. In addition it is recommended that the perioperative management of this 
cancer cohort should be altered, with emphasis placed on fitness assessment post-NACRT 
and on the implementation of an intervention to improve preoperative fitness.  
 
Chapter 5 illustrates the iterative derivation process of the exercise intervention (Section 
5.2). A five patient feasibility and tolerability study was also conducted (Section 5.3). This 
chapter shows important novel findings. Firstly and most importantly, the exercise 
programme was shown to improve objectively measured physical fitness in this cohort of 
patients’ within a 6 week period following NACRT. Secondly, a similar decline in physical 
fitness post-NACRT (baseline vs. week 0) was observed (Figure 5.1 and 5.2). V o2 at ˆ L 
and V o2 Peak declined by -1.1 and -2.9 ml.kg
-1
.min
-1
 respectively between baseline and 
week 0. With the SRETP (week 0 vs. week 6) an improvement in both V o2 at ˆ L and V o2 
Peak by +3.3 and +5.8 ml.kg
-1
.min
-1
 was observed. Although no formal statistical analysis 
was undertaken, the +3.3 ml.kg
-1
.min
-1
 improvement in V o2 at ˆ L was considered to be a 
clinically relevant finding. The benefit of the intervention was considered of large enough 
magnitude to reverse the deleterious effects of NACRT. The frequency, intensity, timing and 
length of the exercise training programme prescribed were well tolerated. Moreover, the 
98% adherence rate to the exercise programme provides initial proof of concept that the 
SRETP is feasible and tolerable in its duration, setting, frequency, intensity and schedule in 
this cohort of patients. No adverse events were encountered by starting the exercise 
programme immediately after finishing NACRT. Taken together these findings show that a 
SRETP immediately post-NACRT is feasible, tolerable and able to acutely improve physical 
fitness in this patient cohort.  
 
In Chapter 6, 39 locally advanced rectal cancer patients were recruited to an interventional 
pilot study scheduled to undergo a standardised NACRT regime and a 6-week structured 
exercise programme (exercise group n=22) or a control period (n=13). A significant mean 
benefit in V o2 at ˆ L of +2.12 ml.kg
-1
.min
-1
 (p<0.0001) (Figure 6.2A) in the exercise group 
at the end of the intervention period was observed. V o2 Peak showed similar changes in the 
exercise group: +2.65 ml.kg
-1
.min
-1 
(p=0.0005) (Figure 6.2B). These changes are similar to 
those found in the feasibility and tolerability study (Section 5.3.2). The control group 
showed a non-significant decline in V o2 at ˆ L by -0.65 ml.kg
-1
.min
-1
 (p=0.204) (Figure 
6.2A). V o2 Peak shows similar changes in the control group worsening  by -1.25 ml.kg
-
1
.min
-1 
 (p=0.19) (Figure 6.2B). A direct comparison of V o2 at ˆ L between groups at week 
6, correcting for differences in V o2 at ˆ L between the groups at Week 0, shows a difference 
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of +2.77 ml.kg
-1
.min
-1 
(95%CI +1.49 to +4.05; p<0.0001). Changes in other CPET variables 
were reported (Table 6.4). In this study the training programme was still deemed safe and 
feasible (96% adherence to the intervention) immediately post-NACRT, with no recorded 
adverse events after CPET or any of the exercise sessions. Moreover, a similar deleterious 
effect of NACRT on physical fitness was observed, with all patients showing a significant 
decline in V o2 at ˆ L between baseline and Week 0 of -1.91 ml.kg
-1
.min
-1 
(p<0.0001) 
consistent with results in Sections 4.5.2 and 5.3.2. When considering other exploratory 
outcomes, the control group had a significantly poorer tumour response to NACRT on re-
staging MRI (mrTRG) (p=0.006), however there was no evidence of a statistical difference 
in TNM on re-staging between the two groups (p=0.822). 85% of the control group and 77% 
of the exercise group underwent elective surgery. This study also reports on in-hospital 
postoperative surgical outcomes, and length of hospital stay in both the exercise and the 
control groups, however no significant differences were found. Furthermore, none of the 
variables selected for univariate logistic regression (Table 6.6) were found to be significantly 
associated with postoperative complications. This was expected as the study is not powered 
to detect differences in such variables. However, interestingly when looking at the 30-day 
readmission rates, 73% of the control group was readmitted to hospital. These findings have 
important clinically significant implications. Over time (Figure 6.3) an acute change in 
fitness was observed in the first 6 weeks in the exercise group, whilst the control group was 
seen to be unable to recover from the physiological insult of NACRT, showing a sustained 
decline from Week 3 to Week 14. Moreover, the exercise group is seen to overshoot their 
baseline fitness ( V o2 at ˆ L pre-NACRT) at Week 6, with their fitness thereafter slowly 
declining to baseline (pre-NACRT) levels. Thus, by Week 6 patients in the exercise group 
have completely recovered from the effects of NACRT on fitness, while those in the control 
group, are now at a higher risk of adverse surgical outcome on the basis of conventional risk 
stratification cut-off points. Moreover, where CPET is part of the routine perioperative 
cancer pathway, rectal cancer patients should undergo CPET after neoadjuvant cancer 
treatment as part of standard re-staging investigations so correct risk stratification is 
performed based upon their current preoperative fitness levels taking into account any 
changes with neoadjuvant cancer therapy. Furthermore this study reinforces the benefits of 
prehabilitation with exercise training to improve physical fitness after the deleterious effects 
of neoadjuvant cancer treatment prior to the added physiological insult of major cancer 
surgery.  
 
In Chapter 7, 12 patients were randomized to a SRETP or to negative control (i.e. no 
exercise intervention) after undergoing standardized NACRT and serial measures of whole 
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body fitness and in vivo mitochondrial function. This study was specifically designed to 
characterise the dynamic interrelationships between changes in whole body physical fitness 
(due to neoadjuvant chemoradiotherapy, structured exercise training or control periods) and 
in vivo mitochondrial function in an attempt to explore potential mechanisms that accounted 
for the observed changes in physical fitness. This study shows significant reductions in V o2 
at ˆ L (-2.36 ml.kg
-1
.min
-1
) and V o2 at Peak (-3.95 ml.kg
-1
.min
-1
) between baseline and 
Week 0 (post-NACRT) (Figure 7.2) consistent with findings observed in Section 6.5. 
Furthermore, in keeping with results from previous chapters, the 6-week structured exercise 
intervention period was shown to improve objectively measured physical fitness following 
standardised NACRT. A clinically significant mean improvement in V o2 at ˆ L of +3.85 
ml.kg
-1
.min
-1
 was seen in the exercise group, as opposed to the control group who showed a 
decline in V o2 at ˆ L by -0.25 ml.kg
-1
.min
-1
. Similar changes were found in V o2 at Peak. 
Between baseline and Week 0, a significant reduction in kPCr of -0.34 was found (Figure 7.8). 
Between Week 0 and Week 6, the exercise group showed a significant improvement in kPCr 
as opposed to the control group of +0.66 (Figure 7.9 A and B). These are important, novel, 
clinically relevant findings which re-confirm the changes seen in whole body measures of 
physical fitness (CPET variables) consistent with previous results seen in Sections 4.5 
(decline in fitness with NACRT), 5.3 (improvement in fitness with SRETP) and 6.5 (decline 
in fitness with NACRT and an improvement in fitness in the exercise group compared with 
the control group). The changes in whole body measures of fitness are also consistent with 
changes in mitochondrial function seen in peripheral muscle. Therefore, the acute decline in 
mitochondrial function with NACRT may account for the acute loss in fitness over the 
neoadjuvant treatment period. Moreover, the dramatic improvement in mitochondrial 
function observed with exercise as opposed to no intervention, might indicate that a 
structured intervention immediately after NACRT is necessary to rescue and reverse 
NACRT’s deleterious effect on mitochondrial function and fitness in this patient cohort.  
 
 
8.2 STRENGTHS AND LIMITATIONS OF THIS PRESENTED WORK 
 
Several strengths and novel aspects of the present work are worth highlighting.  
 
1. Firstly, the major strength of this work lies in the consistently blinded objective 
physiological evaluation used to measure physical fitness by CPET. All of the CPET 
reporting was done by an experienced clinician scientist blind to group allocation 
(i.e. exercise vs. control) and timeline (i.e. baseline, Week 0,3,6,9 or 14).  
209 
 
2. The colorectal MDT, anaesthetists and medical staff collecting outcome data were 
blind to CPET results and patient group allocation, this ensured a low risk of 
confounding by indication (123).  
 
3. All studies presented in this thesis consist of prospectively recruited consecutive 
patients who underwent a standardized NACRT regime and were of a homogenous 
rectal cancer staging (only operable locally advanced >T2N+ with threatened 
circumferential resection margins with no distant radiologically evident metastasis 
were included).  
 
4. All patients in Chapters 4 and 6 underwent a comprehensive short- and medium-
term follow up.  
 
5. The novelty of the structured exercise programme is also worth highlighting. To my 
knowledge no other study reports an exercise training programme that starts 
immediately after neoadjuvant cancer therapy in an operable cancer population. The 
exercise programme underwent a rigorous iterative development and was tested for 
its feasibility and tolerability study tailoring it to the rectal cancer patient cohort 
described above (Chapter 5). Following the F&T study a formal prehabilitation pre-
pilot study was undertaken. This also benefits from the strengths of the studies 
described above; however it is also worth noting the rigorous conduct of the exercise 
intervention and also the statistical modeling undertaken.  
 
6. The final study (Chapter 7) also has several strengths including the detailed 
quantitative analysis of the 
31
P MRS mitochondrial function data, the utilization of 
validated and robust MRS methodology, blinding of 
31
P MRS reporting (to patient 
group allocation, CPET variables and timeline), as well as utilizing of the MRS 
measurement in a cancer patient cohort which has never been done before.  
 
7. Apart from the novelty and clinical importance of the studies performed in this 
thesis efforts have been made to standardise and control for many variables. I 
believe that the robust serial analyses of physical fitness using a consistent CPET 
protocol, consistent delivery of the exercise intervention, consecutive recruitment of 
a homogenous patient cohort, controlling for neoadjuvant cancer therapies, 
consistent blinding and the evaluating of mitochondrial function using a standard 
quantitative approach are key to the high quality experiments that were undertaken 
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and are well reflected in the consistency of the results from the two different 
techniques.  
 
The limitations of each part of this project have been acknowledged and discussed in the 
individual chapters however a summary of the main limitations are discussed hereunder. 
 
1. Firstly, the single-centre design of all studies presented in this thesis might limit 
generalisability, as there may be specific characteristics of the study population that 
are not typical of other populations. 
 
2. The baseline differences between the exercise and the control groups in Chapter 6 is 
a potential source of location bias. 
 
3. The non-randomized design of the study presented in Chapter 6.  
 
4. The observational design of studies in Chapters 4 to 6 limits generalisability. 
 
5. The relatively small number of subjects – although adequately powered – the small 
sample size may increase the likelihood of non-generalisable findings. Moreover, 
studies presented in Chapter 4 and 6 were adequately powered to detect differences 
in V o2 at ˆ L, however these were not designed to have a sufficient sample size to 
detect a link between changes in physical fitness and postoperative outcome. 
  
6. The single type of surgery and homogenous patient cohort maybe considered as a 
strength for exploring potential mechanisms, however, this limits generalizability to 
other types of surgeries or patient cohorts. 
 
7. The inherent limitations of 31P MRS (which were discussed in Chapter 7) as 
opposed to ex vivo muscle mitochondrial respirometry should be acknowledged.  
 
8. The randomized controlled study presented in Chapter 7 was able to demonstrate 
significant changes in muscle mitochondrial function in vivo likely to represent the 
major contribution to changes in whole-body aerobic fitness, however this was a 
pilot study, and was not powered to detect the between-individual correlations 
which the proposed mechanism would predict. 
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9. Finally, the 31P MRS work presented in Chapter 7 should ideally have been 
corroborated with peripheral muscle biopsy tissue based mitochondrial function. 
 
 
8.3 FUTURE WORK 
 
The work described in this thesis has provided a platform for several potential future studies 
which may include the following areas: 
 
Studies to clarify the deleterious effect of neoadjuvant cancer therapies – In Chapter 4 
an observational study was undertaken to study the effects of NACRT on objectively 
measured physical fitness. This study is the first of its kind. Translating these novel findings 
to other cancer cohorts and other neoadjuvant cancer treatments is therefore a priority. A 
study by the Fit-4-Surgery Consortium, of which I am part, has undertaken a similar study in 
an upper gastrointestinal cancer cohort receiving neoadjuvant platinum based chemotherapy 
(339). Using similar methodology we have shown a similar significant decline in V o2 at ˆ L 
and V o2 at Peak. In this group of patients this decline in fitness was significantly related to 
one-year mortality in patients who completed a full course of chemotherapy and surgery, 
suggesting that in some patients the harm of neoadjuvant cancer treatments can be 
sometimes outweighed by its benefits. 
 
Studies to clarify the role of prehabilitation on surgical outcome – In Chapter 6 an 
interventional pre-pilot study was conducted to study the effects of a standardised NACRT 
regime and a 6-week structured exercise programme or a control period on physical fitness 
in locally advanced rectal cancer patients. Results from this chapter where used to inform a 
successful National Institute for Health Research, Research for Patient Benefit grant 
application (PB-PG-0711-25093). This larger, randomized controlled study (currently 
recruiting) will assess changes in physical fitness and quality of life following a 9-week 
exercise intervention in this patient group. Furthermore, a larger trial is also needed to 
investigate the effects of prehabilitation on postoperative surgical morbidity, mortality and 
tumour outcomes. Prehabilitation trials studying different exercise regimes with different 
exercise intensities and durations are also needed. 
 
Studies to clarify the changes in health related quality of life – findings from Chapters 4 
to 7 have shown changes in physical fitness with NACRT and an exercise programme. In 
addition all patients recruited also underwent quality of life assessments either by qualitative 
or quantitative measurements. This has already lead to a publication entitled “Patients’ 
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perceptions of quality of life during active treatment for locally advanced rectal cancer: the 
importance of preoperative exercise” (328). A further publication amalgamating quality of 
life questionnaires and results from semi-structured quality of life interviews undertaken 
with the patients recruited for the work described in this thesis is currently in preparation. 
Further work to clarify the deleterious effects of NACRT, as well as the improvements in 
quality of life following the SRETP needs to be validated by undertaking a larger, 
randomized controlled trial.  
 
Studies to clarify the changes in physical activity - changes in physical fitness might be 
linked to changes seen in physical fitness. Some of the patients recruited in Chapters 4, 6 
and 7 underwent a period of activity monitoring as a pilot study to investigate the changes in 
physical activity in relation to changes in fitness with NACRT and also with exercise vs. 
standard care (control period) (174,175). Changes in physical activity in a colorectal cancer 
population have never been documented, especially when exploring the effects of 
neoadjuvant cancer therapies or an exercise intervention on physical activity. Further work 
to clarify this important clinically relevant issue needs to be done to validate these 
preliminary findings. 
 
Studies to clarify the effects of exercise response on tumour volume, tumour regression 
and mitochondrial function – the improvement in physical fitness seen with the exercise 
programme might translate into a further benefit in tumour response (i.e. larger decrease in 
tumour volume, improved tumour regression and improved post-NACRT MRI staging) 
owing to potentially more favourable oxidative conditions. Further work to clarify the 
mechanisms of the effects of exercise in addition to neoadjuvant therapies on tumour stage 
and volume needs to be investigated. Furthermore, future animal and cellular work could 
prove invaluable in conducting chemotherapy and/or chemoradiotherapy dose intervention 
studies and other exercise intervention studies exploring the role of genetics, epigenetics, 
tumour and fitness phenotyping in various cancer orthotopic animal models.      
 
Studies to clarify the impacts of neoadjuvant cancer therapies and exercise on 
mitochondrial function – the mechanistic relationship of NACRT and exercise on 
mitochondrial function explored in Chapter 7 should be validated in a larger randomized 
controlled trial. The in vivo measurements should be validated by using ex vivo techniques 
(e.g. muscle biopsies) in an attempt to identify a mechanism of harm caused by NACRT and 
the benefit caused by an exercise intervention in a cancer population. If a mechanistic link is 
identified, cancer therapy modulation as well as preventative protective therapies can be 
instigated, instead of ameliorating the deleterious effects post-hoc. This has potential clinical 
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implications as the harm done to patients by specific neoadjuvant cancer therapies might be 
avoided.  
 
 
8.4 CONCLUSION  
 
In conclusion, the work described in this thesis has studied the effects of neoadjuvant 
chemoradiotherapy and a structured responsive exercise training programme on physical 
fitness and in vivo mitochondrial function in resectable locally advanced rectal cancer 
patients. Changes in physical fitness with NACRT and a prehabilitation programme have 
been studied using cardiopulmonary exercise testing. The relationship between 
mitochondrial function and fitness has been studied using 31P MRS. The present work is the 
first to identify a decline in fitness with NACRT and a improvement in fitness using a novel 
patient tailored prehabilitation programme (as opposed to a decline in fitness with no 
intervention). Furthermore, the present work is also the first to successfully identify a 
decline of in vivo mitochondrial function with NACRT and an improvement using a tailored 
exercise programme (as opposed to a small change with no intervention). Taken together 
these are important, novel, clinically relevant findings. These findings suggest that 
physiological reserve i.e. the ability to increase oxygen uptake/utilization in response to a 
major stressor (NACRT) is important in this patient cohort prior to major surgery. The 
possibility of an exercise intervention following the insult of NACRT prior to major cancer 
surgery is feasible, tolerable and achievable. If there is no intervention following NACRT, a 
steady decline in fitness is seen, which remains uncorrected prior to a further physiological 
insult from major surgery. In vivo assessments of mitochondrial function in this patient 
group corroborate the results of whole body physical fitness assessments and illustrate a 
possible mechanism underlying changes in fitness with NACRT and tailored exercise. In this 
cancer cohort, the changes in fitness and mitochondrial function with NACRT will have an 
impact on patients’ perioperative cancer pathways, timing for surgery and timing of fitness 
assessment prior to major surgery. Furthermore, tailored interventions to improve 
preoperative fitness after neoadjuvant cancer treatments should be offered to patients as part 
of their routine cancer treatment. 
 
 
 
 
 
 
214 
 
 
 
 
 
References 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
215 
 
REFERENCES 
1.  Tekkis PP, Poloniecki JD, Thompson MR, Stamatakis JD. Papers Operative mortality 
in colorectal cancer : prospective national study. BMJ. 2003;327(11):1196–201.  
2.  Pearse RM, Harrison DA, James P, Watson D, Hinds C, Rhodes A, et al. 
Identification and characterisation of the high-risk surgical population in the United 
Kingdom. Crit Care. 2006;10(3):1–6.  
3.  Hennis PJ, Meale PM, Grocott MPW. Cardiopulmonary exercise testing for the 
evaluation of perioperative risk in non-cardiopulmonary surgery. Postgr Med J. 
2011;87(1030):550–7.  
4.  West M, Jack S, Grocott MPW. Perioperative cardiopulmonary exercise testing in the 
elderly. Best Pract Res Clin Anaesthesiol. 2011;25(3):427–37.  
5.  Smith TB, Stonell C, Purkayastha S, Paraskevas P. Cardiopulmonary exercise testing 
as a risk assessment method in non cardio-pulmonary surgery: a systematic review. 
Anaesthesia. 2009;64(8):883–93.  
6.  Statistical Bulletin Cancer registrations in England , 2010. 2012 p. 1–11.  
7.  Statistical Bulletin Cancer Incidence and Mortality in the United Kingdom , 2008-10. 
2012 p. 1–24.  
8.  Finan P, Greenaway K. National Bowel Cancer Audit 2012. 2012 p. 47–59.  
9.  Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U, Silva e Sousa AH, et al. 
Operative Versus Nonoperative Treatment for Stage 0 Distal Rectal Cancer 
Following Chemoradiation Therapy. Ann Surg. 2004;240(4):711–8.  
10.  Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, et al. 
Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation 
and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal 
cancer. J Clin Oncol. 2006;24(4):668–74.  
11.  Mohiuddin M, Winter K, Mitchell E, Hanna N, Yuen A, Nichols C, et al. 
Randomized phase II study of neoadjuvant combined-modality chemoradiation for 
distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol. 
2006;24(4):650–5.  
12.  Bosset J-F, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. 
Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 
2006;355(11):1114–23.  
13.  Gérard J-P, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin M-T, et 
al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin 
in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620–5.  
14.  Swellengrebel HAM, Marijnen CAM, Verwaal VJ, Vincent A, Heuff G, Gerhards 
MF, et al. Toxicity and complications of preoperative chemoradiotherapy for locally 
advanced rectal cancer. Br J Surg. 2011;98(3):418–26.  
216 
 
15.  Marijen C, Kapiteijn E, vab de Velde C, Martijn H. Acute side effects and 
complications after short-term preoperative radiotherapy combined with total 
mesorectal excision in primary rectal cancer: Report of a mulitcenter randomized 
trial. J Clin Oncol. 2002;20(3):817–25.  
16.  Cetin T, Arpaci F, Yilmaz MI, Saglam K, Ozturk B, Komurcu S, et al. Oxidative 
stress in patients undergoing high-dose chemotherapy plus peripheral blood stem cell 
transplantation. Biol Trace Elem Res. 2004;97(3):237–47.  
17.  Supinski GS, Callahan LA. Free radical-mediated skeletal muscle dysfunction in 
inflammatory conditions. J Appl Physiol. 2007;102(5):2056–63.  
18.  Powers SK, Jackson MJ. Exercise-induced oxidative stress: Cellular mechanisms and 
impact on muscle force production. Physiol Rev. 2010;88(4):1243–76.  
19.  Tozer RG, Tai P, Falconer W, Ducruet T, Karabadjian A, Bounous G, et al. Cysteine-
rich protein reverses weight loss in lung cancer patients receiving chemotherapy or 
radiotherapy. Antioxid Redox Signal. 2008;10(2):395–402.  
20.  Bonifati DM, Ori C, Rossi CR, Caira S, Fanin M, Angelini C. Neuromuscular 
damage after hyperthermic isolated limb perfusion in patients with melanoma or 
sarcoma treated with chemotherapeutic agents. Cancer Chemother Pharmacol. 
2000;46(6):517–22.  
21.  Chen Y, Jungsuwadee P, Vore M, Butterfield D, St Clair D. Collateral damage in 
cancer chemotherapy: Oxidative stress in nontargeted tissues. Mol Interv. 
2007;7:147–56.  
22.  Mohamed H, Asker M, Ali S, El-Fattah T. Protection against doxorubicin 
cardiomyopathy in rats: Role of phosphodiesterase inhibitors type 4. J Pharm 
Pharmacol. 2004;56:757–68.  
23.  Buttke TM, Sandstrom PA. Oxidative stress as a mediator of apoptosis. Immunol 
Today. 1994;15(1):7–10.  
24.  De Campos-Lobato LF, Geisler DP, da Luz Moreira A, Stocchi L, Dietz D, Kalady 
MF. Neoadjuvant therapy for rectal cancer: the impact of longer interval between 
chemoradiation and surgery. J Gastrointest Surg. 2011;15(3):444–50.  
25.  Kerr SF, Norton S, Glynne-Jones R. Delaying surgery after neoadjuvant 
chemoradiotherapy for rectal cancer may reduce postoperative morbidity without 
compromising prognosis. Br J Surg. 2008;95(12):1534–40.  
26.  Evans J, Tait D, Swift I, Pennert K, Tekkis PDP, Wotherspoon A, et al. Timing of 
Surgery Following Preoperative Therapy in Rectal Cancer : The Need for a 
Prospective Randomized Trial? Dis Colon Rectum. 2011;10(10):1251–9.  
27.  Leslie A, Carey FA, Pratt NR, Steele RJC. The colorectal adenoma-carcinoma 
sequence. Br J Surg. 2002;89(7):845–60.  
28.  Association of Coloproctology of Great Britain and Ireland. National Bowel Cancer 
Audit Annual Report. 2013.  
217 
 
29.  Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the 
modern treatment of rectal cancer? J Clin Oncol. 2008;26(2):303–12.  
30.  Williams N, Bulstrode C, O’Connell P. The Rectum. Bailey and Love: Short 
Practices of Surgery. 2013. p. 1231–3.  
31.  Dukes CE. The classification of cancer of the rectum. J Pathol Bacteriol. 
1932;35(3):323–32.  
32.  Astler V, Coller F. The prognostic significance of direct extension of carcinoma of 
the colon and rectum. Ann Surg. 1953;139(6):846–51.  
33.  Williams G, Quirke P, Shepherd N. Standards and Datasets for Reporting Cancers. 
Dataset for colorectal cancer (2 nd edition). Royal College of. 2007 p. 1–27.  
34.  Guillem JG, Chessin DB, Cohen AM, Shia J, Mazumdar M, Enker W, et al. Long-
term Oncologic Outcome Following Preoperative Combined Modality Therapy and 
Total Mesorectal Excision of Locally Advanced Rectal Cancer. Ann Surg. 
2005;241(5):829–38.  
35.  NICE. Colorectal cancer : the diagnosis and management of colorectal. 2011 p. 119 – 
157.  
36.  Wu JS, Fazio VW. Management of rectal cancer. J Gastrointest Surg. 2004;8(2):139–
49.  
37.  Torkzad MR, Påhlman L, Glimelius B. Magnetic resonance imaging (MRI) in rectal 
cancer: a comprehensive review. Insights Imaging. 2010;1(4):245–67.  
38.  Shihab OC, Moran BJ, Heald RJ, Quirke P, Brown G. MRI staging of low rectal 
cancer. Eur Radiol. 2009;19(3):643–50.  
39.  Brown G for the Mercury Study Group. Extramural depth of tumor invasion at thin-
section MR in patients with rectal cancer: results of the MERCURY study. 
Radiology. 2007;243(1):132–9.  
40.  Martling A, Holm T, Bremmer S, Lindholm J, Cedermark B, Blomqvist L. 
Prognostic value of preoperative magnetic resonance imaging of the pelvis in rectal 
cancer. Br J Surg. 2003;90(11):1422–8.  
41.  Brown G, Davies S, Williams GT, Bourne MW, Newcombe RG, Radcliffe AG, et al. 
Effectiveness of preoperative staging in rectal cancer: digital rectal examination, 
endoluminal ultrasound or magnetic resonance imaging? Br J Cancer. 
2004;91(1):23–9.  
42.  LeBlanc JK. Imaging and management of rectal cancer. Nat Clin Pract Gastroenterol 
Hepatol. 2007;4(12):665–76.  
43.  Smith N, Brown G. Preoperative staging of rectal cancer. Acta Oncol. 
2008;47(1):20–31.  
44.  Taylor A, Sheridan M, McGee S, Halligan S. Preoperative staging of rectal cancer by 
MRI; results of a UK survey. Clin Radiol. 2005;60(5):579–86.  
218 
 
45.  Heald RJ, Ryall RDH. Recurence and survival after total mesorectal excision for 
rectal cancer. Lancet. 1986;327(8496):1479–82.  
46.  Holm T, Ljung A, Häggmark T, Jurell G, Lagergren J. Extended abdominoperineal 
resection with gluteus maximus flap reconstruction of the pelvic floor for rectal 
cancer. Br J Surg. 2007;94(2):232–8.  
47.  Wong R, Tandan V, DeSilva S, Figueredo A. Pre-operative radiotherapy and curative 
surgery for the management of localized rectal carcinoma (Review). Cochrane 
Database Syst Rev. 2007;(2):1–76.  
48.  Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. 
Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and 
local recurrence rate. J Clin Oncol. 2005;23(24):5644–50.  
49.  Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, et al. 
Preoperative radiotherapy versus selective postoperative chemoradiotherapy in 
patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, 
randomised trial. Lancet. 2009;373(9666):811–20.  
50.  Birgisson H, Påhlman L, Gunnarsson U, Glimelius B. Adverse effects of preoperative 
radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer 
Trial. J Clin Oncol. 2005;23(34):8697–705.  
51.  Peeters K, Marijnen C, Nagtegaal I, Kranenbarg E, Putter H, Wiggers T, et al. The 
TME Trial After a Median Follow-up of 6 Years. Increased local control but no 
survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 
2007;246(5):693–701.  
52.  Birgisson H, Påhlman L, Gunnarsson U, Glimelius B. Late adverse effects of 
radiation therapy for rectal cancer - a systematic overview. Acta Oncol. 
2007;46(4):504–16.  
53.  Bujko K, Nowacki MP, Michalski W, Bebenek M, Kryj M, Nasierowska-Guttmejer 
a. Long-term results of a randomized trial comparing preoperative short-course 
radiotherapy with preoperative conventionally fractionated chemoradiation for rectal 
cancer. Br J Surg. 2006;93(10):1215–23.  
54.  Bujko K, Nowacki MP, Nasierowska-guttmejer A, Michalski W, Be M. Sphincter 
preservation following preoperative radiotherapy for rectal cancer : report of a 
randomised trial comparing short-term radiotherapy vs . conventionally fractionated 
radiochemotherapy. Radiother Oncol. 2004;72:15–24.  
55.  Bujko K, Nowacki MP, Kepka L, Oledzki J, Bebenek M, Kryj M. Postoperative 
complications in patients irradiated pre-operatively for rectal cancer: report of a 
randomised trial comparing short-term radiotherapy vs chemoradiation. Color Dis. 
2005;7(4):410–6.  
56.  Pietrzak L, Bujko K, Nowacki MP, Kepka L, Oledzki J, Rutkowski A, et al. Quality 
of life , anorectal and sexual functions after preoperative radiotherapy for rectal 
cancer : Report of a randomised trial. Radiother Oncol. 2007;84(3):217–25.  
219 
 
57.  Fiorica F, Cartei F, Licata A, Enea M, Ursino S, Colosimo C, et al. Can 
chemotherapy concomitantly delivered with radiotherapy improve survival of 
patients with resectable rectal cancer ? A meta-analysis of literature data. Cancer 
Treat Rev. 2010;36(7):539–49.  
58.  De Caluwe L, van Nieuwenhove Y, Ceelen W. Preoperative chemoradiation versus 
radiation alone for stage II and III resectable rectal cancer (Review). Cochrane 
Database Syst Rev. 2013;(2):1–30.  
59.  McCarthy K, Pearson K, Fulton R, Hewitt J. Pre-operative chemoradiation for non-
metastatic locally advanced rectal cancer (Review). Cochrane Database Syst Rev. 
2012;(12):1–33.  
60.  Chessin DB, Enker W, Cohen AM, Paty PB, Weiser MR, Saltz L, et al. 
Complications after preoperative combined modality therapy and radical resection of 
locally advanced rectal cancer: a 14-year experience from a specialty service. J Am 
Coll Surg. 2005;200(6):876–82.  
61.  Coco C, Valentini V, Manno A, Mattana C, Verbo A, Cellini N, et al. Long-term 
results after neoadjuvant radiochemotherapy for locally advanced resectable 
extraperitoneal rectal cancer. Dis Colon Rectum. 2006;49(3):311–8.  
62.  Mermershtain W, Gluzman A, Gusakova I, Walfish S, Cohen Y, Ariad S. 
Preoperative radio-chemotherapy treatment in locally advanced rectal carcinoma. 
Results of 8-year follow-up. Onkologie. 2005;28(5):267–9.  
63.  Twu C-M, Wang H-M, Chen J-B, Chao T-H, Mar H-F. Neoadjuvant concurrent 
chemoradiotherapy in treating locally advanced rectal cancer. J Chinese Med Assoc. 
2009;72(4):179–82.  
64.  Klos CL, Shellito PC, Rattner DW, Hodin RA, Cusack JC, Bordeianou L, et al. The 
effect of neoadjuvant chemoradiation therapy on the prognostic value of lymph nodes 
after rectal cancer surgery. Am J Surg. 2010;200(4):440–5.  
65.  Habr-Gama A, Perez R, Kiss D, Rawet V, Scanavini A, Santinho P, et al. Impact on 
downstaging and sphincter saving operations. Hepato Gastroenterol. 
2004;51(60):1703–7.  
66.  Koukourakis G V, Zacharias G, Tsalafoutas J, Theodoridis D, Kouloulias V. 
Capecitabine for locally advanced and metastatic colorectal cancer : A review. World 
J Gastrointest Oncol. 2010;2(8):311–21.  
67.  Elwanis MA, Maximous DW, Elsayed MI, Mikhail NNH. Surgical treatment for 
locally advanced lower third rectal cancer after neoadjuvent chemoradiation with 
capecitabine: prospective phase II trial. World J Surg Oncol. 2009;7(52):1–9.  
68.  De Bruin AFJ, Nuyttens JJ, Ferenschild FTJ, Planting AST, Verhoef C, de Wilt 
JHW. Preoperative chemoradiation with capecitabine in locally advanced rectal 
cancer. Neth J Med. 2008;66(2):71–6.  
69.  De Paoli A, Chiara S, Luppi G, Friso ML, Beretta GD, Del Prete S, et al. 
Capecitabine in combination with preoperative radiation therapy in locally advanced, 
220 
 
resectable, rectal cancer: a multicentric phase II study. Ann Oncol. 2006;17(2):246–
51.  
70.  Desai SP, El-Rayes BF, Ben-Josef E, Greenson JK, Knol JA, Huang EH, et al. A 
phase II study of preoperative capecitabine and radiation therapy in patients with 
rectal cancer. Am J Clin Oncol. 2007;30(4):340–5.  
71.  Kim JC, Kim TW, Kim JH, Yu CS, Kim HC, Chang HM, et al. Preoperative 
concurrent radiotherapy with capecitabine before total mesorectal excision in locally 
advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2005;63(2):346–53.  
72.  Koeberle D, Burkhard R, von Moos R, Winterhalder R, Hess V, Heitzmann F, et al. 
Phase II study of capecitabine and oxaliplatin given prior to and concurrently with 
preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Br J 
Cancer. 2008;98(7):1204–9.  
73.  Machiels J-P, Duck L, Honhon B, Coster B, Coche J-C, Scalliet P, et al. Phase II 
study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in 
patients with rectal cancer: the RadiOxCape study. Ann Oncol. 2005;16(12):1898–
905.  
74.  Rödel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll H-J, Sauer R. 
Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin 
Oncol. 2003;21(16):3098–104.  
75.  Velenik V, Anderluh F, Oblak I, Strojan P, Zakotnik B. Capecitabine as a 
radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal 
cancer: prospective phase II trial. Croat Med J. 2006;47(5):693–700.  
76.  Dupuis O, Vie B, Lledo G, Hennequin C, Noirclerc M, Bennamoun M, et al. 
Preoperative treatment combining capecitabine with radiation therapy in rectal 
cancer: a GERCOR Phase II Study. Oncology. 2007;73(3-4):169–76.  
77.  Korkolis DP, Boskos CS, Plataniotis GD, Gontikakis E, Karaitianos IJ, Avgerinos K, 
et al. Pre-operative chemoradiotherapy with oral capecitabine in locally advanced, 
resectable rectal cancer. Anticancer Res. 2007;27(1B):541–5.  
78.  Willeke F, Horisberger K, Kraus-Tiefenbacher U, Wenz F, Leitner a, Hochhaus a, et 
al. A phase II study of capecitabine and irinotecan in combination with concurrent 
pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal 
cancer. Br J Cancer. 2007;96(6):912–7.  
79.  Krishnan S, Janjan NA, Skibber JM, Rodriguez-Bigas MA, Wolff RA, Das P, et al. 
Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in 
patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 
2006;66(3):762–71.  
80.  Carlomagno C, Farella A, Bucci L, D’Armiento FP, Pesce G, Pepe S, et al. Neo-
adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination 
with radiotherapy: a phase II study. Ann Oncol. 2009;20(5):906–12.  
81.  Fakih MG, Bullarddunn K, Yang GY, Pendyala L, Toth K, Andrews C, et al. Phase II 
study of weekly intravenous oxaliplatin combined with oral daily capecitabine and 
221 
 
radiotherapy with biologic correlates in neoadjuvant treatment of rectal 
adenocarcinoma. Int J Radiat Oncol Biol Phys. 2008;72(3):650–7.  
82.  Blesa JM, Garde Noguera J, Laforga Canales JB, Giner Bosch V, Alberola A, Soler 
Tortosa M, et al. Phase II trial of concomitant neoadjuvant chemotherapy with 
oxaliplatin and capecitabine and intensity-modulated radiotherapy (IMRT) in rectal 
cancer. J Gastrointest Cancer. 2012;43(4):553–61.  
83.  Craven I, Crellin A, Cooper R, Melcher a, Byrne P, Sebag-Montefiore D. 
Preoperative radiotherapy combined with 5 days per week capecitabine 
chemotherapy in locally advanced rectal cancer. Br J Cancer. 2007;97(10):1333–7.  
84.  Cunningham D, Allum W, Stennig S, Thompson J, van de Velde C, Nicolson M, et 
al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal 
cancer. N Eng J Med. 2006;355(1):11–20.  
85.  Moonesinghe SR, Mythen MG, Grocott MPW. High-risk surgery: epidemiology and 
outcomes. Anesth Analg. 2011;112(4):891–901.  
86.  Barry MJ, Edgman-Levitan S. Shared decision making-pinnacle of patient-centered 
care. N Eng J Med. 2012;366(9):780–1.  
87.  Hightower CE, Riedel BJ, Feig BW, Morris GS, Ensor JE, Woodruff VD, et al. A 
pilot study evaluating predictors of postoperative outcomes after major abdominal 
surgery: Physiological capacity compared with the ASA physical status classification 
system. Br J Anaesth. 2010;104(4):465–71.  
88.  Menon KV, Farouk R. An analysis of the accuracy of P-POSSUM scoring for 
mortality risk assessment after surgery for colorectal cancer. Color Dis. 
2002;4(3):197–200.  
89.  Tekkis PP, Prytherch DR, Kocher HM, Senapati A, Poloniecki JD, Stamatakis JD, et 
al. Development of a dedicated risk-adjustment scoring system for colorectal surgery 
(colorectal POSSUM). Br J Surg. 2004;91(9):1174–82.  
90.  Struthers R, Erasmus P, Holmes K, Warman P, Collingwood A, Sneyd JR. Assessing 
fitness for surgery: a comparison of questionnaire, incremental shuttle walk, and 
cardiopulmonary exercise testing in general surgical patients. Br J Anaesth. 
2008;101(6):774–80.  
91.  Edwards M, Whittle J, Ackland GL. Biomarkers to guide perioperative management. 
Postgrad Med J. 2011;87(1030):542–9.  
92.  Baron J, Mundler O, Bertrand M, Vicaut E, Barre E, et al. Dipyridamole-thallium 
scintigraphy and gated radionuclide angiography to assess cardiac risk before 
abdmominal aortic surgery. N Eng J Med. 1994;330(10):663–9.  
93.  Shaw LJ, Eagle KA, Gersh BJ, Miller DD. Meta-analysis of intravenous 
dipyridamole-thallium-201 imaging (1985 to 1994) and dobutamine 
echocardiography (1991 to 1994) for risk stratification before vascular surgery. J Am 
Coll Cardiol. 1996;27(4):787–98.  
222 
 
94.  Ethan A. Halm, Warren S. Browner, Julio F. Tubau, Ida M. Tateo et al. 
Echocardiography for Assessing Cardiac Risk in Patients Having Noncardiac 
Surgery. Ann Intern Med. 1996;125(6):433–41.  
95.  Reilly DF, McNeely MJ, Doerner D, Greenberg DL, Staiger TO, Geist MJ, et al. 
Self-reported exercise tolerance and the risk of serious perioperative complications. 
Arch Intern Med. 1999;159(18):2185–92.  
96.  Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof EL, Fleischmann KE, et 
al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care 
for noncardiac surgery: a report of the American College of Cardiology/American 
Heart Association Task Force on Practice Guidelines (Writing Committee to Revise 
the 2002 Guideline. J Am Coll Cardiol. 2007;116(17):e418–99.  
97.  Poldermans D, Bax JJ, Boersma E, De Hert S, Eeckhout E, Fowkes G, et al. 
Guidelines for pre-operative cardiac risk assessment and perioperative cardiac 
management in non-cardiac surgery. Eur Heart J. 2009;30(22):2769–812.  
98.  Hlatky MA, Boineau RE, Higginbotham MB, Lee KL, Mark DB, Califf RM, et al. A 
brief self-administered questionnaire to determine functional capacity (the Duke 
Activity Status Index). Am J Cardiol. 1989;64(10):651–4.  
99.  Barnett S, Moonesinghe SR. Clinical risk scores to guide perioperative management. 
Postgrad Med J. 2011;87(1030):535–41.  
100.  Moonesinghe S, Mythen M, Das P, Rowan K, Grocott M. Risk Stratification Tools 
for Predicting Morbidity and Mortality in Adult Patients Undergoing Major Surgery. 
Anesthesiology. 2013;119(4):959–81.  
101.  James S, Jhanji S, Smith A, O’Brien G, Fitzgibbon M, Pearse RM. Comparison of 
the prognostic accuracy of scoring systems, cardiopulmonary exercise testing, and 
plasma biomarkers: a single-centre observational pilot study. Br J Anaesth. 
2014;112(3):491–7.  
102.  Myers J, Prakash M, Froelicher V, Do D, Partington S AJ. Exercise capacity and 
mortality among men referred for exercise testing. N Engl J Med. 2002;346(11):793–
801.  
103.  Gulati M, Pandey DK, Arnsdorf MF, Lauderdale DS, Thisted RA, Wicklund RH, et 
al. Exercise capacity and the risk of death in women: the St James Women Take 
Heart Project. Circulation. 2003;108(13):1554–9.  
104.  Campbell JA, D’Acquisto LJ, D’Acquisto DM, Cline MG. Metabolic and 
cardiovascular response to shallow water exercise in young and older women. Med 
Sci Sports Exerc. 2003;35(4):675–81.  
105.  Sergi G, Coin A, Sarti S, Perissinotto E, Peloso M, Mulone S, et al. Resting VO2, 
maximal VO2 and metabolic equivalents in free-living healthy elderly women. Clin 
Nutr. 2010;29(1):84–8.  
106.  Thomas D. Loss of skeletal muscle mass in aging: examining the relationship of 
stravation, sarcopenia and cacheia. Clin Nutr. 2007;26(4):389–99.  
223 
 
107.  Betik AC, Hepple RT. Determinants of VO2 max decline with aging: an integrated 
perspective. Appl Physiol Nutr Metab. 2008;33(1):130–40.  
108.  Gonzalez-Alonso J, Calbet J. Reductions in Systemic and Skeletal Muscle Blood 
Flow and Oxygen Delivery Limit Maximal Aerobic Capacity in Humans. 
Circulation. 2003;107(6):824–30.  
109.  Murray P, Whiting P, Hutchinson SP, Ackroyd R, Stoddard CJ, Billings C. 
Preoperative shuttle walking testing and outcome after oesophagogastrectomy. Br J 
Anaesth. 2007;99(6):809–11.  
110.  Lim E, Baldwin D, Beckles M, Duffy J, Entwisle J, Faivre-Finn C, et al. Guidelines 
on the radical management of patients with lung cancer. Thorax. 2010;65 Suppl 
3(October):iii1–27.  
111.  Win T, Jackson A, Groves AM, Sharples LD, Charman SC, Laroche CM. 
Comparison of shuttle walk with measured peak oxygen consumption in patients 
with operable lung cancer. Thorax. 2006;61(1):57–60.  
112.  Gauss A, Röhm HJ, Schäuffelen A, Vogel T, Mohl U, Straehle A, et al. 
Electrocardiographic exercise stress testing for cardiac risk assessment in patients 
undergoing noncardiac surgery. Anesthesiology. 2001;94(1):38–46.  
113.  Older P, Hall A, Hader R. Cardiopulmonary exercise testing as a screening test for 
perioperative management of major surgery in the elderly. Chest. 1999;116(2):355–
62.  
114.  Simpson JC, Sutton H, Grocott MPW. Cardiopulmonary exercise testing — a survey 
of current use in England. J Intensive Care Soc. 2009;10(4):275–8.  
115.  Ridgway ZA, Howell SJ. Cardiopulmonary exercise testing: a review of methods and 
applications in surgical patients. Eur J Anaesthesiol. 2010;27(10):858–65.  
116.  Weisman IM, Marciniuk D, Martinez FJ, Sciurba F, Sue D, Myers J, et al. 
ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care 
Med. 2003;167(2):211–77.  
117.  Older P, Smith R, Hone R. Preoperative evaluation of cardiac failure and ischemia in 
elderly patients by cardiopulmonary exercise testing. Chest. 1993;104:701–4.  
118.  Nelson ME, Rejeski WJ, Blair SN, Duncan PW, Judge JO, King AC, et al. Physical 
activity and public health in older adults: recommendation from the American 
College of Sports Medicine and the American Heart Association. Circulation. 
2007;116(9):1094–105.  
119.  Stringer W, Casaburi R, Older P. Cardiopulmonary exercise testing: does it improve 
perioperative care and outcome? Curr Opin Anaesthesiol. 2012;25(2):178–84.  
120.  Wilson RJT, Davies S, Yates D, Redman J, Stone M. Impaired functional capacity is 
associated with all-cause mortality after major elective intra-abdominal surgery. Br J 
Anaesth. 2010;105(3):297–303.  
224 
 
121.  Snowden CP, Prentis JM, Anderson HL, Roberts DR, Randles D, Renton M, et al. 
Submaximal cardiopulmonary exercise testing predicts complications and hospital 
length of stay in patients undergoing major elective surgery. Ann Surg. 
2010;251(3):535–41.  
122.  Snowden CP, Prentis J, Jacques B, Anderson H, Manas D, Jones D, et al. 
Cardiorespiratory fitness predicts mortality and hospital length of stay after major 
elective surgery in older people. Ann Surg. 2013;257(6):999–1004.  
123.  Grocott MPW, Pearse RM. Prognostic studies of perioperative risk: robust 
methodology is needed. Br J Anaesth. 2010;105(3):243–5.  
124.  Junejo MA, Mason JM, Sheen AJ, Moore J, Foster P, Atkinson D, et al. 
Cardiopulmonary exercise testing for preoperative risk assessment before hepatic 
resection. Br J Surg. 2012;99(8):1097–104.  
125.  Otto JM, O’Doherty AF, Hennis PJ, Mitchell K, Pate JS, Cooper JA, et al. 
Preoperative exercise capacity in adult inflammatory bowel disease sufferers, 
determined by cardiopulmonary exercise testing. Int J Colorectal Dis. 
2012;27(11):1485–91.  
126.  Ausania F, Snowden CP, Prentis JM, Holmes LR, Jaques BC, White SA, et al. 
Effects of low cardiopulmonary reserve on pancreatic leak following 
pancreaticoduodenectomy. Br J Surg. 2012;99(9):1290–4.  
127.  Chandrabalan VV, McMillan DC, Carter R, Kinsella J, McKay CJ, Carter CR, et al. 
Pre-operative cardiopulmonary exercise testing predicts adverse post-operative 
events and non-progression to adjuvant therapy after major pancreatic surgery. HPB. 
2013 Feb. In press.  
128.  Junejo MA, Mason JM, Sheen AJ, Bryan A, Moore J, Foster P, et al. 
Cardiopulmonary Exercise Testing for Preoperative Risk Assessment before 
Pancreaticoduodenectomy for Cancer. Ann Surg Oncol. 2014;21(6):1929-36.  
129.  Colson M, Baglin J, Bolsin S, Grocott MPW. Cardiopulmonary exercise testing 
predicts 5 yr survival after major surgery. Br J Anaesth. 2012;109(5):735–41.  
130.  Young EL, Karthikesalingam A, Huddart S, Pearse RM, Hinchliffe RJ, Loftus IM, et 
al. A systematic review of the role of cardiopulmonary exercise testing in vascular 
surgery. Eur J Vasc Endovasc Surg. 2012;44(1):64–71.  
131.  Nugent AM, Riley M, Megarry J, O’Reilly MJ, MacMahon J, Lowry R. 
Cardiopulmonary exercise testing in the pre-operative assessment of patients for 
repair of abdominal aortic aneurysm. Ir J Med Sci. 1998;167(4):238–41.  
132.  Kothmann E, Danjoux G, Owen SJ, Parry A, Turley AJ, Batterham AM. Reliability 
of the anaerobic threshold in cardiopulmonary exercise testing of patients with 
abdominal aortic aneurysms. Anaesthesia. 2009;64(1):9–13.  
133.  Carlisle J, Swart M. Mid-term survival after abdominal aortic aneurysm surgery 
predicted by cardiopulmonary exercise testing. Br J Surg. 2007;94(8):966–9.  
225 
 
134.  Thompson A, Peters N, Lovegrove R, Ledwidge S, Kitching A, Magee T, et al. 
Cardiopulmonary exercise testing provides a predictive tool for early and late 
outcomes in abdominal aortic aneurysm patients. Ann R Coll Surg Engl. 
2011;93(6):474–81.  
135.  McEnrow G, Wilson R. Use of cardiopulmonary exercise (CPX) testing to assess 
patients’ suitability for elective aortic aneurysm surgery. Anaesthesia. 2006;61:415–
7.  
136.  Hartley RA, Pichel AC, Grant SW, Hickey GL, Lancaster PS, Wisely NA, et al. 
Preoperative cardiopulmonary exercise testing and risk of early mortality following 
abdominal aortic aneurysm repair. Br J Surg. 2012;99(11):1539–46.  
137.  Prentis JM, Trenell MI, Jones DJ, Lees T, Clarke M, Snowden CP. Submaximal 
exercise testing predicts perioperative hospitalization after aortic aneurysm repair. J 
Vasc Surg. 2012;56(6):1564–70.  
138.  Nagamatsu Y, Shima I, Yamana H, Fujita H, Shirouzu K, Ishitake T. Preoperative 
evaluation of cardiopulmonary reserve with the use of expired gas analysis during 
exercise testing in patients with squamous cell carcinoma of the thoracic esophagus. J 
Thorac Cardiovasc Surg. 2001;121(6):1064–8.  
139.  Forshaw MJ, Strauss DC, Davies AR, Wilson D, Lams B, Pearce A, et al. Is 
cardiopulmonary exercise testing a useful test before esophagectomy? Ann Thorac 
Surg. 2008;85(1):294–9.  
140.  McCullough PA, Gallagher MJ, Dejong AT, Sandberg KR, Trivax JE, Alexander D, 
et al. Cardiorespiratory fitness and short-term complications after bariatric surgery. 
Chest. 2006;130(2):517–25.  
141.  Hennis PJ, Meale PM, Hurst RA, O’Doherty AF, Otto J, Kuper M, et al. 
Cardiopulmonary exercise testing predicts postoperative outcome in patients 
undergoing gastric bypass surgery. Br J Anaesth. 2012;109(4):566–71.  
142.  Epstein SK, Freeman RB, Khayat A, Unterborn JN, Pratt DS, Kaplan MM. Aerobic 
capacity is associated with 100-day outcome after hepatic transplantation. Liver 
Transpl. 2004;10(3):418–24.  
143.  Prentis J, Manas D, Trenell M. Submaximal cardiopulmonary exercise testing 
predicts 90‐day survival after liver transplantation. Transplantation. 2012;18(2):152–
9.  
144.  West M, Parry M, Lythgoe D, Barben C, Kemp G, Grocott M, et al. 
Cardiopulmonary exercise variables are associated with postoperative morbidity after 
rectal cancer surgery. Br J Surg. 2014; In press.  
145.  West MA, Lythgoe D, Barben CP, Noble L, Kemp GJ, Jack S, et al. 
Cardiopulmonary exercise variables are associated with postoperative morbidity after 
major colonic surgery : a prospective blinded observational study. Br J Anaesth. 
2014;112(4):665–71.  
226 
 
146.  Grocott MPW, Browne JP, Van der Meulen J, Matejowsky C, Mutch M, Hamilton M 
a, et al. The Postoperative Morbidity Survey was validated and used to describe 
morbidity after major surgery. J Clin Epidemiol. 2007;60(9):919–28.  
147.  Piepoli MF, Davos C, Francis DP, Coats AJS. Exercise training meta-analysis of 
trials in patients with chronic heart failure (ExTraMATCH). BMJ. 
2004;328(7433):189.  
148.  Fong DYT, Ho JWC, Hui BPH, Lee AM, Macfarlane DJ, Leung SSK, et al. Physical 
activity for cancer survivors: meta-analysis of randomised controlled trials. BMJ. 
2012;344:e70–e70.  
149.  Riario-Sforza GG, Incorvaia C, Paterniti F, Pessina L, Caligiuri R, Pravettoni C, et al. 
Effects of pulmonary rehabilitation on exercise capacity in patients with COPD: a 
number needed to treat study. Int J Chron Obstruct Pulmon Dis. 2009;4:315–9.  
150.  Sandercock G, Hurtado V, Cardoso F. Changes in cardiorespiratory fitness in cardiac 
rehabilitation patients: A meta-analysis. Int J Cardiol. 2013;167(3):894–902.  
151.  Carli F, Zavorsky GS. Optimizing functional exercise capacity in the elderly surgical 
population. Curr Opin Clin Nutr Metab Care. 2005;8(1):23–32.  
152.  Bolton C, Bevan-Smith E, Blakey J, Crowe P, Elkin S, Garrod R, et al. BTS 
Guideline on Pulmonary Rehabiliation in Adults. Thorax. 2013;68(2):1–30.  
153.  Jack S, West M, Grocott MPW. Perioperative exercise training in elderly subjects. 
Best Pract Res Clin Anaesthesiol. 2011;25(3):461–72.  
154.  Doherty AFO, West M, Jack S, Grocott MPW. Preoperative aerobic exercise training 
in elective intra-cavity surgery : a systematic review. Br J Anaesth. 2013;110(5):679–
89.  
155.  Asoh T, Tsuji H. Preoperative Physical Training for Cardiac Patients Requiring Non-
cardiac Surgery. Jpn J Surg. 1981;11(4):251–5.  
156.  Carli F, Charlebois P, Stein B, Feldman L, Zavorsky G, Kim DJ, et al. Randomized 
clinical trial of prehabilitation in colorectal surgery. Br J Surg. 2010;97(8):1187–97.  
157.  Dronkers JJ, Lamberts H, Reutelingsperger IMMD, Naber RH, Dronkers-Landman 
CM, Veldman A, et al. Preoperative therapeutic programme for elderly patients 
scheduled for elective abdominal oncological surgery: a randomized controlled pilot 
study. Clin Rehabil. 2010;24(7):614–22.  
158.  Kim DJ, Mayo NE, Carli F, Montgomery DL, Zavorsky GS. Responsive measures to 
prehabilitation in patients undergoing bowel resection surgery. Tohoku J Exp Med. 
2009;217(2):109–15.  
159.  Timmerman H, de Groot JF, Hulzebos HJ, de Knikker R, Kerkkamp HEM, van 
Meeteren NLU. Feasibility and preliminary effectiveness of preoperative therapeutic 
exercise in patients with cancer: a pragmatic study. Physiother Theory Pract. 
2011;27(2):117–24.  
227 
 
160.  Jones LW, Peddle CJ, Eves ND, Haykowsky MJ, Courneya KS, Mackey JR, et al. 
Effects of presurgical exercise training on cardiorespiratory fitness among patients 
undergoing thoracic surgery for malignant lung lesions. Cancer. 2007;110(3):590–8.  
161.  Bobbio A, Chetta A, Ampollini L, Primomo GL, Internullo E, Carbognani P, et al. 
Preoperative pulmonary rehabilitation in patients undergoing lung resection for non-
small cell lung cancer. Eur J Cardiothorac Surg. 2008;33(1):95–8.  
162.  Cesario A, Ferri L, Galetta D, Cardaci V, Biscione G, Pasqua F, et al. Pre-operative 
pulmonary rehabilitation and surgery for lung cancer. Lung cancer. 2007;57(1):118–
9.  
163.  Debigare R, Maltais F, Whittom F, Deslauriers J, LeBlanc P. Feasibility and Efficacy 
of Home Exercise Training Before Lung Volume Reduction. J Cardiopulm Reahab. 
2009;19(4):235–41.  
164.  Arthur H, Daniels C, McKelvie R, Hirsh J, Rush B. Effect of a Preoperative 
Intervention on Preoperative and Postoperative Outcomes in Low-Risk Patients 
Awaiting Elective Coronary Artery Bypass Graf Surgery. Ann Intern Med. 
2000;133:253–62.  
165.  Valkenet K, van de Port IGL, Dronkers JJ, de Vries WR, Lindeman E, Backx FJG. 
The effects of preoperative exercise therapy on postoperative outcome: a systematic 
review. Clin Rehabil. 2011;25(2):99–111.  
166.  Singh F, Newton R, Galvao D, Spry N, Baker M. A systematic review of pre-surgical 
exercise intervention studies with cancer patients. Surg Oncol. 2013;22(2):92-104.  
167.  Li C, Carli F, Lee L, Charlebois P, Stein B, Liberman AS, et al. Impact of a trimodal 
prehabilitation program on functional recovery after colorectal cancer surgery: a pilot 
study. Surg Endosc. 2013;27(4):1072–82.  
168.  Jones LW, Eves ND, Haykowsky M, Joy AA, Douglas PS. Cardiorespiratory 
exercise testing in clinical oncology research: systematic review and practice 
recommendations. Lancet Oncol. 2008;9(8):757–65.  
169.  Gulati M, Black HR, Shaw LJ, Arnsdorf MF, Merz CNB, Lauer MS, et al. The 
prognostic value of a nomogram for exercise capacity in women. N Engl J Med. 
2005;353(5):468–75.  
170.  Roca J, Hogan MC, Story D, Bebout DE, Haab P, Gonzalez R, et al. Evidence for 
tissue diffusion limitation of VO2max in normal humans. J Appl Physiol. 
1989;67(1):291–9.  
171.  Fitzgerald M, Tanaka H, Seals D, Tran Z. Age-related declines in maximal aerobic 
capacity in regularly exercising vs. sedentary women: A meta-analysis. J Appl 
Physiol. 1997;83(1):160–5.  
172.  McGuire DK, Levine BD, Williamson JW, Snell PG, Blomqvist CG, Saltin B, et al. 
A 30-Year Follow-Up of the Dallas Bed Rest and Training Study: II. Effect of Age 
on Cardiovascular Adaptation to Exercise Training. Circulation. 2001;104(12):1358–
66.  
228 
 
173.  Jones LW, Eves ND, Mackey JR, Peddle CJ, Haykowsky M, Joy AA, et al. Safety 
and feasibility of cardiopulmonary exercise testing in patients with advanced cancer. 
Lung Cancer. 2007;55(2):225–32.  
174.  West MA, Loughney L, Jack S, Kemp G, Barben C, Grocott M, et al. Does Change 
In Physical Activity Correlate To A Change In Physical Fitness Post Neoadjuvant 
Chemoradiotherapy In Rectal Cancer Patients? Am J Respir Crit Care Med. 
2012;185(2012):A6394.  
175.  West MA, Loughney L, Jack S, Barben C, Kemp G, Grocott M, et al. The Effect Of 
Neoadjuvant Chemoradiotherapy On Physical Activity In Operable Rectal Cancer 
Patients. Am J Respir Crit Care Med. 2012;185(2012):A6392.  
176.  Jones LW, Eves ND, Haykowsky M, Freedland SJ, Mackey JR. Exercise intolerance 
in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol. 
2009;10(6):598–605.  
177.  Cannon DT, Howe FA, Whipp BJ, Ward SA, McIntyre DJ, Ladroue C, et al. Muscle 
metabolism and activation heterogeneity by combined 31P chemical shift and T2 
imaging, and pulmonary O2 uptake during incremental knee-extensor exercise. J 
Appl Physiol. 2013;115(6):839–49.  
178.  Praet SFE, De Feyter HMM, Jonkers R AM, Nicolay K, van Pul C, Kuipers H, et al. 
31P MR spectroscopy and in vitro markers of oxidative capacity in type 2 diabetes 
patients. Magn Reson Mater Phy. 2006;19(6):321–31.  
179.  Fernández-Moreno MA, Bornstein B, Petit N, Garesse R. The Pathophysiology of 
Mitochondrial Biogenesis: Towards Four Decades of Mitochondrial DNA Research. 
Mol Genet Metab. 2000;71(3):481–95.  
180.  Korzeniewski B. Regulation of oxidative phosphorylation through parallel activation. 
Biophys Chem. 2007;129(2–3):93–110.  
181.  Marcinek DJ. Mitochondrial dysfunction measured in vivo. Acta Physiol Scand. 
2004;182(4):343–52.  
182.  Tschakovsky ME, Hughson RL. Interaction of factors determining oxygen uptake at 
the onset of exercise. J Appl Physiol. 1999;86(4):1101–13.  
183.  Chance B, Williams G. Respiratory enzymes in oxidative phosphorylation: I.Kinetics 
of oxygen utilization. J Appl Physiol. 1955;217:383–94.  
184.  Jobsis FF, Keizer JH, Lamanna JC, Rosenthal M, Carolina N. Reflectance 
spectrophotometry of cytochrome aa3 in vivo. J Appl Physiol. 1977;43:858–72.  
185.  Haseler LJ, Richardson RS, Videen JS, Hogan MC, Luke J, John S, et al. 
Phosphocreatine hydrolysis during submaximal exercise : the effect of FIO2. J Appl 
Physiol. 1998;85:1457–63.  
186.  Haseler LJ, Hogan MC, Richardson RS, Luke J, Russell S. Skeletal muscle 
phosphocreatine recovery in exercise-trained humans is dependent on O2 availability. 
J Appl Physiol. 1999;86:2013–8.  
229 
 
187.  Hogan MC, Nioka S, Brechue WF, Chance B, Hogan C. A 31P-NMR study of tissue 
respiration in working dog muscle during reduced O2 delivery conditions. J Appl 
Physiol. 1992;73:1662–70.  
188.  Marcinek DJ, Ciesielski WA, Conley KE, Schenkman KA. Oxygen regulation and 
limitation to cellular respiration in mouse skeletal muscle in vivo. Am J Physiol 
Heart Circ Physiol. 2003;285(5):H1900–8.  
189.  Kuznetsov AV, Veksler V, Gellerich FN, Saks V, Margreiter R, Kunz WS. Analysis 
of mitochondrial function in situ in permeabilized muscle fibers, tissues and cells. 
Nat Protoc. 2008;3(6):965–76.  
190.  Wibom R, Hultman E. ATP production rate in mitochondria from microsamples of 
human muscle isolated. Am J Physiol. 1990;259:204–9.  
191.  Wasserman K, Hansen JE, Sue DS and Whipp BJ. Principles of Exercise Testing and 
Interpretation: Pathophysiology and Clinical Applications. 4th ed. Baltimore; 
Maryland: Lippincott Williams & Wilkins. 2005. p 25-145.  
192.  Bloch F, Hansen W, Packard M. The nuclear induction experiment. Phys Rev. 
1946;70:474–85.  
193.  Purcell E, Torrey H, Packard M. Resonance absorption by nuclear magnetic moments 
in solid. Phys Rev1. 1946;69:37–8.  
194.  Chance B, Im J, Nioka S, Kushmerick M. Skeletal muscle energetics with PNMR : 
Personal views and historic perspectives. NMR Biomed. 2006;19(7):904–26.  
195.  Meyer R, Kuchmerick M, TR B. Application of 31P-NMR spectroscopy to the study 
of striated muscle metabolism. Am J Physiol. 1982;242:1–11.  
196.  Prompers JJ, Jeneson JAL, Drost MR, Oomens CCW, Strijkers GJ, Nicolay K. 
Dynamic MRS and MRI of skeletal muscle function and biomechanics. NMR 
Biomed. 2006;19:927–53.  
197.  Befroy DE, Falk Petersen K, Rothman DL, Shulman GI. Assessment of in vivo 
mitochondrial metabolism by magnetic resonance spectroscopy. 1st ed. Methods in 
enzymology. Elsevier Inc.; 2009.  
198.  Edwards LM, Murray AJ, Tyler DJ, Kemp GJ, Holloway CJ, Robbins P A, et al. The 
effect of high-altitude on human skeletal muscle energetics: P-MRS results from the 
Caudwell Xtreme Everest expedition. PLoS One. 2010;5(5):e10681.  
199.  Kemp G, Radda G. Quantitative interpretation of bioenergetic data from 31P and 1H 
magnetic resonance spectroscopic studies of skeletal muscle: an analytical review. 
Magn Reson Q. 1994;10(1):43–63.  
200.  Kemp GJ, Meyerspeer M, Moser E. Absolute quantification of phosphorus 
metabolite concentrations in human muscle in vivo by 31 P MRS : a quantitative 
review. NMR Biomed. 2007;20:555–65.  
230 
 
201.  Kemp GJ, Brindle KM. What do magnetic resonance-based measurements of 
Pi→ATP flux tell us about skeletal muscle metabolism? Diabetes. 2012;61(8):1927–
34.  
202.  Larson-Meyer D, Newcomer B, Hunter G, Joanisse D, Weinsier R, MM B. 
Relationship between in vivo and in vitro measurements of skeletal musle oxidative 
metabolism. Muscle Nerve. 2001;24:1665–76.  
203.  McCully KK, Turner TN, Langley J, Zhao Q. The reproducibility of measurements 
of intramuscular magnesium concentrations and muscle oxidative capacity using 31P 
MRS. Dyn Med. 2009;8:5.  
204.  Moon RB, Richards JH. Determination of Intracellular pH by 31 P Magnetic 
Resonance. J Biol Chem. 1973;248:7276–8.  
205.  Sweeney H. The importance of the creatine kinase reaction: the concept of metabolic 
capacitance. Med Sci Sport Exerc. 1994;26(1):30–6.  
206.  Hoult D, Busby S, Gadian D, Radda G, Richards R, Seeley P. Observations of tissue 
metabolites using 31 P nuclear magnetic resonance. Nature. 1974;252:285–7.  
207.  Walter G, Vandenborne K, Elliott M, Leigh JS. In vivo ATP synthesis rates in single 
human muscles during high intensity exercise. J Physiol. 1999;519:901–10.  
208.  Hochachka PW, McClelland GB. Cellular metabolic homeostasis during large-scale 
change in ATP turnover rates in muscles. J Exp Biol. 1997;200:381–6.  
209.  Kemp GJ, Roberts N, Bimson WE, Bakran A, Harris PL, Gilling-Smith GL, et al. 
Mitochondrial function and oxygen supply in normal and in chronically ischemic 
muscle: a combined 31P magnetic resonance spectroscopy and near infrared 
spectroscopy study in vivo. J Vasc Surg. 2001;34(6):1103–10.  
210.  Rossiter HB. Exercise: Kinetic Considerations for Gas Exchange. Comprehensive 
Physiology. John Wiley & Sons, Inc.; 2011. p. 203–44.  
211.  Kemp GJ, Manners DN, Clark JF, Bastin ME, Radda GK. Theoretical modelling of 
some spatial and temporal aspects of the mitochondrion/creatine kinase/myofibril 
system in muscle. Mol and Celluar Biochem. 1998;184:249–89.  
212.  Kemp GJ, Ahmad RE, Nicolay K, Prompers JJ. Quantification of skeletal muscle 
mitochondrial function by (31) P magnetic resonance spectroscopy techniques: a 
quantitative review. Acta Physiol. 2014; In press.  
213.  Beaver W. Water vapor corrections in oxygen consumption. J Appl Physiol. 
1973;35:928–31.  
214.  Wasserman K, Hansen JE, Sue DY, Stringer W and Whipp BJ. Principles of Exercise 
Testing and Interpretation: Pathophysiology and Clinical Applications. 4th Editio. 
Baltimore, Maryland: Lippincott Williams & Wilkins; 2005. 29-36. 
215.  Palange P, Ward SA, Carlsen K-H, Casaburi R, Gallagher CG, Gosselink R, et al. 
Recommendations on the use of exercise testing in clinical practice. Eur Respir J. 
2007;29(1):185–209.  
231 
 
216.  Hopker JG, Jobson SA, Pandit JJ. Controversies in the physiological basis of the 
“anaerobic threshold” and their implications for clinical cardiopulmonary exercise 
testing. Anaesthesia. 2011;66(2):111–23.  
217.  William B, Wasserman K, Whipp J. A new method for detecting anaerobic threshold 
by gas exchange. J Appl Physiol. 1986;60(6):2020–7.  
218.  Sue D, Wasserman K, Moricca R, Casaburi R. Metabolic acidosis during exercise in 
patients with chronic obstructive pulmonary disease. Use of the V-slope method for 
anaerobic threshold determination. Chest. 1988;94(5):931–8.  
219.  Sinclair RCF, Danjoux GR, Goodridge V, Batterham AM. Determination of the 
anaerobic threshold in the pre-operative assessment clinic: inter-observer 
measurement error. Anaesthesia. 2009;64(11):1192–5.  
220.  Sleigh A, Stears A, Thackray K, Watson L, Gambineri A, Nag S, et al. Mitochondrial 
oxidative phosphorylation is impaired in patients with congenital lipodystrophy. J 
Clin Endocrinol Metab. 2012;97(3):E438–42.  
221.  Nygaard K, Hagen S, Hansen HS, Hatlevoll R, Hultborn R, Jakobsen A, et al. Pre-
operative radiotherapy prolongs survival in operable esophageal carcinoma: a 
randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The 
second Scandinavian trial in esophageal cancer. World J Surg. 1992;16(6):1104–9.  
222.  Kaklamanos IG, Walker GR, Ferry K, Franceschi D, Livingstone AS. Neoadjuvant 
Treatment for Resectable Cancer of the Esophagus and the Gastroesophageal 
Junction: A Meta-Analysis of Randomized Clinical Trials. Ann Surg Oncol. 
2003;10(7):754–61.  
223.  Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. 
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for 
resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a 
randomised controlled trial. Lancet. 2008;371(9617):1007–16.  
224.  Tabira Y, Okuma T, Kondo K, Yoshioka M, Mori T, Tanaka M, et al. Does 
neoadjuvant chemotherapy for carcinoma in the thoracic esophagus increase 
postoperative morbidity? Japanese J Thorac Cardiovasc Surg. 1999;47(8):361–7.  
225.  Vogt K, Fenlon D, Rhodes S, Malthaner R. Preoperative chemotherapy for resectable 
thoracic esophageal cancer. Cochrane Database Syst Rev. 2006;3(CD001556):1–47.  
226.  Dähn D, Martell J, Vorwerk H, Hess CF, Becker H, Jung K, et al. Influence of 
irradiated lung volumes on perioperative morbidity and mortality in patients after 
neoadjuvant radiochemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 
2010;77(1):44–52.  
227.  Turan A, Shao D, Salmasi V, Honar H, Atim A, Dalton JE, et al. Chemotherapy 
within 30 days before surgery does not augment postoperative mortality and 
morbidity. Can J Anesth. 2012;59:758–65.  
228.  Buie WD, MacLean AR, Attard J-AP, Brasher PM A, Chan AK. Neoadjuvant 
chemoradiation increases the risk of pelvic sepsis after radical excision of rectal 
cancer. Dis Colon Rectum. 2005;48(10):1868–74.  
232 
 
229.  Artioukh DY, Smith RA, Gokul K. Risk factors for impaired healing of the perineal 
wound after abdominoperineal resection of rectum for carcinoma. Color Dis. 
2007;9(4):362–7.  
230.  Sobin LH, Fleming ID. TNM Classification of Malignant Tumors , Fifth Edition ( 
1997 ). Cancer. 1997;80(9):1803–4.  
231.  Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. 
Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J 
Clin Oncol. 1982;5(6):649–55.  
232.  MacFarlane JK, Ryall RDH, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 
1993;341(8843):457–60.  
233.  Heald RJ. Rectal cancer: the surgical options. Eur J Cancer. 1995;31A(7-8):1189–92.  
234.  Bromage SJ, Cunliffe WJ. Validation of the CR-POSSUM risk-adjusted scoring 
system for major colorectal cancer surgery in a single center. Dis Colon Rectum. 
2007;50(2):192–6.  
235.  Dindo D, Demartines N, Clavien P-A. Classification of Surgical Complications. Ann 
Surg. 2004;240(2):205–13.  
236.  Glynne-Jones R, Grainger J, Harrison M, Ostler P, Makris A. Neoadjuvant 
chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: 
should we be more cautious? Br J Cancer. 2006;94(3):363–71.  
237.  Tisdale MJ. Cancer anorexia and cachexia. Nutrition. 2001;17(5):438–42.  
238.  Kern K. Cancer cachexia. J Paren Ent Nutr. 1988;12:286–98.  
239.  Le Bricon T, Gugins S, Cynober L, Baracos VE. Negative impact of cancer 
chemotherapy on protein metabolism in healthy and tumor-bearing rats. Metabolism. 
1995;44(10):1340–8.  
240.  Gilliam LAA, St Clair DK, Clair DKS. Chemotherapy-Induced Weakness and 
Fatigue in Skeletal Muscle : The Role of Oxidative Stress. Antioxid Redox Signal. 
2011;15(9):2543–63.  
241.  Al-Majid S, McCarthy DO. Cancer-Induced Fatigue and Skeletal Muscle Wasting: 
The Role of Exercise. Biol Res Nurs. 2001;2(3):186–97.  
242.  Yamamoto Y, Hoshino Y, Ito T, Nariai T, Mohri T, Obana M, et al. Atrogin-1 
ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac 
myocytes. Cardiovasc Res. 2008;79(1):89–96.  
243.  Karvunidis T, Chvojka J, Lysak D, Sykora R, Krouzecky A, Radej J, et al. Septic 
shock and chemotherapy-induced cytopenia: effects on microcirculation. Intensive 
Care Med. 2012;38(8):1336–44.  
244.  Wang XS, Janjan NA, Guo H, Johnson BA, Engstrom MC, Crane CH, et al. Fatigue 
during preoperative chemoradiation for resectable rectal cancer. Cancer. 
2001;92(6):1725–32.  
233 
 
245.  Schneider CM, Hsieh CC, Sprod LK, Carter SD, Hayward R. Cancer treatment-
induced alterations in muscular fitness and quality of life: the role of exercise 
training. Ann Oncol. 2007;18(12):1957–62.  
246.  Tatematsu N, Ezoe Y, Tanaka E, Muto M, Sakai Y, Tsuboyama T. Impact of 
Neoadjuvant Chemotherapy on Physical Fitness, Physical Activity, and Health-
related Quality of Life of Patients With Resectable Esophageal Cancer. Am J Clin 
Oncol. 2013;36(1):53–6.  
247.  Galvão DA, Newton RU. Review of exercise intervention studies in cancer patients. J 
Clin Oncol. 2005;23(4):899–909.  
248.  Kemi OJ, Wisloff U. High-intensity aerobic exercise training improves the heart in 
health and disease. J Cardiopulm Rehabil Prev. 2010;30(1):2–11.  
249.  Ries AL, Bauldoff GS, Carlin BW, Casaburi R, Emery CF, Mahler D a, et al. 
Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice 
Guidelines. Chest. 2007 May;131(5 Suppl):4S–42S.  
250.  Swank A, Kachelman J, Bibeau W, Quesada P, Nyland J, Malkani A, et al. 
Prehabilitation before total knee arthroplasty increases strenght and function in older 
adults with severe osteoarthritis. J Strength Cond Res. 2011;25(2):318–25.  
251.  Haskell WL, Lee I-M, Pate RR, Powell KE, Blair SN, Franklin BA, et al. Physical 
activity and public health: updated recommendation for adults from the American 
College of Sports Medicine and the American Heart Association. Circulation. 
2007;116(9):1081–93.  
252.  Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee I-M, et al. 
American College of Sports Medicine position stand. Quantity and quality of 
exercise for developing and maintaining cardiorespiratory, musculoskeletal, and 
neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. 
Med Sci Sports Exerc. 2011;43(7):1334–59.  
253.  Pina IL. Exercise and Heart Failure: A Statement From the American Heart 
Association Committee on Exercise, Rehabilitation, and Prevention. Circulation. 
2003;107(8):1210–25.  
254.  Zainuldin R, Mackey R, Alison J. Optimal intensity and type of leg exercise training 
for people with chronic obstructive pulmonary disease (Review). Cochrane Collab. 
2011;(11):1–88.  
255.  Casaburi R, Wasserman K, Patessio A, Ioli F, Zanaboni S, Donner C. Reductions in 
Exercise Lactic Acidosis and Ventilation as a Result of Exercise Training in Patients 
with Obstructive Lung Disease: Reply. Am Rev Respir Dis. American Thoracic 
Society - AJRCCM; 1991;144(5):1221.  
256.  Casaburi R, Porszasz J, Burns M, Carithers ER, Chang RS, Cooper C. Physiologic 
benefits of exercise training in rehabilitation of patients with severe chronic 
obstructive pulmonary disease. Am J Respir Crit Care Med. 1997;155(5):1541–51.  
257.  Vogiatzis I, Nanas S, Roussos C. Interval training as an alternative modality to 
continuous exercise in patients with COPD. Eur Respir J. 2002;20(1):12–9.  
234 
 
258.  Kortianou EA, Nasis IG, Spetsioti ST, Daskalakis AM, Vogiatzis I. Effectiveness of 
Interval Exercise Training in Patients with COPD. Cardiopulm Phys Ther J. 
2010;21(3):12–9.  
259.  Myers JN, White JJ, Narasimhan B, Dalman RL. Effects of exercise training in 
patients with abdominal aortic aneurysm: preliminary results from a randomized trial. 
J Cardiopulm Rehabil Prev. 2010;30(6):374–83.  
260.  Kothmann E, Batterham AM, Owen SJ, Turley a J, Cheesman M, Parry A, et al. 
Effect of short-term exercise training on aerobic fitness in patients with abdominal 
aortic aneurysms: a pilot study. Br J Anaesth. 2009;103(4):505–10.  
261.  Adamsen L, Quist M, Andersen C, Moller T, Herrstedt J, Kronborg D, et al. Effect of 
a multimodal high intensity exercise intervention in cancer patients undergoing 
chemotherapy: randomised controlled trial. BMJ. 2009;339:1–11.  
262.  Courneya KS, Friedenreich CM, Quinney HA, Fields ALA, Jones LW, Fairey AS. A 
randomized trial of exercise and quality of life in colorectal cancer survivors. Eur J 
Cancer Care. 2003;12(4):347–57.  
263.  Courneya KS, Sellar CM, Stevinson C, McNeely ML, Peddle CJ, Friedenreich CM, 
et al. Randomized controlled trial of the effects of aerobic exercise on physical 
functioning and quality of life in lymphoma patients. J Clin Oncol. 
2009;27(27):4605–12.  
264.  Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud’Homme DG, et al. 
Randomized controlled trial of resistance or aerobic exercise in men receiving 
radiation therapy for prostate cancer. J Clin Oncol. 2009;27(3):344–51.  
265.  Courneya KS, Segal RJ, Mackey JR, Gelmon K, Reid RD, Friedenreich CM, et al. 
Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant 
chemotherapy: a multicenter randomized controlled trial. J Clin Oncol. 
2007;25(28):4396–404.  
266.  Herrero F, San Juan AF, Fleck SJ, Balmer J, Pérez M, Cañete S, et al. Combined 
Aerobic and Resistance Training in Breast Cancer Survivors: A Randomized, 
Controlled Pilot Trial. Int J Sport Med. 2006;27:573–80.  
267.  Courneya KS, Mackey JR, Bell GJ, Jones LW, Field CJ, Fairey AS. Randomized 
controlled trial of exercise training in postmenopausal breast cancer survivors: 
cardiopulmonary and quality of life outcomes. J Clin Oncol. 2003;21(9):1660–8.  
268.  Burnham TR, Wilcox A. Effects of exercise on physiological and psychological 
variables in cancer survivors. Med Sci Sports Exerc. 2002;34(12):1863–7.  
269.  Jones LW, Douglas PS, Eves ND, Marcom PK, Kraus WE, Herndon JE, et al. 
Rationale and design of the Exercise Intensity Trial (EXCITE): A randomized trial 
comparing the effects of moderate versus moderate to high-intensity aerobic training 
in women with operable breast cancer. BMC Cancer. 2010;10:531.  
270.  Dimeo FC, Thomas F, Raabe-Menssen C, Pröpper F, Mathias M. Effect of aerobic 
exercise and relaxation training on fatigue and physical performance of cancer 
235 
 
patients after surgery. A randomised controlled trial. Support care cancer. 
2004;12(11):774–9.  
271.  Meyer K, Lehmann M, Sünder G, Keul J, Weidemann H. Interval versus continuous 
exercise training after coronary bypass surgery: a comparison of training-induced 
acute reactions with respect to the effectiveness of the exercise methods. Clin 
Cardiol. 1990;13(12):851–61.  
272.  Moholdt TT, Amundsen BH, Rustad LA, Wahba A, Løvø KT, Gullikstad LR, et al. 
Aerobic interval training versus continuous moderate exercise after coronary artery 
bypass surgery: a randomized study of cardiovascular effects and quality of life. Am 
Heart J. 2009;158(6):1031–7.  
273.  Freyssin C, Verkindt C, Prieur F, Benaich P, Maunier S, Blanc P. Cardiac 
rehabilitation in chronic heart failure: effect of an 8-week, high-intensity interval 
training versus continuous training. Arch Phys Med Rehabil. 2012;93(8):1359–64.  
274.  Wisløff U, Støylen A, Loennechen JP, Bruvold M, Rognmo Ø, Haram PM, et al. 
Superior cardiovascular effect of aerobic interval training versus moderate 
continuous training in heart failure patients: a randomized study. Circulation. 
2007;115(24):3086–94.  
275.  Gloeckl R, Halle M, Kenn K. Interval versus continuous training in lung transplant 
candidates: a randomized trial. J Heart Lung Transplant. 2012;31(9):934–41.  
276.  Daussin N, Zoll J, Dufour P, Ponsot E, Lonsdorfer-wolf E, Mettauer B, et al. Effect 
of interval versus continuous training on cardiorespiratory and mitochondrial 
functions : relationship to aerobic performance improvements in sedentary subjects. 
Am J Physiol Regul Inegr Comp Physiol. 2008;295:264–72.  
277.  Gorostiaga EM, Foster C, Hickson RC. Uniqueness of interval and continuous 
training at the same maintained exercise intensity. Eur J Appl Physiol. 1991;63:101–
7.  
278.  Poole DC, Gaesser GA. Response of ventilatory and lactate thresholds to continuous 
and interval training. J Appl Physiol. 1985;58(4):1115–21.  
279.  Simoneau JA, Lortie G, Boulay MR, Marcotte M, Thibault MC, Bouchard C. Human 
skeletal muscle fiber type alteration with high-intensity intermittent training. Eur J 
Appl Physiol Occup Physiol. 1985;54(3):250–3.  
280.  Puhan M, Busching G, Schunemann J, Van Oort E, Zaugg C, Frey M. Interval versus 
Continuous High-Intensity Exercise in Chronic Obstructive Pulmonary Disease. Ann 
Intern Med. 2006;145:816–25.  
281.  Nilsson BB, Westheim A, Risberg MA. Effects of group-based high-intensity aerobic 
interval training in patients with chronic heart failure. Am J Cardiol. 
2008;102(10):1361–5.  
282.  Demello JJ, Cureton KJ, Boineau RE, Singh MM. Ratings of perceived exertion at 
the lactate threshold in trained and untrained men and women. Med Sci Sport Exerc. 
1987;19(4):354–62.  
236 
 
283.  Londeree BR. Effect of training on lactate/ventilatory thresholds: a meta-analysis. 
Med Sci Sport Exerc. 1997;29(6):837–43.  
284.  Jones LW, Liang Y, Pituskin EN, Battaglini CL, Scott JM, Hornsby WE, et al. Effect 
of exercise training on peak oxygen consumption in patients with cancer: a meta-
analysis. Oncologist. 2011;16(1):112–20.  
285.  Bobbio A, Chetta A, Ampollini L, Primomo GL, Internullo E, Carbognani P, et al. 
Preoperative pulmonary rehabilitation in patients undergoing lung resection for non-
small cell lung cancer. Eur J Cardiothorac Surg. 2008;33(1):95–8.  
286.  Kothmann E, Batterham AM, Owen SJ, Turley a J, Cheesman M, Parry A, et al. 
Effect of short-term exercise training on aerobic fitness in patients with abdominal 
aortic aneurysms: a pilot study. Br J Anaesth. 2009;103(4):505–10.  
287.  Kehlet H. Manipulation of the Metabolic Response in Clinical Practice. World J 
Surg. 2000;24:690–5.  
288.  Kehlet H, Wilmore DW. Multimodal strategies to improve surgical outcome. Am J 
Surg. 2002;183(6):630–41.  
289.  Lai CW, Minto G, Challand CP, Hosie KB, Sneyd JR, Creanor S, et al. Patients’ 
inability to perform a preoperative cardiopulmonary exercise test or demonstrate an 
anaerobic threshold is associated with inferior outcomes after major colorectal 
surgery. Br J Anaesth. 2013;111(4):607–11.  
290.  Ditmyer N, Topp R, Pifer M. Prehabilitation in preparation for orthopaedic surgery. 
Orthop Nurs. 2002;21(5):43–51.  
291.  Silver JK, Baima J. Cancer prehabilitation: an opportunity to decrease treatment-
related morbidity, increase cancer treatment options, and improve physical and 
psychological health outcomes. Am J Phys Med Rehabil. 2013;92(8):715–27.  
292.  West MA, Jack S, Kemp G, Barben C, Grocott M. The Effect Of Neoadjuvant 
Chemoradiotherapy On Fitness In Patients Undergoing Rectal Cancer Surgery - Fit 
For Surgery ? Am J Respir Crit Care Med. 2012. p. A6395.  
293.  West M, Loughney L, Barben C, Sripadam R, Kemp G, Grocott M, et al. The effects 
of neoadjuvant chemoradiotherapy on physical fitness and morbidity in rectal cancer 
surgery patients. Eur J Surg Oncol. 2014; In press.  
294.  Boesch C. Musculoskeletal spectroscopy. J Magn Reson Imaging. 2007;25(2):321–
38.  
295.  Jager a, Sleijfer S, van der Rijt CCD. The pathogenesis of cancer related fatigue: 
could increased activity of pro-inflammatory cytokines be the common denominator? 
Eur J Cancer. 2008;44(2):175–81.  
296.  Ryan JL, Carroll JK, Ryan EP, Mustian KM, Fiscella K, Morrow GR. Mechanisms 
of cancer-related fatigue. Oncologist. 2007;12 Suppl 1:22–34.  
237 
 
297.  Argov Z, De Stefano N, Taivassalo T, Chen J, Karpati G, Arnold DL. Abnormal 
oxidative metabolism in exercise intolerance of undetermined origin. Neuromuscul 
Disord. 1997;7(2):99–104.  
298.  Massie BM, Conway M, Yonge R, Frostick S, Sleight P, Ledingham J, et al. 31P 
nuclear magnetic resonance evidence of abnormal skeletal muscle metabolism in 
patients with congestive heart failure. Am J Cardiol. 1987;60(4):309–15.  
299.  Pipinos II, Shepard AD, Anagnostopoulos PV, Katsamouris A, Boska MD. 
Phosphorus 31 nuclear magnetic resonance spectroscopy suggests a mitochondrial 
defect in claudicating skeletal muscle. J Vasc Surg. 2000;31(5):944–52.  
300.  Puente-Maestu L, Lázaro A, Humanes B. Metabolic derangements in COPD muscle 
dysfunction. J Appl Physiol. 2013;114(9):1282–90.  
301.  Puente-Maestu L, Tejedor A, Lázaro A, de Miguel J, Alvarez-Sala L, González-
Aragoneses F, et al. Site of mitochondrial reactive oxygen species production in 
skeletal muscle of chronic obstructive pulmonary disease and its relationship with 
exercise oxidative stress. Am J Respir Cell Mol Biol. 2012;47(3):358–62.  
302.  Puente-Maestu L, Tena T, Trascasa C, Pérez-Parra J, Godoy R, García MJ, et al. 
Training improves muscle oxidative capacity and oxygenation recovery kinetics in 
patients with chronic obstructive pulmonary disease. Eur J Appl Physiol. 
2003;88(6):580–7.  
303.  Tada H, Kato H, Misawa T, Sasaki F, Hayashi S, Takahashi H, et al. 31P-nuclear 
magnetic resonance evidence of abnormal skeletal muscle metabolism in patients 
with chronic lung disease and congestive heart failure. Eur Respir J. 1992;5(2):163–
9.  
304.  Gosker HR, Hesselink MKC, Duimel H, Ward KA, Schols A et al. Reduced 
mitochondrial density in the vastus lateralis muscle of patients with COPD. Eur 
Respir J. 2007;30(1):73–9.  
305.  Den Hoed M, Hesselink MKC, van Kranenburg GPJ, Westerterp KR. Habitual 
physical activity in daily life correlates positively with markers for mitochondrial 
capacity. J Appl Physiol. 2008;105(2):561–8.  
306.  McKeough ZJ, Alison JA, Bye PTP, Trenell MI, Sachinwalla T, Thompson CH, et al. 
Exercise capacity and quadriceps muscle metabolism following training in subjects 
with COPD. Respir Med. 2006;100(10):1817–25.  
307.  Donaldson AV, Maddocks M, Martolini D, Polkey MI, Man WD. Muscle function in 
COPD : a complex interplay. Int J COPD. 2012;7:523–35.  
308.  Wüst RCI, Degens H. Factors contributing to muscle wasting and dysfunction in 
COPD patients. Int J COPD. 2007;2(3):289–300.  
309.  Tisdale M. Cachexia in cancer patients. Nat Rev Cancer. 2002;2:862–71.  
310.  DeVita V, Hellman S, Rosenberg S. Cancer cachexia. Cancer Principles and Practice 
of Oncology. 2005. p. 15–20.  
238 
 
311.  Bentzen SM. Preventing or reducing late side effects of radiation therapy: 
radiobiology meets molecular pathology. Nat Rev Cancer. 2006;6(9):702–13.  
312.  Marks LB, Yu X, Prosnitz RG, Zhou S-M, Hardenbergh PH, Blazing M, et al. The 
incidence and functional consequences of RT-associated cardiac perfusion defects. 
Int J Radiat Oncol Biol Phys. 2005;63(1):214–23.  
313.  Marks LB, Munley MT, Bentel GC, Zhou S, Hollis D, et al. Physical and biological 
predictors of changes in whole-lung funtion following thoracic irradiation. Int J 
Radiat Oncol Biol Phys. 1997;39(3):563–70.  
314.  Miller KL, Kocak Z, Kahn D, Zhou S-M, Baydush A, Hollis D, et al. Preliminary 
report of the 6-minute walk test as a predictor of radiation-induced pulmonary 
toxicity. Int J Radiat Oncol Biol Phys. 2005;62(4):1009–13.  
315.  Grotto HZW. Anaemia of cancer: an overview of mechanisms involved in its 
pathogenesis. Med Oncol. 2008;25(1):12–21.  
316.  Otto JM, O’Doherty AF, Hennis PJ, Cooper JA, Grocott MP, Snowdon C, et al. 
Association between preoperative haemoglobin concentration and cardiopulmonary 
exercise variables: a multicentre study. Perioper Med. 2013;2(1):18.  
317.  Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR. Early breast cancer 
therapy and cardiovascular injury. J Am Coll Cardiol. 2007;50(15):1435–41.  
318.  Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to 
recognize a new entity. J Clin Oncol. 2005;23(13):2900–2.  
319.  Chen B, Peng X, Pentassuglia L, Lim CC, Sawyer DB. Molecular and cellular 
mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol. 2007;7(2):114–21.  
320.  Mercuro G, Cadeddu C, Piras A, Dessì M, Madeddu C, Deidda M, et al. Early 
epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler 
echocardiography: correlation with inflammatory and oxidative stress markers. 
Oncologist. 2007;12(9):1124–33.  
321.  Wallace DC. Mitochondrial defects in cardiomyopathy and neuromuscular disease. 
Am Heart J. 2000;139:S70–85.  
322.  Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues and nucleobases in 
cancer treatment. Lancet Oncol. 2002;3:415–24.  
323.  Gorman S, Tosetto M, Lyng F, Howe O, Sheahan K, O’Donoghue D, et al. Radiation 
and chemotherapy bystander effects induce early genomic instability events: telomere 
shortening and bridge formation coupled with mitochondrial dysfunction. Mutat Res. 
2009;669(1-2):131–8.  
324.  Clarkson PM, Thompson HS. Antioxidants: what role do they play in physical 
activity and health? Am J Clin Nutr. 2000;72(2 Suppl):637S–46S.  
325.  Jones LW, Demark-Wahnefried W. Diet, exercise, and complementary therapies after 
primary treatment for cancer. Lancet Oncol. 2006;7(12):1017–26.  
239 
 
326.  Mcneely ML, Campbell KL, Rowe BH, Klassen TP, Mackey JR, Courneya KS. 
Effects of exercise on breast cancer patients and survivors: a systematic review and 
meta-analysis. CMAJ 2006;175(1):34-41.  
327.  Schmitz KH, Holtzman J, Courneya KS, Ma LC, Duval S, Kane R. Controlled 
Physical Activity Trials in Cancer Survivors : A Systematic Review and Meta-
analysis. Cancer Epidemiol Biomarkers Prev. 2005;14:1588–95.  
328.  Burke SM, Brunet J, Sabiston CM, Jack S, Grocott MPW, West MA. Patients’ 
perceptions of quality of life during active treatment for locally advanced rectal 
cancer: the importance of preoperative exercise. Support care cancer. 
2013;21(12):3345–53.  
329.  Jones LW, Eves ND, Peterson BL, Garst J, Crawford J, West MJ, et al. Safety and 
feasibility of aerobic training on cardiopulmonary function and quality of life in 
postsurgical nonsmall cell lung cancer patients: a pilot study. Cancer. 
2009;113(12):3430–9.  
330.  Haykowsky MJ, Liang Y, Pechter D, Jones LW, McAlister FA, Clark AM. A meta-
analysis of the effect of exercise training on left ventricular remodeling in heart 
failure patients: the benefit depends on the type of training performed. J Am Coll 
Cardiol. 2007;49(24):2329–36.  
331.  Richardson RS, Noyszewski EA, Kendrick KF, Leigh JS, Wagner PD. Myoglobin 
Desaturation during Exercise. J Clin Invest. 1995;96:1916–26.  
332.  Holloszy J. Biochemical adaptations to exercise: aerobic metabolism. Exerc Sport Sci 
Rev. 1973;1:45–71.  
333.  Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles' heel. Cancer 
Cell. 2008;13(6):472–82.  
334.  Goodyear LJ, Kahn BB. Exercise, glucose transport and insulin sensitivity. Ann Rev 
Med. 1998;49:235–61.  
335.  Narkar VA, Downes M, Yu RT, Embler E, Wang Y, Mihaylova MM, et al. AMPK 
and PPARδ agonists are exercise mimetics Vihang. Cell. 2008;134(3):405–15.  
336.  Morris EJA, Taylor EF, Thomas JD, Quirke P, Finan PJ, Coleman MP, et al. Thirty-
day postoperative mortality after colorectal cancer surgery in England. Gut. 
2011;60(6):806–13.  
337.  Andreoni B, Chiappa A, Bertani E, Bellomi M, Orecchia R, Zampino M, et al. 
Surgical outcomes for colon and rectal cancer over a decade: results from a 
consecutive monocentric experience in 902 unselected patients. World J Surg Oncol. 
2007;5:73.  
338.  Burns EM, Bottle A, Aylin P, Darzi A, Nicholls RJ, Faiz O. Variation in reoperation 
after colorectal surgery in England as an indicator of surgical performance: 
retrospective analysis of Hospital Episode Statistics. BMJ. 2011;343:4836.  
240 
 
339.  Jack S, West M, Raw D, Marwood S, Ambler G, Cope T, et al. The effect of 
neoadjuvant chemotherapy on physical fitness and survival in patients undergoing 
oesophagogastric cancer surgery. Eur J Surg Oncol. 2014; In press.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
241 
 
 
 
 
 
Publications 
Related To This 
Thesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
242 
 
PUBLICATIONS RELATED TO THIS THESIS 
 
 
ABSTRACTS 
 
 
M. West, L. Loughney, C. Barben, M. Grocott, S. Jack. A pilot study to investigate 
improvements in physical fitness resulting from a 6-week structured, responsive, endurance, 
training programme following neoadjuvant chemoradiotherapy prior to elective rectal 
cancer surgery. British Journal of Surgery 2012; 99 (Suppl. 6):83-222  
 
M. West, L. Noble, D. Lythgoe, C. Barben, M. Grocott, S. Jack. Cardiopulmonary exercise 
variables predict postoperative in-hospital morbidity after major colonic surgery – A blinded 
observational study. British Journal of Surgery 2012; 99 (Suppl. 6):4  
 
M. West, D. Lythgoe, C. Barben, M. Grocott, G. Kemp, S. Jack. Cardiopulmonary exercise 
variables predict postoperative in-hospital morbidity after major rectal surgery – A blinded 
observational study. British Journal of Surgery 2013; 100 (Suppl. 7):54-97  
 
M. West, L. Loughney, G. Kemp, M. Grocott, S. Jack. Objectively measured physical 
fitness after neoadjuvant chemoradiotherapy and a six week prehabilitation programme in 
locally advanced rectal cancer patients – A blinded interventional study. Journal of Geriatric 
Oncology 2013(4);S18 (abstract published) 
 
M. West, L. Loughney, S. Jack, C. Barben, G. Kemp, M. Grocott, P. Albert, P. Walker. The 
effect of neoadjuvant chemoradiotherapy on physical activity in operable rectal cancer 
patients. Am J Respir Crit Care Med 2012;185:A6392  
 
M. West, L. Loughney, S. Jack, C. Barben, G. Kemp, M. Grocott, P. Walker, P. Albert. 
Does change in physical activity correlate to a change in physical fitness post-neoadjuvant 
chemoradiotheapy in rectal cancer patients. Am J Respir Crit Care Med 2012;185:A6394  
 
M. West, S. Jack, C. Barben, M. Grocott. The effect of neoadjuvant chemoradiotherapy on 
fitness in patients undergoing rectal cancer surgery. Am J Respir Crit Care Med 
2012;185:A3695  
 
M. West and the Aintree Colorectal Multi Discuplinary Team. Comparison of conventional 
magnetic resonance imaging and histopathological response to chemoradiotherapy in locally 
advanced rectal cancer. Journal of Geriatric Oncology 2013(4);S44-45  
 
R. Astin, S. Jack, M.P.W. Grocott,
 
G.J. Kemp, C Barben, B. Wiles, D. White, G. Brown, M. 
West. Training response to a structured exercise program is associated with greater tumor 
regression in rectal cancer following neoadjuvant chemoradiotherapy. Am J Respir Crit Care 
Med 2014; in press 
 
M. West, R Astin,
 
L. Loughney, M.P.W. Grocott, S. Jack,
 
G.J. Kemp
. 
Exercise training 
following neoadjuvant chemoradiotherapy in rectal cancer restores physical fitness and is 
associated with improved mitochondrial bioenergetics. Am J Respir Crit Care Med 2014; in 
press
 
 
 
 
 
243 
 
M. West, L. Loughney, M.P.W. Grocott, S. Jack,
 
G.J. Kemp.
 
Changes in Muscle 
Mitochondrial Energetics in Vivo and Physical Fitness in Operable Rectal Cancer Patients 
Following Neoadjuvant Chemoradiotherapy – An Observational Pilot Study. International 
Society of Magnetic Resonance Imaging 2014; in press
 
 
 
 
 
PEER REVIEWED PUBLICATIONS 
 
 
M. West, S. Jack, M. Grocott. Perioperative Cardiopulmonary Exercise Testing in the 
Elderly. Best Practice and Research Clinical Anaesthesiology 2011; 25: 427-437.  
 
S. Jack, M. West, M. Grocott. Perioperative exercise training in elderly subjects. Best 
Practice and Research Clinical Anaesthesiology 2011; 25: 461-472.  
 
A. O’Doherty, M. West, S. Jack, M. Grocott. Preoperative aerobic exercise training in 
elective intra-cavity surgery: A systematic review. British Journal of Anaesthesia, 2013 
110(5) 679-689.  
 
S. Burke, J. Brunet, C. Sabiston, S. Jack, M. Grocott, M. West. Patients' perceptions of 
quality of life during active treatment for locally advanced rectal cancer: The importance of 
pre-operative exercise. Supportive Care in Cancer, 2013 21(12):3345-53.  
 
M. West, D. Lythgoe, C. Barben, L. Noble, G. Kemp, S. Jack, M. Grocott. 
Cardiopulmonary exercise variables are associated with postoperative morbidity after major 
colonic surgery – a prospective blinded observational study. British Journal of Anaesthesia, 
2014 112(4):665-71.  
 
S. Jack, M.A. West, D. Raw, S. Marwood, G. Ambler, T.M. Cope, M. Shrotri, R.P. 
Sturgess, P.M.A. Calverley, C.H. Ottensmeier, M.P.W Grocott. The effect of neoadjuvant 
chemotherapy on physical fitness and survival in patients undergoing oesophagogastric 
cancer surgery.
 
European Journal of Surgical Oncology, 2014; S0748-7983(14) 00364-3. 
PMID 24731268 
 
   
M.A. West, L. Loughney, C.P. Barben, R. Sripadam, G.J. Kemp, M.P.W. Grocott, S. Jack.
 
The effects of neoadjuvant chemoradiotherapy on physical fitness and morbidity in rectal 
cancer surgery patients.
 
European Journal of Surgical Oncology, 2014; S0748-7983)14) 
00382-2. PMID 24784775 
 
 
M.A. West, M.G. Parry, D. Lythgoe, C.P. Barben, G.J. Kemp, M.P.W. Grocott, S. Jack. 
Cardiopulmonary exercise testing for the prediction of morbidity risk after rectal cancer 
surgery. British Journal of Surgery, 2014;101(9):1166-72. PMID 24916313  
 
Malcolm A West, Lisa Loughney, Daniel Lythgoe, Christopher P Barben, Valerie L Adams, 
William E Bimson, Michael PW Grocott, Sandy Jack, Graham J Kemp. The effect of 
neoadjuvant chemoradiotherapy on whole-body physical fitness and skeletal muscle 
mitochondrial oxidative phosphorylation in vivo in locally advanced rectal cancer patients – 
An observational pilot study. PloS One, 2014; 5(9):e111526 
 
M. West, L. Loughney, D. Lythgoe, C.P. Barben, R. Sripadam, G.J. Kemp, M.P.W. Grocott, 
S. Jack. The effect of prehabilitation on objectively measured physical fitness following 
neoadjuvant treatment in preoperative rectal cancer patients – a blinded interventional pilot 
study. British Journal of Anaesthesia, 2015;114(2):244-51  
244 
 
 
SM Burke, MA. West, MPW. Grocott, J Brunet, S. Jack. Exploring the experience of 
adhering to a prescribed pre-surgical exercise program for patients with advanced rectal 
cancer: A phenomenological study. Psychology of Sport & Exercise, 2015; 16(3):88-95  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
245 
 
 
 
 
 
Appendices 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
246 
 
APPENDICES 
 
 
APPENDIX I: SYSTEMATIC REVIEW SEARCH STRATEGY FOR SECTION 2.4.1 
AND 2.4.2 
 
 
Search Strategy for Sections 2.4.1 and 2.4.2 
 
 
Question title – For patients with operable rectal cancer, what is the effectiveness of 
preoperative short course radiotherapy or chemoradiotherapy versus surgery alone? 
 
 
Review protocol (using the PICO methodology) 
 
Population – Patients with operable rectal cancer 
Intervention – Preoperative RT or NACRT 
Comparison – Surgery alone with RT or NACRT 
Outcomes – Survival, local control, morbidity, Quality of life, second malignancies 
 
 
All titles and abstracts were reviewed by 2 reviewers (MW and LL), full articles were reviewed 
by the same two reviewers and any discrepancies were resolved before the final articles were 
included. The date limit was set (after consultation with Steven Kerr - Senior Librarian at the 
Royal College of Surgeons, Edinburgh) from 1990 onwards as it was considered that this was 
when relevant data for current practices became available.  All searches were done with the help 
of Steven Kerr. 
 
 
Exclusion criteria: 
 
Comparisons in studies not relevant to PICO 
Population not relevant to PICO 
Outcomes not relevant to PICO 
Foreign language studies not in English 
Expert reviews 
 
 
Medline search strategy (This search strategy is adapted to each database.) 
Rectal Cancer AND Preoperative Therapy 
1. ((rectal$ or rectum$) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or 
carcinoma$ or adenocarcinoma$)).tw. 
2. exp Rectal Neoplasms/ 
3. operable rectal cancer*.tw. 
4. 1 or 2 or 3 
5. exp Drug Therapy/ 
6. exp Antineoplastic Agents/ 
7. exp Neoadjuvant Therapy/ 
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8. exp Antineoplastic Combined Chemotherapy Protocols/ 
9. neoadjuvant chemotherapy*.tw. 
10. exp Radiotherapy/ 
11. (radiotherap* adj (pre operative* or pre-operative* or preoperative* or perioperative*)).tw. 
12. neoadjuvant radiotherap*.tw. 
13. chemoradiotherapy.mp. 
14. (chemoradiotherap* adj (pre operative* or pre-operative* or preoperative* or 
perioperative*)).tw. 
15. neoadjuvant chemoradiotherap*.tw. 
16. (short course radiotherap* or short term radiotherap*).tw. 
17. hyperfraction* radiotherap*.tw. 
18. exp Combined Modality Therapy/ 
19. exp Dose Fractionation/ 
20. exp Radiotherapy Dosage/ 
21. exp Preoperative Care/ 
22. (care adj (pre operative* or pre-operative* or preoperative* or perioperative*)).tw. 
23. exp Treatment Outcome/ 
24. exp Comparative Effectiveness Research/ 
25. exp Postoperative Complications/ 
26. exp Risk Factors/ 
27. exp Prospective Studies/ 
28. exp Follow-Up Studies/ 
29. Or/5-28 
30. 4 and 29 
RCT and SR filters were applied to the search strategy. 
 
 
Search Outputs  
 
Database Dates Covered Number of 
references found 
Number of 
references retrieved 
Medline 1990- 12/2012 2680 456 
Embase 1990- 12/2012 2572 327 
Cochrane 1990- 12/2012 101 29 
Cinahl 1990- 12/2012 93 50 
Web of Science (SCI and 
SSCI) and ISI Proceedings 
1990- 12/2012 1241 281 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
248 
 
 
Total references retrieved (after removal of duplicated articles) – 881  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quality of included studies: 
 
Cochrane reviews = 1 
Systematic review of randomised controlled trials = 3 
Randomised controlled trials = 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Possibly relevant 
papers = 881 
Excluded based on title and 
abstract = 843 
Full text reviews 
= 38 
Excluded after full 
text reviews = 27 
Included = 11 
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APPENDIX II: SYSTEMAIC REVIEW SEARCH STRATEGY FOR SECTION 2.4.3 
 
 
Search Strategy for Section 2.4.3 
 
 
Question title – For patients with locally advanced rectal cancer is preoperative radiotherapy or 
preoperative chemoradiotherapy more effective than immediate surgery alone? 
 
 
Review protocol (using the PICO methodology) 
 
Population – Patients with locally advanced operable rectal cancer 
Intervention - Preoperative RT or NACRT 
Comparison – Surgery alone with RT or NACRT 
Outcomes – Quality of surgery, Safety, Risk, Survival, Local control, Morbidity, Quality of life, 
Local recurrence, Toxicity 
 
 
All titles and abstracts were reviewed by 2 reviewers (MW and LL), full articles were reviewed 
by the same two reviewers and any discrepancies were resolved before the final articles were 
included. The date limit was set (after consultation with Steven Kerr - Senior Librarian at the 
Royal College of Surgeons, Edinburgh) from 1997 onwards as it was considered that this was 
when relevant data for current practices became available.  All searches were done with the help 
of Steven Kerr. 
 
 
Exclusion criteria: 
 
Comparisons in studies not relevant to PICO 
Population not relevant to PICO 
Outcomes not relevant to PICO 
Foreign language studies not in English 
Expert reviews 
Abstract only  
 
 
Medline search strategy (This search strategy is adapted to each database.) 
Locally advanced Rectal Cancer AND (Preoperative Radiotherapy OR Preoperative 
Chemotherapy OR Preoperative Chemoradiotherapy) 
1. ((rectal$ or rectum$) adj3 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or 
carcinoma$ or adenocarcinoma$)).tw. 
2. exp Rectal Neoplasms/ 
3. 1 or 2 
4. locally advanced.mp. 
5. non metastatic.mp. 
6. 5 or 4 
7. exp Drug Therapy/ 
8. exp Antineoplastic Agents/ 
9. exp Angiogenesis Inhibitors/ 
250 
 
10. exp Neoadjuvant Therapy/ 
11. exp Antineoplastic Combined Chemotherapy Protocols/ 
12. neoadjuvant chemotherapy*.tw. 
13. exp Leucovorin/ 
14. leucovorin*.tw. 
15. Bevacizumab*.tw. 
16. oxaliplatin*.tw. 
17. exp Fluorouracil/ 
18. (Fluorouracil* or 5-FU*).tw. 
19. folinic acid*.tw. 
20. 10 or 8 or 16 or 11 or 19 or 14 or 13 or 7 or 17 or 18 or 15 or 9 or 12 
21. exp Radiotherapy/ 
22. (radiotherap* adj (pre operative* or pre-operative* or preoperative* or perioperative*)).tw. 
23. neoadjuvant radiotherap*.tw. 
24. chemoradiotherapy.mp. 
25. (chemoradiotherap* adj (pre operative* or pre-operative* or preoperative* or 
perioperative*)).tw. 
26. neoadjuvant chemoradiotherap*.tw. 
27. 25 or 22 or 21 or 24 or 26 or 23 
28. 27 or 20 
29. 6 and 3 
30. 28 and 29 
31. limit 30 to yr="1997 - 2011" 
RCT, SR and OS filters were applied to this search strategy. 
 
 
Search Outputs  
 
Database Dates Covered Number of 
references found 
Number of references 
retrieved 
Medline 1997 - 12/2012 929 261 
Embase 1997 - 12/2012 772 218 
Cochrane 1997 - 05/2013 176 90 
Cinahl 1997 - 12/2012 388 90 
Web of Science (SCI and 
SSCI) and ISI Proceedings 
1997 - 12/2012 979 256 
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Total references retrieved (after removal of duplicated articles) – 614 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quality of included studies: 
 
Cochrane reviews = 3 
Case Series/Phase II trials = 24 
Review articles = 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Possibly relevant 
papers = 614 
Excluded based on title and 
abstract = 493 
Full text reviews 
= 121 
Excluded after full 
text reviews = 93 
Included = 28 
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APPENDIX III: SYSTEMAIC REVIEW SEARCH STRATEGY FOR SECTION 2.4.3.3 
 
 
Search Strategy for Section 2.4.3.3 
 
 
Question title – Preoperative patient fitness relates to surgical outcome in gastrointestinal 
cancer patients who underwent neoadjuvant chemotherapy, radiotherapy or both. 
 
 
Review protocol (using the PICO methodology) 
 
Population – Patients with gastrointestinal cancer 
Intervention - Preoperative RT or NACRT 
Comparison – Surgery alone with RT or NACRT 
Outcomes – Quality of surgery, Safety, Risk, Survival, Local control, Morbidity, Quality of life, 
Local recurrence, Toxicity, Surgical Outcomes, Fitness 
 
 
All titles and abstracts were reviewed by 2 reviewers (MW and LL), full articles were reviewed 
by the same two reviewers and any discrepancies were resolved before the final articles were 
included. No date limit was set (after consultation with Steven Kerr - Senior Librarian at the 
Royal College of Surgeons, Edinburgh). All searches were done with the help of Steven Kerr. 
Due to the high number of hits produced by the first search (n=1513), we added a second search 
tier looking specifically for MESH terms relating to the 1
st
 search and markers of physical 
fitness (lactate threshold, cardiopulmonary exercise testing, Duke’s score, shuttle walk, 
metabolic equivalents, exercise, anaerobic, aerobic, WHO performance status). This brought the 
hits down to 524. 
 
 
Exclusion criteria: 
 
Comparisons in studies not relevant to PICO 
Population not relevant to PICO 
Outcomes not relevant to PICO 
Foreign language studies not in English 
Expert reviews 
Abstract only  
 
 
Medline search strategy (This search strategy is adapted to each database.) 
 
 
Full-Text Search Terms 
 
 Neoplasm* OR malignan* OR cancer* OR carcino* 
 Chemother* OR Adjuvan* OR "Radiother* OR chemoradiotherap* 
 Surger* OR surgical* OR surgeon* OR *operat* OR procedur* 
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 Outcom* OR Assess* OR complication* OR Mortalit* OR Morbidit*OR Postop* 
 (lactat* AND threshold*) OR (cardiopul* AND exercis*) OR (duke* AND activit*) OR 
(shuttl* AND walk*) OR (6 AND walk*) OR (six AND walk*) OR ("Metabol* AND 
Equivalen*) OR Fitness OR Athlet* OR Exercis* OR Anaerobic* OR aerobic*) 
 
Title/Mesh Terms – 1st Search 
 
 (Neoplasm* [ti] OR malignan* [ti] OR cancer* [ti] OR carcino* [ti]) OR (Neoplasm* 
[mesh] OR malignan* [mesh] OR cancer* [mesh] OR carcino* [mesh]) 
 (Chemother* [ti] OR Adjuvan* [ti] OR "Radiother* [ti] OR chemoradiotherap* [ti]) OR 
(Chemother* [mesh] OR Adjuvan* [mesh] OR "Radiother* [mesh] OR 
chemoradiotherap* [mesh]) 
 (Surger* [ti] OR surgical* [ti] OR surgeon* [ti] OR * operat* [ti] OR procedur* [ti]) 
OR (Surger* [mesh] OR surgical* [mesh] OR surgeon* [mesh] OR * [mesh]operat* 
[mesh] OR procedur* [mesh]) 
 (Outcom* [ti] OR Assess* [ti] OR complication* [ti] OR Mortalit* [ti] OR Morbidit* 
[ti] OR Postop* [ti]) OR (Outcom* [mesh] OR Assess* [mesh] OR complication* 
[mesh] OR Mortalit* [mesh] OR Morbidit* [mesh] OR Postop* [mesh]) 
 
Title/Mesh Terms – 2nd Search 
 
 (lactat* [ti] AND threshold* [ti]) OR (cardiopul* [ti] AND exercis* [ti]) OR (duke* [ti] 
AND activit* [ti]) OR (shuttl* [ti] AND walk* [ti]) OR (6 AND walk* [ti]) OR (six 
AND walk* [ti]) OR ("Metabol* [ti] AND Equivalen* [ti]) OR Fitness OR Athlet* [ti] 
OR Exercis* [ti] OR Anaerobic* [ti] OR aerobic* [ti])  
 (lactat* [mesh] AND threshold* [mesh]) OR (cardiopul* [mesh] AND exercis* [mesh]) 
OR (duke* [mesh] AND activit* [mesh]) OR (shuttl* [mesh] AND walk* [mesh]) OR 
(6 AND walk* [mesh]) OR (six AND walk* [mesh]) OR ("Metabol* [mesh] AND 
Equivalen* [mesh]) OR Fitness OR Athlet* [mesh] OR Exercis* [mesh] OR 
Anaerobic* [mesh] OR aerobic* [mesh]) 
 (lactat* AND threshold*) OR (cardiopul* AND exercis*) OR (duke* AND activit*) OR 
(shuttl* AND walk*) OR (6 AND walk*) OR (six AND walk*) OR ("Metabol* AND 
Equivalen*) OR Fitness OR Athlet* OR Exercis* OR Anaerobic* OR aerobic*) 
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Search History 
 
#64  Search Outcom* OR Assess* OR complication* OR Mortalit* OR Morbidit* OR Postop* 
Limits: English 11:07:45 3631591   
 
#63  Search Outcom* OR Assess* OR complication* OR Mortalit* OR Morbidit*OR Postop* 
Limits: English 11:07:26 3602711   
 
#62  Search (lactat* AND threshold*) OR (cardiopul* AND exercis*) OR (duke* AND activit*) 
OR (shuttl* AND walk*) OR (6 AND walk*) OR (six AND walk*) OR ("Metabol* AND 
Equivalen*) OR Fitness OR Athlet* OR Exercis* OR Anaerobic* OR aerobic*) Limits: English 
11:06:35 373975   
 
#61  Search Surger* OR surgical* OR surgeon* OR operat* OR procedur* Limits: English 
11:05:02 2307338   
 
#60  Search Chemother* OR Adjuvan* OR "Radiother* OR chemoradiotherap* Limits: English 
11:04:50 410411   
 
#59  Search Neoplasm* OR malignan* OR cancer* OR carcino* Limits: English 11:04:21 
1906608   
 
#58  Search Neoplasm* [ti] OR malignan* [ti] OR cancer* [ti] OR carcino* [ti] Limits: English 
11:01:48 714998   
 
#57  Search #55 OR #39 Limits: English 10:58:13 24   
 
#56  Search #55 OR #39 10:57:38 28   
 
#55  Search (#20 OR #46) AND (#38 OR #50) 10:54:39 28   
 
#50  Search (lactat* [ti] AND threshold* [ti]) OR (cardiopul* [ti] AND exercis* [ti]) OR (duke* 
[ti] AND activit* [ti]) OR (shuttl* [ti] AND walk* [ti]) OR (6 [ti] OR (six [ti]) AND walk* [ti]) 
OR ("Metabol* [ti] AND Equivalen* [ti]) OR Fitness[ti] OR Athlet* [ti] OR Exercis* [ti] OR 
Anaerobic* [ti] OR aerobic* [ti]) 10:50:36 113502   
 
#54  Related Citations for PubMed (Select 16822992) 10:40:18 180   
 
#52  Search Perioperative Chemotherapy versus Surgery Alone 10:39:12 60   
 
#46  Search #44 AND #45 10:38:24 498   
 
#51  Search #46 AND #50 10:32:05 0   
 
#49  Search #46 AND #38 10:26:38 0   
 
#48  Search #44 AND #45 AND 2006 AND Perioperative [ti] 10:25:22 3   
 
#47  Search #44 AND #45 AND 2006 10:24:45 173   
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#45 Search Outcom* [ti] OR Assess* [ti] OR complication* [ti] OR Mortalit* [ti] OR Morbidit* 
[ti] OR Postop* [ti] 10:23:43 529772   
 
#44  Search #40 AND #41 AND #42 10:21:22 4391   
 
#43  Search #40 AND #41 OR #42 10:20:54 628985   
 
#42  Search Surger* [ti] OR surgical [ti] OR surgeon* [ti] OR operat* [ti] OR procedur* [ti] 
10:20:17 564332   
 
#41  Search Chemother* [ti] OR Adjuvan* [ti] OR "Radiother* [ti] OR chemoradiotherap* [ti] 
10:20:04 125076   
 
#40  Search Neoplasm* [ti] OR malignan* [ti] OR cancer* [to] OR carcino* [ti] 10:19:48 
1334276   
 
#39  Search #20 AND #38 09:51:18 11   
 
#38  Search #32 OR #33 OR #34 OR #35 OR #36 OR #37 09:50:27 71217   
 
#37  Search lactat* [ti] AND threshold* [ti] 09:46:57 285   
 
#36  Search cardiopul* [ti] AND exercis* [ti] 09:46:24 623   
 
#35  Search duke* [ti] AND activit* [ti] 09:45:57 13   
 
#34  Search shuttl* [ti] AND walk* [ti] 09:45:33 62   
 
#33  Search (6 [ti] OR six [ti]) AND walk* [ti] 09:45:09 511   
 
#32 Search "Metabolic Equivalent"[Mesh] OR "Physical Fitness"[Mesh] OR "Athletic 
Performance"[Mesh] OR "Exercise Test"[Mesh] OR "Anaerobic Threshold"[Mesh] 09:44:16 
70793   
 
#20  Search #4 AND #9 AND #12 AND #19 09:31:16 42974   
 
#19 Search "Outcome Assessment (Health Care)"[Mesh] OR "Outcome and Process Assessment 
Health Care"[Mesh] OR "complications" [Subheading] OR "Mortality"[Mesh] OR "mortality" 
[Subheading] OR "Hospital Mortality"[Mesh]OR "Morbidity"[Mesh] OR "Postoperative 
Complications"[Mesh] 09:25:38 2736081   
 
#18 Search "Outcome Assessment (Health Care"[Mesh] OR "Outcome and Process Assessment 
Health Care"[Mesh] OR "complications" [Subheading]) OR "Mortality"[Mesh] OR "mortality" 
[Subheading] OR "Hospital Mortality"[Mesh] OR "Morbidity"[Mesh] OR "Postoperative 
Complications"[Mesh] 09:24:10 2736081   
 
#12  Search "Surgical Procedures, Operative"[Mesh] OR "Specialties, Surgical"[Mesh] OR 
"surgery" [Subheading] OR "General Surgery"[Mesh] 08:00:10 2678044   
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#9 Search "Chemotherapy, Adjuvant"[Mesh] OR "Drug Therapy"[Mesh] OR 
"Radiotherapy"[Mesh] OR "Neoadjuvant Therapy"[Mesh] OR chemoradiotherap* [ti] 07:42:20 
1005581   
 
#8 Search "Chemotherapy, Adjuvant"[Mesh] OR "Drug Therapy"[Mesh] OR 
"Radiotherapy"[Mesh] OR "Neoadjuvant Therapy"[Mesh] 07:41:46 1004968   
 
#4  Search "Neoplasms"[Mesh] OR (intracavit* [ti] AND malignan* [ti]) 07:27:46 2237272   
 
#3  Search "Neoplasms"[Mesh] 07:27:06 2237264   
 
#1  Search Neoplasms 
 
 
 
Search Outputs – 1st Search 
 
Database Dates Covered Number of references 
found 
Number of references 
retrieved 
Medline 1997 - 12/2012 1456 1456 
Embase 1997 - 12/2012 57 57 
Cochrane 1997 - 05/2013 0 0 
 
 
Search Outputs – 2nd Search 
 
Database Dates Covered Number of references 
found 
Number of references 
retrieved 
Medline 1997 - 12/2012 524 524 
Embase 1997 - 12/2012 35 35 
Cochrane 1997 - 05/2013 0 0 
 
 
 
Total references retrieved (after removal of duplicated articles) – 524 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Possibly relevant 
papers = 524 
Excluded based on title and 
abstract = 483 
Full text reviews 
= 41 
Excluded after full 
text reviews = 39 
Included = 2 
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Quality of included studies: 
 
Cochrane reviews = 0 
Case Series = 1 
Randomised controlled trials = 1 
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APPENDIX IV: SYSTEMATIC REVIEW SEARCH STRATEGY FOR SECTION 2.6.1 
 
 
Search Strategy Section 2.6.1 (Literature review search conducted on 19.09.2011) 
 
 
Question title – Evaluation of outcomes, methods, feasibility, safety and cost-effectiveness in 
studies utilising preoperative aerobic exercise training intervention in patients awaiting intra-
thoracic and intra-abdominal surgery. 
 
 
Review protocol (using the PICO methodology and Down’s Quality assessment) 
 
Population – Patients awaiting thoracic and abdominal surgery 
Intervention – Preoperative aerobic exercise training 
Comparison – Exercise group versus control group 
Outcomes – Exercise outcomes, intervention methodology, feasibility, safety and cost-
effectiveness 
 
 
MW and AFO conducted a systematic search (PubMed and EMBASE) of clinical trials of 
preoperative aerobic exercise training in patients awaiting intra-cavity surgery. Abstracts were 
independently screened by same two investigators and reviewed against inclusion and exclusion 
criteria. Data were extracted by AFO in accordance with predefined criteria. The primary 
hypothesis was; aerobic exercise training prior to elective intra-cavity surgery improves 
postoperative clinical outcome. The secondary hypotheses were; aerobic exercise training prior 
to major surgery improves physical fitness and HRQL and is feasible, safe and cost effective.  
 
Aerobic exercise training was defined as a prescribed period of aerobic physical activity, 
involving large muscle groups with a minimum of 3 planned exercise sessions and each session 
lasting greater than 10 minutes, during the time period leading to surgery. Intra-cavity surgery 
was defined as elective intra-abdominal and intra-thoracic surgery. The primary outcome was 
death following surgery. Secondary outcome measures included; any other measure relating to 
patient clinical outcome following surgery (e.g. postoperative morbidity, length of hospital 
stay), change in physical fitness following aerobic exercise training, HRQL, feasibility 
(adherence, compliance), safety (reported training related adverse events) and cost effectiveness. 
 
 
Search strategy 
Searches were performed on PubMed and EMBASE using search terms defined by the 
reviewers (see below). Two investigators (MW, AFO) independently reviewed the abstracts and 
titles of the studies found in the initial search. After agreement on the primary selection of 
papers, full text versions were accessed and reviewed against the following predefined inclusion 
and exclusion criteria. 
 
Inclusion criteria 
Studies recruiting human adult participants awaiting major cardiac, respiratory or 
gastrointestinal surgery were included in the present review. Studies were eligible for inclusion 
if the intervention was a preoperative aerobic exercise training program evaluated using 
measures of physical fitness. Measures of physical fitness included, but were not restricted to: 
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peak oxygen uptake ( V o2 at Peak), estimated lactate threshold ( V o2 at ˆ L) or 6 minute walk 
distance (6MWD). 
 
 
Exclusion criteria 
Studies which solely investigated the effects of strength training or respiratory muscle training 
were excluded. Studies investigating the effects of postoperative aerobic exercise training, 
aerobic exercise training in patients <18 years and animal studies were excluded. Studies which 
duplicated data that had been reported in an earlier publication and studies that did not report 
measures of physical fitness were also excluded, as were papers not written in the English 
language.  
 
 
Data extraction 
Data were extracted by MW and AFO using a predefined pro-forma. The study characteristics 
data included; the journal and country of publication, the number of centres involved in the 
study, the study design and a quality measure. The patient characteristics data extracted were; 
age, gender and surgical type. The primary outcome variable was mortality following surgery 
(longest follow-up). Secondary outcomes included mortality (all other timeframes), morbidity, 
physical fitness, HRQL, adherence, safety, resource utilisation, and cost effectiveness. The 
exercise outcomes data extracted were; objective and subjective measures of physical fitness. 
The aerobic exercise training characteristics data extracted were; the frequency, intensity, mode 
and duration of the exercise intervention.  
 
 
Quality assessment 
The quality of the included studies was evaluated by using a checklist designed to assess the 
methodological quality of randomised and non-randomised studies. The checklist comprised of 
27 questions under the headings; reporting, external validity, internal validity, and power. Each 
question was scored out of 1, except question 5 which was scored out of 2 and question 27 
which was scored out of 5, giving a total score of 33. High scores reflect high quality studies. 
The studies were scored independently by MW and AFO and discrepancies were resolved by 
discussion. 
 
 
 
PubMed search strategy 
 
Full-Text Search Terms 
 
 (Surgery OR "General Surgery"[Mesh] OR "Surgical Procedures, Operative"[Mesh] OR “pre-
operative” OR “preoperative” OR “preoperative care” OR “pre-assessment”) AND 
(“Prehabilitation” OR “Exercise training” OR “physical training” OR “Pre-conditioning” OR 
“preconditioning” OR “exercise intervention” OR “exercise program” OR “exercise”[Mesh] OR 
“exercise therapy”[Mesh]) AND (“Aerobic capacity” OR “VO2 peak” OR “Functional 
capacity” OR “Anaerobic threshold” OR “VO2 max” OR “exercise tolerance” OR “fitness” OR 
“VO2” OR “oxygen uptake” OR “aerobic fitness” OR “VO2max” OR “VO2peak” OR “AT” 
OR “cardiorespiratory reserve” OR “physical capacity”) NOT animals 
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EMBASE search strategy 
 
Full-Text Search Terms 
 
1. Surgery： Explode 
2. General Surgery： Explode 
3. Surgical Procedures, Operative  
4. pre-operative 
5. preoperative evaluation 
6. preoperative period 
7. preoperative treatment 
8. preoperative care 
9. pre-assessment  
10. preassessment 
11. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 
7 OR 8 OR 9 OR 10 
12. Prehabilitation  
13. Exercise training  
14. physical training  
15. Pre-conditioning 
16. preconditioning 
17. exercise intervention  
18. exercise program  
19. exercise : explode 
20. exercise therapy / kinesiotherapy 
21. 12 OR 13 OR 14 OR 15 OR 16 OR 
17 OR 18 OR 19 OR 20 
22. Aerobic capacity : explode 
23. VO2 peak 
24. Functional capacity 
25. Anaerobic threshold : explode 
26. VO2 max  
27. exercise tolerance  
28. fitness 
29. VO2  
30. oxygen uptake  
31.   oxygen consumption 
32. aerobic fitness   
33. VO2max 
34. VO2peak  
35. cardiorespiratory reserve  
36. physical capacity 
37. 22 OR 23 OR 24 OR 25 OR 26 OR 
27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 
33 OR 34 OR 35 OR 36  
38. 11 AND 21 AND 37 
39.  limit 37 to huma 
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Search Outputs  
 
Database Dates Covered Number of references 
found 
Number of references 
retrieved 
Medline 1950 - 09/2011 873 26 
Embase 1950 - 09/2011 1564 2 
 
 
 
Total references retrieved (after removal of duplicated articles) – 28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quality of included studies: 
 
Cochrane reviews = 0 
Observational Studies = 6 
Randomised controlled trials = 2 
Randomised interventional trials = 2 
 
 
 
Excluded studies 
 
Methods papers 
 
Cho H, Tsuburaya A, Sakamoto J. A Randomized Phase II Trial of Preoperative Exercise to 
Reduce Operative Risk in Gastric Cancer Patients with Metabolic Syndrome: Adjuvant 
Exercise for General Elective Surgery (AEGES) Study Group. Jpn J Clin Oncol. 2008; 
38:71-3. 
 
Jones LW, Douglas PS, Eves ND, et al. Rationale and design of the Exercise Intensity Trial 
(EXCITE): A randomized trial comparing the effects of moderate versus moderate to high-
intensity aerobic training in women with operable breast cancer. BMC Cancer. 2010; 
10:531.  
 
 
Candidate 
abstracts = 2443 
Excluded based on title and 
abstract = 2415 
Full text reviews 
= 28 
Excluded after full 
text reviews = 18 
Included = 10 
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Appropriate measures of physical fitness not reported 
 
Furze G, Dumville JC, Miles JN, Irvine K, Thompson DR, Lewin RJ. “Prehabilitation” prior 
to CABG surgery improves physical functioning and depression. Int J Cardiol. 2009; 
132:51-8. 
 
Herdy AH, Marcchi PL, Vila A, et al. Pre- and postoperative cardiopulmonary rehabilitation 
in hospitalized patients undergoing coronary artery bypass surgery: a randomized controlled 
trial. Am J Phys Med Rehabil. 2008; 87:714-9. 
 
Mooney M, Fitzsimons D, Richardson G. "No more couch-potato!" Patients' experiences of 
a pre-operative programme of cardiac rehabilitation for those awaiting coronary artery 
bypass surgery. Eur J Cardiovasc Nurs. 2007; 6:77-83 
 
Rosenfeldt F, Braun L, Spitzer O, et al. Physical conditioning and mental stress reduction - a 
randomised trial in patients undergoing cardiac surgery. BMC Complement Altern Med. 
2011; 11:20. 
 
Sekine Y, Chiyo M, Iwata T, et al. Perioperative Rehabilitation and Physiotherapy for Lung 
Cancer Patients with Chronic Obstructive Pulmonary Disease. Jpn J Thorac Cardiovasc 
Surg. 2005; 53:237-43. 
 
 
Not exclusively surgical patients or had not undergone surgery at time of follow-up  
 
Adamsen L, Quist M, Andersen C, et al. Effect of a multimodal high intensity exercise 
intervention in cancer patients undergoing chemotherapy: randomised controlled trial. BMJ. 
2009; 13;339:b3410. 
 
Kothmann E, Batterham AM, Owen SJ, et al. Effect of short-term exercise training on 
aerobic fitness in patients with abdominal aortic aneurysms: a pilot study. Br J Anaesth. 
2009; 103:505-10. 
 
Myers JN, White JJ, Narasimhan B, Dalman RL. Effects of exercise training in patients with 
abdominal aortic aneurysm: preliminary results from a randomized trial. J Cardiopulm 
Rehabil Prev. 2010; 30:374-83  
 
 
Duplicate publication of data 
 
Jones LW, Eves ND, Peddle CJ, et al. Effects of presurgical exercise training on systemic 
inflammatory markers among patients with malignant lung lesions. Appl Physiol Nutr 
Metab. 2008; 34:197-202. 
 
Peddle CJ, Jones LW, Eves ND. Effects of Presurgical Exercise Training on Quality of Life 
in Patients Undergoing Lung Resection for Suspected Malignancy. Cancer Nurs. 2009; 
32:158-65. 
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